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Summary 
Iron is an essential micronutrient that is an absolute requirement for correct cellular 
function in all eukaryotic organisms. However, ferrous iron has the ability to catalyze the 
formation of potentially toxic reactive oxygen species and regulation of iron metabolism is 
therefore of critical importance. Currently, there is little known about the co-ordinated 
regulation of the plethora of genes coding for proteins involved in this biochemical pathway, 
with the exception of the well characterized post-transcriptional IRE/IRP system. Regulation 
of gene expression in eukaryotic organisms is a highly intricate process. Transcriptional 
regulation is the first step and is controlled by the presence of specific cis-regulatory regions 
(cis-motifs), residing within the promoter region of genes, and the functional interactions 
between the products of specific regulatory genes (transcription factors) and these cis-
motifs. A combinatorial bioinformatic and functional approach was designed and utilized in 
this study for the analysis of the promoter architecture of genes of the iron metabolic 
pathway. 
 
The upstream non-coding region (~2 kb) of 18 genes (ACO1, CP, CYBRD1, FTH1, FTL, HAMP, 
HEPH, HFE, HFE2, HMOX1, IREB2, LTF, SLC11A2, SLC40A1, STEAP3, TF, TFRC, TFR2), known to 
be involved in the iron metabolism pathway, was subjected to computational analyses to 
identify regions of conserved nucleotide identity utilizing specific software tools. 
 
A subset of nine (CYBRD1, FTH1, HAMP, HFE, HFE2, HMOX1, IREB2, LTF, TFRC) of the genes 
were found to contain a genomic region that demonstrated over 75% sequence identity 
between the genes of interest. This conserved region (CR) is approximately 140 bp in size 
and was identified in each of the promoters of the nine genes. The CR was subjected to 
further detailed examination with comparative algorithms from different software for motif 
detection. Four specific cis-motifs were discovered within the CR, which were found to be in 
the same genomic position and orientation in each of the CR-containing genes. In silico 
prediction of putative transcription factor binding sites revealed the presence of numerous 
binding motifs of interest that could credibly be associated with a biological function in this 
pathway, including a novel MTF-1 binding site in five of the genes of interest. 
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Validation of the bioinformatic predictions was performed in order to fully assess the 
relevance of the results in an in vitro setting. Luciferase reporter constructs for the nine CR-
containing genes were designed containing: 1) the 2 kb promoter, 2) a 1.86 kb promoter 
with the CR removed and 3) the 140 bp CR element. The expression levels of these three 
reporter gene constructs were monitored with a dual-luciferase reporter assay under 
standard culture conditions and simulated iron overload conditions in two different 
mammalian cell lines. Results of the luciferase assays indicate that the CR promoter 
constructs displayed statistically significant variation in expression values when compared to 
the untreated control constructs. Further, the CR appears to mediate transcriptional 
regulatory effects via an iron-independent mechanism. It is therefore apparent that the 
bioinformatic predictions were shown to be functionally relevant in this study and warrant 
further investigation. 
 
Results of these experiments represent a unique and comprehensive overview of novel 
transcriptional control elements of the iron metabolic pathway. The findings of this study 
strengthen the hypothesis that genes with similar promoter architecture, and involved in a 
common pathway, may be co-regulated. In addition, the combinatorial strategy employed in 
this study has applications in alternate pathways, and could serve as a refined approach for 
the prediction and study of regulatory targets in non-coding genomic DNA. 
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Opsomming 
Yster is ‘n noodsaaklike mikrovoedingstof wat ‘n vereiste is vir korrekte sellulêre funksie in 
alle eukariotiese organismes. Yster (II) of Fe2+ het egter die vermoë om die vorming van 
potensiële toksies reaktiewe suurstof spesies te kataliseer en dus is die regulasie van die 
yster metaboliese padweg van kardinale belang. Tans is daar beperkte inligting oor 
koördineerde regulasie van die gene, en dus proteïene waarvoor dit kodeer, in hierdie 
padweg. ‘n Uitsondering is die goed gekarakteriseerde na-transkripsionele “IRE/IRP” 
sisteem. Regulasie van geenuitdrukking in eukariotiese organismes is ‘n ingewikkelde 
proses. Transkripsionele regulasie is die eerste stap en word beheer deur die 
teenwoordigheid van spesefieke cis-regulatoriese elemente (cis-motiewe), geleë in die 
promotor area van gene, en die funksionele interaksies wat plaasvind tussen die produkte 
van spesifieke regulatoriese faktore (of transkripsie faktore) en hierdie cis-motiewe. ‘n 
Gekombineerde bioinformatiese en funksionele benadering was ontwerp en daarna gebruik 
in dié studie vir die analise van die promotor argitektuur van gene wat ‘n rol speel in die 
yster metaboliese padweg. 
 
Die stroomop nie-koderende streek (~2 kb) van 18 gene (ACO1, CP, CYBRD1, FTH1, FTL, 
HAMP, HEPH, HFE, HFE2, HMOX1, IREB2, LTF, SCL11A2, SLC40A1, STEAP3, TF, TFRC, TFR2), 
bekend vir hul betrokkenheid in die yster metabolisme padweg, was bloodgestel aan 
bioinformatiese analises om die streke van konservering te identifiseer met die hulp van 
spesifieke sagteware. 
 
Slegs nege (CYBRD1, FTH1, HAMP, HFE, HFE2, HMOX1, IREB2, LTF, TFRC) van die 
geanaliseerde gene het ‘n genomiese area bevat wat meer as 75% konservering getoon het. 
Hierdie gekonserveerde area (GA) is 140 bp in lengte en is geïdentifiseer in elk van die 
promotors van die nege gene. Die GA was verder bloodgestel aan analises, met die hulp van 
spesifieke sgateware, wat gebruik maak van vergelykende algoritmes vir motief 
karakterisering. Vier cis-motiewe is identifiseer en kom voor in dieselfde volgorde en 
oriëntasie in elk van die gene. In silico voorspelling van moontlike transkripsie faktor 
bindingsplekke het getoon dat daar talle bindingsmotiewe van belang teenwoordig is en dié 
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motiewe kan gekoppel word aan biologiese funksies in hierdie padweg, insluitend ‘n nuwe 
MTF-1 bindingsplek in vyf van die gene van belang. 
 
Die bioinformatiese analises is verder gevalideer om die relevansie van die resultate in ‘n in 
vitro sisteem ten volle te assesseer. Luciferase rapporteerder konstrukte is vir die nege gene 
ontwerp wat die volgende bevat: 1) die 2 kb promotor, 2) ‘n 1.86 kb promotor met die GA 
verwyder en 3) die 140 bp GA element. Die vlakke van uitdrukking van hierdie drie 
rapporteerder konstrukte was genormaliseer met ‘n dubbele-luciferase rapporteerder assay 
onder standaard kultuur kondisies en gesimuleerde ysteroorlading kondisies in twee 
verskillende soogdier sellyne. Resultate van die luciferase assays dui aan dat die GA 
promotor konstrukte statisties betekenisvolle variasie toon in vergelyking met die 
onbehandelde kontrole konstrukte. Verder, die GA blyk om transkipsionele regulatoriese 
effekte te medieer via ‘n yster-onafhanklike meganisme. Dit blyk duidelik dat die 
bioinformatiese voorspellings ook funksioneel getoon kon word en was dus relevant in dié 
studie en regverdig verdere ondersoek. 
 
Hierdie eksperimentele ontwerp verteenwoordig ‘n unieke en omvattende oorsig van nuwe 
transkripsionele beheer elemente wat voorkom in die yster metaboliese padweg. Die 
resultate van dié studie versterk die hipotese dat gene met soortgelyke promotor 
argitektuur en wat betrokke is in ‘n gemene padweg saam gereguleer kan word. 
Daarbenewens, die gekombineerde strategie wat in hierdie studie gebruik is het toepassings 
in alternatiewe metaboliese paaie, en kan dien as ‘n verfynde benadering vir die 
voorspelling en studie van die regulerende teikens in nie-koderende genomiese DNS. 
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1.1 IRON AND IRON METABOLISM 
 
1.1.1 Iron: Historical Perspective and Global Importance 
Iron (chemical symbol; Fe) is a chemical element which forms part of the first transition 
series on the periodic table. Of all the metal elements, iron has the best described history. 
With regard to human civilization, iron has played a significant role in the advancement of 
modern societies. The Iron Age of Man which began around 1200 BC, following the earlier 
Stone and Bronze Ages, saw the development of the ability to heat and forge iron. This led 
to the manufacture of weapons and cutting instruments, which concurrently with changes 
in agricultural practices and religious beliefs led to the development of modern civilizations 
in Europe, Asia and Africa (Wertime and Muhly, 1980). In contrast to the Stone and Bronze 
Ages, few artefacts of this time remain due to the instability of iron in conjunction with 
water and oxygen. 
Iron is the fourth most abundant chemical element in the Earth’s crust, comprising 
approximately 4.7%, in the form of iron oxide minerals such as hematite, siderite and 
magnetite. Both the inner and outer core of the Earth are considered to be made of an iron-
nickel alloy, constituting 35% of the Earth’s mass (Herndon, 2005). The frequent occurrence 
of iron in rocky planets, such as Earth, is due to the last nuclear fusion reaction in the 
collapse of high-mass stars (supernovas) that scatters a radioactive precursor of iron 
abundantly into space (Burrows, 2000). In contrast to the terrestrial abundance of iron, only 
trace amounts are found in the world’s oceans (3 x 10-3 mg/L) due to the insolubility of iron 
in salt water (Mason and Moore, 1982). Historically, iron was delivered to pelagic systems 
via dust storms (Aeolian processes) from arid deserts carrying 3 – 5% iron. In recent decades 
this mechanism of iron deposition has decreased by almost 25% due to climatic changes 
(Cassar et al., 2007). These low ocean iron levels are thought to limit the production of 
phytoplankton, thereby contributing to the relatively high atmospheric carbon dioxide (CO2) 
levels of the present day. This phenomenon is particularly well studied in the Southern 
Ocean, which is known to exert a major control over atmospheric CO2 levels (Bishop et al., 
2004). In 2002, The Southern Ocean Iron Experiment (SOFeX) was launched, during which 
1.7 tonnes of iron sulphate was added to the seawater (Coale et al., 2004). The data 
collected from this mammoth experiment demonstrated that for each atom of iron added, 
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10 000 to 100 000 atoms of carbon were able to be pulled out of the atmosphere via large 
phytoplankton blooms. To date, there have been upwards of ten different `iron fertilization’ 
experiments in many of the world’s oceans, with some researchers estimating that 15% of 
the atmospheric CO2 build up (contributing to global warming) could be removed (Boyd et 
al., 2000; Boyd et al., 2007). 
In addition to the effects of iron on a global scale, it also operates as a micronutrient 
and is an absolute requirement for a host of cellular functions (replication, differentiation 
and ultimately, survival) in almost all animals, plants and microorganisms. Members of the 
lactic acid bacteria, including the Lactobacillus and Lactococcus family, as well as some 
Streptococcus species are the only known exceptions with regard to iron requirements. 
These microorganisms utilize other transition metals, residing next to iron in the periodic 
table, such as manganese and cobalt to fulfil the essential role that iron plays in all other 
organisms (Crichton, 2009). Early human civilizations attributed therapeutic properties to 
iron, with the ancient Greeks administering iron to injured soldiers to improve muscle 
weakness caused by anaemia as a result of blood loss (Beard et al., 1996). In the 16th 
century, physicians prescribed iron salts to women suffering from chlorosis (an old term 
used to describe anaemia) often as a consequence of protein deficiency or pregnancy 
(Poskitt, 2003). Between 1832 and 1843, chlorosis was further defined by low numbers of 
red blood cells and reduced plasma iron levels (McCay, 1973 as reviewed by Poskitt, 2003). 
The essential requirements of iron in nutrition were first described by Boussingault in 1872 
(as reviewed by Beard et al., 1996). The basics of iron metabolism, particularly with regard 
to disorders of iron metabolism, as well as the nutritional importance of this mineral have 
been recognized for centuries. However, it is only in recent decades that the molecular 
underpinnings of this indispensable biochemical pathway have begun to be elucidated. 
 
1.1.2 Chemical and Biochemical Properties of Iron 
Iron occupies a position in the middle of the elements in the first transition series in the 
periodic table. The chemical properties of iron allow for it to exist in various oxidative states 
(from –II to +VI) with the predominate forms being Fe(II) (or Fe2+, ferrous iron) and Fe(III) (or 
Fe3+, ferric iron). The bioavailability of iron is limited by the fact that soluble Fe2+ is readily 
oxidized under aerobic conditions to Fe3+, which is insoluble in water and at the 
physiological pH of 7 (Papanikolaou and Pantopolous, 2005). The ability of iron to 
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interconvert between oxidation states is the primary mechanism through which reversible 
iron-ligand binding takes place, as well as the manner in which electron transport occurs. 
The binding of iron to specific biological ligands (usually oxygen for Fe3+ and nitrogen or 
sulphur atoms for Fe2+) is the only way in which significant concentrations of water-soluble 
Fe3+ can be attained and made available for use in metabolic functions (Crichton, 2009). The 
extreme range of the Fe2+/Fe3+ redox potential of iron makes it uniquely suited to perform a 
variety of cellular functions that encompass almost the entire redox range from -0.5 V to 
+0.6 V. This redox potential can be finely controlled by the binding of iron to different 
ligands which influence the electron spin speed of the complexes and thus the chemical 
reactivity of iron (Crichton, 2009). The biological activity of many enzymes is therefore 
impeded during times of tissue iron deficiency. Iron is essential for a multitude of important 
biochemical activities such as oxygen transport by haemoglobin, DNA synthesis and electron 
transport by the cytochrome proteins of the respiratory chain (Aisen et al., 2001). 
 
1.1.3 Toxicity of Iron 
The variable redox potential of iron which makes it uniquely suited to perform the complex 
biological functions required, also means that this metal is potentially toxic to cellular 
components. The ability of iron to readily interconvert between oxidation states under 
aerobic conditions results in the creation of hazardous free radicals by means of the 
chemistry of the Fenton and Haber-Weiss reactions (Fenton, 1984 as reviewed by 
Papanikolaou and Pantopolous, 2005). During the Fenton process, trace amounts of Fe2+ 
and hydrogen peroxide (H2O2, formed by the protonation of the peroxide ion, O22-, at 
physiological pH) result in hydroxyl radical (•OH) formation (Figure 1.1 A). The superoxide 
radical (O2-) can then reduce Fe3+ to molecular oxygen (O2) and Fe2+ (Figure 1.1 B). During 
the sum of this reaction and the Fenton reaction, O2- and H2O2 in the presence of catalytic 
amounts of iron produce O2, •OH and the hydroxyl anion (OH-) – the Haber-Weiss reaction 
(Figure 1.1 C) (Haber and Weiss, 1934 as reviewed by Koppenol, 2001). 
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A.   Fe2+  + H2O2     →      Fe3+ + •OH + OH- 
 
B.   Fe3+  + O2-        →      Fe2+ + O2 
 
C.      O2- + H2O2      →       O2+ •OH + OH- 
 
Figure 1.1 Fenton and Haber-Weiss reactions. 
(A) The Fenton reaction. (B) The production of molecular oxygen and Fe3+ from the superoxide radical 
via an intermediate reaction. (C) The Haber-Weiss reaction; the sum of reactions A and B. 
 
The free radicals produced by Fenton and Haber-Weiss reactions; hydroxyl-, superoxide 
radicals and hydroxyl anions are termed reactive oxygen species (ROS). Increases in steady 
state ROS levels, above the antioxidant capacity of an individual, result in the development 
of oxidative stress. Oxidative stress, in turn, leads to the damage of cellular structures and 
macromolecules and is associated with tissue injury and disease (Galaris and Pantopolous, 
2008; Kell, 2009). In order to mitigate this double-edged sword nature of iron, intricate 
biological mechanisms of iron homeostasis exist within all organisms that utilize iron for 
metabolic functions. 
 
1.1.4 Iron Distribution and Circulation 
In healthy, adult humans, the total body iron content is approximately 3 – 5 g, constituting 
roughly 45 mg Fe/kg of body weight in men and a slightly lower level of 35 mg Fe/kg in 
women (Andrews, 1999). The vast majority of iron (30 mg Fe/kg or 60-70%) is bound to the 
haem prosthetic group of haemoglobin, the circulating oxygen transport protein, found 
within the red blood cells (erythrocytes). A further 4 mg Fe/kg (10%) of iron is present in 
muscles in the form of myoglobin and the remainder of the total body iron, 10 – 12 mg 
Fe/kg (20 to 30%), which is surplus to immediate cellular requirements, is stored as ferritin 
and haemosiderin in the liver, spleen and bone marrow (Conrad et al., 1999). In the plasma, 
a miniscule fraction of total body iron (0.05 mg Fe/kg or ± 0.1%) is transported by forming a 
complex with transferrin (TF), an iron transport protein that contains two iron binding sites 
(Emerit et al., 2001). TF-bound iron (TBI) supplies the majority of iron required for the 
production of haemoglobin by erythroid precursor cells, as well as delivering iron to a host 
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of other tissues and cells and delivers the maternal supply of iron utilized at high levels 
during pregnancy. The vast majority of iron required by the erythrocytes (20 mg per day) for 
erythropoiesis, comes from the destruction of old red blood cells by the mononuclear 
phagocytic system (MPS). Mature erythrocytes, produced in the bone marrow, circulate in 
the blood plasma for around 120 days, where after they are taken up by the MPS of the 
reticuloendothelial system in cells of the spleen and liver (Deiss, 1983). Macrophage iron 
recycling releases iron from haem molecules into the circulation where it once again binds 
to TF. The distribution of iron in adults is illustrated in Figure 1.2. 
 
Figure 1.2 Distribution of iron in adults. 
In the balanced state, 1 – 2 mg of iron enters and leaves the body each day. Dietary iron is absorbed by 
duodenal enterocytes. It circulates in the plasma bound to transferrin. Most of the iron in the body is 
incorporated into haemoglobin in erythroid precursors and mature red cells. Approximately 10 to 15% is 
present in muscle fibers (in myoglobin) and other tissues (in enzymes and cytochromes). Iron is stored in 
parenchymal cells of the liver and reticuloendothelial macrophages. These macrophages provide most of 
the usable iron by degrading haemoglobin in senescent erythrocytes and reloading ferric iron onto 
transferrin for delivery to cells. 
 
Reproduced with permission from (Andrews, 1999), Copyright Massachusetts Medical Society. 
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1.1.5 Dietary Iron Uptake 
The human body does not possess any regulated mechanism for the excretion of excess 
iron. Small amounts of body iron stores are lost during the sloughing of mucosal and skin 
cells (approximately 1 mg/day). Due to regular blood loss during menstruation and 
childbirth, women lose additional iron from the high concentrations contained in the 
haemoglobins (Andrews et al., 1999). However, this loss of iron is around one tenth of that 
of other mammals (per kg body weight). This daily iron loss is compensated for by uptake of 
a similar amount of iron from the diet. 
As a consequence of the potential biohazardous effects of iron overload (refer to 
Section 1.1.3), the control of iron balance within the body is of paramount importance. This 
balance is primarily maintained at the level of intestinal iron absorption. An inverse 
relationship exists between iron absorption and iron stores in various tissues of the body 
(predominately the liver, spleen and bone marrow): as tissue iron stores decrease iron 
uptake is increased, and vice versa. The rate of erythropoiesis is another important factor 
driving the uptake of iron. Rapid red cell development results in an increased need for iron 
and consequently the assimilation of iron is heightened (Andrews, 1999). The principle site 
of iron absorption is in specialized cells (enterocytes) of the upper regions of the 
gastrointestinal tract, specifically the duodenum and upper ileum. Other factors such as the 
bioavailability of iron and its composition, pH and mucosal and luminal factors affect the 
efficient uptake of iron (Hutchinson et al., 2007). 
 Typical Western diets contribute around 5 – 6 mg of iron per 1000 kcal consumed, 
amounting to 12 – 18 mg of iron ingested per day. This dietary iron is comprised chiefly of 
two forms: haem iron and non-haem iron (Reddy et al., 2000). 
 
Haem Iron 
Haem iron is derived from haemoglobin and myoglobin proteins associated with meat 
intake. Haem is a common prosthetic group composed of protoporphyrin IX and a Fe(II) ion. 
The reaction whereby Fe(II) is incorporated into protoporphyrin IX, takes place in the 
mitochondria and is catalyzed by the ferrochelatase enzyme. Haem-derived iron is 
extremely bioavailable and is easily absorbed however, it accounts for only 10% of dietary 
iron ingestion (reviewed by Anderson et al., 2005). Despite the scarcity of haem iron, it 
amounts to nearly 50% of the iron absorbed by the body from a standard diet (Majuri and 
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Grasbeck, 1987). Haem iron is absorbed as an intact metalloporphyrin involving specific 
haem-binding sites on the brush border of the intestinal enterocytes. Cooking processes 
such as frying can significantly reduce the bioavailability of haem-iron by breaking down the 
structure of the haemoglobin molecule, thereby impeding entry into the intestinal cells 
(Conrad et al., 1999). 
 
Non-haem Iron 
The inorganic form of iron is by far the most abundant form of dietary iron and originates 
principally from plant dietary components. It constitutes almost 90% of ingested dietary iron 
daily but conversely, only 2 – 20% of the iron that is absorbed, depending on body iron 
status and the presence of enhancers or inhibitors (Lombard et al., 1997). The foremost 
enhancers of non-haem iron absorption are meat and organic acids. Ascorbic acid (vitamin 
C) is the primary enhancer and is able to reduce Fe3+ to soluble Fe2+ in the presence of the 
acidic pH provided by the stomach during digestion (Hutchinson et al., 2007). Other 
enhancers include lactic, citric, malic and tartaric acids (Conrad et al., 1999). 
 
1.1.5.1 Proteins Involved in Dietary Iron Uptake 
The myriad proteins associated with the uptake of iron from the gastrointestinal lumen can 
be grouped into three distinct roles: the uptake of iron from the intestinal lumen, across the 
brush-border membrane at the apical pole of the enterocytic cell; the transport of iron 
within the enterocyte, as well as iron sequestration; and the release of iron from the 
mucosal cell basolateral membrane into the plasma (Fleming, 2005). Knowledge of the 
involvement of the proteins involved in these processes has greatly increased in recent 
years with the advent of modern molecular biology techniques, and many proteins that 
were previously hypothetically predicted to occur have now been identified. However, the 
understanding of the physiological role that these proteins perform is still somewhat limited 
(Miret et al., 2003). The proteins illustrated in Figure 1.3 will be discussed further in this 
Section. 
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Figure 1.3 Dietary iron uptake. 
Haem is hypothesized to be transported from the intestinal lumen via HCP1 (currently the protein remains 
unidentified). Within the enterocyte, Fe2+ is released during the degradation of haem by HMOX1. Dietary non-
haem iron is reduced by CYBRD1 from Fe3+ to Fe2+ which is then transported across the apical membrane by 
DMT1. Intracellular Fe2+ is either stored as ferritin or transported out of the cell by FPN1, which is located on 
the basolateral membrane. Facilitation of iron export takes place with the oxidation of Fe2+ to Fe3+ by HEPH 
(membrane-bound) and CP (in the plasma), aiding in the subsequent binding of Fe3+ to transferrin.  
Abbreviations: CP, ceruloplasmin; CYBRD1, cytochrome b reductase 1; DMT1, divalent metal transporter 1; 
Fe3+, ferric iron; Fe2+, ferrous iron; FPN1, ferroportin 1; H+, hydrogen ion; HCP1, haem carrier protein 1; HEPH, 
hephaestin; HMOX1, haem oxygenase 1; TF, transferrin. 
 
Adapted from Trinder et al. (2002). 
 
Cytochrome b reductase 1 (CYBRD1) 
Cytochrome b reductase 1 (CYBRD1), also referred to as duodenal cytochrome b (DCYTB) or 
duodenal iron-regulated transporter (IREG1), is a brush-border ferrireductase enzyme that is 
responsible for mediating the reduction of the Fe3+ to Fe2+ primarily from dietary non-haem 
iron (McKie et al., 2001). Some studies have suggested that CYBRD1 may utilize ascorbate as 
an electron donor during the reduction of Fe3+ (Oakhill et al., 2008). The protein was first 
identified in 2000 by McKie and colleagues, by means of a subtractive cloning technique 
from iron-deficient rats. Further studies conducted on CYBRD1 in rats have shown that 
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protein levels are increased during iron deficiency and hypoxia, and decreased in response 
to iron supplementation, indicating the importance that CYBRD1 plays in regulation of iron 
absorption. Conversely, studies in mice have illustrated that there is little effect on dietary 
iron uptake when the gene coding for the murine homologue (Cybrd1) of CYBRD1 is 
disrupted (Frazer et al., 2005; Gunshin et al., 2005). This may indicate that there are other 
mechanisms responsible for the reduction of dietary non-haem iron that have yet to be 
identified. 
The CYBRD1 protein is 286 amino acids long and 31641 Da in size with six 
transmembrane domains and four conserved histidine residues. It is transcribed from the 
CYBRD1 gene located on chromosome 2q31.1, which is 35.78 kb in size and consists of 4 
exons (McKie et al., 2001). 
 
Divalent metal transporter 1 (DMT1) 
Following reduction of non-haem dietary iron to Fe2+ by CYBRD1, it is then transported 
across the apical membrane, and into the lumen of the enterocytes (Fleming et al., 1997). 
The divalent metal transporter 1 (DMT1), also known as divalent cation transporter 1 (DCT1) 
or natural resistance-associated macrophage protein 2 (NRAMP2) is responsible for the 
transport of Fe2+ as well as the uptake of a broad range of divalent metal ions (manganese, 
cobalt, cadmium, nickel, vanadium and lead) (Garrick et al., 2003). DMT1 was first identified 
as the common iron transport enzyme in mammals by positional cloning experiments in 
rodents with impaired iron transport (Gunshin et al., 1997). The DMT1 transporter is also 
found in cells other than those of the gastrointestinal system; it plays a role as an 
endosomal iron transporter in peripheral tissues. The intestinal isoform of DMT1 is 
characterized by an altered C-terminus and is produced by differential splicing of the DMT1 
mRNA. DMT1 is electrogenic, and requires proton co-transport to be able to act as a 
divalent cation transporter (Gunshin et al., 1997). The low pH provided by gastric acid in the 
proximal portion of the duodenum provides a proton-rich environment which facilitates this 
transport. This mechanism provides a plausible explanation for the aberrant iron absorption 
observed with antacid treatment (Stein et al., 2010). 
The DMT1 protein is comprised of 12 helical transmembrane domains and is 568 
amino acids in size (Li et al., 2012). It is encoded by the solute carrier family 11 (proton-
coupled divalent metal ion transporter), member 2 (SLC11A2) gene on chromosome 
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12q13.12. The SLC11A2 gene forms part of the SLC superfamily, which includes around 300 
genes that encode solute carrier proteins. The SLC genes can be categorized into many 
smaller families depending on the types of molecules transported by the protein. Each 
family is indicated by the first number in the gene name (He et al., 2009). 
 
Haem carrier protein 1 (HCP1) 
Iron uptake in the form of dietary haem is significant due to the fact that it is more 
efficiently absorbed than non-haem iron (West and Oates, 2008). However, the mechanism 
behind haem import is still unidentified to date. For many years, it has been reasonably 
postulated that haem may be taken up in a receptor-mediated manner (HCP1 in Figure 1.3) 
but this remains to be shown scientifically. In 2005, Shayeghi and colleagues published a 
report in the journal Cell, identifying HCP1 (designated as SLC46A1) as the intestinal 
importer of haem in the enterocytes of mice. The following year, Qui et al. (2006) reported 
that SLC46A1 is actually a transporter of the vitamin folic acid, not haem. They identified a 
family in which a loss of function mutation in SLC46A1 resulted in hereditary folate 
malabsorption. This family were shown to have no defects in iron metabolism although they 
did require folic acid supplementation to maintain proper growth. 
 There have been descriptions of haem exporters (Krishnamurthy et al., 2004; Quigley 
et al., 2004), but the elusive haem importer remains unknown. Current scientific theory 
centres on the haem oxygenase enzyme (HMOX1 – discussed below) as the mechanism 
behind the liberation of dietary haem iron from protoporphyrin. 
 
Haem oxygenase 1 (HMOX1) 
After haem has entered the enterocyte, it is degraded by the enzyme haem oxygenase 1 
(HMOX1), located on the surface of the endoplasmic reticulum (ER). The chemical reaction 
of haem degradation requires NADPH and molecular O2 and produces bilirubin, carbon 
monoxide and Fe2+ (Stocker, 1990). The Fe2+ which is released from haem is either stored as 
ferritin or enters the circulation across the basolateral membrane. HMOX1 has been shown 
to play a critical role in the general maintenance of cellular homeostasis due to the fact that 
excess free haem can lead to the generation of ROS with subsequent cellular and tissue 
damage (Maines, 2000), in much the same manner as free iron (Jeney et al., 2002). 
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The human HMOX1 gene was identified experimentally using a cDNA hybridisation 
method where rat hmox1 was hybridized to a human cDNA library that had been treated 
with hemin (Yoshida et al., 1988). The HMOX1 gene was later localized to chromosome 
22q12 using fluorescent in situ hybridisation (FISH) techniques (Kutty et al., 1994). The gene 
comprises five exons and encodes the 288 amino acid HMOX1 protein. HMOX1 contains a 
membrane segment composed of hydrophobic amino acids at the C-terminus (Yoshida et 
al., 1988). 
 
Ferritin 
Ferrous iron that enters the intestinal cell joins the so-called “labile iron pool” (LIP) and has 
one of two fates: either it can be directly exported into the plasma for use elsewhere in the 
body, or it can be stored within the enterocyte. The proteins responsible for the mucosal 
sequestration of excess Fe2+ are ferritin and, to a lesser extent, haemosiderin. Mucosal cells 
have an extremely high rate of cellular turnover and iron stored in ferritin is lost when the 
enterocyte becomes senescent and is sloughed from the intestinal surface (Theil, 1987). 
Mobilisation of iron from ferritin stores is essential during periods of iron depletion, 
however, no known mechanism for the movement of Fe2+ out of ferritin has been fully 
elucidated as of yet. It has been hypothesized that ferritin is degraded by lysosomes or 
proteasomes in order to provide iron for systemic requirements (Aisen et al. 2001). Ferritin 
is present in every cell type in the human body including the leukocytes of the blood where 
it is termed serum ferritin (Worwood et al., 2008). Serum ferritin is used as a non-invasive 
diagnostic marker for the estimation of iron stores due to the fact that serum ferritin levels 
correlate roughly with total body iron stores under normal conditions (Strandberg Pedersen 
and Morling, 2009). 
The ferritin protein was first isolated by a Czech physiologist Vilem Laufberger in 
1937 from horse spleen (as reviewed by Wang et al., 2010). Ferritin consists of 24 protein 
subunits that together, form a hollow spherical molecule which is able to store up to 4500 
atoms of iron in a soluble, bioavailable manner. In mammals, heteropolymeric ferritin is 
made up of two distinct ferritin subunits, known as heavy- (H) and light- (L) chains. H-ferritin 
is coded for by the ferritin, heavy polypeptide 1 (FTH1) gene on chromosome 11q13. L-
ferritin is transcribed from the ferritin, light polypeptide (FTL) gene in chromosomal position 
19q13.33. Both FTH1 and FTL are comprised of four exons but share only approximately 54% 
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sequence similarity. H-ferritin contains a diiron, ferroxidase centre and is postulated to play 
a role in the oxidation of Fe2+ to Fe3+. L-ferritin is responsible for the nucleation of iron into 
the ferritin core (Torti and Torti, 2002). 
 
Ferroportin 1 (FPN1) 
The iron export protein, ferroportin 1 (FPN1), is the only known mammalian exporter of iron 
that has been identified to date. It was described, almost simultaneously, by three different 
research groups (McKie et al., 2000; Donovan et al., 2000; Abboud and Haile, 2000) and 
designated by the names solute carrier family 40 (iron-regulated transporter) member 1 
protein (SLC40A1), solute carrier family 11 (proton-coupled divalent metal ion transporter) 
member 3 protein (SLC11A3), ferroportin 1 (FPN1), iron-regulated transporter 1 (IREG1) or 
metal transporter 1 (MTP1). FPN1 is localized to the basolateral membrane of intestinal 
enterocytes and has 10-12 transmembrane domains. It does not share any sequence 
homology with DMT1 or any other mammalian proteins and is the only member of the SLC 
family 40. FPN1 is responsible for mediating the transport of Fe2+ across the basolateral 
membrane (and the membranes of other cell types not involved in dietary iron homeostasis) 
and into the plasma (Knutson and Wessling-Resnick, 2003). 
 FPN1 is transcribed from the SLC40A1 gene which was mapped to chromosome 2q32 
using FISH analysis (Haile 2000). SLC40A1 consists of eight exons and encodes a 571 amino 
acid protein. 
 
Ceruloplasmin (CP) and Hephaestin (HEPH) 
FPN1 works in conjunction with the proteins ceruloplasmin (CP) and hephaestin (HEPH). CP 
and HEPH are homologous multicopper ferroxidase proteins responsible for the oxidation of 
Fe2+ to Fe3+. CP is the major copper binding protein of the plasma and cation binding sites 
have been identified adjacent to the mononuclear copper sites, indicating the potential role 
of CP in iron oxidation (Lindley et al., 1997). It is a blue alpha-2-glycoprotein that is 
responsible for binding 6 to 7 copper ions per molecule. CP is hypothesized to create ion 
gradients that favour the export of iron out of cells, thereby assisting in iron export (Harris 
et al. 1999). Both CP and HEPH are thought to aid binding of Fe3+ to the plasma iron 
transporter, transferrin (TF, discussed in Section 1.1.6.1 below) (Hellman and Gitlin, 2002). 
The role of CP as the primary ferroxidase involved in iron export from intestinal enterocytes 
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has been contested due to lack of experimental evidence. In patients with 
aceruloplasminemia (Yoshida et al., 1995), and in CP null mutant mice, iron accumulation 
occurs primarily in hepatic and pancreatic cells, but no sign of abnormal intestinal iron 
absorption is observed (Harris et al. 1999). Aceruloplasminemia is a disease caused by the 
complete loss of CP ferroxidase activity and is characterized by the accumulation of iron in 
the brain (Kono, 2012). CP appears to have more of a physiological role in peripheral tissues 
and the central nervous system (CNS), as demonstrated by magnetic resonance imaging 
(MRI) of the brains of individuals with aceruloplasminemia, which show marked iron 
deposition (Kono and Miyajima, 1997). 
 The presence of an alternate ferroxidase enzyme was first revealed in mice with X-
linked, recessive hypochromic microcytic anaemia (Bannerman and Cooper, 1966; Edwards 
and Bannerman, 1970). These sla (sex-linked anaemia) mice were shown to possess the 
ability to transport iron from the intestinal lumen, but were unable to transfer iron out of 
the enterocytes into circulation. Vulpe and colleagues (1999) identified a homologue of 
murine CP using genome sequencing technologies. In 2002, the human HEPH gene was 
mapped to the X chromosome (Syed et al., 2002). The CP and HEPH polypeptides share 50% 
amino acid identity with conservation at sites specific for copper binding. 
 In contrast with CP, HEPH is a membrane-bound enzyme found predominately on 
the basolateral membrane of intestinal mucosal cells. It is anchored to the membrane by a 
glycol-phospho-inositol (GPI) anchor at the C-terminus. It represents a fundamental link 
between copper and iron metabolism in mammals. An alternatively-spliced CP transcript, 
expressed primarily in astrocyte cells of the brain, is also bound to the cell membrane by a 
GPI anchor. This form of CP has not been identified in cells of the intestine, liver or spleen 
(Patel and David, 1997). 
 
The CP gene was mapped to the long arm of chromosome 3 (3q21-24) by Southern blot 
analysis of human-mouse somatic cell hybrids (Naylor et al., 1985, Yang et al., 1986). CP 
spans a genomic region of approximately 50 kb and contains 19 coding exons (Daimon et al., 
1995). The HEPH gene is localized to chromosome Xq11-12 and has 20 coding exons 
spanning a genomic region of ~100 kb (Syed et al., 2002). It demonstrates almost 85% 
nucleotide and amino acid homology with the murine homologue, Heph, first identified in 
sla mice. 
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1.1.6 Systemic Iron Transport and Cellular Iron Uptake 
Following absorption from the diet by intestinal enterocytes, iron is transported to 
peripheral tissues and cells around the body by the blood plasma. In order to minimize the 
potentially toxic effects of free iron, circulating iron in the plasma is bound to the primary 
iron transport protein, TF (Ponka et al., 1998). This plasma iron pool amounts to between 3 
and 4 mg of iron in an adult human (Andrews, 1999). The demand for iron is highest in the 
bone marrow, where more than 2 million new erythrocytes are produced every second 
(Cavill, 2002). This translates to an iron requirement of 20-30 mg per day, which is delivered 
by TF. Almost 80% of circulating TBI is redirected to the bone marrow erythroblasts (Hentze 
et al., 2004). In order for TBI to gain access to the specific cells in which iron is required, a 
process of receptor-mediated endocytosis of the TF-Fe complex is achieved by means of 
binding to specific receptors on the cell membrane, TFR1 and TFR2. Proteins illustrated in 
Figure 1.4 will be discussed further. 
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Figure 1.4 Systemic iron homeostasis. 
Ferric iron binds to apo-transferrin in the plasma. The diferric transferrin then binds to TFR1 (or TFR2 in the 
hepatocyte cells of the liver) and is internalized via receptor-mediated endocytosis. HFE can compete for 
binding to TFR1 or TFR2 and subsequently decrease the amount of TBI imported into the cell. A proton pump 
on the endosomal membrane lowers the pH of the organelle in order to facilitate the release of Fe3+. Within 
the endosome, STEAP3 reduces Fe3+ to Fe2+. DMT1 then transports Fe2+ into the cytoplasm where it can be 
stored in ferritin or transported out of the cell by FPN1. TFR1-apo-TF complexes are returned to the cell 
surface and recycled for further cellular iron uptake. CP oxidizes Fe2+ to Fe3+ and facilitates binding to apo-TF. 
Abbreviations: ATP, adenosine triphosphate; CP, ceruloplasmin; DMT1, divalent metal transporter 1; Fe3+, 
ferric iron; Fe2+, ferrous iron; FPN1, ferroportin 1; H+, hydrogen ion; HFE, haemochromatosis; STEAP3, six-
transmembrane epithelial antigen of the prostate 3; TBI, transferrin-bound iron; TF, transferrin; TFR1, 
transferrin receptor 1; TFR2, transferrin receptor 2. 
 
Adapted from Lieu et al. (2001). 
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1.1.6.1 Proteins Involved in Systemic Iron Transport and Cellular Iron Uptake 
Transferrin (TF) 
As mentioned previously, TF is the major iron transport molecule in the blood plasma of 
humans. It is responsible for the transport of iron from sites of iron absorption or haem 
degradation to those of iron storage and utilization (Ponka et al., 1998). As well as TF, other 
members of the family of transferrin proteins have been identified in physiological fluids of 
almost all vertebrates studied (Crichton, 2009). The TF family was first recognized during the 
discovery of a transferrin in egg white, ovotransferrin, in 1900 (Osborne and Campbell, 1900 
as reviewed by Montreuil et al., 1997). The subsequent elucidation of an antimicrobial 
function for TF occurred almost 50 years later (Alderton et al., 1946 as reviewed by 
Crichton, 2009). All transferrins have been shown to demonstrate a potent antimicrobial 
effect – due, indirectly, to the deprivation of iron from invading pathogens by the iron-
binding capacity of TF. 
All TF family members are monomeric glycoproteins with a molecular weight of 
around 80 kDa. The TF family is divided into classes based on the function and location of 
the protein in question. They can reversibly bind two atoms of Fe3+ with concurrent binding 
of two anions, usually bicarbonate. In order for the bound iron to be released, acidification 
must occur as a result of a decrease in the pH of the surrounding fluids (Eckenroth et al., 
2011). Characteristically, TF is comprised of two globular protein domains, one at the N-
terminus and the other at the C-terminus (Bailey et al., 1988). Each of these lobes is 330 
amino acids in length and has identical iron-binding capacity and a very similar fold 
structure. The N-lobe and the C-lobe are joined together by a three-turn α-helix. The same 
structure has been confirmed for every member of the TF family in which X-ray 
crystallography studies have been performed (Anderson et al., 1990). 
 
The process of serum TF (sTF) binding to Fe3+ is facilitated by the plasma ferroxidase, CP, in 
cellular iron uptake; and the membrane-bound homologue, HEPH, during intestinal iron 
mobilization (see Section 1.1.5.1). It is however, unknown whether these ferroxidases 
interact with TF directly or not. In vivo, TF has been shown to exist in three different states: 
iron-free (apo-transferrin), one iron molecule bound (monoferric transferrin) and two iron 
molecules bound (diferric transferrin) (Bou-Abdallah, 2012). CP and HEPH oxidize Fe2+ to 
Fe3+ in order to permit iron binding to apo-TF and the subsequent protein conformational 
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change resulting in the generation of monoferric-TF or diferric-TF. This ligand-induced 
conformational change in TF upon iron binding was first demonstrated with studies on 
human apo-lactotransferrin (Anderson et al., 1990). 
Cellular uptake of diferric-TF takes place upon binding of TF to transferrin receptors 
on the cellular membranes of target cells (described below). Within the cell, Fe3+ is released 
from TF in a pH-dependent manner. It is thought that acidification of the endosome (to a pH 
of 5.5) and subsequent protonation of the bicarbonate anion, results in destabilization of 
the TF protein structure and the release of the iron molecules (Bali and Aisen, 1991). 
Numerous studies with labelled TF have revealed that the half-life of the TF molecule is 
much longer than that of TBI (7.6 days vs 1.7 hours) indicating that whilst iron is rapidly 
removed from the circulation, apo-TF is recycled and utilized in upwards of 100 iron 
transport cycles before degradation occurs (Dautry-Varsat et al., 1983; Yamashiro et al., 
1984). 
 
The gene for TF is comprised of 17 exons and is localized to chromosome 3q22.1. Defects in 
this gene cause atransferrinemia (ATRAF), a rare autosomal recessive disorder resulting in 
iron overload and hypochromic anaemia. It has been proposed by Park and colleagues 
(1985) that the present day genes for the TF family arose from gene duplication and fusion 
events more than 580 million years ago (Lambert et al., 2005). The hypothesis is based on 
the fact that the two lobes of the TF polypeptide show almost identical structure, and each 
is transcribed from seven homologous pairs of exons within the gene. 
 
Lactotransferrin (LTF) 
Lactoferrin or lactotransferrin (LTF) is a member of the TF family of proteins and has the 
same characteristic two-lobed structure of other transferrins. However, LTF is distinct from 
other members of the TF family with regard to function due to its higher isoelectric point 
and an increased iron-binding affinity (Pakdaman et al., 1998). In contrast to TF, LTF does 
not release bound-iron in the presence of an acidic pH. In humans, LTF is expressed in milk, 
and in secretions such as tears and saliva. It is also secreted at high levels by neutrophils, 
abundant white blood cells in mammals that form an integral part of the innate immune 
system (Metz-Boutigue et al., 1984). Receptors for LTF have been identified on the brush-
border membrane of foetal enterocytes (Kawakami and Lönnerdal, 1991) which has led to 
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speculation that LTF may form part of an integral alternative mechanism of iron uptake in 
early postnatal stages (Lopez et al., 2006). 
In adults, however, it appears as if the primary biological function of LTF is not as a regulator 
of iron homeostasis. Studies in mice have demonstrated that when the LTF gene is 
disrupted, no noticeable effect on relevant iron parameters or levels was observed (Ward et 
al., 2003). Whilst TF is responsible for the transport of Fe3+ into the cytosol of proliferative 
cells, LTF is believed to act as a molecular “iron scavenger” thereby sequestering iron from 
invading microorganisms and proliferating tumour cells that require elevated levels of iron 
for growth and survival (Aguila et al., 2001). The high affinity of LTF for iron provides indirect 
evidence for its principle biological role as an inhibitor of bacterial growth, tumour 
development and free radical formation. In addition to the indirect antimicrobial effects 
mentioned, LTF also contains a bactericidal peptide-binding sequence, which is distinct from 
iron-binding regions, in the N-terminus (Bellamy et al., 1992). 
 
The LTF gene is located on chromosome 3p21.31 and spans a genomic region of ~30 kb. LTF 
comprises 17 coding exons and, like TF, is thought to have arisen from a gene duplication 
event (Seyfert et al., 1994). 
 
Transferrin receptor 1 (TFR1) and Transferrin receptor 2 (TFR2) 
In all actively dividing mammalian cells, uptake of TBI is mediated by the presence of 
transferrin receptors (TFRs) on the cell membrane. Currently two TFRs have been identified; 
transferrin receptor 1 (TFR1) and transferrin receptor 2 (TFR2). Both TFRs are homodimeric 
membrane-bound glycoproteins which are able to bind to diferric-TF thereby permitting the 
cellular uptake of iron. 
 TFR1 was the first of the TFRs to be identified and has since been extensively 
characterized (Cheng et al., 2004). TFR1 is comprised of two identical subunits of 90 000 kDa 
linked by disulfide bridges. It possesses a single cytoplasmic domain, one transmembrane 
domain and a large extracellular domain. It is ubiquitously expressed in all proliferative cells 
of the human body, and particularly in erythroid precursor cells which have a high demand 
for iron for haemoglobin synthesis (Cavill, 2002). 
A second TFR, TFR2, was identified by Kawabata and colleagues in 1999. TFR2 shares 
significant sequence similarity with TFR1 and is also able to mediate cellular uptake of 
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diferric-TF. Unlike the universal expression of TFR1, the tissue distribution and expression 
pattern of TFR2 is markedly different (Deaglio et al., 2002). It is transcribed only by cells of 
the liver, erythroid precursors and to a lesser extent, by cells of the spleen, lungs and 
muscles. The affinity of TFR2 for TBI is also 30-fold lower than that of TFR1 (Kawabata et al., 
2000; West et al., 2000). Unlike TFR1, expression of TFR2 is not regulated by the IRE/IRP 
system (described below in Section 1.1.7) or by cellular iron levels. The TFR2 hepatocyte 
mRNA levels in mice fed an iron deficient, normal or iron overloaded diet showed no 
difference (Fleming et al., 2000). It is thought that disruptions in TFR2 contribute toward the 
often observed phenomenon of iron loading observed in the liver in disorders of iron 
metabolism (Fleming et al., 2000). 
 
The process of TBI iron uptake takes place via a receptor-mediated endocytosis mechanism 
(Ponka et al., 1998). In the plasma, Fe3+ is loaded onto TF, which is then able to interact and 
bind with TFR on the target cell membrane. TFRs do not recognize iron-free apo-TF and 
preferentially bind to diferric-TF. Upon binding of the ligand to TFR, the complex localizes to 
a clathrin-coated pit and is internalized via endocytosis. The endosome containing the TFR-
TF complex is then acidified by means of an ATPase proton pump; the resulting decrease in 
pH aids in the release of iron from the complex during a protein conformational change 
(Eckenroth et al., 2011). Within the endosome, Fe3+ is reduced to Fe2+ by STEAP3 and 
transported into the cytosol by DMT1 on the endosomal membrane (Gkouvatsos et al., 
2012). The iron-free TFR-TF complex is recycled back to the cell membrane where the 
external physiological pH of 7.4 results in the liberation of apo-TF which is free to chelate 
more iron (Eckenroth et al., 2011). 
 
The gene encoding TFR1, TFRC, is located on chromosome 3q29 and is ~50 kb in length. 
TFRC contains 19 coding exons, with exons 17-19 encoding residues essential for TF binding 
to occur (Evans and Kemp, 1997). TFR2 is encoded by the TFR2 gene on chromosome 
7q22.1. Nine mutations in TFR2 have been linked to the recessive disorder hereditary 
haemochromatosis type III (HH-III). It is also comprised of 19 exons and spans a genomic 
region of 22 kb (Fleming et al., 2002). 
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Six-transmembrane epithelial antigen of the prostate 3 (STEAP3) 
After initiation of the TFR-TF cycle of cellular iron uptake, inorganic iron is released within 
the endosome in the presence of an acidic environment. This is then reduced to Fe2+ by the 
ferrireductase enzyme, six-transmembrane epithelial antigen of the prostate 3 (STEAP3), 
permitting transport of Fe2+ across the endosomal membrane by DMT1. STEAP3 was 
discovered by positional cloning in iron-deficient anaemic nm1054 mice (Ohgami et al., 
2005a; Ohgami et al., 2005b). It is a member of a unique family of transmembrane 
ferrireductases containing a C-terminal domain comprised of six transmembrane helices. 
The reduction activity of STEAP3 is thought to occur via sequential electron transfer from 
NADPH to endosomal Fe3+ in association with intramembrane haem and flavin derivatives 
(Sendamarai et al., 2008). 
 Human STEAP3 was mapped to chromosome 2q14.2 and is comprised of six exons 
coding for a 498 amino acid protein (Korkmaz et al., 2002). Korkmaz and colleagues cloned 
STEAP3 in the process of discovering differentially expressed genes in a prostate cancer cell 
line. They named it six transmembrane protein of prostate 1 (STAMP1) and demonstrated 
that it is highly expressed in epithelial tissues of the human prostate gland. They attributed 
a secretory or endocytic trafficking role to the STAMP1 protein. This same gene was later 
reclassified as STEAP3 during work by the Ohgami research group on nm1504 mice mutants. 
 
1.1.6.2 Regulation of Systemic Iron Homeostasis Cellular Iron Uptake 
At organism level, the regulation of iron balance is an essential process in order to ensure 
the availability of iron to meet body requirements, without the associated risk of toxicity as 
a consequence of excess iron. The regulation of systemic iron levels is reflected by iron entry 
into the plasma in response to the iron status of peripheral tissues that are distinct from the 
intestinal mucosa (Anderson et al., 2007). Various external signals such as hypoxia and 
inflammation are known to regulate the amount of iron absorbed by cells from the plasma. 
With regard to low levels of intracellular oxygen (hypoxia), iron absorption is increased, 
probably as a result of decreased erythropoiesis as a consequence of tissue hypoxia (Pak et 
al., 2006). In the case of inflammation, cytokines mediate the reduction of iron export from 
cells by regulating the synthesis of the peptide hormone hepcidin (Nicolas et al., 2002) 
(discussed in Section 1.1.6.2.1 below). The rate of erythropoiesis is the driving force behind 
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systemic iron regulation due to the large amount of iron required for haemoglobin synthesis 
in developing red blood cells (Cavill, 2002). 
 
1.1.6.2.1 Proteins Involved in Regulation of Systemic Iron Homeostasis 
Haemochromatosis (HFE) 
The haemochromatosis protein, HFE, is a 348 amino acid type I transmembrane 
glycoprotein which is homologous to members of the class I major histocompatibility 
complex (MHC) (Lebrón and Bjorkman, 1999). It is known to form complexes with the light 
chain of β2-microglobulin for cell surface expression. Unlike other class I MHC molecules 
HFE is unable to bind peptide antigens and has demonstrated no known role within the 
immune system (Lebron et al., 1998). This is postulated to be due to a narrow peptide 
binding groove. The HFE protein is composed of three distinct domains; an extracellular 
domain (α1, α2 and α3 loops), a transmembrane domain and a cytoplasmic tail. 
 With regard to regulation of iron homeostasis, HFE competes with TF for binding to 
the transferrin receptors, TFR1 and TFR2, thereby reducing the affinity of TFRs for diferric-TF 
and subsequently decreasing the levels of iron absorbed by peripheral tissues (Figure 1.4) 
(Parkkila et al., 1997; Gross et al., 1998; Waheed et al., 1999). The decrease of TFR1 affinity 
for TBI in the presence of HFE is thought to be as high as 5-10 fold (Feder et al., 1998). The α 
helices 1 and 2 of HFE, and the helical domain of TFR1 are principally responsible for the 
interaction of the two proteins in a pH dependant manner. Diferric-TF can displace HFE from 
TFR1 because they both compete for overlapping binding sites on TFR1. TFR2 has also been 
implicated in HFE binding and is thought to compete with TFR1 in this regard, although the 
protein domains involved are different (Goswami and Andrews, 2006). Unlike TFR1, TFR2 
has the ability to bind HFE and diferric-TF simultaneously which may suggest a role as an 
iron-sensing molecule for TFR2 (Gao et al., 2009). Evidence for the role of HFE as a regulator 
of hepcidin expression has been inferred from experiments in which patients with HFE 
mutations have unexplained low levels of urinary hepcidin in relation to overall body iron 
status (Bridle et al., 2003). Mouse models with targeted disruptions of HFE also 
demonstrate decreased hepcidin mRNA levels in liver tissues (Nicolas et al., 2003). 
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The HFE gene was initially mapped to chromosome 6 in 1976 (Simon et al., 1976) but it was 
not until 1996 that Feder and his team localized it to 6p21.3 using a positional cloning 
strategy. HFE consists of seven exons and spans 11 kb. Mutations in HFE are responsible for 
the primary cause of iron overload in individuals of Northern European descent, hereditary 
haemochromatosis type I (HH-I). The main causative polymorphisms are C282Y and H63D. 
C282Y occurs at nucleotide position 845 which corresponds to the α3 domain of HFE and 
results in disruption of the β2-microglobulin interaction and subsequent misfolding of HFE 
(Feder et al., 1996). Homozygosity for C282Y occurs in more than 90% of HH cases, whereas 
H63D is only identified in 4.5% of HH individuals but occurs frequently in the heterozygous 
state with C282Y (Merryweather-Clarke et al., 1997). 
 
Hepcidin (HAMP) 
Hepcidin is a circulating antimicrobial peptide hormone that is the major regulator of 
systemic iron balance and controls cellular iron export into the plasma (Ganz, 2005). It is 
produced primarily by the liver and was discovered by accident during an experiment in 
mice in which an attempt was made to knock-out an adjacent gene (Nicolas et al., 2001). It 
is a member of the defensin family of proteins and shows high sequence conservation 
between different species (Ganz, 1999). The biologically active isoform of hepcidin is a 25 
amino acid β-sheet hairpin peptide processed from preprohepcidin, an 84 amino acid 
precursor molecule. Only this form of hepcidin demonstrates iron regulatory activity and 
was the first variety to be identified in human urine and plasma (Krause et al., 2000; Park et 
al., 2001). 
 The biological mechanism whereby hepcidin influences regulation of iron 
homeostasis is through an interaction with FPN1, the only known mammalian cellular 
exporter of iron. As previously mentioned (Section 1.1.5.1), FPN1 facilitates the efflux of Fe2+ 
out of the cytosol and into the plasma. Hepcidin is able to bind directly to FPN1 on the 
cellular basolateral membrane where it results in the internalisation and degradation of 
FPN1 (Figure 1.5 A). In response to hepcidin binding, FPN1 is phosphorylated and 
internalized, followed by ubiquitination and trafficking to the lysosome for degradation (De 
Domenico et al., 2007). An inverse relationship exists between levels of hepcidin and FPN1: 
when hepcidin levels are high, the rate of FPN1 degradation exceeds its rate of synthesis 
and it is lost from the cell membranes resulting in internal sequestration of iron within 
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enterocytes, macrophages and hepatocytes; when hepcidin levels decrease, FPN1 is able to 
export iron to the plasma with a subsequent decrease in cellular iron stores (Falzacappa and 
Muckenthaler, 2005). 
Hepcidin expression is known to be regulated by the same factors that control 
overall systemic iron homeostasis; levels are increased in response to high serum iron, iron 
overload and inflammation. In response to iron deficiency, hypoxia or elevated 
erythropoiesis rates the expression of hepcidin is diminished (Figure 1.5 B) (Papanikolaou 
and Pantopoulos, 2005). Hepcidin is therefore a negative regulator of body iron 
homeostasis. In addition, hepcidin is positively regulated under normal conditions by 
signalling through the bone morphogenetic proteins (BMPs) and the SMAD4 pathway which 
activates hepcidin expression (Babitt et al., 2007). 
Hepcidin is transcribed from the hepcidin antimicrobial peptide (HAMP) gene located 
on chromosome 19q13.1. The HAMP gene consists of only three exons (Krause et al., 2000), 
of which exon 3 encodes the active peptide, which contains a unique 17-residue stretch with 
eight cysteine residues which stabilize the peptide (Hunter et al., 2002). Mutations of this 
gene have been linked to a severe form of HH, juvenile haemochromatosis or HH type II 
(Merryweather-Clarke et al., 2003). 
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Figure 1.5 Hepcidin – regulator of iron homeostasis. 
A.) Binding of hepcidin to FPN1 on the cell surface results in its lysosomal internalization and degradation. A 
subsequent decrease in Fe2+ efflux is observed. B.) Erythropoiesis requirements, hypoxia or a reduction in body 
iron stores results in decreased levels of plasma hepcidin and increased dietary iron absorption and iron efflux 
from macrophages. Iron overload or inflammation result in increased levels of plasma hepcidin with ensuing 
inhibition of dietary iron absorption and iron release from macrophages. 
Abbreviations: Fe2+, ferrous iron; FPN1, ferroportin 1. 
 
Part A adapted from Andrews (2008); part B adapted from Papanikolaou and Pantopoulos (2005). 
 
Hemojuvelin (HJV) 
Hemojuvelin (HJV) is a C-terminal GPI-anchored protein which acts as a co-receptor for BMP 
with ensuing regulation of hepcidin expression via the BMP-SMAD4 signalling cascade 
(Casanovas et al., 2009). HJV can present in either the membrane-bound, GPI-anchored 
form or as a soluble molecule (sHJV) (Lin et al., 2008). HJV contains a number of functional 
sequence motifs including a signal peptide, an arginine-glycine-aspartic acid (RGD) motif and 
a partial von Willebrand factor type D domain (Papanikolaou et al., 2004). It shares over 
50% amino acid identity with members of the repulsive guidance molecule (RGM) family, 
which are known to act as co-receptors for enhanced BMP signalling (Babitt et al., 2006). 
Tissue expression of HJV is similar to that of hepcidin and occurs principally in cells of the 
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liver, skeletal muscle and heart. It has also been identified to a lesser degree in the pancreas 
and lungs (Papanikolaou et al., 2004). It appears as though the physiological location of HJV 
action is the liver, despite high expression patterns in skeletal muscle, as evidenced by 
recent work on murine HJV (Chen et al., 2011). 
 HJV binds to type I BMP receptors (BMPR) thereby amplifying the signal produced by 
BMP binding. It can also enhance phosphorylatation of SMAD in conjunction with BMP 
resulting in elevated hepcidin expression (Figure 1.6). The physiological role that HJV plays 
in hepcidin regulation was demonstrated by parallel research carried out by two 
independent groups (Wang et al., 2005; Babitt et al., 2006). Wang and colleagues 
inactivated SMAD4 and observed a dramatic haemochromatosis phenotype, similar to that 
observed in hepcidin-knockout mice. Babitt’s group studied HJV and showed that treating 
hepatocytes with BMP in the presence of SMAD and HJV increased hepcidin expression. It is 
thought likely that SMAD4 binds directly to recognition sequences in the hepcidin promoter 
after activation by BMP. HJV therefore functions as a positive regulator of hepcidin 
expression. In contrast, it has been proposed that sHJV acts as an antagonist of GPI-
anchored HJV by suppressing the mRNA expression of hepcidin (Figure 1.6) (Lin et al., 2005). 
 
The 426 amino acid protein HJV is transcribed from the haemochromatosis 2 (HFE2) gene on 
chromosome 1q21.1 (Papanikolaou et al., 2004). It was first identified with a positional 
cloning approach during studies on juvenile haemochromatosis (Papanikolaou et al., 2004). 
HFE2 is comprised of four coding exons covering a 4 kb region. Five differentially spliced 
gene transcripts of HFE2 have been identified (Severyn and Rotwein, 2010). More than 20 
different mutations in HFE2 have been described which lead to the development of juvenile 
HH (HH-II) due to perturbation of hepcidin expression (Niederkofler et al., 2005). The same 
phenotype is observed in patients with mutations in the HAMP gene (Papanikolaou et al., 
2004). 
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Figure 1.6 Regulation of hepcidin expression by hemojuvelin. 
Cell surface BMPRs are activated by binding to BMPs with membrane-bound HJV acting as a co-receptor and 
increasing the binding efficiency. Activated BMPRs phosphorylate R-SMAD4 which forms a dimer with SMAD4. 
The R-SMAD4-SMAD4 heterodimer relocates to the nucleus where it binds to nucleotide recognition sites on 
the HAMP promoter and induces elevated hepcidin expression. sHJV has the ability to bind to BMP and inhibit 
the activation of BMPR resulting in lower levels of downstream hepcidin expression. 
Abbreviations: 5’, five prime; BMP, bone morphogenetic protein; BMPR, bone morphogenetic protein 
receptor; HAMP, hepcidin antimicrobial peptide gene; HJV, hemojuvelin; sHJV, soluble hemojuvelin; P, 
phosphate group; R-SMAD4, SMAD4 receptor. 
 
Adapted from De Domenico et al. (2008). 
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1.1.7 Post-transcriptional Control of Iron Homeostasis 
Overall, iron homeostasis is largely regulated at the level of protein synthesis instead of at 
the level of mRNA synthesis (Meyron-Holtz et al., 2004). This post-transcriptional regulation 
is mediated by repressors and enhancers in mammalian iron transcribing mRNAs during 
translation (Johansson and Theil, 2002). These mRNA regulatory recognition sites are 
located in noncoding, untranslated regions (UTRs), either upstream (5’) or downstream (3’) 
of the coding component. Regulatory sequences in the 5’UTR are primarily associated with 
translation initiation, and those situated in the 3’UTR are involved in mRNA turnover by 
influencing stability and degradation (Pantopoulos, 2004). In mammals, two iron regulated 
proteins have been identified; IRP1 and IRP2 (Rouault et al., 1987; Leibald and Munro, 
1988). 
 
Iron regulatory protein 1 (IRP1) and iron regulatory protein 2 (IRP2) 
Iron regulatory protein 1 (IRP1) and iron regulatory protein 2 (IRP2) are cytosolic RNA 
binding proteins. They recognize, and bind to, specific nucleotide sequences in the UTRs of 
mRNA, iron responsive elements (IREs). Several proteins of the iron metabolism pathway 
are encoded for by mRNAs which contain IREs, which form phylogenetically conserved 
hairpin structures to which the IRPs bind (Johansson and Theil, 2002). IREs are usually ~30 
bp in length and form a characteristic 5’-CAGUGN-3’ loop and a stem of moderate stability 
(Pantopoulos, 2004). 
 IRP1 and IRP2 are homologous proteins of the iron-sulphur cluster family of 
isomerases. They share ~70% sequence similarity with each other and are 889 and 963 
amino acids in length respectively. During conditions of sufficient iron, IRP1 is bound by an 
iron-sulphur cluster consisting of four atoms each of Fe and S (4FE-4S). The presence of this 
cluster renders IRP1 unable to bind to IREs and it also facilitates the conversion of IRP1 into 
a cytosolic aconitase enzyme (Figure 1.7) (Rouault, 2006; Wallander et al., 2006; Recalcati et 
al., 2010). IRP1 therefore has dual functions in both iron homeostasis and in the control of 
redox potential by promoting the formation of cytosolic NADPH. 
Under conditions of cellular iron deprivation, the 4Fe-4S cluster is disassembled and 
IRP1 regains IRE-binding activity. The removal of the Fe-S cluster is also induced by stimuli 
such as hydrogen peroxide (H2O2) and nitric oxide (NO) implicating IRP1 in the inflammatory 
pathway during ROS formation (Cairo and Pietrangelo, 2000). IRP2 synthesis is triggered 
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during times of iron depletion and it remains stable and able to bind to IREs under hypoxic 
conditions. Unlike IRP1, IRP2 undergoes proteosomal degradation when cells are iron 
replete (Figure 1.7). 
 
IREs in the 5’UTR have been identified in H- and L-ferritin and FPN1 which show decreased 
expression in times of iron starvation due to IRP binding (Beaumont, 2010). As a 
consequence, cells minimize iron efflux via FPN1 and also enhance iron bioavailability by 
lowering the levels of iron sequestration by ferritin (Gkouvatsos et al., 2012). In the 3’UTR, 
an IRE has been found in two isoforms of DMT1 (Gunshin et al., 1997) and there are five 3’ 
IREs in TFR1 (Hentze and Kühn, 1996). IRP binding to these IREs results in stabilization of the 
DMT1 and TFR1 mRNAs with ensuing cellular iron uptake and transport via these proteins 
under iron deficient conditions. Targeted disruption of the IRP/IRE system is lethal in early 
embryonic development (Smith et al., 2006), indicating the importance of this regulatory 
mechanism in sustaining life. 
 
IRP1 is encoded for by the aconitase 1 (ACO1) gene on chromosome 9. ACO1 has 21 exons 
spanning a genomic region of 3.5 kb (Kühn, 1998). The 963 residue IRP2 protein is 
transcribed from the iron regulatory binding protein 2 (IREB2) gene localized to 
chromosome 15 (Guo et al., 1995). IREB2 covers 6.3 kb and contains 22 exons. Both genes 
are hypothesized to have arisen from a gene duplication event (Wang, 2011). 
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Figure 1.7 IRP/IRE mechanism of post-transcriptional regulation. 
Under iron sufficient conditions, IRPs have intact iron-sulphur clusters and function as enzymes during redox 
reactions. However, under iron deficient conditions, the iron-sulphur cluster is lost from the IRP allowing it to 
function as a RNA-binding protein. IRPs bind to specific nucleotide sequences called IREs on the mRNA. The 
binding of an IRP to an IRE located in the 5’UTR of a mRNAs results in translation inhibition. In contrast, the 
binding of an IRP to a 3’UTR IRE ensures increased translation due to the protection of the mRNA from possible 
degradation. 
Abbreviations: 3’, three prime; 5’, five prime; IRE, iron responsive element; IRP, iron regulatory protein; 
mRNA, messenger RNA; UTR, untranslated region. 
 
Adapted from Banerjee et al. (2011). 
 
 
 
 
 
Stellenbosch University http://scholar.sun.ac.za
CHAPTER ONE: Literature Review 
30 
 
1.1.8 Disorders of Iron Metabolism 
The profound effect of disordered iron homeostasis has been recognized, if not fully 
understood, for centuries. Disorders of iron metabolism were some of the earliest described 
human conditions and were often treated with iron supplementation (Sheftel et al., 2012). 
In recent years, the understanding of iron pathophysiology has improved enormously with 
modern molecular and genetic tools utilized to elucidate the molecular basis for disruptions 
of iron metabolism. Studies on mutant mice, rats, zebrafish and humans presenting with 
inherited disorders of iron metabolism have been enormously beneficial in the identification 
of novel iron transport proteins (Andrews, 2000). Disorders of iron homeostasis can be 
classed broadly into those that result in an overload phenotype, and those demonstrating 
an iron deficiency phenotype. 
 
1.1.8.1 Iron Overload 
Iron overload disorders are characterized by the progressive tissue and organ damage as a 
direct result of the accumulation of intracellular iron stores (Turlin and Deugnier, 2002). The 
accrual of excess iron leads to the generation of ROS which damage cellular structures and 
ultimately, result in organ failure if left untreated (Deugnier et al., 2008). Only the most 
common and well described cause of iron overload, hereditary haemochromatosis, will be 
discussed here. However, other primary causes of iron overload are well established; 
aceruloplasminaemia (defects in the CP gene resulting in iron deposition in tissues of the 
CNS), atransferrinaemia (parenchymal iron overload caused by mutations in the TF gene) 
and Friedreich’s ataxia (a class of syndromes characterized by iron accumulation in specific 
cellular compartments) (reviewed by Kushner et al., 2001). Secondary iron overload is also 
observed in individuals with various haematological disorders such as β-thalassaemia, sickle 
cell disease and red cell deficiencies (Nemeth and Ganz, 2006). 
 
Hereditary Haemochromatosis (HH) 
The German pathologist Friedrich Daniel von Recklinghausen (1889) was the first to use the 
term “haemochromatose” to describe the bronze-like appearance of the organs of a 
diabetic patient upon autopsy (as reviewed by Pietrangelo, 2006). It is now known that the 
characteristic hyperpigmentation of the skin and internal organs occurs as a result of the 
genetic disorder, hereditary haemochromatosis (HH). HH is an inherited family of disorders 
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with numerous subtypes that are all characterized by a hereditary origin (usually autosomal 
recessive), progressively elevated transferrin saturation levels from the normal ~30% to 
complete saturation, parenchymal iron deposits in endocrine tissues, heart and liver and no 
noticeable effect on the rate of red blood cell synthesis (Pietrangelo, 2006). In recent years, 
it has been shown that all subtypes of HH are characterized by inappropriately low levels of 
hepcidin expression, which results in unrestricted activity of the iron exporter, FPN1. The 
downstream effects of unrestricted iron efflux are increased sTF saturation and serum 
ferritin levels, which are the prognostic indicators for HH diagnosis. 
 The most prevalent form of HH, HH type 1, results from genetic defects in the HFE 
gene (Feder et al., 1996). It occurs at a frequency of ~1 in 200 individuals from North 
European descent. The most common genetic mutations associated with HH-I are the C282Y 
(substitution of a Cys for a Tyr resulting from a G to A base change at position 845) and 
H63D (Waheed et al., 1999). The mechanism underlying C282Y pathogenesis has been 
described and is attributed to the disruption of a disulphide bond in HFE, preventing 
association with β2-microglobullin and TFR1 interaction (Feder et al., 1997, Waheed et al., 
1999). The molecular effects of H63D are not yet fully understood as it does not impede HFE 
associations or expression (Waheed et al., 1999). 
 In addition to classic HH-I, three other subtypes of HH have been described and have 
assisted further understanding of iron metabolism and regulation (Roetto and Camaschella, 
2004). 
Juvenile HH (type 2, HH-II) is rare in relation to HH-I but presents at an earlier age 
and with a much more severe iron overload phenotype. Causative mutations are usually in 
the HFE2 (Papanikolaou et al., 2004) and HAMP (Roetto et al., 2003) genes. Hepcidin 
expression is severely impaired in HH-II patients with subsequent excessive iron overload via 
impairment of the FPN1 inhibition. 
Mutations in the TFR2 gene lead to development of the third HH subtype, type 3 
(HH-III). The prevalence of HH-III is low compared to the other subtypes and was initially 
diagnosed in two Sicilian families (Camaschella et al., 2000). The majority of TFR2 mutations 
are identified in the heterozygous state and their functional effects have yet to be 
described. HH-III symptoms and severity parallel those of HH-I, however, the age of onset is 
similar to that of HH-II presenting in younger individuals. 
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Type 4 HH (HH-IV) is also called ferroportin disease type B and is caused by relatively 
rare mutations in the SLC40A1 gene that transcribes FPN1. Unlike the other HH subtypes, 
HH-IV is inherited in an autosomal dominant pattern and patients present with a typical 
haemochromatosis phenotype (Sham et al., 2005). 
 
Treatment of HH-related iron overload begins after correct diagnosis and classification of 
the molecular basis of the observed phenotype. Advances in genetic testing techniques and 
imaging technologies allow for the accurate non-invasive determination of HH subtype. 
Traditional therapeutic phlebotomy is the treatment method of choice for HH (Pietrangelo, 
2006). Generally, 400-500 ml of whole blood is removed weekly until serum ferritin levels 
stabilize at ~30 µg/L and TF saturation is decreased to below 30%. Following this, 
maintenance therapy is continued by removing 1-2 L of blood each year in order to sustain 
normal physiological iron levels (Hicken et al., 2003). Phlebotomy therapy is highly effective 
in the management of iron overload symptoms however, it has little or no effect if started 
once organ impairment has developed, once again highlighting the importance of accurate 
and early disease diagnosis. In some cases treatment with iron chelators is indicated, 
especially for HH-IV individuals as weekly phlebotomy is not well tolerated and can result in 
moderate anaemia (Brissot et al., 2011). 
 Research is currently being conducted on the development of specific 
pharmacological mediators which interact with hepcidin in order to increase production in a 
targeted manner. However, the efficacy of these antagonists/agonists remains to be fully 
tested and elucidated in vivo (Pietrangelo, 2010). 
 
1.1.8.2 Iron Deficiency 
Iron deficiency refers to total body iron deficits that occur when the requirement for iron 
(primarily for the production of red blood cells) exceeds the supply of iron from depleted 
stores. 
 
Dietary Iron Deficiency 
Dietary iron deficiency is the most common nutritional disorder afflicting developed 
countries (Stoltzfus, 2003). Despite iron fortification of cereal grain-based foods in most 
industrial nations, internationally it is estimated that 15% of the population suffer from iron 
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deficiency anaemia (Looker et al., 1997; Scholl, 2005). Women, and particularly those who 
have had more than one child, comprise the bulk of iron deficient individuals within a 
population (WHO, 2004). The major cause of body iron deficit is diets based primarily on 
plants, with low haem content, and inhibition of dietary non-haem absorption by high fibre 
contents and other repressors of iron assimilation (Zimmermann and Hurrell, 2007). In 
developing nations, persistent microbial and parasitic infections result in chronic blood loss 
and inflammation. Frequently observed vitamin A deficiencies also contribute to the poor 
absorption of dietary iron (Larocque et al., 2005). 
 Several different stages categorize iron deficiency: latent iron deficiency during 
which all available iron stores are mobilized, although iron parameters may remain within 
normal ranges; iron deficient erythropoiesis occurs when lack of iron severely limits 
haemoglobin production; iron deficiency anaemia (IDA) where functional concentrations of 
haemoglobin decrease and lead to the impairment of oxygen transport and changes in red 
cell morphology (Crichton et al., 2005). 
 Treatment for iron deficient individuals involves administration of oral iron 
supplementation, usually in the form of ferrous salts, and is a simple and cost effective 
strategy (Patterson et al., 2001). 
 
Anaemia of Chronic Disease 
Anaemia of chronic disease (ACD) is the phenotypic opposite of haemochromatosis in many 
respects. ACD is an acquired anaemia second to IDA in prevalence in Western populations 
(Weiss, 2002) and results from chronic immune system activation during infection, cancer, 
autoimmune disorders and organ transplantation. During periods of prolonged 
inflammation or infection, hepcidin production is increased via direct cytokine induction, 
which results in disruptions of intestinal iron absorption and macrophage iron recycling. In 
addition, diminished serum iron is available for erythropoiesis and macrophage 
sequestration of iron is observed (Roy and Andrews, 2005). 
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1.2 TRANSCRIPTIONAL REGULATION OF GENE EXPRESSION 
The cellular environment of an individual organism is in a constant state of flux. The ability 
to co-ordinate the regulation of a complex network of genes is imperative for the growth 
and survival of an organism (Carter et al., 2004). The complexity of gene regulation reflects 
the intricacy of the environment in which the products of transcription fulfil a myriad of 
physiological and functional roles. The molecular control of gene expression allows for 
certain genes to be turned on or off, both spatially and temporally, thereby determining 
tissue specificity and cellular development and growth (Butler and Kadonaga, 2002). 
In eukaryotic organisms the term “gene expression” encompasses a variety of 
distinct mechanisms responsible for co-ordinated control of the genome (Pedersen et al., 
1999). These include: transcription of DNA to RNA; post-transcriptional modification of 
mRNA targets (Lareau et al., 2004); translation of mRNA to protein; post-translational 
processing and modification of protein products; protein folding; epigenetic adjustments 
such a DNA methylation (Jaenish and Bird, 2003) and chromatin remodelling and 
adenylation. Different regulatory mechanisms control each of the processes listed above 
contributing another layer of complexity to the procedure of genetic regulation (Gottesfeld 
et al., 1997; Steger et al., 2003; Mattick et al., 2009). 
 
Transcriptional regulation is the foremost mechanism by which the genome is able to react 
and adapt to cellular changes throughout development and in response to external 
influences (Figure 1.8). Genes are able to react to a cacophony of external stimuli by 
regulating expression levels appropriately. Each coding gene in eukaryotic genomes is 
flanked, both upstream and downstream, by regions of genomic DNA that are untranslated. 
In humans, the amount of this untranslated DNA constitutes ~98% of total genomic content 
(Elgar and Vavouri, 2008). Prior to the advent of modern sequencing technologies, this so 
called “junk” DNA was thought to be largely functionless and it was proposed as a type of 
“molecular scaffold” to simply support the protein coding genes (Carninci et al., 2005). 
However, with the vast amounts of genomic data that have been generated in the years 
following the complete sequencing of the human genome (Venter et al., 2001), it is now 
recognized that these regions are essential for transcriptional regulation. 
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Figure 1.8 Components of transcriptional regulation. 
Trans-acting regulatory factors (Tfs) bind to specific TfBSs located either proximal or distal to the TSS. Groups 
of Tfs can operate together in functional cis-regulatory modules (CRMs) to co-ordinate regulation. Cofactors 
interact with bound Tfs and stabilize the transcription initiation complex assembly to enable regulation of 
transcription initiation and subsequent gene expression. The three-dimensional chromatin structure can 
influence the regulation of expression through interference of Tf-binding. 
Abbreviations: CRM, cis-regulatory module; TF/Tf, transcription factor; TFBS/TfBS, transcription factor binding 
site; TSS, transcription start site. 
 
Reprinted by permission from Macmillan Publishers Ltd: [Nature Reviews Genetics] (Wasserman and Sandelin, 2004), 
copyright (2004). 
 
1.2.1 Promoter Architecture 
The untranslated region upstream (5’UTR) of the coding portion of a gene is responsible for 
mediating the transcription of the gene and contains the promoter region to which RNA 
polymerase binds and is directed to the transcription start site (TSS). Exact promoter 
architecture has proved extremely difficult to define in higher eukaryotes; it may be close to 
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the transcriptional initiation codon (ATG) or it may be many kb away, or even within another 
flanking gene. Generally, however, eukaryotic promoters can de described in three sections: 
the core or basal promoter, to which RNA polymerase II binds, situated about 40 bp 
upstream of the TSS; the proximal promoter region, ~250-500 bp from the TSS and the distal 
promoter, which is classified by promoter elements further upstream (Maston et al., 2006). 
 
The core promoter region is defined as the minimum length of sequence required for 
binding of RNA polymerase and general transcription factors (pre-initiation complex) to 
initiate accurate transcription (Smale and Kadonga, 2003). Many core promoters contain a 
sequence recognized by the transcription machinery, the TATA box, which consists of the 
consensus TATAAAA sequence and directs transcription ~30 bp downstream. It is highly 
conserved in the promoters of eukaryotes, although mismatches are tolerated in numerous 
instances. Another class of genes do not contain a TATA-box (TATA-less promoters) and the 
transcription apparatus is thought to bind to an initiator (Inr) element. TATA-less promoters 
are generally weaker initiators of transcription (Green, 2005). 
Eukaryotes have three different types of RNA polymerases: i) RNA polymerase I 
transcribes genes for ribosomal RNAs, ii) RNA polymerase II (PolII) transcribes genes 
encoding mRNAs (the focus of this study) and iii) RNA polymerase III transcribes genes for 
tRNAs and other small RNA species (Smale and Kadonga, 2003). During in vitro transcription, 
PolII requires the addition of specific auxiliary factors (general Tfs – GTfs) for the initiation of 
transcription. Binding of a subunit of the GTf, TFIID [comprised of the TATA-binding protein 
(TBP) and TBP associated factors (TAFs)] to the TATA box initiates the process of 
transcription by recruiting other GTfs that make up the pre-initiation transcriptional 
complex (Orphanides et al., 1996). 
Transcription mediated by the binding of the pre-initiation assembly to the core 
promoter proceeds at a basal rate which can be greatly enhanced by the action of additional 
factors (Figure 1.8). 
 
1.2.2 Cis-acting Elements: Transcription Factor Binding Sites (TfBSs) 
The mediation of transcription tempo is effected by regulatory sequence elements located 
upstream of the core promoter (Bolouri and Davidson, 2003). Regulation of gene expression 
involves occupancy of cis-regulatory motifs (CRMs) by transcription factors – often by 
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recognition of specific binding site motifs, recruitment of co-activators and co-repressors 
and modifications of the chromatin structure. These specific CRMs are composed of 
multiple binding sites (transcription factor binding sites, TfBSs) for numerous transcription 
factors, therefore acting as “molecular switches”. Groups of genes may contain identical 
sequences for particular cis-motifs, however, the relative importance of specific motifs may 
differ in a tissue- and physiological-dependent manner, thereby indicating that not all TfBSs 
have functional importance in vivo (Li and Johnston, 2001). 
 
In general, TfBSs are composed of consensus recognition sites, 6-25 bp in length, which are 
highly conserved in higher vertebrates (Cooper and Sidow, 2003). The binding of a specific Tf 
to its cognate TfBS in a sequence specific manner results in activation or repression of 
transcription (Jones and Takai, 2001). Initiation of transcription is carried out by enhancers, 
which appear to aid in RNA polymerase II binding and a subsequent increase in 
transcription, above basal levels (Szutorisz et al., 2005). In contrast, repression of 
transcription is mediated by silencers. Several types of silencers have been identified that 
differ on the basis of their mechanism of action. Typically, silencers interfere with positive 
acting Tfs or they result in modification to chromatin structure and intron splicing which 
leads to down regulation of gene transcription (Monsalve et al., 2000). 
 
The importance of the interaction between cis- and trans-acting factors in the regulation of 
transcription is now widely accepted. Numerous elements in the untranslated regions of 
genes, particularly the promoter region, contribute to the overall regulation of gene 
expression with resulting influences on intracellular homeostasis and cell differentiation and 
growth (Chen et al., 2005). 
 
1.2.3 Trans-acting Elements: Transcription Factors (Tfs) 
The regulation of transcription by cis-acting elements is mediated through binding by trans-
acting Tfs (Figure 1.8). A multitude of Tfs have been described (>1400) although not all are 
biologically active in trans-regulation in the UTR of all genes (Dröge and Müller-Hill, 2001). 
The complexity of Tf interaction is illustrated by the fact that out of the ~25 000 genes in the 
human genome, only ~1800 of them encode Tfs, far less than the number of expression 
patterns regulated by Tfs for each gene (Maston et al., 2006). Tfs can be classed as either 
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activators or repressors of transcription depending on interaction with cis-regulatory 
enhancers or silencers respectively. 
 Activator Tfs are characteristically comprised of two protein domains, a DNA binding 
domain and an activator domain. Different classes of activators have been identified and are 
categorized on the basis of structural differences in their DNA binding domains (Scarpulla, 
2002). Examples include those containing homeobox, helix-loop-helix (HLH), basic leucine 
zipper (bZIP) and cysteine rich zinc finger DNA binding domains (Pabo and Sauer, 1992). The 
activator domain is required for recruitment of the pre-initiation complex, thereby 
enhancing relative concentration and promoter-binding. Many activators form hetero- or 
homodimers and binding efficiency is determined by the consensus sequence of the 
corresponding TfBS. Disruptions to TfBS recognition sequences can dramatically alter the 
strength of activator binding, influencing regulatory output (Merika and Orkin, 2003). 
Mutations in numerous TfBSs that result in varied human disorders have been described 
and illustrate the importance of accurate Tf-TfBS association (summarized in Maston et al., 
2006). 
 Tfs that negatively regulate transcription are termed repressors. In comparison to 
activators, little about the mechanism underlying transcriptional inhibition by repressor 
molecules is known. They are postulated to function by a variety of different mechanisms 
including: recruitment to promoters by other proteins without direct promoter-binding, 
disruption of the protein levels of the pre-initiation complex, activators or co-activators and 
direct binding to the activator domain of activator molecules reducing the positive 
interaction with the pre-initiation complex (Gaston and Jayaraman, 2003). 
 
To complicate the matter further, Tfs (whether activators or repressors) are often 
modulated by co-regulators themselves (Figure 1.8). These co-regulators do not possess a 
DNA binding domain, but appear to have functional protein-protein interaction domains and 
mediate activity of Tfs through direct molecular interactions. In this manner, a single Tf can 
act as an activator of expression of one gene and as a repressor of transcription of another 
gene (Spiegelman and Heinrich, 2004). 
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1.2.4 Prediction of regulatory promoter elements 
The biological study of molecular regulatory elements has been conducted for almost 30 
years (Nardone et al., 2004). In recent times, the advent of advanced sequencing 
technologies has led to the deposition of huge amounts of high-quality sequence data into 
publically available databases (Edgar et al., 2002). Traditional genomic research has seen a 
shift toward the interpretation of mechanisms of gene regulation and understanding the 
complexities of the genome (Nardone et al., 2004). 
 
1.2.4.1 In silico promoter analysis 
The development of computational tools for the discovery and identification of regulatory 
elements in non-coding DNA has paralleled the exponential rise in sequencing technologies 
(Wasserman and Sandelin, 2004). This has largely been due to a deficit, in the past, of 
methods with which to analyze sequence data accurately. The burgeoning field of 
bioinformatics and in silico research has been driven by the need to accurately annotate and 
characterize genomic information. In addition, relatively little is understood about the 
regulation of gene expression by the genome as a consequence of limited laboratory 
experiments on non-coding flanking regions of genes (Pastinen and Hudson, 2004). 
 In the years following the sequencing and publication of the human genome, 
numerous projects were started with the goal of investigating the daunting task of 
annotating the functional elements of the genome, further illustrating the importance of 
this field of study. The largest of these is the ENCODE (ENCyclopedia of DNA Elements) 
Project launched by the National Human Genome Research Institute (NHGRI) in 2003 (The 
ENCODE Project Consortium, 2004). The ENCODE project utilizes a combination of 
technologies, including bioinformatic analysis, to identify functional elements. 
 
The computational approach to promoter investigation can be viewed in three parts: i) 
pattern discovery, during which the UTRs of a group of co-regulated genes are examined to 
determine over-represented motifs that are shared among the genes of interest; ii) pattern 
matching, by predicting the location of TfBSs within the given sequence; iii) pattern 
recognition, during which the presence of putative Tfs is inferred from the identified TfBSs 
(van Helden, 2003). 
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 A huge variety of web-based resources are available for bioinformatic investigation 
of genomic data (summarized in Nardone et al., 2004; Wasserman and Sandelin, 2004) using 
different computational algorithms to detect patterns of TfBSs. The degeneracy and short 
recognition sequences for these trans-acting regulatory elements makes their identification 
in sequence data an overwhelming task and has driven the search for new and more 
powerful means of analysis. The most widely used algorithm underlying software 
predication programs is the position weight matrices (PWMs) approach. This is a 
computationally stringent method of scoring motif matches by generating a matrix of score 
values for a substring of fixed length (Das and Dai, 2007). However, other algorithms have 
been developed and are the basis for many other software tools, therefore it is often 
sensible to utilize different programs for data analysis in order to identify a consensus 
result. This approach is advisable as it adds weight to the identification of functional 
elements, as those identified by in silico tools with diverse underlying statistical methods 
may be more functionally relevant (Bulyk, 2003). 
 
Computational analysis of promoters therefore offers a powerful method for uncovering cis- 
and trans-acting factors implicated in promoter regulation of gene expression, and can be 
enormously beneficial in the downstream design of biological experiments. 
 
1.2.4.2 Experimental approaches for identifying regulatory elements 
Experimental validation of promoter regulatory targets identified through an in silico 
approach is crucial in order to assess the functional role that these elements may play. 
Various different in vitro assays are utilized for this purpose. 
 
Reporter gene assays 
In vitro assays using a reporter gene strategy are among the most versatile techniques 
available (Maston et al., 2006). DNA fragments of interest are cloned into a plasmid, 
upstream of a reporter gene, in order to assess the activity of the cloned fragment. Reporter 
genes are numerous, green fluorescent protein (GFP), luciferase or β-galactosidase are all 
examples, and are selected on the basis of the particular assay to be performed (Naylor, 
1999). The selected reporter gene is quantitatively assayed to measure activity (Alam and 
Cook, 1990). Within the plasmid, the precise location of the fragment to be cloned depends 
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on the nature of the functional element. DNA fragments suspected to contain core 
promoter elements may be cloned directly upstream of the reporter gene (promoterless 
constructs) (Figure 1.9 A). Proximal promoter elements are cloned upstream of a weak core 
promoter that drives reporter gene expression at a basal rate and allows for detection of 
transcriptional enhancement (minimal promoter constructs) (Figure 1.9 B). Enhancer and 
silencer activity can also be detected upon assay of reporter gene expression levels in 
plasmids with the appropriate promoters selected (Figure 1.9 C and D). 
 
 
 
Figure 1.9 Functional assays to measure transcriptional regulation. 
A.) In order to assay core promoter activity, the DNA segment of interest (light blue) is cloned into a plasmid 
upstream of a reporter gene that lacks a functional promoter (promoterless construct). B – D.) Proximal 
promoters, enhancers or silencers are cloned upstream of an appropriate promoter to initiate basal 
transcription of the reporter gene. 
Abbreviations: TATA, consensus binding site for the pre-initiation complex; TSS, transcription start site.  
 
Reprinted by permission from Annual Reviews: [Genomics and Human Genetics] (Maston et al., 2006), copyright (2006). 
 
 
 
A. 
B. 
C. 
D. 
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DNaseI hypersensitive site mapping 
DNaseI site mapping is a technique that can be used to identify TfBSs. It is based on the 
principle that chromatin in genomic regions where particular Tfs have bound undergoes a 
structural change, and is more sensitive to digestion with DNaseI than unbound chromatin. 
Mapping of functional regulatory sites by this method has the potential to be a powerful 
tool in the identification of cis-motifs, however it is limited by the fact that it only implies Tf-
binding without actual demonstration of the fact (Crawford et al., 2004). 
 
Chromatin immunoprecipitation (ChIP) assays 
ChIP analysis allows for the detection of DNA sequences bound by proteins and is an ideal 
tool for the discovery of Tf-binding. The technique can detect core promoters and provide 
the possibility of detecting silencers, provided the correct, highly specific antibody for the Tf 
of interest is used (Kim et al., 2005). ChIP has also been modified for use in large-scale 
genome wide analysis of Tf-binding by hybridising the DNA purified during ChIP to a DNA 
microarray (ChIP-chip) (Horak et al., 2002). 
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1.3 MOTIVATION FOR THIS STUDY 
The human genome is a system regulated at many different levels. Transcriptional 
regulation is the first step in the process of gene expression and is governed by the presence 
of specific cis-regulatory regions (cis-motifs), residing within the promoter region of genes, 
and the functional interactions of trans-acting factors (transcription factors-Tfs) and these 
cis-motifs (Maston et al., 2006). Accurate bioinformatic analyses of cis-motif architecture 
combined with experimental validation could offer insights into complex mechanisms 
governing transcriptional regulation, serving as a refined approach for prediction and the 
study of regulatory targets (Venter and Warnich, 2009). 
Understanding gene regulation and the subsequent analysis of cis-motifs in 
promoters can be a demanding endeavour. It is therefore necessary to explore new 
technologies such as the use of various in silico tools to attempt to formulate putative 
predictions on how specific cis-motifs residing in these regions may influence the expression 
patterns of specific genes or groups of genes (Wasserman and Sandelin, 2004). 
To date, little is known about the co-ordinated transcriptional regulation of genes of 
the iron metabolism pathway, other than well established post-transcriptional regulation by 
the IRE/IRP system (Pantopoulos, 2004). Iron is a trace element that is required by almost 
every living organism. It is used in a variety of cellular functions, and as a result, changes in 
iron homeostasis within the body can have important clinical consequences (Hentze et al., 
2010). Disorders of iron metabolism, be they iron overload or iron deficiency, are amongst 
the most prevalent conditions affecting individuals globally (Brissott et al., 2011). A 
combination of factors such as nutrition, environment and genetics play a role in the control 
of iron levels within an individual. As a result, the cellular mechanisms responsible for iron 
transport and homeostasis are worthy of significant investigation, as they have the potential 
to provide future targets for pharmacological intervention thereby benefitting individuals 
afflicted by disorders of iron metabolism (Pietrangelo, 2010). 
The requirement for tight molecular control of iron homeostasis makes this 
particular biochemical pathway an ideal candidate for the proposed proof-of-concept study 
of co-ordinated transcriptional regulation. Results of these experiments would represent a 
unique and comprehensive overview of novel transcriptional control elements of the iron 
metabolism pathway. 
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1.4 AIMS AND OBJECTIVES 
 
1.1.4 Aim 
To extensively investigate and characterize the promoter and upstream untranslated region 
of genes implicated in the iron metabolism biochemical pathway, in order to design a 
strategy for the identification of novel regulatory targets and to contribute toward the 
understanding of the molecular mechanisms of transcriptional regulation. 
 
1.4.2 Objectives 
 Design and establishment of a combinatorial bioinformatic and experimental system for 
the analysis of gene promoters: 
 
1) Bioinformatic promoter analysis 
 Selection of candidate genes involved in the biochemical pathway of iron metabolism 
and homeostasis. 
 Comprehensive in silico analyses of the 5’ untranslated region of the candidate genes 
utilizing a variety of open source prediction software. 
 Identification and characterization of novel transcriptional regulatory targets. 
 
2) Functional promoter analysis 
 Experimental determination of the in vitro validity of the bioinformatic results utilizing a 
functional genetic approach. 
 Isolation and molecular cloning of the identified target promoter elements into reporter 
vectors. 
 Transformation of the reporter constructs into a mammalian in vitro culture system to 
evaluate the transcriptional effects of the promoter elements. 
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Materials and Methods 
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2.1 IN SILICO PROMOTER ANALYSES 
 
2.1.1 Promoter Sequences 
The promoter sequences for 18 of the genes [ACO1 (ENSG00000122729), CP 
(ENSG00000047457), CYBRD1 (ENSG00000071967), FTH1 (ENSG00000167996), FTL 
(ENSG00000087086), HAMP (ENSG00000105697), HEPH (ENSG00000089472), HFE 
(ENSG00000010704), HFE2 (ENSG00000168509), HMOX1 (ENSG00000100292), IREB2 
(ENSG00000136381), LTF (ENSG00000012223), SLC11A2 (ENSG00000110911), SLC40A1 
(ENSG00000138449), STEAP3 (ENSG00000076351), TF (ENSG00000091513), TFRC 
(ENSG00000072274), TFR2 (ENSG00000106327)] involved in the metabolism of iron were 
obtained from the Ensembl database (Flicek et al., 2012). 2000 bp (upstream of the 
initiating ATG) of sequence from the 5’UTR of each gene was utilized for further in silico 
analyses. 
 
2.1.2 Promoter Prediction 
Core promoter prediction of the 5’UTR sequence of the 18 iron metabolism genes (Section 
2.1.1) was performed to confirm that the sequences retrieved from Ensembl contained 
transcription start sites (predominately vertebrate PolII promoters), which are key elements 
of eukaryotic promoter architecture. The 5’UTR sequences were analyzed using the 
Eukaryotic Promoter Database (Schmid et al., 2005), the Promoter 2.0 program (Knudsen, 
1999) and the Neural Network Promoter Prediction program (Reese, 2001). 
 
2.1.3 Pattern Discovery 
The promoter sequences of the genes of interest were submitted to mVISTA (Frazer et al., 
2004) and YASS (Noe and Kucherov, 2005) in order to search for areas of sequence similarity 
between the genes. mVISTA is a set of programs developed for the comparison of DNA 
sequences, up to megabases in length. It provides access to global pairwise, multiple and 
glocal (global with rearrangements) alignment tools. The program determines the percent 
identity between two sequences using a sliding window of predefined length, and displays it 
as a continuous curve. The program also identifies and colours regions of high conservation. 
YASS is a genomic similarity search tool that produces local pairwise alignments. It is a 
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heuristic DNA local alignment software which detects potential similarity regions, and then 
tries to extend them to actual alignments. In contrast to mVISTA, YASS allows only two 
sequences to be inputted at any one time. For this reason, each gene promoter sequence 
was compared individually to each of the others in turn, and the results then compared 
between them. 
 
2.1.4 Pattern Matching 
ClustalW (Thompson et al., 1994) was utilized to generate multiple alignments of the 
regions of similarity in order to prepare a consensus sequence, which was employed in a 
BLASTn search against the nucleotide (nr/nt) collections and Human ALU repeat elements 
databases. 
 
The suite of programs, MEME (Bailey et al., 2006) was utilized to further analyze the 
conserved region (CR) of the gene promoters that was identified in Section 2.1.3. 
 
Motif Discovery 
Initially, MEME (Multiple EM for Motif Elicitation) itself was used to discover repeated, 
ungapped sequence patterns (motifs) that occur in the DNA sequences provided. MEME 
represents motifs as position-dependent letter-probability matrices which describe the 
probability of each possible letter at each position in the pattern. MEME allows the user to 
specify the number of motifs to return in the output. Gaps in motif sequences are not 
allowed, and as such, MEME splits the motifs with variable-length gaps into one or more 
separate motifs. For this reason, it is best to search for motifs with a shorter length than 
that which is specified by the program as default. The parameters used were as follows: 
Distribution of motif occurrences: one motif per sequence; Number of different motifs: 10; 
Minimum motif width: 4; Maximum motif width: 15. 
 
2.1.5 Pattern Recognition 
In silico analysis was performed in order to identify putative transcription factor binding 
sites (TfBSs) within each of the identified motifs in the CR of the gene promoters. Several 
bioinformatic databases are available for in silico analysis of the promoter region, of which 
the following were used in this study: TOMTOM (Gupta et al., 2007), JASPAR CORE (Sandelin 
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et al., 2004) and TRANSFAC®7 (Wingender et al., 2001). From TRANSFAC®7, two programs 
were used, namely PATCH and MATCH™ (v1.0) (Kel et al., 2005). Both JASPAR CORE and 
TRANSFAC®7 contain annotated, matrix-based transcription factor binding site profiles for 
eukaryotic organisms in an open-access database. Experimentally validated sets of 
nucleotide sequences that bind transcription factors (Tfs) form the basis of these profiles. 
The TRANSFAC®7 programs (such as PATCH and MATCH™) use the integrated matrices and 
site sequences in TRANSFAC®7 to perform matrix-or pattern-based searches of factor 
binding sites in regulatory DNA sequences. The default parameters were employed in the 
use of both of these databases. The motifs discovered with MEME were compared to the 
elements of a database of known motifs using TOMTOM. Matching motifs are ranked by q-
value. Motifs were searched against the following databases as specified by TOMTOM: 
JASPAR and UniPROBE, JASPAR CORE vertebrates and All Vertebrates. 
In order to compare the putative TfBSs identified by these databases, another 
program, namely rVISTA (Loots and Ovcharenko, 2004) was also utilized. rVISTA (regulatory 
VISTA) combines searching the major transcription binding site database TRANSFAC 
Professional with a comparative sequence analysis and alignment using the global alignment 
program AVID (Bray et al., 2003). 
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2.2 DETAILED EXPERIMENTAL PROCEDURES 
 
2.2.1 Polymerase Chain Reaction (PCR) Amplification  
Based on the results obtained from the in silico promoter analyses, the 5’ promoter regions 
of the CYBRD1, FTH1, HAMP, HFE, HFE2, HMOX1, IREB2, LTF and TFRC genes were analyzed 
for differences in transcriptional regulation and expression. For each gene, three different 
promoter elements were generated via PCR for use in subsequent in vitro analyses: 
1) an area of 2 kb upstream of the initiating ATG, containing the core- and proximal 
promoter (termed the 2 kb promoter fragment); 2) a conserved region of 140 bp (termed 
the CR promoter element); 3) a promoter fragment in which the CR promoter element was 
removed from the 2 kb promoter fragment (termed the 1.86 kb CR-removed fragment). 
 
Genomic DNA 
Human Genomic DNA (hgDNA, Promega Corporation, Madison, WI, USA) was purchased for 
use in this study in order to minimize possible confounding factors that may exist (e.g. 
presence of specific disease-related mutations) when selecting individual persons for use as 
study subjects. The hgDNA was obtained from whole blood samples of multiple anonymous 
donors and is negative for HIV antibodies (HIV-1/HIV-2) and Hepatitis B surface antigens. 
 
Oligonucleotide Primers 
The oligonucleotide primers used in this study were designed to flank the promoter areas of 
interest using the Primer3 v0.2 program (Rozen and Skaletsky 2000) and are listed in Tables 
2.1 – 2.3. All primers were manufactured by Integrated DNA Technologies (IDT, Coralville, 
IA, USA). The published reference sequence for each gene was obtained from the Ensembl 
database (Flicek et al., 2012) and is illustrated in Appendix 2, with the relevant positions of 
the designed primers indicated. Primers that were to be used for cloning were designed to 
include restriction endonuclease (RE) recognition sites at their 5’ ends (either NheI, BglII, 
XhoI or HindIII), flanked by 3 bp random nucleotide overhangs (underlined in Tables 2.1 – 
2.2). Appropriate RE sites were assessed by utilizing the reference sequence of the amplicon 
of interest with an in silico RE mapping tool (www.restrictionmapper.org) prior to primer 
design. 
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Table 2.1 Oligonucleotide primers designed for PCR amplification of the 2 kb promoter region. 
   
       
Gene Forward Primer (a)  (5' - 3') Tm (°C) Reverse Primer (d)  (5' - 3') 
Tm  
(°C) 
Product 
size        
(bp) 
Ta  
(˚C) 
CYBRD1 CAGGCTAGCAAGTGAACGTTCCCAAATGC 63.3 AATAGATCTCTGGCCCCAACTCAGAAAT 59.4 2053 75 
FTH1 AATGCTAGCACAACCCTGCCCGATCTT 64.0 AATAGATCTGCCTCTGAGTCCTGGTGGTA 61.6 2232 75 
HAMP CAGGCTAGCCACTCTGCTCACCTTGTGGA 66.3 AATCTCGAGAAACAGAGCCACTGGTCAGG 63.0 2229 75 
HFE CAGGCTAGCAGGAGGAGGAGAATGGAGGA 65.4 AATAGATCTGCTCAGGAGATGCCCAGTAA 60.4 2164 60 
HFE2 AATGCTAGCTGGCCTCTAATGGTTGAGAAA 61.3 AATCTCGAGCTGAGGTCAGGGAACCAGAG 64.1 2060 60 
HMOX1 AATGCTAGCGCTGCCTCAGAGTCAAGGTC 65.0 CAGAGATCTTGAGGACGCTCGAGAGGA 62.4 2284 75 
IREB2 CAGGCTAGCCTCCTAGCATCAAGCGATCC 64.9 AATAGATCTAGGGAGGAAAGAAGGAAGCA 58.5 1998 65 
LTF AATGCTAGCGCTGAGCCTCTTGGTAGTGG 64.9 AATAGATCTAGCAGGACGAGGAAGACAAG 59.0 2166 65 
TRFC ATTGCTAGCAGCCAGGCATGTTAGCTCAT 63.6 CAGAGATCTTTCTAGAAGCCCGCACTCAC 61.7 1985 75 
 
Abbreviations: 5', 5-prime; 3', 3-prime; °C, degrees Celsius; bp, base pair; CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin heavy polypeptide 1 gene; HAMP, 
Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; HMOX1, Haem oxygenase 1 gene; IREB2, Iron-responsive element-binding 
protein 2  gene; LTF, Lactotransferrin gene; PCR, polymerase chain reaction; Ta, annealing temperature; Tm, melting temperature; TFRC, Transferrin receptor protein 1 
gene. 
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Table 2.2 Oligonucleotide primers designed for PCR amplification of the 140 bp CR promoter element. 
   
       
Gene Forward Primer   (5' - 3') Tm (°C) Reverse Primer   (5' - 3') 
Tm  
(°C) 
Product 
size        
(bp) 
Ta  
(˚C) 
CYBRD1 CGGGCTAGCGGTTTTTTTTGTTTTTTGTTTT 59.7 CGGAAGCTTCCTGTCTCTACTGAAAATACAAAT 59.7 145 60 
FTH1 CGGGCTAGCTCTTTCTTTCTTTCTTTTT 57.7 CGGAAGCTTCAAAAATTAGCCGGGCGTGGTG 66.0 145 60 
HAMP CGGGCTAGCAGCTATTACTATTACTGCTA 59.0 CGGAAGCTTAAATTTAGCCAGGCGTGGTG 63.1 141 65 
HFE CGGGCTAGCATGCCACCACACCCAGCTAA 68.6 CGGAAGCTTCAAAAATTAGCCGGGCGTGATA 63.7 146 65 
HFE2 CGGGCTAGCCTTGGTTGCAGTATCTCTTT 63.5 CGGAAGCTTGGAATAACATAATCTTGTGACC 59.2 150 65 
HMOX1 CGGGCTAGCAGTTTTTTTTTTTTTTTTTTGTTTTT 57.9 GGAAGCTTTAAATTAGCTGGGCATGGTG 60.1 145 65 
IREB2 CGGGCTAGCGGACACATTTAATGTCCAAT 62.3 GGAAGCTTTAAAAATTAGCTGAGTGTGGTG 58.3 145 65 
LTF CGGGCTAGCCTTCACTTAGTTACCCTTTT 61.6 GGAAGCTTCAAAAATTAGCCCAGCATGGTG 61.8 147 65 
TRFC CGGGCTAGCTGCTCCTGCTCATATGACTT 64.7 GGAAGCTTAAAATTAGCCAGGCATAGTG 58.0 145 65 
 
Abbreviations: 5', 5-prime; 3', 3-prime; °C, degrees Celsius; bp, base pair; CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin heavy polypeptide 1 gene; HAMP, 
Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; HMOX1, Haem oxygenase 1 gene; IREB2, Iron-responsive element-binding 
protein 2  gene; LTF, Lactotransferrin gene; PCR, polymerase chain reaction; Ta, annealing temperature; Tm, melting temperature; TFRC, Transferrin receptor protein 1 gene. 
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Table 2.3 Oligonucleotide primers designed for PCR-driven overlap extension of the gene promoters. 
 
     
Gene Forward Overlap Extension Primer (c) (5' - 3') Tm  (°C) Reverse Overlap Extension Primer (b) (5' - 3') 
Tm  
(°C) 
CYBRD1 TTTGTTTTTTGTTTTATTTGTATTTTCAGT 51.1 TCAGAAAATACAAATAAAACAAAAAACAAA 50.9 
FTH1 CTTTCTTTCTTTTTTCACCACGCCCGGCTA 62.6 TAGCCGGGCGTGGTGAAAAAAGAAAGAAAG 62.6 
HAMP TTACTATTACTGCTACACCACGCCTGGCTA 61.9 TAGCCAGGCGTGGTGTAGCAGTAATAGTAA 61.9 
HFE ACCACACCCAGCTAATATCACGCCCGGCTA 67.1 TAGCCGGGCGTGATATTAGCTGGGTGTGGT 67.1 
HFE2 TTGCAGTATCTCTTTGGTCACAAGATTATG 57.1 CATAATCTTGTGACCAAAGAGATACTGCAA 57.1 
HMOX1 TTTTTTTTTGTTTTTCACCATGCCCAGCTA 58.7 TAGCTGGGCATGGTGAAAAACAAAAAAAAA 58.7 
IREB2 CATTTAATGTCCAATCACCACACTCAGCTA 58.7 TAGCTGAGTGTGGTGATTGGACATTAAATG 58.7 
LTF CTTAGTTACCCTTTTCACCATGCTGGGCTA 61.5 TAGCCCAGCATGGTGAAAAGGGTAACTAAG 61.5 
TRFC CTGCTCATATGACTTCACTATGCCTGGCTA 61.0 TAGCCAGGCATAGTGAAGTCATATGAGCAG 61.0 
 
Abbreviations: 5', 5-prime; 3', 3-prime; °C, degrees Celsius; bp, base pair; CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin heavy polypeptide 1 gene; HAMP, 
Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; HMOX1, Haem oxygenase 1 gene; IREB2, Iron-responsive element-
binding protein 2  gene; LTF, Lactotransferrin gene; PCR, polymerase chain reaction; Ta, annealing temperature; Tm, melting temperature; TFRC, Transferrin receptor 
protein 1 gene. 
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2 kb Promoter and CR Promoter Element PCR Amplification 
PCR amplification of the 2 kb promoter fragment and the 140 bp CR promoter element was 
performed in a gradient thermocycler (Veriti 96 Well Thermocycler, Applied Biosystems, 
Carlsbad, CA, USA) in reactions with a total volume of 50 µl, consisting of 0.5 U Taq 
polymerase high fidelity, proofreading enzyme [KAPA HiFi™ (HotStart) DNA Polymerase, 
Kapa Biosystems, Boston, MA, USA], 10 ng hgDNA template, 0.3 mM of each dNTP (dATP, 
dCTP, dTTP, dGTP) (Kapa), 0.3 µM of each primer and 5 × KAPA HiFi™ Buffer (Kapa). For 
every round of PCR amplification performed, a negative control (reaction without hgDNA 
template) was included to indicate the possibility of contamination in the PCR reaction. 
Individual annealing temperatures for each primer set were optimized and are listed in 
Tables 2.1 and 2.2. General PCR cycling conditions were: an initial denaturation step at 95˚C 
for 2 minutes, followed by 35 cycles of denaturation at 98˚C for 20 seconds, annealing at a 
temperature optimized for each primer set (indicated as the Ta of each amplicon in Table 2.1 
and Table 2.2) for 15 seconds and an elongation step of 72˚C for 2 minutes. This was 
followed by a final extension step of 72˚C for 5 minutes. 
 
PCR-driven Overlap Extension 
In order to generate the 1.86 kb CR-removed promoter fragments, the overlap extension 
PCR technique (Heckman and Pease, 2007) was utilized. This method allows for the deletion 
of a specified region without the need to introduce foreign nucleotides (as in the case of RE 
digestion), which have the potential to act as novel TfBSs in the PCR fragment generated. 
The protocol requires an initial PCR with primers that generate overlapping, complementary 
3’ ends and results in intermediate segments. These intermediate fragments are then used 
as template DNA for a subsequent PCR with flanking primers that result in a full length 
product (Figure 2.1). The primers for the first PCR (b and c) generate overlapping sequences 
by including nucleotides that span the junction of the AB (dotted line) and CD (dashed line) 
fragments. The next PCR generates the chimeric gene product AD using flanking primers a 
and d. 
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Figure 2.1 Schematic outline of PCR-driven overlap extension. 
Adapted from Heckman and Pease (2007). 
 
For the initial PCR, the forward flanking primer (a) was used in combination with the internal 
overlap primer (b) resulting in the fragment AB; the reverse flanking primer (d) was used 
with the internal overlap primer (c) to generate the fragment CD. This PCR was performed 
as a nested reaction; the 2 kb promoter fragment which was previously generated for each 
gene was used as DNA template. For the second PCR, the two flanking primers (a and d) 
were used in a PCR reaction with equal concentrations (50 ng) of both the AB and CD 
fragments as DNA template. Flanking primers (a and d) were the same primers designed for 
PCR amplification of the 2 kb promoter region (Table 2.1). Internal overlap primers are listed 
in Table 2.3. The components of the PCR reactions, as well as the cycling conditions were 
kept the same as those listed in Section 2.2.1.3. The size of each of the PCR amplicons for 
each gene and their respective annealing temperatures are listed in Table 2.4.
Stellenbosch University http://scholar.sun.ac.za
 54 
 
 
 
 
Table 2.4 Product sizes for the fragments generated by the PCR-driven overlap extension. 
    Gene Primer Combination Product size        (bp) 
Ta  
(°C) 
CYBRD1 
Forward Primer (a)/Reverse Overlap Extension Primer (b) 514 55 
Forward Overlap Extension Primer (c)/Reverse Primer (d) 1424 55 
Forward Primer/Reverse Primer (ad) 1938 60 
FTH1 
Forward Primer (a)/Reverse Overlap Extension Primer (b) 114 55 
Forward Overlap Extension Primer (c)/Reverse Primer (d) 2003 60 
Forward Primer/Reverse Primer (ad) 2117 60 
HAMP 
Forward Primer (a)/Reverse Overlap Extension Primer (b) 1195 55 
Forward Overlap Extension Primer (c)/Reverse Primer (d) 923 60 
Forward Primer/Reverse Primer (ad) 2118 60 
HFE 
Forward Primer (a)/Reverse Overlap Extension Primer (b) 338 60 
Forward Overlap Extension Primer (c)/Reverse Primer (d) 1710 60 
Forward Primer/Reverse Primer (ad) 2048 60 
HFE2 
Forward Primer (a)/Reverse Overlap Extension Primer (b) 851 55 
Forward Overlap Extension Primer (c)/Reverse Primer (d) 1089 55 
Forward Primer/Reverse Primer (ad) 1940 60 
HMOX1 
Forward Primer (a)/Reverse Overlap Extension Primer (b) 887 55 
Forward Overlap Extension Primer (c)/Reverse Primer (d) 1282 55 
Forward Primer/Reverse Primer (ad) 2169 60 
IREB2 
Forward Primer (a)/Reverse Overlap Extension Primer (b) 777 55 
Forward Overlap Extension Primer (c)/Reverse Primer (d) 1106 55 
Forward Primer/Reverse Primer (ad) 1883 60 
LTF 
Forward Primer (a)/Reverse Overlap Extension Primer (b) 769 55 
Forward Overlap Extension Primer (c)/Reverse Primer (d) 1280 55 
Forward Primer/Reverse Primer (ad) 2049 60 
TRFC 
Forward Primer (a)/Reverse Overlap Extension Primer (b) 612 55 
Forward Overlap Extension Primer (c)/Reverse Primer (d) 1258 55 
Forward Primer/Reverse Primer (ad) 1870 60 
 
Abbreviations: °C, degrees Celsius; bp, base pair; CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin 
heavy polypeptide 1 gene; HAMP, Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, 
Hemojuvelin gene; HMOX1, Haem oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2  gene; 
LTF, Lactotransferrin gene; PCR, polymerase chain reaction; Ta, annealing temperature; TFRC, Transferrin 
receptor protein 1 gene. 
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2.2.2 Agarose Gel Electrophoresis 
Amplified PCR products were electrophoresed on either 0.8% (w/v) or 1% (w/v) agarose gels 
[consisting of either 1.6 g or 2 g agarose in 200 ml 1 × Tris-Acetate-EDTA (TAE) (40 mM Tris-
HCl, 20 mM acetic acid (C2H4O2) and 1 mM EDTA (C10H16N2O8), pH 8.0) and 0.01% (v/v) 
ethidium bromide (EtBr)] depending on the size of the relevant DNA fragment. An equal 
volume of cresol red loading dye solution [2 mg/ml cresol red and 35% (w/v) sucrose] was 
added to each of the PCR products prior to sample loading in order to resolve each 
fragment. An appropriate molecular size marker [O’GeneRuler™ 100 bp DNA ladder 
(Fermentas Life Sciences, Burlington, Ontario, Canada) or O’GeneRuler™ 1 kb DNA ladder 
(Fermentas Life Sciences)] was electrophoresed alongside the PCR products for accurate size 
comparison of each specific fragment. Electrophoresis was performed at 120 V for 1 hour in 
1 x TAE, after which the DNA fragments were visualized with an ultraviolet (UV) light 
transilluminator system. The resulting images were captured using the MultiGenius Bio 
Image System (Syngene, Cambridge, England). 
 
2.2.3 PCR Product and Gel Extraction Purification 
The Wizard® SV Gel and PCR Clean-Up System (Promega Corporation) was utilized in order 
to purify PCR products directly, or to clean-up samples excised from agarose gels using 
microcentrifugation in a silica membrane-based column system. Incubation and 
centrifugation times were extended to 5 minutes each. Following agarose gel 
electrophoresis, the band of interest was excised under UV transillumination and placed in a 
pre-weighed 1.5 ml microcentrifuge tube (Axygen, Union City, CA, USA). The weight of the 
gel slice was calculated by subtracting the weight of the empty tube from the total weight. 
Membrane Binding Solution (4.5 M guanidine isothiocyanate, 0.5 M C2H3KO2, pH 5.0) was 
added at a ratio of 10 µl solution to 10 mg of agarose gel slice and incubated at 55°C for 10 
minutes to dissolve the gel slice. For PCR amplifications, an equal volume of Membrane 
Binding Solution was added directly to the PCR product. The dissolved gel mixture or the 
prepared PCR product was then added to a SV Minicolumn assembly and incubated for 5 
minutes at room temperature. The columns were then subjected to centrifugation 
(Centrifuge 5415D, Eppendorf, Hamburg, Germany) at 16 000 x g for 5 minutes and the 
flow-through was discarded. The column was then washed by adding 700 µl of Membrane 
Wash Solution (10 mM C2H3KO2, 16.7 µM EDTA, 80% EtOH) and centrifuging again at 16 000 
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x g for 5 minutes. The collection tube was emptied as before and the wash step was 
repeated with 500 µl Membrane Wash Solution. The flow-through was emptied and the 
empty column was centrifuged at 16 000 x g for 2.5 minutes to remove any traces of 
ethanol from the wash solution. The SV Minicolumn was transferred to a clean 1.5 ml 
microcentrifuge tube and 25 µl of Nuclease-Free Water (pre-warmed to 60°C) was added. 
The samples were incubated at room temperature for 5 minutes followed by a 
centrifugation at 16 000 x g for 5 minutes. The SV Minicolumn was discarded and the 
samples stored at 4°C. 
 
2.2.4 DNA Quantification 
The concentration of the purified DNA fragments was determined using a 
spectrophotometer (NanoDrop® ND-100, NanoDrop Technologies Inc., DE, USA) which 
measures the absorbance of nucleic acids at 260 nm. In this study, A260/A280 ratios in the 
range of 1.8 – 2.0 and A260/A230 ratios of 2.2 were considered to be high quality, purified 
and protein-free DNA. 
 
2.2.5 Semi-automated DNA Sequencing Analysis 
Purified PCR products were subjected to bidirectional semi-automated DNA sequencing 
analysis at an analytical facility (CAF, Stellenbosch University or Inqaba Biotec, Pretoria, 
South Africa) on an ABI Prism 3130XL Genetic Analyser (Applied Biosystems). In order to 
obtain coverage of the whole region of the 2 kb and 1.86 kb CR-removed amplicons, the 
sequencing reactions were performed in overlapping fragments using the designed PCR 
primers (Table 2.1) as well as nested primers that were designed specifically for sequencing 
analysis (Table 2.5). The 140 bp CR amplicons were sequenced bidirectionally with the 
relevant PCR primers (Table 2.2). 
 
Analysis of the DNA sequences and chromatograms was performed by alignment with the 
published reference (wild-type) sequence (accession numbers listed in Section 2.1.1 and 
Appendix 2) using the BioEdit Sequence Alignment Editor v7.0.9.0 (Hall, 1999) and CLC 
Sequence Viewer 6.7.1, as well as visual inspection of the electropherograms to detect 
differences from the reference sequence. 
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Table 2.5 Internal oligonucleotide sequencing primers. 
   Gene Forward Primer (5' - 3') Reverse Primer (5' - 3') 
CYBRD1 GGAGGTGGTCCTTACATG GAGAACATGTTACATGATG 
FTH1 CACCCTAATTCCGTCGGCAAT GGTGTGTGTGGCTAAGCTGAG 
HAMP CATCGGACTGTAGATGTTAGC TCAAGACTAGCCTGGGCAAC 
HFE CGGAGCTCTGAACCAGCAAT GTGCTGAGTTCACTTCGCAG 
HFE2 TGACCGTATTTGGAATCGGTC TCCTTCCTTCCGAGATGAG 
HMOX1 GGCCAGTCTCGAACTCAAAG AATCAATTCTGCATGAGGTGG 
IREB2 AATGGACAGAGGGAGGAGGT CAAGACCAAACACAGCAACG 
LTF CACCATGCTGGGCTAATTTTT TGGGCAAGATAGGGAAACCCC 
TRFC CAGCAATGCTCCTGCTCATA AGGTGAGCGGATCACGAG 
 
Abbreviations: 5', 5-prime; 3', 3-prime; CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin heavy 
polypeptide 1 gene; HAMP, Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, 
Hemojuvelin gene; HMOX1, Haem oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2  
gene; LTF, Lactotransferrin gene; TFRC, Transferrin receptor protein 1 gene. 
 
2.2.6 Luciferase Reporter Vectors 
For in vitro transfection experiments, two different pGL4 luciferase reporter vectors were 
selected; the promoterless pGL4.10[luc2] vector (GenBank accession number: AY738222) 
and the minimal promoter pGL4.23[luc2/minP] vector (EMBL accession number: DQ904455) 
(Promega). The pGL4 reporter vectors are optimized for expression in mammalian cells and 
have been engineered to contain reduced consensus transcription factor binding sites 
(Appendix 3). Each vector contains the synthetic firefly luc2 (Photinus pyralis) reporter gene. 
In addition, the pGL4.73[hRluc/SV40] (GenBank accession number: AY738229) vector was 
selected as an internal control reporter for co-transfection with the experimental reporter 
vectors. The SV40 early enhancer/promoter region contained in this plasmid provides strong 
constitutive expression of the Renilla hRluc (Renilla reniformis) reporter gene. 
 
The pGL4.10[luc2] vector does not contain any promoter or enhancer elements and the 
multiple cloning region (MCR) is located immediately upstream of the luciferase reporter 
gene. This vector was selected in order to clone the 2 kb promoter and 1.86 kb CR-removed 
fragments. In contrast, the pGL4.23[luc2/minP] vector contains a TATA-box promoter 
element upstream of the luciferase reporter gene and downstream of the MCR, and was 
used for the cloning of the 140 bp CR promoter elements. 
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2.2.7 Digestion and Purification 
The pGL4.10[luc2] and pGL4.23[luc2/minP] vectors along with all of the purified promoter 
fragments of interest (whole 2 kb promoters, the 1.86 kb CR-removed promoters and the 
140 bp CR elements) were digested overnight at 37°C in a waterbath in order to generate 
the correct overhangs for subsequent ligation of the promoter fragments into the revelant 
vector (Table 2.6). All restriction digests were performed in 20 µl double digestion reactions 
with 10 U (NheI, XhoI and HindIII; BglII was doubled to 20 U as this enzyme only 
demonstrates 75% performance in buffer 2) of each of the appropriate restriction enzymes 
for each construct (Table 2.6), 1 x buffer 2 (New England Biolabs, Ipswich, MA, USA), 0.01% 
BSA (New England Biolabs) and 500 ng of DNA. 
 The products of the double digest reactions were subjected to purification using the 
Wizard® SV Gel and PCR Clean-Up System (Promega Corporation) as per Section 2.2.3. The 
concentration of the digestion products was determined spectrophotometrically as 
described in Section 2.2.4. 
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Table 2.6 Double digest restriction enzymes for the pGL4 vectors and each of the promoter 
elements. 
   
 Enzyme 1 Enzyme 2 
Vector 
pGL4.10[luc2] NheI BglII 
pGL4.10[luc2] NheI XhoI 
pGL4.23[luc2/minP] NheI HindIII 
2 kb/1.86 kb CR-removed promoter fragments 
CYBRD1 NheI BglII 
FTH1 NheI BglII 
HAMP NheI XhoI 
HFE NheI BglII 
HFE2 NheI XhoI 
HMOX1 NheI BglII 
IREB2 NheI BglII 
LTF NheI BglII 
TFRC NheI BglII 
140 bp CR promoter fragments 
CYBRD1 NheI HindIII 
FTH1 NheI HindIII 
HAMP NheI HindIII 
HFE NheI HindIII 
HFE2 NheI HindIII 
HMOX1 NheI HindIII 
IREB2 NheI HindIII 
LTF NheI HindIII 
TFRC NheI HindIII 
 
Abbreviations: bp, base pair; CR, conserved region; CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin 
heavy polypeptide 1 gene; HAMP, Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, 
Hemojuvelin gene; HMOX1, Haem oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2 gene; 
kb, kilobase pair; LTF, Lactotransferrin gene; TFRC, Transferrin receptor protein 1 gene. 
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2.2.8 Dephosphorylation of the pGL4 Luciferase Reporter Vectors 
Following double digestion, but prior to purification, each of the pGL4 luciferase reporter 
vectors was treated with the enzyme shrimp alkaline phosphatase (SAP) (Fermentas Life 
Sciences). SAP removes the 5’ terminal phosphate residue in a dephosphorylation reaction 
that results in the prevention of circularization of the plasmid during ligation. The reaction 
took place in 1 x SAP dephosphorylation buffer (Fermentas Life Sciences for 30 minutes at 
37°C. Heat inactivation of the enzyme was performed at 65°C for 15 minutes. The SAP-
treated plasmids were then purified and the concentration determined as described in 
Sections 2.2.3 and 2.2.4 
 
2.2.9 Ligation into pGL4 Luciferase Reporter Vectors 
The purified double digestion products for each promoter fragment were ligated into the 
appropriate vector in overnight ligation reactions at 4°C. The amount of each insert DNA 
was calculated using the following equation: 
insert concentration (ng) =  vector concentration (ng) x 
insert size (kb) 
x insert:vector ratio 
vector size (kb) 
 
Ligation reactions took place in a final volume of 20 µl consisting of 1 U T4 DNA Ligase 
(Fermentas Life Sciences), 1 x T4 DNA Ligase buffer [400 mM Tris-HCl, 100 mM MgCl2, 100 
mM DTT, 5 mM ATP (pH 7.8 at 25°C); Fermentas Life Sciences)], varying concentrations of 
insert DNA (see below) and 25 ng of vector. Following the overnight incubation step, the T4 
DNA Ligase was heat inactivated at 70°C for 5 minutes. 
 
The pGL4.10[luc2] Constructs 
The 2 kb promoter elements and the 1.86 kb CR-removed fragments were ligated into the 
pGL4.10[luc2] vector at an insert:vector ratio of 3:1. In order to achieve this ratio with a 
vector concentration of 25 ng, 33.9 ng (2 kb promoters) or 32.9 ng (1.86 kb CR-removed 
promoters) of each insert was added to the ligation reaction. 
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The pGL4.23[luc2/minP] Constructs 
The 140 bp CR elements were ligated into the pGL4.23[luc2/minP] vector at an insert:vector 
ratio of 10:1. In order to achieve this ratio with a vector concentration of 25 ng, 8.2 ng of 
each insert was added to the ligation reaction. 
 
2.2.10 Transformation of E. cloni ® 10G Chemically Competent Cells  
E. cloni ® 10G Chemically Competent Cells (Lucigen Corporation, Middleton, WI, USA) are 
derivatives of E. coli that have been optimized for high transformation efficiency with the 
heat-shock method. They contain the endA1 and recA1 mutations that result in high yield 
and high quality plasmid DNA. Before transformation of the E. cloni cells, sterile 1.5 ml 
microcentrifuge tubes were chilled on ice (one for each transformation reaction). The cells 
were then removed from the -80°C freezer and thawed for 15-20 minutes on ice. A 20 µl 
aliquot of competent cells was added to each of the chilled 1.5 ml tubes and 5 µl of the 
specific ligation reaction for each transformation was added. To serve as negative controls, 
1 µl unligated vector and/or 5 µl dH2O were added to the competent cells. The sample was 
then mixed by gentle pipetting to avoid bubble formation. Incubation for 30 minutes on ice 
was concluded with a 45 second heat-shock step in a 42°C waterbath, after which the cells 
were returned to ice for 2 minutes. A volume of 480 µl of room temperature Recovery 
Medium was added to the cells which were then placed on a platform shaker at 250 rpm at 
37°C for one hour. For each transformation reaction, 100 µl of the transformed cells were 
plated out on Luria-Bertani (LB) plates containing 50 µg/ml ampicillin [Sigma-Aldrich (Pty) 
Ltd., St Louis, MO, USA]. The plates were incubated overnight at 37°C in order for colony 
formation to occur. 
 
2.2.11 Clone Selection 
Following overnight incubation, colonies were observed on the LB-ampicillin plates. Colony 
growth is indicative of bacteria that contain the vector-insert combination, as the ampicillin 
resistance gene (Ampr) is contained on the pGL4 vector backbone and can only be expressed 
in cells that have taken up the recircularized plasmid. Colonies were picked with a sterile 
pipette tip and inoculated into 5 ml LB-ampicillin medium in a 50 ml tube and incubated 
overnight at 37°C on a platform shaker at 150 rpm.  
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The following day: 1) For pGL4.10[luc2] constructs, the overnight cultures were used for 
plasmid miniprep isolation with the GeneJET™ Plasmid Miniprep Kit (Fermentas Life 
Sciences) as per Section 2.2.12. The purified plasmids (250 ng) were then subjected to 
overnight double digestion reactions with 10 U of each of the appropriate restriction 
enzymes for each construct (see Table 2.6), 1 x buffer 2 (New England Biolabs) and 0.01% 
BSA (New England Biolabs) in a waterbath at 37°C (as per Section 2.2.7). The digested 
pGL4.10[luc2] constructs were resolved on a 1% (w/v) agarose gel in 1 x TAE for 1.5 hours at 
100 V. The agarose gel was visualized under UV light transillumination for the identification 
of plasmids containing the insert of interest. 
2) For pGL4.23 [luc2/minP] constructs, 1 µl of the overnight culture was used in a colony 
PCR reaction with a total volume of 25 µl, consisting of 0.5 U Taq polymerase enzyme 
(Fermentas Life Sciences), 0.2 mM of each dNTP (dATP, dCTP, dTTP, dGTP) (Fermentas Life 
Sciences), 1 x Buffer (Fermentas Life Sciences), 1.5 mM of magnesium chloride (MgCl2), 10 
pmol of the vector-specific RV3 forward primer (5’ CTAGCAAAATAGGCTGTCCC 3’) which 
flanks the MCR and 10 pmol of the relevant insert-specific reverse primer. Colony PCR 
amplifications were assessed on a 1% (w/v) agarose gel in 1 x TAE buffer. 
 
2.2.12 Small-scale Isolation of Plasmid DNA (Miniprep) 
Following identification of positive colonies, the 5 ml overnight culture was utilized for 
plasmid DNA extraction using the GeneJET™ Plasmid Miniprep Kit (Fermentas Life Sciences) 
which makes use of SDS/alkaline lysis to liberate the plasmid DNA. Firstly, the bacterial 
culture was harvested by centrifugation at 6000 rpm for 2 minutes at room temperature. 
The supernatant and the remaining medium were decanted and the pelleted cells 
thoroughly resuspended in 250 µl of Resuspension Solution (with RNase A added). The 
resuspension was transferred to a 1.5 ml microcentrifuge tube and 250 µl of Lysis Solution 
was added. The solution was mixed by inverting the tube 4-6 times until viscous, followed 
by the addition of 350 µl of Neutralization Solution. The tube was immediately inverted 4-6 
times to mix the solution. Following a centrifugation step at 16 000 x g in a microcentrifuge, 
the supernatant was transferred to a GeneJET™ spin column without disturbing the white 
precipitate. The column was then centrifuged for 1 minute at 16 000 x g, the flow-through 
discarded and 500 µl of Wash Solution added. This was followed by a centrifugation step for 
1 minute at 16 000 x g. This wash step was repeated twice and the flow-through discarded 
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before another centrifugation step at 16 000 x g for 1 minute with the empty column. The 
GeneJET™ spin column was then transferred to a new 1.5 ml microcentrifuge tube and 50 µl 
Elution Buffer was added to the centre of the column membrane. The spin column was 
incubated at room temperature for 2 minutes and centrifuged for an additional 2 minutes at 
16 000 x g to elute the plasmid DNA. The spin column was discarded and concentration of 
each extracted plasmid was determined (as per Section 2.2.4). The purified plasmid was 
stored at -20°C. 
 
The correct orientation and nucleotide sequence of the promoter inserts were verified by 
DNA sequence analysis (as described in Section 2.2.5) utilizing a plasmid-specific forward 
primer (RV3; 5’ CTAGCAAAATAGGCTGTCCC 3’) and an insert-specific reverse primer (Tables 
2.1 and 2.2). 
 
2.2.13 Preparation of Glycerol Stocks 
Following identification of positive colonies, 850 µl of the 5 ml overnight culture that was 
prepared for plasmid DNA minipreps was used to create glycerol stocks: 1/10 volume of 
100% glycerol and 9/10 volumes of the bacterial culture were mixed vigorously and stored 
at -80°C. 
 
2.2.14 Large-scale Endotoxin-free Plasmid Isolation (Maxiprep) 
Following DNA sequence analysis, the glycerol stocks of the positive clones were used to 
inoculate 200 ml LB-ampicillin medium which were incubated overnight at 37°C. The 
overnight bacterial culture was used for endotoxin-free plasmid extraction with the 
PureYield™ Plasmid Maxiprep System (Promega Corporation). The cells were pelleted by 
centrifugation at 5000 x g for 10 minutes in an ultracentrifuge (Hermle LaborTechnick 
GmbH, Wehingen, Germany) and the supernatant discarded. The cell pellets were then 
resuspended in 12 ml of Cell Resuspension Solution after which, 12 ml of Cell Lysis Solution 
was added and the solution mixed by inverting the tube 3-5 times. This was followed by a 3 
minute incubation at room temperature. To the lysed cells, 12 ml of Neutralization Solution 
was added and mixed by inverting the tube 10-15 times until the solution appeared 
flocculent. A centrifugation step for 30 minutes at 6000 rpm followed. A column stack was 
assembled by placing a PureYield™ Clearing Column on top of a PureYield™ Maxi Binding 
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Column which was then placed onto the vacuum manifold [Vac-Man® Laboratory Vacuum 
Manifold (Promega Corporation)]. Approximately one-half of the lysate was poured into the 
column stack assembly and maximum vacuum was applied until all the liquid had passed 
through both columns. The remainder of the lysate was added and allowed to pass through 
the columns. The PureYield™ Clearing Column was removed after releasing the vacuum and 
5 ml of Endotoxin Removal Wash was added to the PureYield™ Maxi Binding Column. The 
vacuum was turned on and the solution allowed to pass through the column. This was 
followed by the addition of 20 ml Column Wash Solution. The column membrane was 
allowed to dry for 5 minutes under vacuum before it was removed from the vacuum 
manifold. In order to elute the plasmid DNA, the PureYield™ Maxi Binding Column was 
placed in a new 50 ml tube (Greiner Bio-one, Frickenhausen, Germany) and 1.5 ml Nuclease-
free Water was added to the DNA binding membrane in the column. The column was then 
centrifuged in a swinging bucket rotor at 2000 x g for 5 minutes (Unicen 20 Ultracentrifuge, 
Orto Alresa, Madrid, Spain). The eluate was collected from the 50 ml tube and transferred 
to a 1.5 ml microcentrifuge tube. The concentration of each extracted plasmid was 
determined (as per Section 2.2.4) and stored at -20°C. 
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2.3 CELL CULTURE, TRANSIENT TRANSFECTIONS AND DUAL-LUCIFERASE 
REPORTER ASSAYS 
 
2.3.1 Cell Culture 
In this study, two different cell types were used to assess the effect of the various iron gene 
promoter elements on transcriptional activity. Human hepatocarcinoma liver (HepG2, Cat # 
85011430) cells and African green monkey kidney (COS-1, Cat # 88031701) cells were 
purchased from the European Collection of Cell Cultures (ECACC, Wiltshire, England). Both 
cell types were cultured in 75 cm2 sterile polystyrene culture flasks (Cellstar®, Greiner Bio-
one). Cells were grown in 15 ml Dulbecco’s Modified Eagles Medium with 4.5 g/L glucose 
and 2mM L-Glutamine [DMEM, Sigma-Aldrich (Pty) Ltd.], supplemented with 10% fetal calf 
serum (v/v) [FCS, Sigma-Aldrich (Pty) Ltd.] and 100 U/ml penicillin and streptomycin solution 
[Sigma-Aldrich (Pty) Ltd.]. In the case of the HepG2 cells, 1% Non-essential Amino Acid 
Solution (v/v) [MEM, Sigma-Aldrich (Pty) Ltd.] was added. The cells were kept in an 
incubator (Heraeus Cell 150, Kendro Laboratory Products, USA) at 37°C with an atmosphere 
of 5% CO2. The growth medium was replaced with fresh medium every four days in a sterile 
laminar flow hood. 
 
In order to determine approximate confluency, cells were examined under an inverted 
microscope (Nikon DIAPHOT-TMD Biological Inverted Microscope, Nikon Instruments Inc, 
Melville, NY, USA). Upon reaching 80% confluency, cells were passaged by removing the 
growth medium and rinsing with Hank’s Balanced Salt Solution [Sigma-Aldrich (Pty) Ltd.] to 
remove any non-adherent or dead cells. Detachment of the cells was achieved by applying 3 
ml of 0.25% trypsin-EDTA solution [Sigma-Aldrich (Pty) Ltd.] and incubating the flasks at 
37°C for four minutes (COS-1 cells) or 10 minutes (HepG2 cells). Following incubation, 5 ml 
of fully supplemented culture medium was added and the cell suspension transferred to a 
sterile 15 ml polypropylene tube (Cellstar®, Greiner Bio-one). The cells were pelleted by 
centrifugation at 800 rpm for 5 minutes. The supernatant was then discarded and the cells 
resuspended in another 5 ml of fully supplemented DMEM. Cells counts were performed 
using an automated cell counter (Countess® Automated Cell Counter, Life Technologies, 
Carlsbad, CA, USA) with the addition of 0.4% Trypan Blue Stain (Life Technologies) in order 
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to differentiate between live and dead cells. The cell suspension was then used to seed the 
cells in new 75 cm2 flasks at a density of 1 x 105 cells/ml, and the flasks were returned to the 
incubator. 
 
2.3.2 Transient Transfection 
Transient transfections of the HepG2 and COS-1 cells with the promoter constructs of 
interest were achieved with TransIT®-LT1 Transfection Reagent (Mirus Bio LLC, Madison, 
Wisconsin, USA). TransIT®-LT1 Transfection Reagent is a broad spectrum, low toxicity, 
serum-compatible reagent that provides high efficiency delivery of plasmid DNA in many 
primary cell types. Approximately 24 hours prior to transfection, HepG2 and COS-1 cells 
were plated in 500 µl complete culture medium in 24-well plates (Cellstar®, Greiner Bio-one) 
at a density of 1 x 105 cells/well. The plates were then incubated overnight (37°C, 5% CO2). 
After a 24 hour incubation period, the TransIT®-LT1 Transfection Reagent was warmed to 
room temperature and vortexed gently before use. A total DNA (µg): transfection reagent 
(µl) ratio of 1:3 was used per well. For each construct, 200 ng (1 µl) of plasmid DNA and 10 
ng (1 µl) of the control reporter vector (pGL4.73[hRluc/SV40], Promega Corporation) were 
added to 21 µl of serum- and antibiotic-free medium [100 x the DNA concentration (µg)] 
and 0.63 µl of TransIT®-LT1 Transfection Reagent. To allow for the formation of the 
TransIT®-LT1 Transfection Reagent:DNA complexes, the solution was pipetted gently and 
incubated at room temperature for 30 minutes. Following incubation, 23.63 µl of each 
complex solution was added dropwise to different areas of the appropriate wells. The 24-
well plates were then rocked gently to ensure even distribution of the TransIT®-LT1 
Transfection Reagent:DNA complexes and incubated for a further 24 hours (37°C, 5% CO2). 
 
2.3.3 Exogenous Iron Supplementation  
In order to simulate iron overload conditions in vitro, cells were treated with ferric 
ammonium citrate [FAC, Sigma-Aldrich (Pty) Ltd.] as an external stimulus 24 hours after 
transient transfection. FAC was added to the cells in a dropwise fashion at a final 
concentration of 200 µg/ml. The same volume of dH2O was added to the untreated cells. 
The cells were then incubated for 24 hours (37°C, 5% CO2) before lysis. 
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2.3.4 Dual-Luciferase® Reporter Assay 
The Dual-Luciferase® Reporter (DLR™) Assay System (Promega Corporation) was used in this 
study to assay the activities of firefly (Photinus pyralis) and Renilla (Renilla reniformis, or sea 
pansy) luciferases sequentially in a single sample. 
 
Passive Cell Lysis 
Following a 24 hour incubation period with FAC, the growth medium was removed by 
aspiration from each well of the 24-well plate and 200 µl of phosphate buffered saline (PBS) 
was added to wash the surface of the culture vessel. The plate was swirled to remove 
detached cells and residual culture medium and the PBS removed. Passive Lysis Buffer (PLB, 
Promega Corporation), supplied as a 5 x concentrate, was diluted prior to use by adding 1 
volume of 5 x PLB to 4 volumes of dH2O and mixing well. Fresh 1 x PLB was prepared just 
before use. According to the manufacturer’s recommendation, 100 µl of 1 x PLB was added 
to each well and the culture plates placed on a rocking platform (BellyDancer®, Stovall Life 
Science Inc., Greensboro, NC, USA) at room temperature for 15 minutes. The plates were 
then placed at -80°C overnight to ensure complete lysis of the cells. 
 
Dual-Luciferase® Reporter Assay Protocol 
Following overnight incubation of the 24-well plates at -80°C, 20 µl of cell lysate was 
transferred to a 96-well Assay Plate (Costar®, Corning Inc., NY, USA). Luciferase Assay 
Reagent II (LARII) was prepared by resuspending the lyophilized Luciferase Assay Substrate 
in 10 ml of the supplied Luciferase Assay Buffer II. In addition, an adequate amount of Stop 
& Glo® Reagent was prepared just before use for the number of DLR™ assays to be 
performed (50 µl per assay): 1 volume of 50 x Stop & Glo® Substrate was added to 50 
volumes of Stop & Glo® Buffer in a 15 ml polypropylene tube. The plate was then placed 
within a luminometer (Veritas™ Microplate Luminometer, Promega Corporation) which 
automatically added 50 μl of LARII to the appropriate wells and monitored the relative light 
units (RLU) observed using the Veritas v2.0.4401 coupled software program. 
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2.3.5 Statistical Analysis 
The firefly luciferase values obtained for each construct were divided by the Renilla 
luciferase readings in the same well in order to obtain normalized values to account for 
variation in transfection efficiency. For each construct, an average of the normalized values 
in each experiment was calculated to determine the relative expression of the specific 
construct under different experimental conditions (i.e. FAC-treated or untreated). Relative 
expression values for each construct were then divided by those of the constructs 
designated as control constructs to calculate fold change in luciferase expression. 
The fold change values were analyzed using GraphPad Prism® version 5.10 (GraphPad 
Software). Only values within 20% of one another were used to determine arithmetic 
means, standard deviation (SD) and standard error (SE) of the means. One-way ANOVA and 
Dunnett’s multiple comparison post-test were used for statistical analysis. Two-tailed paired 
t tests after ANOVA were used when a significant result was obtained in order to evaluate 
individual p-values. Assays for each construct were performed in triplicate in both cell lines 
and three independent transfection experiments were performed. Error bars represent the 
standard error of the means (SEM) of the three independent experiments. 
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CHAPTER THREE 
 
In silico analyses of promoter regulatory targets in 
the iron metabolism pathway 
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3.1 ABSTRACT 
Transcriptional regulation is governed by the presence of specific cis-regulatory regions (cis-
motifs), residing within the promoter region of genes, and the functional interactions 
between the products of specific regulatory genes (transcription factors-Tfs) and these cis-
motifs. Accurate bioinformatic analyses of cis-motif architecture could offer insights into 
complex mechanisms governing transcriptional regulation, serving as a refined approach for 
prediction and the study of regulatory targets of specific genes or groups of genes, such as 
the iron metabolism pathway. 
The DNA sequence of the upstream non-coding region (refer to Appendix 2 for the 
respective genes) of 18 genes (ACO1, CP, CYBRD1, FTH1, FTL, HAMP, HEPH, HFE, HFE2, 
HMOX1, IREB2, LTF, SLC11A2, SLC40A1, STEAP3, TF, TFRC, TFR2) known to be involved in the 
iron metabolism pathway was retrieved from the human Ensembl database. These 
sequences were subjected to in silico analyses to identify regions of conserved nucleotide 
identity utilising specific software tools. 
 The sequences of nine (CYBRD1, FTH1, HAMP, HFE, HFE2, HMOX1, IREB2, LTF, TFRC) 
of the 18 genes when examined were found to contain a genomic region that demonstrated 
over 75% sequence identity between the genes of interest. This conserved region (CR) is 
approximately 140 bp in size and is common to each of the promoters of the nine genes. 
This finding adds strength to the hypothesis that genes with similar promoter architecture, 
and involved in a common pathway, may be co-regulated. The CR was further examined 
using comparative algorithms from specific platforms for motif detection. Specific 
combinations of cis-motifs were discovered within the CR identified in the promoter 
regions. In silico analysis of putative TfBSs revealed the presence of numerous binding 
motifs of interest that were detected by more than one bioinformatic tool. 
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3.2 INTRODUCTION 
Within a biological context, iron is an essential micronutrient that is an absolute 
requirement for life in almost all organisms (exceptions include a few members of lactic acid 
bacteria and some Streptococcus species) (Crichton, 2009). The bioactive form of iron, Fe2+, 
has the potential to generate free radicals and ROS via Fenton and Haber-Weiss chemistry 
which can lead to cellular and tissue damage, and ultimately disease if untreated 
(Papanikolaou and Pantopolous, 2005). Globally, disorders of iron metabolism are amongst 
the most frequent nutritional maladies in humans. The inherited, genetic condition 
Hereditary Haemochromatosis (HH) is the most common cause of iron overload in 
Caucasians of North European ancestry with a carrier frequency of 1 in 200 individuals 
(Feder et al., 1997, Waheed et al., 1999). It has been proposed that the causative HH 
polymorphisms in different genes, either directly or indirectly, lead to altered levels of the 
hepcidin protein, thought to function as the “master regulator” of iron metabolism, 
therefore resulting in the HH phenotype (Nemeth and Ganz, 2006). 
 In contrast, dietary iron deficiency is the most widespread nutritional disorder 
affecting industrialized nations, with an estimated 15% of the general population afflicted. 
In developing countries, this is further exacerbated by chronic microbial and parasitic 
infections, as well as other vitamin and mineral deficiencies (Looker et al., 1997; Scholl, 
2005). 
 
Homeostatic regulation of iron metabolism is of critical importance as there is no known 
physiological mechanism for the excretion of excess iron. The maintenance of bodily iron 
levels therefore takes place primarily at the level of iron absorption form the diet (Andrews 
et al., 1999). To date, little is known about the co-ordinated regulation of the plethora of 
genes coding for proteins involved in iron metabolism, with the exception of the well 
characterized post-transcriptional IRE/IRP system (Pantopoulos, 2004). This regulatory 
method is mediated by the interaction of iron regulatory proteins (IRPs) 1 and 2 with iron 
responsive elements (IREs) in the untranslated regions (UTRs) either upstream (5’) or 
downstream (3’) of specific coding mRNAs. These IREs are cis-acting consensus recognition 
sites which result in mRNA degradation or stabilization upon IRP binding in response to 
different cellular iron levels (Johansson and Theil, 2002). Thus far, IREs have only been 
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identified in five mammalian iron encoding mRNAs (DMT1, FTH1, FTL, SLC40A1 and TFR1) 
implying that there may be other regulatory factors responsible for control of 
transcriptional regulation in this pathway (Hentze and Kühn, 1996; Gunshin et al., 1997; 
Beaumont, 2010). However, this particular mechanism does serve to illustrate the 
importance of UTRs and cis-motifs in the regulation of iron homeostasis. 
 
In the context of overall gene expression, the human genome is a system regulated at 
numerous different levels. Transcriptional regulation is the first and arguably the most 
important step in this process. Initiation of transcription involves the occupancy of specific 
cis-regulatory modules (CRMs) by trans-acting transcription factors (Tfs), often by the 
recognition of binding site motifs, recruitment of co-activators and co-repressors and 
modifications to chromatin structure (Dröge and Müller-Hill, 2001). Determination of these 
regulatory features has proved a challenging endeavour and the exact mechanisms 
underlying activation and repression of transcription remain to be elucidated in the vast 
majority of physiological pathways (Wasserman and Sandelin, 2004). The rapid 
development of numerous bioinformatic tools for the analysis of regulatory architecture has 
paralleled the exponential rise in modern sequencing technologies. These tools are available 
as open source software in many instances and have the potential to be exploited by the 
biologist for the identification of specific regulatory elements in a cost- and time-effective 
manner (van Helden, 2003).  
 
Due to the pervasive nature of disorders of iron metabolism, there is a requirement for the 
development of effective treatment strategies that would benefit those individuals afflicted. 
The elucidation of specific cis-motifs for the co-ordinated regulation of this biochemical 
pathway could potentially provide targets for pharmaceutical intervention. The molecular 
control of iron homeostasis in response to physiological iron levels, as a direct consequence 
of an absence of excretory methods for excess iron, means that this pathway is an ideal 
model system in which to apply various bioinformatic analyses in order to identify novel 
transcriptional control elements. 
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3.3 MATERIALS AND METHODS 
The reader is referred to Chapter 2 (Sections 2.1.1 to 2.1.5) for further information 
regarding the detailed methodology utilized. 
 
3.3.1 Sequence Retrieval and Promoter Prediction 
2000 bp (upstream of the initiating ATG, refer to Appendix 2 for the respective genes) of 
non-coding sequence for 18 of the genes (ACO1, CP, CYBRD1, FTH1, FTL, HAMP, HEPH, HFE, 
HFE2, HMOX1, IREB2, LTF, SLC11A2, SLC40A1, STEAP3, TF, TFRC, TFR2) implicated in the iron 
metabolic pathway were retrieved from the Ensembl database (Flicek et al., 2012). 
Core promoter prediction was conducted on the 5’UTR sequence of each gene using the 
Promoter 2.0 program (Knudsen, 1999, the Neural Network Promoter Prediction program 
(Reese, 2001) and the Eukaryotic Promoter Database (Schmid et al., 2005). 
 
3.3.2 In silico Detection of Promoter Regulatory Targets 
Pattern Discovery 
The gene sequences were submitted to mVISTA (Frazer et al., 2004) and YASS (Noe and 
Kucherov, 2005) in order to search for areas of sequence similarity between the genes. 
 
Pattern Matching 
ClustalW (Thompson et al., 1994) was utilized to generate multiple alignments of the 
regions of similarity in order to prepare a consensus sequence, which was employed in a 
BLASTn search against the nucleotide (nr/nt) collections and Human ALU repeat elements 
databases. The regions identified were further analyzed using the suite of programs, MEME 
(Bailey et al., 2006) to discover repeated sequence motifs. 
 
Pattern Recognition 
In order to identify putative transcription factor binding sites (TfBSs) within each of the 
identified motifs several databases were used: the Motif Comparison Tool, TOMTOM, from 
the MEME suite was used to compare the identified MEME motifs to the constituents of a 
database of known motifs (Gupta et al., 2007), JASPAR CORE (Sandelin et al., 2004), 
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TRANSFAC®7 (Wingender et al., 2001) and rVISTA (Loots and Ovcharenko, 2004). From 
TRANSFAC®7, two programs were used, PATCH and MATCH™ (v1.0) (Kel et al., 2005). 
 
3.4 RESULTS 
3.4.1 Sequence Retrieval and Promoter Prediction 
Upstream non-coding sequences were obtained from the human Ensembl database for each 
of the 18 genes of interest in this study, and are illustrated in Appendix 2. In order to 
confirm that these sequences contained elements of promoter architecture essential for 
transcription initiation they were each analyzed with three different promoter prediction in 
silico tools. The results of the analyses from the Neural Network Promoter Prediction 
(NNPP) software, Promoter 2.0 and the Eukaryotic Promoter Database (EPD) are listed in 
Table 3.1. Both NNPP and Promoter 2.0 search for binding factors associated with 
transcription initiation, specifically vertebrate PolII binding sites. NNPP generates scores 
between 0 and 1, with user-specified cut-off thresholds. For this analysis, 0.8 was selected 
as the threshold prediction score for maximum stringency, with scores closer to 1 indicating 
a greater likelihood for the prediction. Predicted transcription start sites (TSS) are depicted 
in bold, red text in Table 3.1. For Promoter 2.0, a likelihood score is calculated; by default, 
scores < 0.5 are ignored, those between 0.5 and 0.8 indicate marginal predictions and 
scores > 0.8 are indicative of highly likely predictions. EPD contains eukaryotic PolII 
promoters for which the TSS has been experimentally validated. 
In Table 3.1, the genomic position corresponds with the sequence for each gene listed in 
Appendix 2, where 1 was randomly assigned as the first base pair in the sequence. 
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Table 3.1 In Silico Promoter predictions.    
               
 Neural Network Promoter Prediction Promoter 2.0 Eukaryotic Promoter Database 
Gene Start End Score TSS Position Score Likelihood Start End 
ACO1 1175 1225 0.88 attagtactggctattgtt 1800 1.102 High 1534 2116 
CP 2192 2242 0.97 TTTTACTTCATTTCTTCTC 400 0.55 Marginal 1732 2266 
CYBRD1 2047 2097 0.93 tctttgagcaactaactag 2200 1.237 High 1835 2402 
FTH1 2190 2240 1.00 CGCAGGGCCAGACGTTCTT 2300 1.05 High 1775 2374 
FTL 1961 2011 1.00 cgtcccctcGCAGTTCGGC 700 0.54 Marginal 1503 2102 
HAMP 2182 2232 0.97 GTCCCAGACACCAGAGCAA 1800 1.02 High 1724 2323 
HEPH 1392 1442 0.92 gtaaatggaagtgtgtgca 1100 0.60 Marginal  1503 2102 
HFE 2080 2130 0.90 ggatcacctagtgtttcac 1200 0.64 Marginal  1665 2264 
HFE2 2054 2104 0.96 agccacctccctccctgct 1500 1.12 High 1668 2267 
HMOX1 2422 2472 0.99 CCGGCAGTCAACGCCTGCC 2100 0.626 Marginal 1963 2542 
IREB2 1316 1366 1.00 gaggtctgcagaggagcct 2000 0.70 Marginal  1690 2268 
LTF 2417 2467 1.00 GCGCAAGTGGCAGAGCCTT 1800 0.62 Marginal  1960 2539 
SLC11A2 2283 2333 0.99 ATTGGGAAAGTCAAACTAG 1900 0.591 Marginal  1009 2390 
SLC40A1 2083 2133 0.82 GGCGGAGAGAGCTGGCTCA 2200 0.654 Marginal  1647 2246 
STEAP3 1893 1943 0.91 agggcggccacctcccctg 1800 0.67 Marginal  1503 2523 
TF 2400 2450 0.98 AGGCTGCACAGAAGCGAGT 1700 0.63 Marginal  1503 2102 
TFRC 2257 2307 1.00 CGCCATCCCCTCAGAGCGT 1000 0.64 Marginal  1800 2377 
TFR2 2814 2864 0.95 ggggcacccatgtctctgc 1600 0.658 Marginal  2707 3214 
 
Abbreviations: ACO1, Aconitase 1 gene; CP, Ceruloplasmin gene; CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin heavy polypeptide 1 gene; FTL, Ferritin light 
polypeptide gene; HAMP, Hepcidin antimicrobial peptide gene; HEPH, Hephaestin gene; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; HMOX1, Haem 
oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2 gene; LTF, Lactotransferrin gene; SLC11A2, Solute carrier family 11 member 2 gene; SLC40A1, Solute 
carrier family 40 member 1 gene; STEAP3, Six-transmembrane epithelial antigen of the prostate 3 gene; TF, Transferrin gene; TFRC, Transferrin receptor 1 gene; TFR2, 
Transferrin receptor 2 gene. 
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3.4.2 Pattern Discovery 
Submission of the 2 kb UTR sequences to mVISTA demonstrated a region of sequence 
similarity between nine of the 18 (50%) iron metabolism genes (CYBRD1, FTH1, HAMP, HFE, 
HFE2, HMOX1, IREB2, LTF and TFRC). The other nine genes of interest (ACO1, CP, FTL, HEPH, 
SLC11A2, SLC40A1, STEAP3, TF and TFR2) did not show any defined regions of sequence 
similarity when compared to each other (Figure 3.1). mVISTA requires a single inputted 
sequence to be used as a so-called “base genome”; therefore each of the genes in turn was 
utilized as the base genome for comparison to each of the others in order to generate an 
accurate representation of the alignment. Figure 3.1 illustrates the alignment of all the 
sequences against HFE which was utilized as the base genome in this instance. 
 
In order to confirm the accuracy of the predictions by mVISTA, the genomic similarity search 
tool, YASS, was utilized. The 2 kb sequences of all 18 genes were submitted and YASS results 
indicated that an area of sequence conservation was detected in the same nine genes 
(CYBRD1, FTH1, HAMP, HFE, HFE2, HMOX1, IREB2, LTF and TFRC) as in those predicted by 
mVISTA (Table 3.2). In Table 3.2, the numbers underneath the gene names correspond to 
the genomic position of the region of sequence similarity in the 5’UTR of each gene, with 1 
arbitrarily assigned as the first base pair in the sequence for each gene listed in Appendix 2. 
The positions of the sequence conservation as predicted by mVISTA have been included for 
comparison, as well as the percentage similarity for the relevant alignment. Percentage 
similarities ≥ 75.0% are highlighted in red. In addition, YASS generated an E-value for each 
alignment pair: the smaller the E-value, the greater the significance of the proposed 
sequence similarity. E-values are a parameter used to describe the number of hits expected 
when searching a database of a particular size. 
 
The design of the strategy employed in this study (to search for and identify conserved 
motifs in the promoters of the genes involved in iron metabolism) was based on an 
assertion of some degree of detectable genomic sequence similarity between the genes. As 
a consequence, further in silico analyses were restricted to those nine genes containing the 
region of sequence homology discovered in the initial step of pattern discovery with mVISTA 
and YASS. 
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Figure 3.1 mVISTA sequence alignments of each of the 18 iron metabolism genes.     
Pink coloured areas indicate regions of sequence similarity. In this example HFE was utilized as the base 
genome for visualization of the alignments against: A.) ACO1; B.) CP; C.) CYBRD1; D.) FTH1; E.) FTL; F.) HAMP; 
G.) HEPH; H.) HFE2; I.) HMOX1; J.) IREB2; K.) LTF; L.) SLC11A2; M.) SLC40A1; N.) STEAP3; O.) TF; P.) TFRC and 
Q.) TFR2.                         
Abbreviations: ACO1, Aconitase 1 gene; CP, Ceruloplasmin gene; CYBRD1, Cytochrome b reductase 1 gene; 
FTH1, Ferritin heavy polypeptide 1 gene; FTL, Ferritin light polypeptide gene; HAMP, Hepcidin antimicrobial 
peptide gene; HEPH, Hephaestin gene; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; HMOX1, Haem 
oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2 gene; LTF, Lactotransferrin gene; 
SLC11A2, Solute carrier family 11 member 2 gene; SLC40A1, Solute carrier family 40 member 1 gene; STEAP3, 
Six-transmembrane epithelial antigen of the prostate 3 gene; TF, Transferrin gene; TFRC, Transferrin receptor 1 
gene; TFR2, Transferrin receptor 2 gene. 
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Table 3.2 mVISTA and YASS sequence alignments.   
                         mVISTA  YASS  
Gene 1 Gene 2 Percentage Similarity Gene 1 Gene 2 
Size (bp) 
(Gene1/Gene2) E-value 
 
CYBRD1 FTH1  CYBRD1 FTH1    
669-813 358-503 75.9% 649-945 339-654 297/316 2.0114e-52   
CYBRD1 HAMP  CYBRD1 HAMP    
669-813 1302-1442 77.2% 659-954 1293-1608 296/316 1.01832e-45   
CYBRD1 HFE  CYBRD1 HFE    
669-813 382-527 74.0% 550-975 294-706 426/413 4.84393e-54   
CYBRD1 HFE2  CYBRD1 HFE2    
686-781 984-1074 78.8% 644-798 937-1090 155/154 9.61974e-17   
CYBRD1 HMOX1  CYBRD1 HMOX1    
689-813 1098-1222 71.2% 649-976 1057-1425 328/369 4.21095e-45   
CYBRD1 IREB2  CYBRD1 IREB2    
672-813 1020-1161 81.0% 668-940 1016-1307 273/292 1.2211e-44   
CYBRD1 LTF  CYBRD1 LTF    
698-806 1142-1250 69.7% 636-946 1083-1408 311/326 1.01832e-45   
CYBRD1 TFRC  CYBRD1 TFRC    
669-813 980-1124 75.9% 661-965 972-1297 305/326 2.03663e-49   
FTH1 HAMP  FTH1 HAMP    
358-503 1302-1442 72.4% 343-654 1285-1597 312/313 3.84786e-24   
FTH1 HFE  FTH1 HFE    
358-503 382-527 83.6% 359-654 382-676 296/295 6.49006e-69   
FTH1 HFE2  FTH1 HFE2    
394-491 997-1093 75.5% 354-491 948-1093 138/146 3.35897e-14   
FTH1 HMOX1  FTH1 HMOX1    
358-503 1078-1222 71.7% 312-654 1033-1394 343/362 6.0802e-42   
FTH1 IREB2  FTH1 IREB2    
362-503 1020-1161 75.4% 350-653 1011-1311 304/301 7.05255e-49   
FTH1 LTF  FTH1 LTF    
377-501 1131-1256 69.4% 338-654 1089-1407 317/319 6.87887e-55   
FTH1 TFRC  FTH1 TFRC    
358-503 980-1124 87.6% 333-653 957-1276 321/320 1.10518e-68   
HAMP HFE  HAMP HFE    
1302-1442 375-681 75.3% 1296-1602 375-681 307/307 4.02278e-56   
HAMP HFE2  HAMP HFE2    
1320-1440 982-1104 73.0% 1320-1430 982-1093 111/112 3.33117e-16   
HAMP HMOX1  HAMP HMOX1    
1329-1442 1105-1222 72.9% 1276-1597 1050-1394 322/345 1.20097e-48   
HAMP IREB2  HAMP IREB2    
1309-1442 1024-1161 76.1% 1300-1591 1018-1306 292/289 4.74432e-59  
HAMP LTF  HAMP LTF    
1322-1429 1133-1244 75.0% 1317-1609 1128-1419 293/292 9.76868e-56   
HAMP TFRC  HAMP TFRC    
1302-1442 980-1124 77.2% 1284-1598 965-1278 315/314 8.04553e-60   
HFE HFE2  HFE HFE2    
402-515 984-1093 72.8% 141-353 874-1093 213/220 2.78955e-16   
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HFE HMOX1  HFE HMOX1    
384-513 1078-1208 69.2% 182-540 1035-1393 359/359 6.02988e-44   
HFE IREB2  HFE IREB2    
385-528 1020-1161 72.0% 378-671 1012-1307 294/296 4.15877e-48   
HFE LTF  HFE LTF    
401-513 1132-1243 72.6% 378-681 1106-1412 304/307 2.0114e-52   
HFE TFRC  HFE TFRC    
382-527 980-1124 85.6% 335-695 930-1297 361/368 2.63952e-72   
HFE2 HMOX1  HFE2 HMOX1    
991-1091 1107-1208 77.5% 948-1091 1071-1208 144/138 1.94808e-17   
HFE2 IREB2  HFE2 IREB2    
959-1092 1023-1147 72.1% 982-1093 1035-1149 112/115 2.30706e-19   
HFE2 LTF  HFE2 LTF    
959-1090 1112-1240 69.2% 946-1091 1099-1243 146/145 2.77798e-17   
HFE2 TFRC  HFE2 TFRC    
991-1090 1009-1112 77.8% 988-1093 1006-1112 106/107 3.96145e-17   
HMOX1 IREB2  HMOX1 IREB2    
1079-1222 1018-1161 73.6% 1075-1279 1016-1219 205/204 1.26764e-35    
HMOX1 LTF  HMOX1 LTF    
1098-1218 1133-1253 76.0% 1057-1395 1085-1408 339/324 4.80384e-56  
HMOX1 TFRC  HMOX1 TFRC    
1078-1222 980-1124 73.1% 1074-1335 978-1245 262/268 7.26073e-42   
IREB2 LTF  IREB2 LTF    
1037-1154 1133-1250 76.3% 1002-1308 1094-1403 307/310 3.98948e-58   
IREB2 TFRC  IREB2 TFRC    
1020-1161 982-1124 78.9% 1016-1430 979-1391 415/413 3.31318e-60   
LTF TFRC  LTF TFRC    
1131-1251 998-1118 72.7% 1107-1406 981-1276 300/296 2.89222e-50   
 
Abbreviations: bp, base pair; CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin heavy polypeptide 1 
gene; HAMP, Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; 
HMOX1, Haem oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2 gene; LTF, Lactotransferrin 
gene; TFRC, Transferrin receptor 1 gene. 
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The conserved regions (CRs) predicted by mVISTA and YASS were inspected visually and 
narrowed down to the most representative sequence from each of the genes, in order to 
include the entire region of conservation that was common to all of the genes examined. A 
140 bp area was selected from each gene (illustrated in green text in Appendix 2) and these 
sequences were resubmitted to mVISTA for alignment of the CR. A representative example 
of the mVISTA results of the CR alignment is illustrated in Figure 3.2. In this illustration 
CYBRD1 was utilized as the base genome and compared to the eight remaining genes. The 
mVISTA results for each of the other genes in turn are depicted in Appendix 4: Figure S1, 
page 179). 
 
 
Figure 3.2 mVISTA sequence alignments of the CR in each of the nine iron metabolism genes.    
Pink coloured areas indicate regions of sequence similarity. In this example CYBRD1 was utilized as the base 
genome for visualization of the alignments against: A.) FTH1; B.) HAMP; C.) HFE; D.) HFE2; E.) HMOX1; F.) 
IREB2; G.) LTF and H.) TFRC.                      
Abbreviations: CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin heavy polypeptide 1 gene; HAMP, 
Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; HMOX1, Haem 
oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2 gene; LTF, Lactotransferrin gene; TFRC, 
Transferrin receptor 1 gene. 
A. 
B. 
C. 
D. 
E. 
F. 
G. 
H. 
     CYBRD1 
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3.4.3 Pattern Matching 
In order to generate a consensus CR sequence from each of the genes of interest, ClustalW 
(Thompson et al., 1994) was utilized to produce a multiple alignment (Figure 3.3). The 
consensus sequence was prepared by hand due to the fact that the majority of 
commercially available resources require sequences of equal length, and the CR in this case 
differs by a few base pairs between the different genes. Base pairs that were responsible for 
the introduction of gaps in the multiple alignment (particularly in the case of HFE2), and 
therefore did not align with nucleotides in any of the other genes, were excluded from the 
consensus sequence. The consensus CR sequence was subjected to a nucleotide Basic Local 
Alignment Search (BLASTn) against the nucleotide (nr/nt) collection as well as the Human 
ALU repeat elements databases. The BLASTn search result with the lowest E-value (7 x 10-
52), the highest maximum identity (93%) and a total coverage of 92% was to the human Alu-J 
subfamily consensus sequence (Figure 3.4 A). This 290 bp sequence was retrieved from the 
nucleotide database on GenBank (accession number U14567) and utilized in a ClustalW 
Multiple alignment with the CR consensus sequence (Figure 3.4 B). 
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Figure 3.3 ClustalW multiple alignment of the CR of each of the nine iron genes.                     
Abbreviations: CR, conserved region; CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin heavy 
polypeptide 1 gene; HAMP, Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, 
Hemojuvelin gene; HMOX1, Haem oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2 gene; 
LTF, Lactotransferrin gene; TFRC, Transferrin receptor protein 1 gene. 
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Figure 3.4 Alignment of the consensus CR with the human Alu-J consensus sequence.                                        
A.) BLASTn output of CR consensus query; B.) ClustalW alignment of CR consensus and full human Alu-J 
sequence retrieved from Genbank.                             
Abbreviations: CR, conserved region. 
 
The CR region from each of the nine genes was submitted to the in silico program MEME 
(Multiple EM for Motif Elicitation) for identification of statistically significant, novel 
sequence signals or cis-regulatory modules (CRMs) residing within this area. MEME 
discovered the presence of four CRMs (Motif 1 to Motif 4) that were shown to be present in 
the same order, position and orientation in each of the nine CR sequences submitted. 
However, Motif 3 (red block) was not predicted to occur in the CR of HFE2 or LTF (Figure 
3.5). Combined p-values for the four CRMs were highly statistically significant for all nine 
CRs, and are illustrated in Figure 3.5. In addition, individual p-values for each motif in the 
nine CRs were calculated and were found to be statistically significant (Appendix 4: Figure 
S2, page 183). 
 
A. 
B. 
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Figure 3.5 CRM discovery using MEME.                                                                     
The CR of each gene is shown with the identified CRMs (Motif 1 to Motif 4) indicated by different coloured blocks. The genomic order and location of each motif is the 
same for each of the nine genes investigated. Combined p-value scores for the four motifs are listed.                             
Abbreviations: CR, conserved region; CRM, cis-regulatory module; CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin heavy polypeptide 1 gene; HAMP, Hepcidin 
antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; HMOX1, Haem oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2 
gene; LTF, Lactotransferrin gene; TFRC, Transferrin receptor 1 gene. 
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3.4.4 Pattern Recognition 
The TOMTOM Motif Comparison Tool, within the MEME suite, was utilized to further 
analyze each motif individually in order to identify putative transcription factor binding sites 
(TfBSs). The JASPAR CORE vertebrates database was chosen as the target database for the 
identification of overrepresented TfBSs. Sequence logos corresponding to each of the four 
motifs, or CRMs, were generated by TOMTOM and used to align predicted TfBSs from 
JASPAR in the pertinent positions (Figure 3.6). Only TfBSs with a statistically significant p-
value < 0.05 and an E-value < 10 were considered relevant and are illustrated by their own 
sequence logos, arranged in ascending order of significance, in Figure 3.6. 
 
Due to the different computational algorithms employed by individual prediction software, 
identification of the same TfBS by more than one program increases the likelihood that the 
motif exists. The 140 bp CR from each of the nine genes was therefore analyzed with the 
PATCH and MATCH™ programs within the TRANSFAC®7 database, as well as rVISTA to 
compare the putative TfBSs resulting from the TOMTOM search of the JASPAR CORE 
database. For the PATCH and MATCH™ programs, the default settings and parameters were 
employed. For rVISTA, a subset of motifs were selected based on the results of the 
TOMTOM search, as well as known liver-specific TfBSs, and used in the analysis of the CR. 
The default core similarity values of 0.75 and matrix similarity values of 0.70 were utilized. 
 
The results obtained through in silico analysis of the nine CRs are shown in Table 3.3. An 
rVISTA graphical representation of the results of the TfBS alignments with the consensus 
sequence generated from the nine CRs is shown in Appendix 4: Figure S3, page 184. The 
majority of TfBSs predictions were confirmed by at least two of the different programs 
utilized. The results from both MATCH™ and PATCH appeared to correspond more 
accurately with the results from rVISTA than with each other. MATCH™ predicted the 
presence of consensus binding sites for NKX2-5 (in the CR of CYBRD1, HFE2 and HMOX1) and 
PAX4 (in the CR of HFE and TFRC), which was confirmed by the rVISTA program (Table 3.3). 
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Figure 3.6 TOMTOM TfBS prediction for each CRM.                                               
For each CRM, a sequence logo representing the individual motif sequence was aligned to sequence logos 
produced for the most statistically significant TfBSs. TfBSs names are indicated next to the relevant sequence 
logo, arranged in ascending order of significance. A.) Motif 1 and B.) Motif 2.                
Abbreviations: CRM, cis-regulatory module; TfBSs, transcription factor binding sites. 
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Figure 3.6 Cont. TOMTOM TfBS prediction for each CRM.                                              
For each CRM, a sequence logo representing the individual motif sequence was aligned to sequence logos 
produced for the most statistically significant TfBSs. TfBSs names are indicated next to the relevant sequence 
logo, arranged in ascending order of significance. C.) Motif 3 and D.) Motif 4.                
Abbreviations: CRM, cis-regulatory module; TfBSs, transcription factor binding sites. 
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Table 3.3 Predicted TfBSs in the CR of the iron metabolism genes. 
    
Gene 
Putative Transcription Factor Binding Sites 
PATCH MATCH™ rVISTA 
CYBRD1 AP-1, c-MYC, GR, HNF-3α, HNF-3β, PAX2, PAX5, PAX8, RXR-α, RXR-γ, SP1, USF2 NKX2-5 
AP-1, AP-2, C/EBP, FOXD3, FOXM1, GATA-1, GATA-2, GATA-3, GR, HNF-1, HNF-3, HNF-4, MEF2A, 
MTF1, NKX2-5, NKX3-2, PAX4, PAX6, PPAR, SMAD-1, SMAD-3, SMAD-4, SP1, STAT5A, USF, YY1 
FTH1 AP-2, FOXO3a, HNF-3α, HNF-3β, MTF-1, RXR-α, RXR-β, RXR-γ, SP1, STAT5A, STAT5B - 
AP-1, AP-2, C/EBP, FOXD3, FOXM1, GATA-1, GATA-2, GATA-3, GR, HNF-1, HNF-3, HNF-4, MEF2A, 
MTF-1, NKX2-5, NKX3-2, PAX4, PAX6, PPAR, SMAD-1, SMAD-3, SMAD-4, SP1, STAT5A, USF, YY1 
HAMP AP-1, AP-2, GR, HNF-3α, HNF-3β, MTF-1, PAX2, PAX5, PAX8, RXR-α, RXR-β, RXR-γ, SP1, STAT5A, STAT5B - 
AP-1, AP-2, C/EBP, FOXD3, FOXM1, GATA-1, GATA-2, GATA-3, GR, HNF-1, HNF-3, HNF-4, MEF2A, 
MTF-1, NKX2-5, NKX3-2, PAX4, PAX6, PPAR, SMAD-1, SMAD-3, SMAD-4, SP1, STAT5A, USF, YY1 
HFE AP-1, AP-2, c-MYC, GATA-1, GR, HNF-1α, HNF-3α, HNF-
3β, RXR-α, RXR-β, RXR-γ, STAT5A, STAT5B PAX4 
AP-1, AP-2, C/EBP, FOXD3, FOXM1, GATA-1, GATA-2, GATA-3, GR, HNF-1, HNF-3, HNF-4, MEF2A, 
MTF-1, NKX2-5, NKX3-2, PAX4, PAX6, PPAR, SMAD-1, SMAD-3, SMAD-4, SP1, STAT5A, USF, YY1 
HFE2 AP-2, GATA-1, GATA-2, GR, HNF-3α, HNF-3β, MTF-1, PAX2, PAX5, PAX8, RXR-γ, SMAD-3, SMAD-4, SP1, USF2 NKX2-5 
AP-1, AP-2, C/EBP, FOXD3, FOXM1, GATA-1, GATA-2, GATA-3, GR, HNF-1, HNF-3, HNF-4, MEF2A, 
MTF-1, NKX2-5, NKX3-2, PAX4, PAX6, PPAR, SMAD-1, SMAD-3, SMAD-4, SP1, STAT5A, USF, YY1 
HMOX1 AP-1, AP-2, c-MYC, HNF-1α, HNF-1β, PAX2, PAX5, PAX8, RXR-α, RXR-β, RXR-γ, SP1, STAT5A, STAT5B NKX2-5 
AP-1, AP-2, C/EBP, FOXD3, FOXM1, GATA-1, GATA-2, GATA-3, GR, HNF-1, HNF-3, HNF-4, MEF2A, 
MTF-1, NKX2-5, NKX3-2, PAX4, PAX6, PPAR, SMAD-1, SMAD-3, SMAD-4, SP1, STAT5A, USF, YY1 
IREB2 AP-1, c-MYC, GATA-1, GR, HNF-3α, HNF-3β, MTF-1, PAX2, PAX5, PAX8, RXR-γ, SP1, USF2 - 
AP-1, AP-2, C/EBP, FOXD3, FOXM1, GATA-1, GATA-2, GATA-3, GR, HNF-1, HNF-3, HNF-4, MEF2A, 
MTF-1, NKX2-5, NKX3-2, PAX4, PAX6, PPAR, SMAD-1, SMAD-3, SMAD-4, SP1, STAT5A, USF, YY1 
LTF AP-1, AP-2, PAX2, PAX5, PAX8, RXR-γ, SP1, STAT5A, STAT5B, USF2 - 
AP-1, AP-2, C/EBP, FOXD3, FOXM1, GATA-1, GATA-2, GATA-3, GR, HNF-1, HNF-3, HNF-4, MEF2A, 
MTF-1, NKX2-5, NKX3-2, PAX4, PAX6, PPAR, SMAD-1, SMAD-3, SMAD-4, SP1, STAT5A, USF, YY1 
TFRC AP-1, GR, MTF-1, RXR-α, RXR-β, RXR-γ, SP1, STAT5A, STAT5B PAX4 
AP-1, AP-2, C/EBP, FOXD3, FOXM1, GATA-1, GATA-2, GATA-3, GR, HNF-1, HNF-3, HNF-4, MEF2A, 
MTF-1, NKX2-5, NKX3-2, PAX4, PAX6, PPAR, SMAD-1, SMAD-3, SMAD-4, SP1, STAT5A, USF, YY1 
 
Abbreviations: AP-1, Activator protein 1; AP-2, Activator protein 2; C/EBP, CCAAT enhancer binding protein; c-MYC, Myelocytomatosis viral oncogene c; FOXM1, Forkhead box 
protein M1; FOXO3a, Forkhead box protein O3a; GATA-1, GATA-binding protein 1; GATA-2, GATA-binding protein 2; GATA-3, GATA-binding protein 3; GR, Glucocorticoid receptor; 
HNF-1α, Hepatocyte nuclear factor 1 alpha; HNF-1β, Hepatocyte nuclear factor 1 beta; HNF-3α, Hepatocyte nuclear factor 3 alpha; HNF-3β, Hepatocyte nuclear factor 3 beta; MEF2A, 
Myocyte-specific enhancer factor 2A; MTF-1, Metal transcription factor 1; NKX2-5, NK 2 homeobox 5; NKX3-2, NK 3 homeobox 2; PAX2, Paired box 2; PAX4, Paired box 4; PAX5, 
Paired box 5; PAX6, Paired box 6; PAX8, Paired box 8; PPAR, Peroxisome proliferator-activated receptor; RXR-α, Retinoid X receptor alpha; RXR-β, Retinoid X receptor beta; RXR-γ, 
Retinoid X receptor gamma; SMAD-1, Mothers against decapentaplegic homolog 1; SMAD-3, Mothers against decapentaplegic homolog 3; SMAD-4, Mothers against decapentaplegic 
homolog 4; SP1, Specificity protein 1; STAT5A, Signal transducer and activator of transcription 5A; STAT5B, Signal transducer and activator of transcription 5B; USF, Upstream 
transcription factor ; USF2, Upstream transcription factor 2; YY1, Ying Yang 1. 
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3.5 DISCUSSION 
Promoter prediction software was utilized to assess the upstream sequences retrieved from 
the Ensembl database for 18 of the iron metabolism genes of interest in this study. 
Conventionally, promoter prediction has proved a stumbling block in the search for 
regulatory elements in non-coding eukaryotic sequences due to difficulties presented by the 
complexity of these regions and the limited power and accuracy of software programs to 
precisely identify promoter signals (Fickett and Hatzigeorgiou, 1997). However, 
experimental data from large scale ChIP- and microarray studies for the identification of TSS 
in human and mouse genomes has led to the availability of precise promoter sequences for 
numerous genes (deposited into databases such as EPD) and a subsequent improvement of 
the algorithms underlying promoter prediction software (Down and Hubbard, 2002; 
Okazaki, et al., 2002). In this study, experimentally determined promoter sequences were 
obtained from EPD (Schmid et al., 2005) and compared to predictions performed by 
Promoter 2.0 and NNPP, two of the most popular and frequently used programs for the 
identification of vertebrate PolII binding sites (Table 3.1). All of the 2 kb upstream sequences 
for the genes of the iron metabolism pathway were found to contain promoter elements 
essential for basal transcription levels and thus were considered to be true promoters. From 
the results, it is evident that the NNPP program performed more accurately than Promoter 
2.0 when compared to the data from EPD (Table 3.1). Both prediction programs were able 
to identify regions that overlapped those contained within EPD, however those identified by 
NNPP were more exact in terms of the regions identified. 
 
The promoter sequences from all of the genes were then submitted to mVISTA in order to 
search for regions of sequences similarity between the genes (pattern identification) which 
could be further utilized to search for conserved regulatory elements common to the iron 
metabolism pathway. mVISTA forms part of the VISTA family of comparative genomic tools 
and is a constantly maintained and updated resource (Frazer et al., 2004). Traditionally, it is 
designed for the comparison and alignment of multi-species sequences, however, the AVID 
alignment engine used to generate the pairwise global alignments can be utilized for the 
evaluation of any subset of user-submitted sequences (Bray et al., 2003). RepeatMasker is 
automatically used by the mVISTA server to mask repetitive sequences in the sequence 
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selected as the reference or “base genome”. The results of the mVISTA alignment of the 
promoter sequences demonstrated a region of sequence conservation in nine of the 18 
genes (CYBRD1, FTH1, HAMP, HFE, HFE2, HMOX1, IREB2, LTF and TFRC) (pink region in 
Figure 3.1). Examination of the alignments between each of the genes showed that 
sequence similarity was between ~70.0 and 85.0% (Table 3.2, sequence similarities ≥ 75.0% 
are highlighted in red), indicating a high magnitude of sequence conservation of these areas. 
 In order to validate the mVISTA prediction, all 18 sequences were submitted to 
another alignment program, YASS (Noe and Kucherov, 2005). Comparison of the regions of 
sequence similarity predicted by mVISTA and YASS (Table 3.2) illustrated that both programs 
were able to identify the same genomic area when each of the genes were aligned to each 
other in turn. The E-values generated by YASS for each alignment were highly statistically 
significant (Table 3.2) although the alignments were slightly longer than those obtained 
from mVISTA. 
 The conserved region, predicted by mVISTA and YASS, from each of the nine genes 
was examined visually in order to obtain a genomic region which was representative for 
each of the genes and excluded erroneous flanking sequences that may be common to 
some of the genes, but not all. This conserved region (termed the CR) includes 140 bp of 
sequence from each gene (highlighted in green in Appendix 2) representing a high level of 
sequence conservation which has implications for regulatory control mechanisms of these 
genes. The nine CRs were again submitted to mVISTA for alignment of the sequences and a 
visualization of the results (utilizing CYBRD1 as the reference) is presented in Figure 3.2. A 
clear conservation (pink area) of the CR is visible in the results, once again confirming the 
strength of similarity of the identified CR. 
 The results of the pattern discovery portion of the in silico analysis represent a novel 
finding in the 5’-UTR of the iron metabolism pathway which is worthy of further 
investigation on the premise that genes which share similar promoter features, and are 
involved in a common pathway, may be co-regulated (Wasserman and Sandelin, 2004). 
 
A BLAST search of the consensus sequence generated from the CR of each gene (Figure 3.4) 
demonstrated a significant (E value = 7 x 10-52) hit to the GenBank human Alu-J subfamily 
consensus sequence. Alu elements are repetitive elements that arose from the fusion of the 
7SL RNA gene approximately 65 million years ago (Batzer and Deininger, 2002). Although 
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not yet fully elucidated, it is believed that Alu elements amplified across primate genomes 
through a retrotransposition mechanism via RNA intermediates (Rowold and Herrera, 
2000). Alu elements are ~300 bp in length and are located primarily in AT-rich areas of the 
genome. They are the most abundant member of the SINE (Short Interspersed Nuclear 
Elements) family of repetitive elements and more than a million copies are present 
throughout the human genome, comprising 10% of total genomic mass (Häsler and Strub, 
2006). These mobile elements are grouped into two subfamilies based on their relative ages, 
the Alu-J and Alu-S subfamilies (Jurka and Smith, 1988). Due to their profusion within human 
and primate genomes, Alu elements are thought to have played a significant role from an 
evolutionary perspective, both in a positive and negative manner. Due to their conserved 
sequence homology, Alus have been proposed to provide regulatory elements to 
neighbouring genes. They have been identified in numerous 5’- and 3’-UTRs gene transcripts 
and are transcribed by RNA polymerase II to form part of the resulting mRNAs. They act as 
enhancers, repressors and may present novel promoter elements to modulate gene 
transcription and mRNA translation (Brosius, 1999; Tomilin, 1999). Several studies have 
implicated UTR (either 5’ or 3’) Alu repeats in the regulation of transcription in specific gene 
transcripts; human growth hormone receptor (hGHR) (Goodyer et al., 2001), manganese 
superoxide dismutase (MnSOD) (Stuart et al., 2000) and the best described example, BRCA1, 
in which a 5’-UTR Alu element in the normal BRCA1 transcript results in translational 
inhibition (Sobczak and Krzyzosiak, 2002). In addition, Alu elements have been shown to 
contain binding sites for various Tfs and are able to interact with Tfs in vivo to regulate the 
transcription of genes (Polak and Domany, 2006). Polak and Domany identified numerous 
Tfs, able to bind to Alu elements, with particular relevance to this study including, NKX2-5, 
HNF-4, MEF2A, HNF-1, PAX4, PAX6 and YY1. Binding sites for these Tfs were all predicted to 
be present in the CR of the nine genes investigated in this study, therefore adding credibility 
to the proposition that the CR may potentially be comprised of an Alu repeat. Although Alu 
elements have not yet been described for the iron metabolism pathway, the level of 
sequence conservation between the CR consensus sequence and the Alu-J subfamily 
consensus identified in this study has potential implications for a possible mechanism of co-
ordinated regulation. It is probable that the Alu element identified here may represent a 
reservoir of TfBSs for specific Tfs, which could act to modulate the transcriptional activation 
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or repression of this subset of the iron metabolism genes, therefore representing a novel 
regulatory mechanism. 
Investigation of the CR of the nine iron genes utilizing MEME (pattern matching) 
demonstrated that four different sequence motifs (Motif 1 – Motif 4) were present in this 
140 bp sequence (Figure 3.5). Each of these CRMs was statistically significant on an 
individual basis, as well as when combined together (Figure 3.5 and Appendix 4: Figure S2, 
page 183). Of interest, was the fact that each of these four CRMs was located in the same 
genomic location, orientation and order in each of the nine genes, with the exception of 
HFE2 and LTF which were found not to possess Motif 3 (red block, Figure 3.5) at the 3’ end 
of the CR. This CRM conservation strongly suggests a functional role for the CR in each of 
the genes examined. It is however imperative to assess the in vitro functionality of this 
region in order to substantiate the bioinformatic predictions. 
 In the context of gene regulation CRMs represent multiple binding sites for 
numerous Tfs thereby enabling a superior level of transcriptional control (Blanchette et al., 
2006). CRMs are responsible for the activation and repression of transcriptional initiation by 
mediating the binding of specific Tfs in different combinations depending on the needs of a 
particular cell in response to a variety of stimuli (so-called “molecular switches”). Multiple 
bound Tfs therefore have the ability to act in a combinatorial manner to alter transcriptional 
activity and genes regulated by a common set of Tfs tend to be co-expressed (Gupta and Liu, 
2005). 
 
The characteristic features of CRMs described can be exploited in the search for regulatory 
elements for specific Tfs (Bulyk, 2003). In silico analysis of the CR identified in this study 
demonstrated the presence of numerous putative TfBSs (pattern recognition) (Table 3.3). 
Only Tfs that were predicted to be conserved across all CRs examined or that are biologically 
relevant (involved in iron metabolism or liver-specific) will be discussed further. The 
program TOMTOM, part of the MEME suite, predicted potential TfBSs for each of the four 
identified CRMs comprising the CR (Figure 3.6). TOMTOM utilizes the JASPAR CORE 
vertebrates database to search for conserved binding sites, and only statistically significant 
(p < 0.05) Tfs were selected from the results generated from the investigation. In addition, 
other bioinformatic analyses for the identification of putative TfBSs were performed with 
the aim to increase the likelihood of the predictions and therefore the potential functional 
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relevance. Results from a TRANSFAC®7 (utilizing the PATCH and MATCH™ programs) and 
rVISTA search (Table 3.3) were compared to the results obtained from TOMTOM. 
With respect to Motif 1, TOMTOM predicted the following TfBSs with p-values indicated: 
MAFB (p = 0.01), PAX5 (p = 0.03) and MAX (p = 0.04) (Figure 3.6 A). After analysis with the 
other TfBS prediction programs, members of the PAX family of Tfs were the only TfBS to be 
identified by PATCH, MATCH and rVISTA (Table 3.3). PAX (paired box) factors are a class of 
basic helix-loop-helix (bHLH) Tfs that are highly conserved in vertebrates (Wang et al., 
2010). There are nine members of the PAX family assembled into four distinct groups: PAX1 
and PAX9 (PAX group I); PAX2, PAX5 and PAX8 (PAX group II); PAX3 and PAX7 (PAX group III); 
PAX4 and PAX6 (PAX group IV). PAX5 encodes a B-cell specific activator protein (BSAP) and is 
implicated in the differentiation of B-cells during early stage delineation (Adams et al., 
1992). The PAX Tfs are known to be involved in cell development and organogenesis, 
although little is known about their specific target genes (Lang et al., 2007). Due to the 
ubiquitous distribution of the PAX factors in vertebrate organisms, they are considered to 
be universal master gene regulators with the capability to bind to the upstream regions of a 
multitude of genes (Buckingham and Relaix, 2007). PAX Tfs have not been extensively 
described with regard to regulation of genes involved in iron metabolism however a study 
by Chaudhary et al. (1997) revealed the presence of E-box motifs in the transferrin (TF) 
promoter in Sertoli cells, capable of binding bHLH Tfs resulting in elevated expression of TF. 
Expression was abrogated upon inhibition of bHLH factors indicating the importance of 
these Tfs in the regulation of TF expressed in this cell type. Although TF was not found to 
contain the CR of interest in this study, the fact that bHLH TfBSs have been identified in this 
gene and are actively involved in regulation of expression indicates that PAX Tfs may have a 
defined role in regulation of other genes involved in iron metabolism. PAX (PAX2, PAX4, 
PAX5, PAX6 and PAX8) Tfs were consistently identified by all in silico tools utilized in this 
study (Table 3.3), across the different motifs comprising the CR, and therefore warrant 
further investigation in this metabolic pathway. In addition, it remains to be elucidated if 
PAX and other bHLH Tfs are actively involved in gene regulation in cells of the liver, intestine 
and macrophages which are the primary sites of expression of iron metabolizing genes. 
Traditionally PAX factors have been found to be involved in gene regulation primarily in cells 
of the thyroid, kidney (Poleev et al., 1995) and pancreas (Brun et al., 2005) and appear to 
exert their functions during early stage cell differentiation and development, with a less 
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defined role in adult tissues (Calame et al., 2003). Due to a lack of substantial evidence for 
the involvement of PAX factors in the regulation of iron gene expression, functional 
investigation would be required to validate the in silico predictions from this study. 
 
A TOMTOM search of Motif 2 revealed putative TfBSs for NKX3-2 (p = 0.02), HNF-4α (p = 
0.03), PAX6 (p = 0.03), PPARγ-RXRα (p = 0.04) and PAX5 (p = 0.05) (Figure 3.6 B). 
 In conjunction with the PAX factors discussed above, a HNF-4α binding site was 
predicted by TOMTOM as well as rVISTA (Table 3.3). The HNF (hepatocyte nuclear factor) Tfs 
are expressed predominately in the liver in large quantities and are known to regulate liver-
specific expression of target genes in a synergistic manner by binding to enhancer or 
repressor elements in the promoter region. Members of the HNF family are phylogenetically 
unrelated and are grouped into four subfamilies based on their functional characteristics 
and interactions (Cereghini, 1996). HNF-4α is a member of the hepatocyte nuclear family 4 
(HNF-4) of Tfs that are characterized as nuclear hormone receptors. The HNF-4 nuclear 
hormone receptors exert their function via DNA-binding as a homodimer or as a 
heterodimer with members of the RXR (retinoid X receptor) family of Tfs (Li et al., 2000). 
Interestingly, binding sites for RXR-α, RXR-β, RXR-γ in the CR were predicted by the PATCH 
program in this study (Table 3.3), and may therefore indicate a functional role for HNF-4α in 
this pathway. Furthermore, functionally confirmed binding sites for HNF-4α have been 
identified in the hepcidin promoter (Courselaud et al., 2002) and were associated with 
negative regulation of gene expression during in vitro assays. Furthermore, PATCH and 
rVISTA predicted binding sites for other HNF Tfs, specifically HNF-1α, HNF-1β, HNF-3α and 
HNF-3β (Table 3.3) in the CR, therefore increasing the likelihood of functional regulation by 
these Tfs. Genes of the iron metabolism pathway, particularly hepcidin, are expressed 
largely in hepatocytes and therefore gene regulation by the HNF family of Tfs is not 
unexpected and requires further examination. 
 
In addition, TOMTOM predicted the presence of a PPARγ TfBS in Motif 2 of the CR. 
Conservation of this TfBS across the CR of the nine genes was confirmed by analysis with 
rVISTA (Appendix 4: Figure S3, page 184). PPARs (peroxisome proliferator-activated 
receptors) are a group of nuclear receptor proteins that are involved in the regulation of 
cellular metabolism and differentiation in eukaryotic organisms (Feige et al., 2006). PPAR 
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proteins form heterodimers specifically with RXRs facilitating DNA-binding to PPREs 
(peroxisome proliferator hormone response elements) with the consensus sequence -
AGGTCANAGGTCA- (Michalik et al., 2006). Numerous studies have demonstrated an 
association with iron and PPAR, particularly in reference to hepatic insulin resistance and 
liver disease (Silva et al., 2010; Kell, 2009; Valenti et al., 2007). Excess iron has been shown 
to result in an increase in triglyceride levels mediated by a decrease in PPAR interaction 
(Silva et al., 2008), therefore illustrating the relationship between iron, PPAR and hepatic 
lipid metabolism. In addition, a number of pharmacological agents are utilized for the 
activation of PPAR (particularly PPARα) which result in lower levels of hepatic triglycerides 
and are used in the treatment of chronic obesity and liver disease (Rakhshandehroo et al., 
2007; Ip et al., 2004). As in the case of HNF-4α, the presence of numerous RXR TfBSs 
predicted by PATCH (Table 3.3) strengthens the potential association of PPAR with 
regulation of iron-metabolizing genes. 
 
TfBSs predicted for Motif 3 included NHLH1 (p = 0.01), ZEB1 (p = 0.02), C/EBPα (p = 0.03) 
and PAX4 (p = 0.05) (Figure 3.6 C). TOMTOM predictions of C/EBPα TfBSs were confirmed by 
rVISTA (Table 3.3). C/EBPα is a bZIP (basic leucine zipper) Tf that binds to gene promoters as 
a homodimer or as a heterodimer in association with other C/EBP proteins. Sequence-
specific DNA-binding of C/EBPα, followed by the recruitment of co-activators such as CBP 
(CREB1-binding protein) and basal Tfs, activates transcription of a variety of liver-specific 
genes implicated in cell proliferation, differentiation and metabolism (Kovács et al., 2003). 
C/EBP binding sites are characteristic of CRM architecture as a result of their innate ability 
to recruit additional Tfs, specifically the leucine zipper domain-containing family (eg. c-FOS 
and JUN) (Shaulian and Karin 2002). C/EBP Tfs have been associated with the regulation of 
hepatic iron, nitrogen and lipid metabolism (Pedersen et al., 2007) and it is therefore 
feasible that potential C/EBPα TfBSs reside within the CR of the genes of interest in this 
study. The hepcidin promoter has been experimentally shown to contain binding sites for 
C/EBPα that are associated with enhanced hepatocyte-specific promoter activity in both 
human and mouse via direct interaction of C/EBPα with recognition sites in the hepcidin 
promoter (Courselaud et al., 2002). 
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The in silico investigation of Motif 4 revealed putative binding sites for FOXD3 (p = 0.00), 
FOXI1 (p = 0.01), MEF2A (p = 0.03) and SOX2 (p = 0.04) (Figure 3.6 D). Within this motif, FOX 
(forkhead box) Tfs were overrepresented due to their affinity for recognizing T-rich 
stretches of DNA characteristic of Motif 4 at the 5’-end of the CR (see Appendix 2 for CR 
sequences or Appendix 4: Figure S2 D, page 183). The FOX family are a large group of 
functionally diverse Tfs that are classified phylogenetically according to structure into 15 
distinct subfamilies (Coffer and Burgering, 2004). They form part of the bHLH class of Tfs and 
are composed of a winged helix domain that comprises the distinctive forkhead motif of 
these proteins (Katoh and Katoh, 2004). TOMTOM analysis of Motif 4 revealed the presence 
of two FOX family members, FOXD3 and FOXI1, which were substantiated by rVISTA (Table 
3.3). Although literature pertaining to the relationship between FOX factors and iron 
metabolism is scarce, a large-scale microarray study of differentially expressed genes under 
conditions of iron deficiency resulted in the identification of conserved SP1 (specificity 
protein 1) and FOX TfBSs in the promoters of known iron-metabolizing genes (Collins and 
Hu, 2007). With particular relevance to this study was the discovery that CYBRD1, HMOX1, 
SLC11A2 and TFRC were upregulated under conditions of iron deficiency in rat intestinal 
tissue and were enriched for SP1 and FOX Tfs. The authors hypothesize that SP1 and FOX 
may synergistically regulate transcription of a subset of the genes induced by iron deficiency 
in rat, mouse and human. In this study, SP1 TfBSs were identified in the CR of all nine iron-
metabolizing genes following in silico analysis with PATCH and rVISTA (Table 3.3), indicating 
a potential functional regulatory role, in combination with the FOX TfBSs predicted in Motif 
4, as suggested by Collins and Hu. In humans, SP1 is part of a large family of zinc finger Tfs 
involved in a wide variety of cellular processes and is among the most potent activators of 
transcription identified to date. 
 
In addition to the TfBSs already discussed, in silico analyses predicted putative binding sites 
for MTF-1 (metal transcription factor 1) in the CR of the nine genes of interest (Table 3.3). 
This Tf is of particular interest in this subset of genes due to the recent discovery of MTF-1 
TfBSs in the hepcidin promoter (Balesaria et al., 2010). MTF-1 proteins are divalent metal 
ion sensitive Tfs that mediate their regulatory effect by binding to cognate MREs (metal 
responsive elements) in the promoter region of target genes (Günther et al., 2012). The 
study by Balesaria and colleagues identified four MRE motifs in the hepcidin promoter, one 
Stellenbosch University http://scholar.sun.ac.za
CHAPTER THREE: In silico promoter analyses 
96 
 
of which lies within the CR element identified in this study. Hepcidin expression levels were 
shown to increase in response to MTF-1 binding activated by the addition of zinc. It has 
been shown that zinc activates DNA binding of MTF-1 by reversible interactions with specific 
zinc finger domains (Dalton et al., 1997; Bittel et al., 1998). In addition to hepcidin, SLC40A1 
expression is directly induced by MTF-1 binding (Troadec et al., 2010). The previously 
identified hepcidin MRE corresponds to the recognition sequence of -GAGTGCAG- in the CR 
identified in this study, which is in the reverse orientation to the consensus MRE sequence, -
TGCRCNC- (where R stands for A or G and N for any of the four bases). The other eight CR-
containing genes (Appendix 2) were examined and identical recognition sites were found in 
reverse orientation in the CR (corresponding to Motif 2) of FTH1, HFE2, IREB2 and TFRC. 
Despite an in-depth literature search, information regarding MTF-1 associations with these 
genes could not be found, indicating the uniqueness of this discovery. 
 Tfs such as USF1 (upstream regulatory factor 1) (Andrews et al., 2001) and C/EBPα 
(Datta et al., 2007) have been previously reported to interact with MTF-1 in order to 
mediate transcriptional regulation. Binding sites for both of these Tfs were identified with 
the PATCH and rVISTA computational tools (Table 3.3) and it is therefore feasible to 
consider that regulation of the CR-containing genes may be controlled by MTF-1 in 
conjunction with USF1 and C/EBPα. 
 
3.6 CONCLUSION 
The search for regulatory elements within non-coding regions of the human genome has 
traditionally proved an immensely difficult task. The expanding field of bioinformatics has 
lead to a vast improvement in the in silico tools available for investigation of potential 
functionally relevant regulatory regions. These software tools present a cost- and time 
effective method to explore the genome for transcriptional control elements, and have the 
potential to serve as a starting point for the design of experimental methodologies. 
 In silico analysis of the promoter region of 18 of the genes implicated in iron 
metabolism resulted in the identification of a novel region of sequence conservation in nine 
of the genes examined. Furthermore, the identified CR is proposed to be comprised of an 
Alu-J transposable element that may harbour numerous TfBSs thereby contributing toward 
co-ordinated transcriptional regulation of this subset of genes. Numerous TfBSs were 
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identified upon in silico analyses which could be credibly associated with transcriptional 
regulation in a tissue- and pathway-specific manner. Further functional investigation is 
warranted to determine if the CR element contributes toward co-ordinated transcriptional 
regulation of the genes implicated in iron metabolism in vitro, as suggested by the 
unexpectedly high level of sequence similarity. 
 Taken together, the results presented here represent a comprehensive and novel 
computational investigation of iron gene promoter regions with the identification of cis-
regulatory motifs that have the potential to serve as targets for future experimental 
investigations. 
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4.1 ABSTRACT 
Previously, computational analysis of the upstream non-coding region of genes involved in 
the iron metabolism pathway resulted in the identification of a novel region of sequence 
similarity in a subset of the genes. Validation of the bioinformatic predictions is essential in 
order to fully assess the relevance of the results in an in vitro setting. The nine CR-containing 
genes were functionally investigated following the design of luciferase reporter constructs 
containing: 1) the 2 kb promoter, 2) a 1.86 kb promoter with the CR removed and 3) the 140 
bp CR element. These three reporter gene constructs were transfected into HepG2 and COS-
1 cell lines and expression levels were monitored with a dual-luciferase reporter assay under 
standard culture conditions and simulated iron overload conditions. Results of the luciferase 
assays indicate that the 1.86 kb CR-removed promoter constructs displayed variances in 
expression values when compared to the untreated control construct. Further, the CR 
appears to mediate transcriptional regulatory effects via an iron-independent mechanism. 
With a few exceptions, the trends in expression observed for each of the constructs for the 
respective genes were consistent in both of the cell lines utilized and represent repeatable 
results across the different experiments performed. It is therefore apparent that the 
bioinformatic predictions were shown to be functionally relevant in this study and warrant 
further investigation. 
 
4.2 INTRODUCTION 
The wealth of sequence information available from high-throughput sequencing projects of 
numerous eukaryotic genomes have resulted in projects intent on annotating the functional 
elements responsible for gene expression. The majority of these groups employ a 
combinatorial bioinformatic and experimental approach to investigate regulatory 
components (Pilpel et al., 2001; Pedro, 2002; Wilson et al., 2010). One of the largest is the 
ENCODE (ENCyclopedia of DNA Elements) Project launched by the National Human Genome 
Research Institute (NHGRI) in 2003, following the sequencing of the human genome (The 
ENCODE Project Consortium, 2004). Recent results have shown that over 80% of the human 
genome is comprised of these functional elements; an exponentially higher amount than 
was earlier predicted (The ENCODE Project Consortium, 2012). In addition, it was found that 
numerous SNPs identified in previous genome-wide association studies (GWAS) on different 
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human diseases mapped to these areas regulating gene expression or transcription 
(Maurano et al., 2012; Schaub et al., 2012). The results are representative of a shift from 
traditional investigations of disease-causing variation and are indicative of the complexity of 
regulation of gene expression. 
 
Utilizing a similar combinatorial approach, comprehensive computational analyses of the 
promoter and flanking regions of genes implicated in iron metabolism revealed the 
presence of a region of sequence conservation (termed the CR) in nine of the genes 
investigated in this study (Chapter 3). This region demonstrated greater than 75% sequence 
identity between the genes of interest and, based on sequence homology, was proposed to 
be an Alu element comprising four CRMs. Alu elements have been previously been shown to 
contain binding sites for numerous Tfs (Polak and Domany, 2006) and have been associated 
with transcriptional regulation in a number of instances (Goodyer et al., 2001; Sobczak and 
Krzyzosiak, 2002; Stuart et al., 2000). The CR element was therefore hypothesized to act as a 
novel target for Tf binding resulting in a level of co-ordinated gene expression in vivo. The 
use of bioinformatic software for the prediction of regulatory elements in eukaryotic 
organisms has the potential to be an effective tool for the study of transcriptional 
regulation. However, it is imperative to validate in silico results in an experimental manner 
as computational analyses are by nature predictive and do not serve to characterize the 
presence or function of regulatory targets in vivo. Numerous experimental assays are 
available for functional validation, the choice of which depends on the nature of the 
research to be conducted. Examples include: electrophoretic mobility shift assays (EMSA) 
(Fried and Crothers, 1981), DNase I footprinting (Brenowitz et al., 1986), real-time PCR 
(qPCR) (VanGuilder et al., 2008), chromatin immunoprecipitation (ChIP) (Collas, 2010) and 
reporter genes assays (Wasserman and Sandelin, 2004). In an attempt to elucidate the 
potential effect of the CR with regard to differential gene expression, functional analyses 
were performed in this study. Expression levels of each of the nine CR-containing iron genes 
were investigated under normal culture conditions and iron overload conditions in vitro 
utilizing a reporter gene assay system. Reporter gene assays are amongst the most versatile 
techniques available and are frequently utilized to assess gene expression under a variety of 
conditions and in different cell types (Naylor, 1999). Reporter genes themselves are 
numerous and can be tailored to suit the type of assay to be performed (Alam and Cook, 
Stellenbosch University http://scholar.sun.ac.za
CHAPTER FOUR: Functional promoter analyses 
100 
 
1990). In this study, the firefly luciferase reporter gene was chosen to quantitatively 
measure expression of the different promoter constructs that were assembled. 
 
4.3 MATERIALS AND METHODS 
The reader is referred to Chapter 2 (Sections 2.2 and 2.3) for further information regarding 
the detailed methodology utilized. 
 
4.3.1 Construct Preparation 
For each of the nine genes (CYBRD1, FTH1, HAMP, HFE, HFE2, HMOX1, IREB2, LTF and TFRC) 
examined, three different reporter gene constructs were prepared. The full 2 kb promoter 
region as well as the 140 bp CR element were subjected to PCR utilizing flanking primers 
designed to incorporate appropriate restriction sites at the 5’-end (Chapter 2, Tables 2.1 and 
2.2). A promoter, in which the 140 bp CR was deleted from the full 2 kb 5’UTR, was 
constructed utilizing an adaptation of the PCR-driven overlap extension technique (Heckman 
and Pease, 2007). The 1.86 kb CR-removed fragments were generated from a nested PCR of 
the 2 kb promoter for each gene utilizing different primer combinations (Chapter 2, Tables 
2.3 and 2.4). The PCR products were sent for semi-automated bidirectional sequencing in 
order to confirm the sequence of interest. 
 Following sequencing, the 2 kb and 1.86 kb PCR products were cloned into a 
promoterless firefly luciferase reporter vector, pGL4.10[luc2], and the 140 bp CR PCR 
fragments were cloned into the minimal promoter pGL4.23[luc2/minP] vector (Promega) 
(Appendix 3) using standard methodologies. The pGL4.10[luc2] vector was selected due to 
the fact that it does not contain any basal promoter or enhancer elements and the genomic 
sequence of interest is cloned immediately upstream of the luciferase gene. The 2 kb and 
1.86 kb CR-removed promoter constructs were shown to contain the core promoter for 
each gene, based on the in silico investigation, and therefore do not require any additional 
promoter elements to drive transcription. In contrast, the 140 bp CR element for each of the 
genes was shown to lie upstream of the core promoter and it is unlikely that this relatively 
small genomic region contains basal transcriptional factors. For this reason, the 
pGL4.23[luc2/minP] vector was chosen in order to clone these fragments. The 
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pGL4.23[luc2/minP] vector includes a minimal promoter region with a TATA-box capable of 
initiating basal transcription of the luciferase gene. 
 After competent cell transformation and plasmid extraction, positive colonies were 
selected and again subjected to sequencing analysis to verify insert inclusion and 
orientation. 
 
4.3.2 Reporter Gene Assays 
The prepared luciferase reporter vectors were analyzed using the Dual-Luciferase® Reporter 
Assay System (Promega) in order to determine their respective effects on gene expression. 
Each reporter construct was transfected into two mammalian cells lines – human 
hepatocarcinoma liver (HepG2) cells and African green monkey kidney (COS-1) cells (ECACC, 
Wiltshire, England) – cultured under standard conditions. Co-transfection with a control 
reporter vector (pGL4.73[hRluc/SV40], Promega Corporation) was conducted for 
normalization of luciferase activity to correct for differences in transformation efficiency. 
Conditions of iron overload were simulated by the addition of ferric ammonium citrate 
(FAC) as an exogenous stimulus to assess the effect of high iron levels on expression levels 
of the relevant promoter constructs. For each cell line, assays were performed in triplicate 
for each individual construct and experiments were repeated on three independent 
occasions. 
 
4.3.3 Statistical Analyses 
For each individual experiment, the firefly luciferase values obtained for each construct 
were divided by the Renilla control luciferase readings to obtain normalized values, which 
were then averaged. The normalized averaged values were divided by the average 
normalized value of the construct acting as a control (grey shaded boxes, Appendix 5: Table 
S1.1 to S9.4, page 190) to determine the fold change in expression of the respective 
constructs for each experiment. 
GraphPad Prism® version 5.10 (GraphPad Software) was utilized to analyze the data and to 
generate graphical representations of the results. One-way ANOVA and Dunnett’s multiple 
comparison post-test were used for statistical analysis. In instances where statistically 
significant (p < 0.05) differences were detected by ANOVA, paired t tests were performed in 
Stellenbosch University http://scholar.sun.ac.za
CHAPTER FOUR: Functional promoter analyses 
102 
 
order to determine variance. For all experiments error bars represent the SEM of three 
independent experiments. 
 
4.4 RESULTS 
4.4.1 PCR Amplification 
PCR amplification of the 2 kb promoter fragments, the 140 bp CR element and the 1.86 kb 
CR-removed promoter were performed as described in Chapter 2, Section 2.2.1. Results of 
the agarose gel electrophoresis of the PCR amplicons for the 2 kb promoter fragments and 
the 140 bp CR element are illustrated in Appendix 5, Figure S5, page 186. Appropriate 
fragment sizes are listed in Tables 2.1 and 2.2 respectively. The results of the PCR-driven 
overlap extension technique utilized to generate the 1.86 kb CR-removed promoter 
amplicons are illustrated in Figures 4.1 and 4.2. Respective amplicon sizes are listed in Table 
2.4. Due to difficulties experienced when attempting to optimize the PCR-driven overlap 
extension, fragments of the correct size were excised from the agarose gel and used in a 
Wizard® SV Gel and PCR Clean-up (as per Chapter 2, Section 2.2.3). This was followed by 
semi-automated DNA sequencing analysis as described in Chapter 2, Section 2.2.5. 
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Figure 4.1 Agarose gel electrophoresis of intermediate PCR-driven overlap extension products (AB and CD).  
PCR products highlighted in red were excised from the agarose gel and used in a Wizard® SV Gel and PCR 
Clean-up. For each gene, A.) five or B.) three samples were amplified for AB and CD and electrophoresed 
adjacent to each other.                              
Abbreviations: bp, base pair; CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin heavy polypeptide 1 
gene; HAMP, Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; 
HMOX1, Haem oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2  gene; kb, kilobase pair; L., 
Ladder; LTF, Lactotransferrin gene; PCR, polymerase chain reaction; TFRC, Transferrin receptor protein 1 gene. 
A. 
B. 
2 kb 
2 kb 
2 kb 
2 kb 
1 kb 
1 kb 
 
1 kb 
1 kb 
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Figure 4.2 Agarose gel electrophoresis of PCR-driven overlap extension products (AD).     
PCR products highlighted in red were excised from the agarose gel and used in a Wizard® SV Gel and PCR 
Clean-up.                              
Abbreviations: bp, base pair; CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin heavy polypeptide 1 
gene; HAMP, Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; 
HMOX1, Haem oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2  gene; kb, kilobase pair; L., 
Ladder; LTF, Lactotransferrin gene; PCR, polymerase chain reaction; TFRC, Transferrin receptor protein 1 gene. 
 
4.4.2 Clone selection 
Following preparation of the pGL4 constructs (as explained in Chapter 2, Section 2.2.6 to 
2.2.9) and transformation of chemically competent cells (Chapter 2, Section 2.2.10), colonies 
were selected from the LB agar ampicillin plates and screened for positive transformants as 
described in Chapter 2, Section 2.2.11. The results of the plasmid minipreps performed for 
the 2 kb constructs and the 1.86 kb CR-removed promoter constructs, as well as the colony 
PCR results for the 140 bp CR elements are illustrated in Appendix 5: Figure S6, page 187. 
(bands of the correct insert size are surrounded by red boxes). Positive colonies were 
subjected to DNA sequence analysis to verify correct insert orientation and nucleotide 
sequence (Chapter 2, Section 2.2.12). Alignments of the sequencing results with the 
reference promoter sequence of the respective genes were performed with CLC Sequence 
Viewer 6.7.1. Graphical representations of the 1.86 kb CR-removed promoter sequence 
alignments are shown in Appendix 5: Figure S6, page 187. 
 
2 kb 
1 kb 
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4.4.3 Reporter Gene Assays 
For each of the genes under investigation, normalized expression values as well as fold 
changes for each construct are indicated in Appendix 5 (Tables S1.1 to S9.4). These values 
were indicative of consistent and repeatable expression during all of the repetitive 
experiments performed. In order to calculate fold change values, the untreated 2 kb 
construct (with respect to the pGL4.10 constructs) and the untreated pGL4.23 vector (with 
respect to the 140 bp CR constructs) were used as reference (control constructs) and 
assigned a value of 1. The untreated 2 kb pGL4.10 construct was selected as a control due to 
the fact that the full, untreated 2 kb promoter is representative of the “wildtype” state 
when compared to the FAC-treated 2 kb construct and the 1.86 kb CR-removed plasmids. 
The empty, untreated pGL4.23[luc2/minP] was chosen as the control plasmid for 
comparison to the 140 bp CR constructs (untreated and FAC-treated) as a result of the 
inclusion of a minimal promoter in this vector. Basal transcription of the luciferase gene, 
driven by the minimal promoter, is therefore considered as “wildtype” and any differences 
in expression observed can be attributed to the cloned CR of interest. 
 Normalized values for the other constructs were expressed as a value relative to that 
of the untreated 2 kb construct or untreated pGL4.23 vector, respectively. The empty 
promoterless pGL4.10 vector was included as a negative control in those experiments in 
which the constructs were cloned into this plasmid. In all cases, the expression levels for this 
vector were negligible, as was expected, due to the lack of functional promoter elements 
with which to drive luciferase expression. In contrast, the empty pGL4.23 vectors 
demonstrated a basal level of transcription driven by the minimal promoter upstream of the 
luciferase reporter gene. The results obtained for the different constructs will be presented 
with respect to the individual genes investigated. 
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4.4.3.1 Cytochrome b reductase 1 (CYBRD1) 
Examination of the 140 bp CR CYBRD1 constructs illustrated that no significant change in 
expression occurred (right panel, Figure 4.3). A marginal increase in expression was 
observed in the FAC-treated constructs in the HepG2 cells. However, the opposite was seen 
in the COS-1 cell line. With respect to the pGL4.10 CYBRD1 constructs, comparison of the 
values obtained for both the HepG2 and COS-1 cell lines demonstrated the same trend in 
expression (left panel, Figure 4.3), although the fold increases were lower in the COS-1 cells. 
In the HepG2 cells, a statistically significant increase in expression (p = 0.03) was exhibited 
with the untreated 1.86 kb construct. This increase was 10-fold higher than that of the 
untreated 2 kb control. FAC treatment of the 1.86 kb CR-removed promoter construct 
resulted in a slight decrease in expression, although it was still significantly higher (p = 0.02) 
than that of the control. The values obtained for the untreated and FAC-treated 1.86 kb 
construct in the COS-1 cells were again elevated above the control (p = 0.03 and p = 0.01 
respectively). 
 
4.4.3.2 Ferritin heavy polypeptide 1 (FTH1) 
In both cell lines, the 140 bp CR FTH1 constructs demonstrated a significant increase in 
expression when compared to the untreated pGL4.23 control (right panel, Figure 4.4). For 
the untreated 140 bp constructs statistically significant p values of 0.00 and 0.01 were 
observed in the HepG2 and COS-1 cells respectively. Expression was further increased upon 
addition of FAC [p = 0.00 (HepG2) and p = 0.00 (COS-1)]. 
Overall, addition of FAC resulted in higher expression values for the FTH1 constructs. This 
increase was statistically significant in the HepG2 cells with the FAC-treated 2 kb promoter 
(p = 0.00) (left panel, Figure 4.4 A). With respect to the CR-removed FTH1 constructs (left 
panel, Figure 4.4), removal of the CR resulted in a 66% decrease in expression of the 
untreated 1.86 kb construct when compared with the control [p = 0.01 (HepG2) and p = 0.00 
(COS-1)]. Addition of FAC increased the levels slightly, although the values for this construct 
were still significantly decreased (p = 0.00) in the COS-1 cell line (left panel, Figure 4.4 B). 
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Figure 4.3 Cytochrome b reductase 1 (CYBRD1) expression.                              
The cloned human CYBRD1 promoter constructs were transfected into A.) HepG2 cells or B.) COS-1 cells. Transfected cells were subsequently treated with ferric ammonium citrate 
(FAC). Fold activation was calculated with respect to the activity of the untreated 2 kb construct (left panels) and the untreated pGL4.23 vector (right panels). All transfections 
were performed in triplicate and included pGL4.73[hRluc/SV40] as internal control; luciferase levels were normalized to Renilla activity. Data are representative of three 
independent experiments and are presented as means ± SEM. * p < 0.05, ** p < 0.01. 
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Figure 4.4 Ferritin heavy polypeptide 1 (FTH1) expression.                               
The cloned human FTH1 promoter constructs were transfected into A.) HepG2 cells or B.) COS-1 cells. Transfected cells were subsequently treated with ferric ammonium citrate 
(FAC). Fold activation was calculated with respect to the activity of the untreated 2 kb construct (left panels) and the untreated pGL4.23 vector (right panels). All transfections 
were performed in triplicate and included pGL4.73[hRluc/SV40] as internal control; luciferase levels were normalized to Renilla activity. Data are representative of three 
independent experiments and are presented as means ± SEM. * p < 0.05, ** p < 0.01. 
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4.4.3.3. Hepcidin (HAMP) 
Although not determined to be statistically significant, a modest increase in expression upon 
FAC treatment was observed with each of the HAMP constructs tested in both cell lines 
(Figure 4.5). Results indicated a significant decrease in expression, with a p value of 0.00, for 
the untreated 140 bp construct when compared to the pGL4.23 control in the HepG2 cells 
(right panel, Figure 4.5 A). A similar decrease of 20% was demonstrated in the COS-1 cell line 
however, this was not significant following statistical analysis. Addition of FAC increased 
expression levels slightly in both cell lines although the values were still below those of the 
untreated control and were only significant in the HepG2 cells (p = 0.01) (right panel, Figure 
4.5 A). 
Of interest was the observation that removal of the CR element from the HAMP promoter 
had little effect on expression levels in the HepG2 cells (right panel, Figure 4.5 A). In 
contrast, transcript levels in the COS-1 cell line for the 1.86 kb CR-removed promoter were 
significantly decreased in both untreated (41% decrease; p = 0.01) and FAC-treated (26% 
decrease; p = 0.01) constructs (left panel, Figure 4.5 B). 
 
4.4.3.4 Haemochromatosis (HFE) 
Expression levels of the HFE 140 bp CR constructs were dramatically decreased in both cell 
lines (right panel, Figure 4.6). In the HepG2 cells, the untreated CR construct showed 
significantly reduced luciferase levels (p < 0.00). FAC-treatment increased these levels 
slightly but did not abrogate the observed decrease in expression when compared to the 
control vector (p < 0.00). The same trend was observed in the COS-1 cells with p values for 
both the untreated and FAC-treated constructs below 0.00 (right panel, Figure 4.6 B). 
FAC treatment of the 2 kb HFE constructs resulted in a 30% increase in expression in both 
cells lines relative to the untreated 2 kb control (left panel, Figure 4.6), although this was 
deemed statistically significant in only the COS-1 cells (p = 0.05). Although not significant, 
deletion of the CR from the HFE promoter led to an 84% expression increase in the HepG2 
cells and a 14% increase in the COS-1 cells when compared to the control construct. FAC 
treatment of the 1.86 kb constructs had a negligible effect on these levels. 
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Figure 4.5 Hepcidin (HAMP) expression.                                
The cloned human HAMP promoter constructs were transfected into A.) HepG2 cells or B.) COS-1 cells. Transfected cells were subsequently treated with ferric ammonium citrate 
(FAC). Fold activation was calculated with respect to the activity of the untreated 2 kb construct (left panels) and the untreated pGL4.23 vector (right panels). All transfections 
were performed in triplicate and included pGL4.73[hRluc/SV40] as internal control; luciferase levels were normalized to Renilla activity. Data are representative of three 
independent experiments and are presented as means ± SEM. * p < 0.05, ** p < 0.01. 
Stellenbosch University http://scholar.sun.ac.za
CHAPTER FOUR: Functional promoter analyses 
111 
 
 
 
Figure 4.6 Haemochromatosis (HFE) expression.                                
The cloned human HFE promoter constructs were transfected into A.) HepG2 cells or B.) COS-1 cells. Transfected cells were subsequently treated with ferric ammonium citrate 
(FAC). Fold activation was calculated with respect to the activity of the untreated 2 kb construct (left panels) and the untreated pGL4.23 vector (right panels). All transfections 
were performed in triplicate and included pGL4.73[hRluc/SV40] as internal control; luciferase levels were normalized to Renilla activity. Data are representative of three 
independent experiments and are presented as means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.0001. 
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4.4.3.5 Hemojuvelin (HFE2) 
The untreated 140 bp CR HFE2 construct resulted in a 329% increase (p = 0.00) in expression 
levels in the HepG2 cell line and a 146% increase (p = 0.02) in the COS-1 cells (right panel, 
Figure 4.7). Expression was further increased (p = 0.02) in the HepG2 cells upon FAC-
treatment (right panel, Figure 4.7 A) however, a decrease in expression relative to the 
untreated 140 bp CR construct was seen in the COS-1 cells (right panel, Figure 4.7 B). The 
overall fold change in expression of the FAC-treated 140 bp CR construct in the COS-1 was 
still significantly higher than the untreated pGL4.23 control (p = 0.04) although the trend 
differed from observations in the HepG2 cells. 
Simulation of iron overload with addition of FAC led to a modest increase in luciferase 
expression of between 12 and 34% in the 2 kb and 1.86 kb constructs in both cell lines. This 
increase was not determined to be statistically significant. In addition, the CR-removed 
promoter constructs demonstrated insignificant changes from the untreated 2 kb control 
plasmid (left panel, Figure 4.7). 
 
4.4.3.6 Haem oxygenase 1 (HMOX1) 
With regard to the HMOX1 140 bp CR constructs, a significant decrease was observed in 
both the untreated (54% decrease, p = 0.01) and FAC-treated constructs (45% decrease, p = 
0.01) in the HepG2 cells (right panel, Figure 4.8 A). The same trend could be seen in the 
COS-1 cells, however the differences in expression were marginal and not statistically 
significant (right panel, Figure 4.8 B). 
Removal of the CR resulted in a 6-fold and 2-fold increase in expression of the untreated 
1.86 kb constructs in the HepG2 (p = 0.01) and COS-1 (p = 0.03) cell lines respectively (left 
panel, Figure 4.8). FAC treatment further enhanced this effect with statistically significant 
increases [p = 0.01 (HepG2) and p = 0.01 (COS-1)] when compared with the untreated 2 kb 
control. 
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Figure 4.7 Hemojuvelin (HFE2) expression.                                
The cloned human HFE2 promoter constructs were transfected into A.) HepG2 cells or B.) COS-1 cells. Transfected cells were subsequently treated with ferric ammonium citrate 
(FAC). Fold activation was calculated with respect to the activity of the untreated 2 kb construct (left panels) and the untreated pGL4.23 vector (right panels). All transfections 
were performed in triplicate and included pGL4.73[hRluc/SV40] as internal control; luciferase levels were normalized to Renilla activity. Data are representative of three 
independent experiments and are presented as means ± SEM. * p < 0.05, ** p < 0.01. 
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Figure 4.8 Haem oxygenase 1 (HMOX1) expression.                                
The cloned human HMOX1 promoter constructs were transfected into A.) HepG2 cells or B.) COS-1 cells. Transfected cells were subsequently treated with ferric ammonium citrate 
(FAC). Fold activation was calculated with respect to the activity of the untreated 2 kb construct (left panels) and the untreated pGL4.23 vector (right panels). All transfections 
were performed in triplicate and included pGL4.73[hRluc/SV40] as internal control; luciferase levels were normalized to Renilla activity. Data are representative of three 
independent experiments and are presented as means ± SEM. * p < 0.05, ** p < 0.01. 
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4.4.3.7 Iron regulatory binding protein 2 (IREB2) 
Results for the untreated 140 bp CR IREB2 constructs indicated a decrease in luciferase 
expression of 67% in the HepG2 cells and 41% in the COS-1 cells (p = 0.00 and p = 0.00 
respectively) (right panel, Figure 4.9). Expression was modestly increased following addition 
of FAC, although the overall decrease was still significant with respect to the untreated 
pGL4.23 control [p = 0.00 (HepG2) and p = 0.02 (COS-1)] (right panel, Figure 4.9). 
The 1.86 kb CR-removed promoter constructs in the HepG2 cells did not demonstrate any 
significant deviations from the control vector, although a small increase in expression was 
demonstrated upon FAC treatment (left panel, Figure 4.9 A). In contrast, the untreated 1.86 
kb construct showed a significant decrease (p = 0.00) relative to the control in the COS-1 cell 
line. FAC treatment of this construct led to a further decrease in luciferase expression (p = 
0.00) relative to the untreated control (left panel, Figure 4.9 B). 
 
4.4.3.8 Lactotransferrin (LTF) 
With the exception of the 2 kb construct transfected into the HepG2 cells, an overall 
increase in expression was observed upon FAC treatment with all of the LTF constructs 
(Figure 4.10). The FAC-treated 2 kb construct resulted in decreased levels of expression (p = 
0.01) in the HepG2 cells when compared to the untreated control (left panel, Figure 4.10 A). 
A 72% decrease in expression of the untreated 140 bp CR construct (p = 0.00) and a 65% 
decrease with the FAC-treated CR construct (p = 0.00) were observed in the HepG2 cells 
(right panel, Figure 4.10 A). The same trend was observed in the COS-1 cells although the 
expression levels were not as low as those observed in the HepG2 cells [p = 0.01 (untreated) 
and p = 0.02 (FAC-treated)] (right panel, Figure 4.10 B). 
In both cell lines, targeted deletion of the CR resulted in decreased expression levels relative 
to the untreated 2 kb control (left panel, Figure 4.10). Statistical analyses revealed that 
these observations were only significant in the HepG2 cells; p = 0.04 for the untreated 1.86 
kb construct and p = 0.01 for the FAC-treated equivalent. 
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Figure 4.9 Iron regulatory binding protein 2 (IREB2) expression.                              
The cloned human IREB2 promoter constructs were transfected into A.) HepG2 cells or B.) COS-1 cells. Transfected cells were subsequently treated with ferric ammonium citrate 
(FAC). Fold activation was calculated with respect to the activity of the untreated 2 kb construct (left panels) and the untreated pGL4.23 vector (right panels). All transfections 
were performed in triplicate and included pGL4.73[hRluc/SV40] as internal control; luciferase levels were normalized to Renilla activity. Data are representative of three 
independent experiments and are presented as means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.0001. 
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Figure 4.10 Lactotransferrin (LTF) expression.                               
The cloned human LTF promoter constructs were transfected into A.) HepG2 cells or B.) COS-1 cells. Transfected cells were subsequently treated with ferric ammonium citrate 
(FAC). Fold activation was calculated with respect to the activity of the untreated 2 kb construct (left panels) and the untreated pGL4.23 vector (right panels). All transfections 
were performed in triplicate and included pGL4.73[hRluc/SV40] as internal control; luciferase levels were normalized to Renilla activity. Data are representative of three 
independent experiments and are presented as means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.0001.  
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4.4.3.9 Transferrin receptor 1 (TFRC) 
Overall, FAC treatment of the TFRC constructs in both the HepG2 and COS-1 cells resulted in 
modest expression increases (Figure 4.11). In the HepG2 cells, a statistically significant 
decrease (p = 0.00) of 56% with the untreated 140 bp CR construct and a 41% decrease (p = 
0.02) with the FAC-treated CR construct was observed relative to the control pGL4.23 vector 
(right panel, Figure 4.11 A). In the COS-1 cell line, an insignificant decrease in expression 
resulted from transfection of the untreated 140 bp CR construct. Following FAC treatment, 
expression increased to levels above those of the untreated control (p = 0.05), an elevation 
of 17% (right panel, Figure 4.11 B). 
In both cell lines, the untreated CR-removed promoter constructs demonstrated discernable 
expression increases relative to the untreated 2 kb control although these were not 
determined to be statistically significant (left panel, Figure 4.11). The addition of FAC to 
these constructs resulted in further small expression increases (between 49% and 52%) 
which were not statistically significant when compared to the control. 
Stellenbosch University http://scholar.sun.ac.za
CHAPTER FOUR: Functional promoter analyses 
119 
 
 
Figure 4.11 Transferrin receptor 1 (TFRC) expression.                               
The cloned human TFRC promoter constructs were transfected into A.) HepG2 cells or B.) COS-1 cells. Transfected cells were subsequently treated with ferric ammonium citrate 
(FAC). Fold activation was calculated with respect to the activity of the untreated 2 kb construct (left panels) and the untreated pGL4.23 vector (right panels). All transfections 
were performed in triplicate and included pGL4.73[hRluc/SV40] as internal control; luciferase levels were normalized to Renilla activity. Data are representative of three 
independent experiments and are presented as means ± SEM. * p < 0.05, ** p < 0.01. 
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4.5 DISCUSSION 
PCR amplification of the different promoter elements of interest in this study was 
performed successfully. The PCR-driven overlap extension technique that was employed for 
the generation of the 1.86 kb CR-removed promoters proved effective (Figure 4.1 and 4.2). 
Standard mutagenesis-based techniques to introduce restriction sites in order to remove 
sequences by enzymatic digestion often introduce erroneous base pairs into the sequence. 
These sites have the potential to act as binding sites for new Tfs, thus inadvertently 
influencing transcriptional regulation of the genes of interest. In this study, the CR was 
deleted from the whole promoter amplicons of the respective genes in a manner that did 
not affect the native sequence, as evidenced by DNA sequence analysis (Appendix 5: Figure 
S6, page 187). Subsequent to PCR amplification and molecular cloning, positive colonies for 
each of the different promoter constructs for all nine genes were successfully identified 
(Appendix 5: Figure S5, page 186). Due to difficulties experienced during the optimization of 
colony PCR conditions for the larger constructs (2 kb and 1.86 kb), double digestion 
reactions of the extracted plasmids were performed. This departure from customary colony 
PCR methodology proved useful in this study for the identification of positive transformants 
(Appendix 5: Figure S5 A and B, page 186). 
 
In general, in vitro functional data for the upstream coding regions of human genes 
implicated in iron metabolism is scarce. Exceptions include the HAMP promoter region, 
which has been extensively characterized (Falzacappa et al., 2008; Parajes et al., 2010), and 
selected cases of individual disease-associated mutations which have been assessed in some 
of the genes studied here (Constantine et al., 2009; Gao et al., 2009). The data presented 
here therefore represent an overview of the activity of the promoters of the genes of 
interest under standard culture conditions, and in response to simulated conditions of iron 
overload, in two different mammalian cell lines. In this study, HepG2 cells were chosen for 
the in vitro assays due to the fact that the majority of iron sequestration and metabolism 
takes place in the hepatocyte cells of the liver. The genes under investigation here, with the 
possible exception of LTF (Levay and Viljoen, 1995), are all ubiquitously expressed in 
hepatocytes. In contrast, COS-1 cells, which are derived from the kidney of the African green 
monkey, represent an alternate in vitro environment for the determination of differential 
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gene expression due to the tissue-specific nature of particular Tfs which may interact with 
the gene promoters. The HNF family are one group of Tfs that demonstrate this tissue-
specificity and are known to regulate transcription of genes expressed in the liver (Costa et 
al., 2003). Consequently, differences observed in the expression values for the different 
constructs, between the two cell lines, could potentially be attributed to the 
absence/presence of tissue-specific Tfs. 
 
With respect to FAC treatment of the promoter constructs, a summary of the graphical 
results previously presented is illustrated in Table 4.1. The results of three independent 
transfection experiments are shown as a percentage change in luciferase expression for 
each of the constructs, for all nine genes, and in both cell lines. Statistically significant 
differences are shown in bold text and are indicated by the relevant asterisks. Constructs 
that demonstrated over expression (↑) or under expression (↓) relaƟve to the respecƟve 
constructs utilized as a control are also indicated in Table 4.1. 
 With particular reference to transfections of the full 2 kb promoter constructs for 
each gene, the majority demonstrated moderate fold change increases upon FAC treatment 
when compared to the untreated 2 kb construct (Table 4.1). The observations for the 
CYBRD1, HMOX1 and TFRC constructs were unexpected in a biological context where 
expression of these genes would be likely to decrease in response to high iron conditions 
(Hentze and Kühn, 1996; Gunshin et al., 2005). However, none of the observations were 
statistically significant and it is possible that a longer exposure time to FAC is required for 
these effects to become noticeable. In addition, previously performed functional studies, in 
which these genes were shown to be upregulated in response to iron deprivation, were 
conducted on mice (Gunshin et al., 2005) and rat intestinal cells (Collins, 2006) and slightly 
different expression profiles may be revealed in vivo in other mammalian species. With 
regard to TFRC, five tandem IREs have been identified in the 3’-UTR of the gene which are 
responsible for stabilizing the mRNA under low iron conditions resulting in increased 
expression (Hentze and Kühn, 1996). The focus of this study was on gene promoters and 
thus only the 5’-UTR of TFRC was utilized for construct preparation. This region may not be 
sufficient for appropriate TFRC response to iron as would be expected in an in vivo context. 
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Table 4.1 Percentage change in luciferase activity for the FAC-treated constructs. 
           
 
 Treated (FAC) 
    HepG2 COS-1 
Gene 140 bp CR pGL4.23 1.8 kb pGL4.10 2 kb pGL4.10 140 bp CR pGL4.23 1.8 kb pGL4.10 2 kb pGL4.10 
CYBRD1 ↑  17 ↑ *798 ↑ 45 ↓ 18 ↑ **200 ↑ 13 
FTH1 ↑ **1056 ↓ 38 ↑ **49 ↑ **445 ↓ **51 ↑ 42 
HAMP ↓  *43 ↑ 11 ↑ 31 ↓ 14 ↓ *26 ↑ 5 
HFE ↓ ***99 ↑ 73 ↑ 30 ↓ ***98 ↑ 12 ↑ *34 
HFE2 ↑ **534 ↑ 13 ↑ 25 ↑ *109 ↑ 12 ↑ 34 
HMOX1 ↓ **45 ↑ *708 ↑ 53 ↑ 4 ↑ **152 ↑ 55 
IREB2 ↓ **62 ↑ 16 ↑ 8 ↓ *28 ↓ **18 ↓ 5 
LTF ↓ ***65 ↓ *49 ↓ **48 ↓ *23 ↓ 36 ↑ 10 
TFRC ↓  *41 ↑ 52 ↑ 15 ↑ 17 ↑  49 ↑ 20 
           Abbreviations: *, p < 0.05; **, p < 0.01; ***, p < 0.0001; ↑, over expression; ↓, under expression; bp, base pair; COS-1, African green monkey kidney cells; CR, 
conserved region; CYBRD1, Cytochrome b reductase 1 gene; FAC, ferric ammonium citrate; FTH1, Ferritin heavy polypeptide 1 gene; HAMP, Hepcidin antimicrobial 
peptide gene; HepG2, human hepatocarcinoma liver cells; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; HMOX1, Haem oxygenase 1 gene; IREB2, Iron-
responsive element-binding protein 2 gene; kb, kilobase pair; LTF, Lactotransferrin gene; TFRC, Transferrin receptor protein 1 gene. 
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Statistically significant increases in expression were seen in the FAC-treated 2 kb constructs 
for FTH1 in HepG2 cells (p = 0.00) and HFE in COS-1 cells (p = 0.05) (Table 4.1). The raised 
values obtained for the FAC-treated FTH1 promoter construct were expected in this study 
because of the inclusion of the FTH1 IRE in the 2 kb construct. FTH1 expression is known to 
be elevated in iron sufficient circumstances as a consequence of the inability of iron-bound 
IRP1 or IRP2 to interact with the 5’-UTR IRE, therefore permitting translation of the FTH1 
mRNA to proceed unhindered (Thomson et al., 1999). When cells are iron replete, synthesis 
of both FTH1 and FTL is enhanced to allow for sequestration of the excess iron within the 
ferritin molecule, thereby reducing the bioavailability of potentially toxic free iron (Torti and 
Torti, 2002). Although not determined to be statistically significant, a 42% increase in 
expression of the FAC-treated FTH1 2 kb construct was also observed in the COS-1 cells. In 
the case of HFE, increased expression levels in response to iron overload can be explained 
by examining the interaction between the HFE protein and TFR1 in vivo. Under iron overload 
conditions, competitive binding of HFE to TFR1 leads to a decrease in the affinity of TFR1 for 
diferric-TF and a subsequent decline in cellular iron uptake, minimizing intracellular iron 
concentrations (Feder et al., 1998). It is therefore feasible that FAC-treatment would result 
in heightened transcription of the luciferase reporter driven by the 2 kb HFE promoter. 
 
Deviations from the increased expression trend were observed with the FAC-treated 2 kb 
constructs for LTF and IREB2 (Table 4.1). In HepG2 cells, LTF showed a statistically significant 
decrease in expression of 48% (p = 0.01) and in COS-1 cells, IREB2 transfection resulted in a 
5% decrease. The decline observed in LTF-driven expression was unexpected as, like TF, LTF 
levels are normally elevated in response to high iron conditions (Kawakami and Lönnerdal, 
1991). It is possible that due to the defined role of LTF in the immune system, a longer 
period of FAC treatment may be required to be able to visualize the appropriate increase in 
expression. In addition, hepatocytes are not the primary tissue type for LTF expression and 
may therefore not be the ideal in vitro environment in which to assess transcriptional 
regulation of this gene. Corroboration of this theory is evidenced by the 10% increase in 
expression of the FAC-treated LTF 2 kb construct in the COS-1 cell line (Table 4.1). The 
decrease in expression observed for the FAC-treated IREB2 construct in COS-1 cells was 
expected. IREB2 mRNA has previously been demonstrated to undergo proteosomal 
degradation when exposed to high cellular iron levels (Wang et al., 2008). However, in the 
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HepG2 cells a marginal increase in IREB2-driven expression of 7% relative to the untreated 
control was observed. This finding was not statistically significant and may have been as a 
consequence of a single experimental repeat with fold change values slightly above those of 
the other experiments. 
 
For the 1.86 kb CR-removed promoter constructs, supplementation with FAC resulted in 
luciferase activity differences that were consistent with what was observed in the 2 kb 
untreated versus FAC-treated constructs (Table 4.1). Any FAC-related expression deviations 
in the 2 kb constructs were maintained in almost every instance in the 1.86 kb CR-removed 
constructs, even in those cases where the effect of targeted deletion of the CR was dramatic 
(FTH1, HMOX1, LTF). This finding is in accordance with observations from the FAC-treated 
140 bp CR constructs and it is therefore unlikely that the CR element alone exerts a 
transcriptional effect in an iron-dependent manner. This assumption is not unexpected, as 
the previously described IRE/IRP system clearly fulfils the iron-sensory role necessary for 
transcriptional regulation of a subset of the genes of interest. It is probable that the CR 
element functions more as a general transcriptional regulator, which from the results of this 
study, appears to be unrelated to conditions of iron overload in an in vitro setting. 
 
Although of interest and scientific value, the functional activity of the gene promoters in 
response to iron was of secondary importance in this study. The primary goal of the 
luciferase reporter assays performed was to assess any potential effect that may be 
mediated by the CR that was identified in the in silico portion of this study. A summary of 
the graphical results previously presented for the untreated 140 bp CR constructs and the 
1.86 kb CR-removed constructs, for each gene of interest and in both cell lines, is illustrated 
in Table 4.2. The results of three independent transfection experiments are shown as a 
percentage change in luciferase expression for each of the constructs. Statistically significant 
differences are shown in bold text and are indicated by the relevant asterisks. Those 
constructs that demonstrated over expression (↑) or under expression (↓) relaƟve to the 
respective constructs utilized as a control are also indicated in Table 4.2. 
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Table 4.2 Percentage change in luciferase activity for the untreated constructs. 
     
 
   
 
Untreated (dH2O) 
    HepG2   COS-1 
Gene 140 bp CR pGL4.23 1.8 kb pGL4.10 140 bp CR pGL4.23 1.8 kb pGL4.10 
CYBRD1 ↑ 6 ↑ *1090 ↓ 15 ↑ *233 
FTH1 ↑ **800 ↓ *66 ↑ **344 ↓ **66 
HAMP ↓ **50 ↑ 4 ↓ 20 ↓ *41 
HFE ↓ ***99 ↑ 84 ↓ ***99 ↑ 14 
HFE2 ↑ *329 ↓ 7 ↑ 146 ↑ 2 
HMOX1 ↓ ** 54 ↑ *503 ↓ 6 ↑ *133 
IREB2 ↓ **67 ↑ 4 ↓ ***41 ↓ **13 
LTF ↓ ***72 ↓ *38 ↓ **40 ↓ 34 
TFRC ↓ **56 ↑ 45 ↓ 7 ↑ 39 
         Abbreviations: *, p < 0.05; **, p < 0.01; ***, p < 0.0001; ↑, over expression; ↓, under expression; bp, base 
pair; COS-1, African green monkey kidney cells; CR, conserved region; CYBRD1, Cytochrome b reductase 1 
gene; dH2O, distilled water; FTH1, Ferritin heavy polypeptide 1 gene; HAMP, Hepcidin antimicrobial peptide 
gene; HepG2, human hepatocarcinoma liver cells; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; 
HMOX1, Haem oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2 gene; kb, kilobase pair; 
LTF, Lactotransferrin gene; TFRC, Transferrin receptor protein 1 gene. 
 
The CR-removed promoter constructs that displayed statistically significant increases in 
expression in both cell lines when compared to the untreated 2 kb control were CYBRD1 
(Figure 4.3) and HMOX1 (Figure 4.8). Both CYBRD1 and HMOX1 demonstrated an increase in 
expression with p-values, for the untreated 1.86 kb construct, of 0.0305 and 0.0112 
respectively in the HepG2 cells. This significant increase was maintained in the COS-1 cell 
line (Table 4.2). In addition, expression of the 1.86 kb untreated construct for HFE was also 
increased above the 2 kb control, although this was not determined to be statistically 
significant (Figure 4.6). An increase of 84% was observed in the HepG2 cells and a 14% 
expression increase in the COS-1 cells (Table 4.2). For CYBRD1 and HFE, FAC-treatment of 
the 1.86 kb CR-removed promoter construct resulted in an almost negligible decrease in 
expression relative to treated construct (Table 4.1). For HMOX1, a marginal increase was 
observed following FAC treatment of the 1.86 kb promoter (Table 4.1). However, for each of 
these genes, the changes were insignificant and consistent with what was observed 
between the untreated and FAC-treated 2 kb constructs and are therefore unlikely to be 
related to removal of the CR from the respective gene promoters. 
 The results obtained from the luciferase assays of the 140 bp CR cloned into the 
pGL4.23 vector indicate that this promoter element may have an inhibitory effect on 
transcription of CYBRD1, HFE and HMOX1. Luciferase expression values for all three of these 
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constructs were reduced in one or both of the cell lines tested, and the opposite effect was 
observed upon removal of the CR with the 1.86 kb promoters (Table 4.2). The untreated HFE 
CR appeared to result in the most dramatic decrease in expression with p-values of <0.0001 
for both the HepG2 and COS-1 cells (right panel, Figure 4.6). The untreated HMOX1 140 bp 
CR construct also exhibited a significant decrease in luciferase expression in the HepG2 cells 
(p = 0.01) and a slight decrease in the COS-1 cells (right panel, Figure 4.8). As with the larger 
CR-removed promoter constructs, FAC treatment did not result in any significant differences 
in expression, over and above what was observed between the empty pGL4.23 vectors 
themselves (Table 4.1). 
 
With respect to the 1.86 kb CR-removed promoter constructs for HAMP, HFE2, IREB2 and 
TFRC, no significant change in expression was observed relative to the wildtype 2 kb 
construct in the HepG2 cells (Table 4.2). For HAMP (Figure 4.5) and IREB2 (Figure 4.9) 
however, a significant decrease in expression was exhibited in the COS-1 cells (p = 0.01 and 
p = 0.00, respectively) with the untreated constructs (Table 4.2). It is interesting to note that 
each of these genes was found to contain an identical binding site (MRE) for the MTF-1 Tf 
originally identified in the HAMP CR (Chapter 3, Table 3.3). Balesaria and colleagues (2010) 
proved that induction of HAMP expression by MTF-1 binding in an in vitro environment is 
dependent on the metal zinc. Other metals such as copper and cadmium were also able to 
positively influence luciferase activity in a dose-dependent manner. It is postulated that the 
CR identified in these four genes may require the presence of another metal to manipulate 
transcriptional activity via MTF-1 binding in hepatocyte cells. In this study, cells were only 
treated with FAC to simulate iron overload conditions which may explain the lack of 
significant change in luciferase activity observed with the CR-removed promoter constructs 
in the HepG2 cells. Further experimentation would be required to prove this hypothesis. 
 Significant decreases in luciferase activity resulted from transfection of both cell 
lines with the 140 bp CR for HAMP, IREB2 and TFRC (Figures 4.5, 4.9 and 4.11; Table 4.2). It 
therefore appears that this promoter element elicits an inhibitory effect on gene expression 
in these genes in vitro. Despite the significant change in activity exhibited, it should be 
noted that due to the MRE discussed above, the CR element may have a more positive 
effect in vivo, and in the presence of zinc, than was demonstrated by the reporter gene 
assays. Transfection of the HFE2 140 bp CR however, resulted in a significant increase in 
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luciferase activity [p = 0.00 (HepG2) and p = 0.02 (COS-1)] (Table 4.2). The reason for this 
deviation from the trend seen in the other genes is unclear. However, results of the in silico 
analysis of the HFE2 CR indicated that Motif 3 (Chapter 3, Figure 3.5, red block) was missing 
from this gene when compared to the others. TfBSs located in the CRM represented by 
Motif 3 may be responsible for the repression of transcriptional activity. The lack thereof 
could be responsible for the observed increase in luciferase expression with the HFE2 CR. 
 
Transfection of FTH1 (Figure 4.4) and LTF (Figure 4.10) CR-removed promoter constructs 
resulted in luciferase activity changes that followed a different overall trend in comparison 
to the genes discussed above (Table 4.2). FTH1 was found to contain the MRE in the CR 
element, however the 1.86 kb CR-removed promoter appeared to decrease luciferase 
activity in both cell lines tested [p = 0.01 (HepG2) and p = 0.00 (COS-1)]. It is plausible that 
the removal of the MRE from the FTH1 promoter resulted in the decrease in expression. 
However, the reason for the much larger reduction in luciferase activity relative to the other 
MRE-containing genes, also in the absence of zinc, cannot be satisfactorily explained. A 
similar decrease was observed with the LTF 1.86 kb construct in both cell lines, although this 
was only significant in the HepG2 cells (p = 0.04) (Table 4.2). As in the case of HFE2 
discussed above, Motif 3 was predicted to be absent from the LTF CR following 
bioinformatic investigation. One of the Tfs identified in Motif 3 was C/EBPα. This particular 
Tf has been shown to act a positive regulator of transcription in conjunction with other 
molecules that form part of the pre-initiation complex required for basal transcriptional 
activation (Nerlov, 2007). With regard to the role of C/EBPα in iron metabolism, studies on 
the HAMP promoter have confirmed that C/EBPα binding is capable of activating HAMP 
expression in a hepatocyte-specific manner (Courselaud et al., 2002). Absence of the TfBS 
for C/EBPα could explain the difference in luciferase activity that was observed for LTF in 
comparison to the other genes that were investigated. 
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4.6 CONCLUSION 
The functional influence of the CR identified in this study warrants further investigation. 
Overall, it seems as if the CR may be mediating an inhibitory response (with the exception of 
FTH1 and HFE2), decreasing the tempo of transcription, via an iron-independent 
mechanism. It is evident that deletion of the CR did not abrogate or alter the response of 
the respective promoter regions to FAC treatment. This region may therefore have a role in 
the regulation of transcription under physiologically normal conditions by effecting the co-
ordinated regulation of this gene network. In the majority of the genes of interest (CYBRD1, 
HFE, HMOX1, IREB2, TFRC), targeted deletion of the CR led to higher expression values when 
compared to the control. Examination of the findings of the in vitro cell culture assays 
demonstrate that this promoter element results in significant differences in promoter 
activity, especially when examined individually in the 140 bp CR constructs. Although the 
effect of the CR appeared less statistically significant when removed from the full promoter, 
as in the case of the 1.86 kb CR-removed constructs, discernible variations in luciferase 
activity were still visible. Expression variations were stable and repeatable over the triplicate 
experiments performed, indicating the validity of the functional importance of this region. 
These results are crucial indicators that the methodology utilized in this study has merit for 
future investigations of gene regulatory features. The bioinformatic predictions were 
validated by the reporter assays conducted thus establishing a platform for future work in 
this critical pathway. Further studies should focus on examining the individual motifs 
predicted within the CR, possibly utilizing a deletion construct-type approach. In addition, it 
will be of paramount importance to elucidate the authentic functional interactions that take 
place between the CR (or individual motifs) and Tfs of interest. Techniques such as EMSA or 
ChIP would be of benefit in this regard (Euskirchen et al., 2007; Gurevich et al., 2010; Hu et 
al., 2010). 
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In the era following the publication of the human genome, genetic research of eukaryotic 
genomes is experiencing a departure from traditional methods. The technologies available 
to study DNA sequences, with particular reference to next-generation sequencing, have 
improved rapidly over the years and are widely available and utilized. Computational tools 
required for the analysis of the vast quantities of data produced by these techniques have 
been developed in parallel and are numerous in their number and potential applications. A 
large proportion of these software tools are available as freeware, the use of which has 
great potential to assist the bench biologist with limited bioinformatic expertise. It would be 
negligent to ignore this new avenue of research, particularly with regard to the study of 
functional regulatory elements in the genomes of complex organisms. Evidence of the 
emerging study of regulatory features of the human genome is illustrated by consortiums 
such as the ENCODE project. Recently, the researchers involved simultaneously published a 
series of 30 papers in different scientific journals containing the results of their study (see 
http://www.encodeproject.org/ENCODE/pubs.html for publication collection). The main 
findings effectively dismiss the theory that the human genome consists primarily of “junk 
DNA”. The ENCODE results have shown that more than 80% of non-coding DNA sequence 
takes part in biochemical- or chromatin-associated events and most lie close to areas of 
protein-DNA interaction (The ENCODE Project Consortium, 2012). Results of this type 
reiterate the importance of research into identifying promoter regulatory elements that 
may help to explain the complex process of transcription. 
 
The overall aim of the current proof-of-concept study was to investigate the upstream 
untranslated region of specific genes utilizing a combinatorial computational and functional 
genetic approach to identify potential transcriptional regulatory targets. With regard to the 
bioinformatic portion of the strategy, the first objective involved the selection of candidate 
genes. The iron metabolism pathway was chosen as a model system due to the inherent 
level of physiological control required to maintain homeostatic iron levels within the body. 
Despite intensive investigation, the transcriptional mechanisms responsible for regulation of 
gene expression in this pathway are only beginning to be unravelled. In addition, disorders 
of iron metabolism are among the most common diseases affecting individuals worldwide 
and warrant further research. In order to satisfy the first objective of this study, eighteen 
genes encoding the most central role players of the iron metabolism pathway were chosen. 
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The decision was made not to select those genes known to overlap extensively with 
alternate biochemical pathways, such as the haem biosynthesis pathway, and mitochondrial 
genes. Examples of the protein products of these genes include: ABCB7, a membrane 
transporter required for [Fe-S] cluster transport in the mitochondria (Dunn et al., 2006); 
frataxin (FXN), which aids in [Fe-S] cluster formation (Schmucker et al., 2011) and δ-
aminolevulinic acid synthase (ALAS), the first rate-limiting enzyme in the synthesis of haem 
(Nilsson et al., 2009). Genes encoding proteins with multiple functions in different pathways 
are likely to be regulated via diverse mechanisms, thus complicating the process of motif 
discovery unnecessarily at this stage. This represents a potential limitation of this study 
which would be remedied in future investigations by applying the strategy designed in this 
study to these genes. Expanding analyses of this type to these genes, as well as to others 
that have yet to be discovered, would supplement the current understanding of this critical 
pathway. 
 
The second and third objectives for the bioinformatic section of this study included the in 
silico analyses of the non-coding sequences of the respective genes with the aim to 
potentially identify novel regulatory targets (discussed in Chapter 3). This was achieved 
through the use of a variety of software tools that were selected based on their relative 
popularity and ease of use. The main findings included a previously uncharacterized region 
of unexpectedly high sequence conservation in nine of the genes. This region is proposed as 
a novel Alu-J element based on sequence alignments. These mobile elements have been 
associated with TfBSs in numerous cases thus substantiating the idea that this region may 
contribute to regulation of the genes of this pathway (Polak and Domany, 2006). In silico 
prediction of TfBSs resulted in the identification of numerous putative Tfs that will serve as 
the basis for future work based on the outcomes of this study. The results of the in silico 
analyses of the promoter region of the genes of interest represent a novel contribution to 
the field of iron research. 
 
Functional promoter assays were designed in an attempt to validate the in silico predictions 
and are discussed in Chapter 4. The objectives for this subset of the study were effectively 
achieved in each instance. Three different promoter constructs were prepared for each of 
the genes found to contain the region of sequence conservation. These were successfully 
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transfected into mammalian cell lines in an in vitro culture system and promoter activity was 
assessed with a dual-luciferase reporter assay system. For each of the genes, statistically 
significant variations in luciferase expression were observed with the constructs 
representing the CR element. Although the trends in expression were not always consistent 
with what was expected for each gene, it has been shown in previous studies that 
interactions with specific Tfs can result in markedly different effects between different 
genes. Wu and colleagues (1999) demonstrated that the interaction of the Tf, c-myc, with 
FTH1 resulted in repression of expression. The same interaction with c-myc was responsible 
for the stimulation of IREB2 expression in an in vitro environment (Wu et al., 1999). Deletion 
of the CR may therefore have unexpected consequences with regard to transcriptional 
regulation of gene expression. 
 
Functional validation confirmed the bioinformatic predictions with regard to the postulated 
effect of the CR on transcriptional regulation. However, relative to the constructs 
designated as controls, these variations were not notably different upon treatment of the 
cells with FAC indicating that the CR functions in an iron-independent manner under the 
conditions tested. As previously eluded to, it is more likely that the CR is exerting functional 
effects in a manner that is related transcriptional regulation under physiologically normal 
conditions. Although not a new concept, the hypothesis of co-ordinated regulation of a 
network of genes is supported by the findings of this study. Based on the bioinformatic 
investigation conducted, the possibility that the CR element may actually be an Alu element 
substantiates this idea. From an evolutionary perspective, transposable elements are more 
likely to have been conserved in the non-coding regions of genes if they confer some type of 
advantage (Häsler and Strub, 2006). 
 
Despite the vital data that resulted from the functional assays, certain limitations exist 
which could be addressed in further studies. The cell lines utilized for transfection of the 
constructs should be expanded to include different cell types, particularly an intestinal cell 
line such as Caco-2 (Alvarez-Hernandez et al., 1991; Han et al., 1995; Tallkvist et al., 2000; 
Tandy et al., 2000), which was unfortunately unavailable for the current study. Although the 
majority of the genes investigated have been shown to demonstrate expression in the cell 
types employed, it is possible that divergent results with regard to the CR may be observed 
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in alternate tissue types. It should also be emphasized that the suitability of the particular 
cell type to be utilized should be evaluated extensively. Recent work has shown that HepG2 
cells cultured with relatively high glucose concentrations (as is standard for this cell type) 
may have significantly lower levels of endogenous HNF4-α (Selva et al., 2007; Simó et al., 
2012). The down regulation of this important liver-specific Tf could have severe 
consequences with respect to the evaluation of expression levels in a HepG2 in vitro 
experiment. The use of exogenous stimuli, other than FAC, is recommended for further 
work of this nature. It will be important is assess the potential effects of zinc on the CR and 
CR-removed promoters to confirm if the MTF-1 TfBS identified in five of the genes is 
relevant in the context of transcriptional regulation as suggested by the results presented 
here. Exogenous stimuli such as bacterial lipopolysaccharide (LPS) and interferon gamma 
(INF-γ) should also be tested to determine if the CR responds to these immunomodulators. 
LPS and INF-γ are typically added to culture medium to induce an immune response in the 
growing cells (Lewis et al., 1990). Iron metabolism genes, and HAMP in particular, are 
known to be regulated by conditions of inflammation (Ganz and Nemeth, 2005). 
 
Although not within the scope of this study, the most crucial aspect of future work should 
involve the determination of the physical interactions between the CR DNA sequence and 
Tfs selected on the basis of the bioinformatic results. Antibody-based techniques such as 
Western blots (Brunet et al., 2004), EMSA (Gurevich et al., 2010) and ChIP (Hu et al., 2010) 
would be ideal to carry out this task. It would also be imperative to confirm that the cell 
lines selected for this type of work express the Tfs of interest. Determination of Tf mRNA 
concentration in the relevant cells could be easily performed by means of qRT-PCR prior to 
the instigation of experimental protocols (Czechowski et al., 2004). Co-transfection of cell 
lines with vectors expressing the Tfs of interest together with the promoter constructs 
prepared in this study would also allow for determination of the effect of the potential 
interaction(s) on gene expression (Trujillo et al., 1991). Deletion constructs of the 140 bp CR 
should also be prepared to identify if the individual motifs within this region are 
contributing significantly to the changes observed in luciferase activity. It may be a simpler 
undertaking to pursue candidate Tf-interaction investigations on smaller genomic regions 
(represented by the conserved motifs) than the whole span of 140 bp. Identification of a 
core subset of Tfs that are responsible for the induction or repression of the respective 
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genes, by binding to the CR, would provide tantalizing possibilities for the development of 
Tf-specific agonists or antagonists. Drugs of this nature have proved effective for the control 
of diabetes mellitus and other conditions of insulin resistance. In these examples, the Tf, 
PPARγ, is targeted and activated by the drug class thiazolidinedione. Activated PPARγ is able 
to bind to DNA, when complexed to RXR, and modulate the expression of a variety of lipid 
metabolism genes (Krentz and Friedmann, 2006) 
 
Standard molecular genetic screening approaches for the identification of DNA sequence 
variants that could confer risk for disease development would benefit from the type of 
study performed here. Putative regulatory regions identified by computational means would 
represent an ideal starting position within which to search for mutations in modifier genes 
for HH. One of the significant findings from the ENCODE publications was related to the re-
analysis of previous GWAS conducted on various human disorders (Butter et al., 2012). It 
was demonstrated than an abundance of the non-coding SNPs, which were the focus of the 
GWAS were associated with ENCODE-annotated functional regions (Schaub et al., 2012). 
SNPs located within TfBSs have the ability to influence cognate Tf-binding and can 
potentially result in aberrant gene expression, particularly if the Tf in question is responsible 
for recruiting transcriptional co-activators and repressors (Kasowski et al., 2010). Numerous 
human diseases result from mutations in TfBSs (reviewed in Maston et al., 2006) illustrating 
the importance of regulatory SNPs. Variations identified within functionally important 
regions, during mutational screens of non-coding DNA sequences, may therefore have more 
significant clinical consequences than has generally been acknowledged until recently. 
 
To our knowledge, this is the first study to employ a strategy of this nature in an 
investigation of the iron metabolic pathway. Results indicate that the design of experiments 
can be greatly facilitated by prior computational examination of genomic sequences, and 
that these software programs have the capability to predict functionally relevant DNA 
regions. A novel regulatory element was identified in this study that has potential 
implications for the co-ordinated regulation of genes of this pathway. The further studies 
described above will be required to fully elucidate the physiological mechanisms underlying 
the observations from this work. It is hoped that studies, such as the one presented in this 
dissertation, will provide invaluable information that will help to unravel the complexities 
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associated with transcriptional regulation. Although not an overnight process, the 
development of pharmaceutical interventions for the diseases associated with aberrant iron 
metabolism will be extremely beneficial to affected individuals, and will be facilitated by 
research of this nature. 
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Appendix 1: Conference Presentations and Publications 
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* NJ Strickland, MG Zaahl (2012) In silico analyses of promoter regulatory targets in the iron 
metabolism pathway. (Oral). Joint Congress of the Southern African Genetics Society South African 
Society for Bioinformatics and Computational Biology, Stellenbosch, 10-12 September. 
 
* NJ Strickland, MG Zaahl (2011) In silico analyses of promoter regulatory targets in the iron 
metabolism pathway. (Poster). Joint Congress of the Southern African Society of Human Genetics 
and Africa Society for Human Genetics, Cape Town, 6-9 March. 
 
NJ Strickland, T Matsha, MG Zaahl (2009) Molecular Genetic Analysis of Ceruloplasmin in 
Oesophageal Cancer. (Poster). International Bioiron Society Biannual Meeting (IBIS), Porto, Portugal, 
7-11 June. 
 
SH Krikler, CA Whittington, M-A Hallendorff, NJ Strickland, VR Human, NW McGregor, JA Vervalle, 
MG Zaahl (2009) Mutation analysis of seven genes involved in iron metabolism in a Mennonite 
population. (Poster). International Bioiron Society Biannual Meeting (IBIS), Porto, Portugal, 7-11 
June. 
 
NJ Strickland, T Matsha, MG Zaahl (2009) Molecular Genetic Analysis of Ceruloplasmin in 
Oesophageal Cancer. (Poster). South African Society of Human Genetics (SASHG) Annual Meeting, 
Spier Estate, Stellenbosch, 5-8 April. 
 
* Presentation directly related to the current study. 
 
Previous Publications Related to Work in the Iron Metabolism Field 
Strickland NJ, Matsha T, Erasmus RT, Zaahl MG (2011) Molecular analysis of Ceruloplasmin in a South 
African cohort presenting with oesophageal cancer. Int J Cancer 131: 623-632. 
 
Panton NA, Strickland NJ, Hift RJ, Warnich LW, Zaahl MG (2012) Iron homeostasis in porphyria 
cutanea tarda: mutation analysis of promoter regions of CP, CYBRD1, HAMP and SLC40A1. J Clin 
Pathol; doi: 10.1136/jclinpath-2012-200988. 
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Appendix 2: Gene Promoter Sequences 
The promoter (5’ to 3’) region of each of the genes investigated in this study was acquired 
from Ensembl (reference numbers indicated). The primer binding sites for primers designed 
for the amplification of the 2 kb promoter region are shaded in grey. Primer binding sites for 
the primers designed for the amplification of the CR element are underlined. The translation 
initiation site (ATG) is indicated in bold red text. The 5’UTR (black text), the CR element 
(green text) and the introns (blue text) are indicated in lowercase text. The first exon is 
indicated in uppercase text; untranscribed regions in purple and transcribed regions in black 
text. 
Aconitase (ACO1); ENSG00000122729. 
ttgtaagcttcctgaagcctccccagcatgcagaactgtgagccaattaaacctccttccctatgaattacccagtctc
agggttctttacagcagcgtgagaacggtctaatacagacacctttggaatatccaggtggggttgccacatatggctg
caaatcaagagtgtgaaggtcagaaagttaactaagaccaatgacagagacatagcaggcttcagctagaagtggcagg
cagtctgcatactgagaaaatagatgaagaaaaactcagcaaatggagaaacatataaagcaagaggagagagtgtagg
gaaagaccttaaaaaagagggacaaaagagggaagaggtgactcctaagagcggagggctgaaaagccaaaaggaggtt
aacatttctaggaaaacgaatcgccagtgtcaaataccacagagtagtgagtaaggacaggaacagaggacaggccctg
ggattcacgatctgcacgtcactggtgacaacgtccaagagcaacagactggggggatgtggaactatttccttcacgg
ttttgaccagcgtgcttactaataaatctcaattcccttcatagctctgatttgattgttttctgcgaaggattctcag
ttacacggatgttatcattgaacattagatactttgctttccgaatggctgcctcattaagaatcgcaatttagctgga
tgtgtcctcatcggacttccccagccttctactcactctcaccttgcccctactctccctacctcccaaggggactgga
gcatgatttttcagggattgtggtgcacctctgccatatggtggacattcaaagaaaatttaattactaatgtgaatgg
aaaggatttaggaagtgggtgggaaaacagtctcctctcatattggaaatacagttacttcccctttcaaaataaatat
aagtatttatatttcaaagttaaatataactagacgatagttgtaccctatagtgcagtatgacagggaaggtgtaggc
tttggtgtcaaaccaacctaaggactgagtctcagctgttgcgcattgcacacctgcaaagacgggtaatattctttac
ttgtaaggtggttggaagagctgaactgaataacgtggaaagagtcgatcacagggctttgtgcagaataggagggcag
tataaagtagcaggggggctattagtactggctattgtttactcatcctataagctgcttattcagaaaactacagtaa
ctttccaaataatttgggcaggaaaacctcaccacctttcatctagaaagatctaatcacttctttgaacgccattcac
ccaagagggcacaactcctaccaacatgaaaagcagatcttgtgaaagcccacttgctgccatctcccagccatttctc
cgacttcagaccggtgaacatcgtgcattagaaagtgttgttacatgtccaaggaaatctacatatagaacttttgcca
cggaaatgctgaagtcctattctgacagcgtgactccgatgtccacttggcaggctttgcgcaaagaattaaggcgagg
gtggagagggtgggtagggtggggacggacaaagtgagaagggaggcgggccaagtgaccacacgtacatgaagcctct
ccagttatggccaaatcattttttaaaaataattccatttcttccccaccctttggtcacttcctaacgccggctgggg
agtcacatgctaagctccaaagtgagcaacagacaccctcgtcccaggtcccatgctggcagaagcggacccgggccga
gggatcagccctcccacttccagcggaggagcccttcgcaaccctagcctccagcccggggcgaagtcctccaggcccg
cgggggcgcccgcaggctccgccccttcttcggctagctgcccgtccgtcccgcccctgctccgcccttcccgcccctg
ctccgcccatcgcgcggcggccccgGGGGCGAGAGGGGGCGGAGCGTGGAGGCGGCAGCTGGAACCGCGCAGCGCACGG
GAACGCGTCCCGCTGCTTGGGTCAGGTTCGCCGGTCGCGGGAGCCCCGCCGTGCAGTCGGAG 
Ceruloplasmin (CP); ENSG00000047457. 
acagtgttactgtttaaccatttcatttcaccaccaatatgaggggtgtgctatgcatacattctggaaccctcagcaa
ctatttgaacaggtttgtttgttggatggttggttggtacaatttgctgaaacaagtgactctgggcatggttacggtg
ctctgatcaacatctttccatgcacaagattggggctgagtttgagcactgagtgaaaaatgaaaagcaaatggctgag
acagttgctggttcacatcgtggcttcatgccaattagaaaaagaactgtcccccttctccatgccctggggaggataa
acggctgaaaaatgccccccgtctgtgtggaccattaggggaaaagcagcttcttgcaaggcacagggtatggccggtg
gcatctgagcaagattttagtccttcgtcagtcctctcagtggacatgacggcacaattgttcaaggcagtcctagaag
gaggccttggggcatcctgggcaacatgattcagttttctgtaccaagccatttagttaagattattaccagctggtga
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gagaagctcctccactgtctgccttaacataggtcatttcaattaacctgagattttcagatgaggaaactgaagctgg
gctgaagtatcttacttgaggtcatttggtagcatcagatttttccctagcactccttattctccttctctgctttatt
tttctccatagcattcaccactaatattgtgtatttcatttttcatttttatattttcagtttccccaagtagaatgta
agttgcatgatggtaggtgttttgttctctgcggtattcccagtgagtagaacagaacttggcacagactgctgtattc
ccagtgagtagaacagaacttggctcattcaataatatttcctaaatgaaggaattgttcaaatatcgcatgctttctt
ctataccaatctatttcaacaagtggccttcagcaaatacacaacgttttgaggtatttgagagaaaaaaaattatact
aacacaaagtgtcaactgttatcaggattttcttcagctaaaaaaaaaagccatttcatacttttagacatatacttcc
tgactaaaaacagggttttaagaaaaagtcttccaccttaaaattcatatccacttcaaagagaaaaatttcagtctaa
tgataaactggggtactttctatttactaagactaatctttgcctctgaagacaggtttagttatggtttgtttatttg
atgattaaaacaaagttattagcccctgttaggctctgctagttatttgcatatagcaatacagaatgatctggtaaag
tttttatgcagatttggtccaagctcataaaacagataaattcttccaaattaaattcttatttttgtttacttaaatt
tggcatgctagatatcatgtttcatatcataaagctgcaattaatcatttgttagacttttagaaatagtcatgcacca
cataataatgtttgagtaaatgacaaactgcatatgtgatggtggtcccataagattataataacatatttttactgta
cattttctatgtttgcatatgtatagatacagaaatatcattgtgttacaattgtctatagcattcagcatagttatag
actgtacaggtttgtagcctaggagcaataggtataccatatagcctacctagatgtatagtaggctatatcatataag
tctgtgtaagtacactctgtgatagtcacacaatgacaaaatagcctaacaatgcatttctcagaacgtatccctgtca
ttaagaatgactgtagtaaaaagctacatgttttgattcattttacataattcttatcctgatttactaaaagtgcact
gtttgcaggacactgtgctgtgacatattgtcagaggaacaaagggagcatttagacacgttctctgccctcctggaat
ttacacaatgaatggaaaaaggcacAGAGTTATGCACACCCTAATGCCTCCAACAATAACTGTTGACTTTTTATTTTCA
GTCAGAGAAGCCTGGCAACCAAGAACTGTTTTTTTGGTGGTTTACGAGAACTTAACTGAATTGGAAAATATTTGCTTTA
ATGAAACAATTTACTCTTGTGCAACACTAAATTGTGTCAATCAAGCAAATAAGGAAGAAAGTCTTATTTATAAAATTGC
CTGCTCCTGATTTTACTTCATTTCTTCTCAGGCTCCAAGAAGGGGAAAAAAATG 
Cytochrome b reductase 1 (CYBRD1); ENSG00000071967. 
actctgagcccttaatcctgccctactaccatggcttgccactcctatttccttagcctgctttgaaaatcatccccgt
atacttcctgcacattctaaggtctttcaagacggcaacaagacaatatagcaaagtagtccttggagatgagctacag
aagagggctagaagtgaacgttcccaaatgcattctggaagcccctggcagtcagaaccctttttcttataatagcatt
agataatgctgacattgtttttgtccagtggagaagggtgaggataatgttggaaagagggcagggagcaagcttcact
tcatcaaggaggggctttggttcaaattggtttgggtgggcgggcactttgaaaatccatttgtcacactaaacggcaa
gtccaggtccaggaggttcctgtcttccctctctcaagagcaaactgcaagtagtttcattgcaggataaggccaagcc
caccgctgcccatgctgtttttgttttgtttccagacagagtctagctgtcaccaggctgcagtgcagtggtgcgatca
tacctctcctgagctcaagtgattctcttgcctccacctcccaaagccctgggattacagctgtgagacacctcatggg
gacccggtttactgggttttttttgttttttgttttttgtttttttttgagacagagtctcactttgtcacccaagctg
aagtgcagtggtgcaacctcagctcactgcagcctcgaccttctgggctcaagtgatcctccttcctcagtcccccaag
tagctggggctacaggtgcatgcatttgtattttcagtagagacagggtttcaccttgttgcccaggctgttctcaaac
tcctggactcaagtgatctgcccgccttagcctcccaaagtgctaagattacaggtgtgaggcactgcgcctggccttt
actgttaacttaaaacaaaaaattataaatttgaaaaaagaggagactttatttcttataaaaggttatagcctgcaag
gaggccattccataggctgataaacatagcctctggcctaagaccagagacaggcacttggaaggcagaggggttgggg
taggagctttatgctgaacagtttggccaaacatacatacgtaacaggttacaggaggagctatgaatattaatggagg
tggtccttacacatgcatattgaacaaacatgcatgtaacatgttctctttggggtggagacttaacatttaattgtat
tacttcaaatacatttaaatgtattacttcaaacctacacttcaaaaggtcttttcaggacgtgaatgcatacaagtgc
acaatccctgtacactggccagaaccggtccatggtcggtcttcttatcatgaaaaagttcctgaaatcagcccagtga
aagctgtagttctggctggtgcaacaggggttcagctggtcagcatctgtgaactgattaagttgtaattgttttaata
ttgcttatctcaagccagtgcttgtttagcctctagaggaaaagaaaacctttgtggcagttagaccatagtttatttc
ttaagtgtaggagtgtgtgacttaggtcctttttataatttgatgtcttattgctacaaagagtctgttctgtccgcct
tatgatttctattttaaacattaatgctagtcagctgttgagtctaaattccaaaatggagggggtagacttcccttcc
ggctgtagctagaaactcagctttaaggtttttctggggtctgcttggccaaggaggtccattcagtcagtgaggggct
taggattttatttttagtttacaccaccttacaggttcctccttaacaccctttgatgtcagagacagccaattctcca
gcactgtggctaaggaggcttcgttagtagttaaaagcacacacataaccctacccaacggatccctctcttctcttaa
ccaagagggcgcaccactgccctactcaacctccccacaaataaggacgagacacgggaagtgttaaaagcaagtggtg
agtataaaatcctcggaattttctctttgagcaactaactaggtctgttactgaagccctctgcgagcttggatgctgg
acgagggagagggtgaggccaccaggcaatgagcgccctcggcggccgcgtgatcccgggggtggggcCCATTTCTGAG
TTGGGGCCAGCTCCCCACCCCCAAGAGGCCCCACATTCCGGGCCAGCAGCCCAGAAAGTCCCTCCCCGCAGGCGGAGAC
AGCCCCAAGAAGTCGACGCCCCGGTCCCGCCGCCCGGCCACTACCCAGAGGGCTGCCGCCGCCTCTCCAAGTTCTTGTG
GCCCCCGCGGTGCGGAGTATGGGGCGCTGATG 
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Ferritin Heavy Polypeptide 1 (FTH1); ENSG00000167996. 
tatttcttgttaactttattccaaggtactttaagcttttgttgtcaatgtaagtgaaaaacatttttttttccattct
tttttccccatattttctaactggtggttactgttataaaggaaagctttggatcctatatatggtgactttgctatac
tcttatcctaagagattcccagtgtaaggtttctaaaaacaaagctaatgaggtgtctctatgctgtctctaggatcaa
gtttaacctctttttatggaacacaaccctgcccgatcttgcccctattctccaccctaaccagcatcccccaacataa
actgtactttccaggccaacattctttctttctttcttttttttttttttttttgagacggagttttgttttgtcttcc
aggctggagtgcaaaggcgcgatctcggctcactgcaacctccgcctcccaggttcaagcgattctcctgcctcagcct
ccagaatagctaggattacaggcgcatgccaccacgcccggctaatttttgtattttcagtagagaagggtttagccat
gttagttagccaggctgatctccaactccgacctcaagtgatccgcccgcctcggcctcccaaaatgctgggattacag
gcatgagccaccgcgcccagccccaggcaacatattttcttaaggcagctttaacaggccatgcatttccacatttcca
cacctttgcatatgctgttcactctgctccaaattcccttccctgtttctctcccgcacttcaccttccttttaacttt
ttcttcaaactcagctcacgtgtcttgcttagggagggcttccccgacctcctcctatcccagactgggtaaggtactc
ctggtctagcagcatccttctgtttaccttattcttgtagctctagcaccactaaaacgtttttcctgtaaataacata
ggtgcatttttaaatgaaaccgtgaacaagaaatcaccctaattccgtcggcaatttattttagtatttcagtagagtt
gcttttttaaactaaggtttggaagtctagcttccagctgcaggtttgtgagcatcctgaaattcagttcttccaccga
tgcgtcaaaagacgcgacagaacagtggacctcgaagccaggacctaggtaagggcagggcctagctctagctctgcca
cccataaattcacatccaccctgtgcctgggactcagcttagccacacacaccggccccacccctccggggtctctttc
acctgtcacccgccattaaccccgtcagcttctctccaatgacaccccagggttgtcctacagggccaccgaagcctga
agctcctgtgagtggggccgataagaggccattttgaaaagtcctcagcatgggcttcgcctttagatccacgtcgttt
ctcctttctaacccgagatgtgtcccttgggtgcgaagcgacaccagcgattctctcggaggccccggtggctcacccc
cacgactccccggggaggcggtccccatccctagggaaacccggcccgcccagcctttgttgcagaaaccgcacacgga
gccatatttgctttcagccaaaggcagacgtggtcggaggagtcggaagggcaggggcggacccgaaacccgccgtgcg
ccccacttctccatcgcgctccttcctggactctgaggaagagaaaatgcgctcgaccacctaaggaccgcgtctccac
cttccaccttcccaatcatctgcagcttcccaatctgcagcaaggtgtcacaagggcttctccgcagctatgatttcta
acaccatgccccgggccaggagcctcagggtgcccgttcgggaaaatgggagccgaatcaggatcaccccatgcgcccc
cgcacccttcccccgccggttccaacgcccgggcgcccctagaccggggggggggttctgaggtggacttcctgcgcct
cctcgcagcttccctccaactccactaaacgggcacagagacgccaccgctgtcccagaggcagtcggctaccggtccc
cgctcccgagctccgccagagcgcgcgagggcctccagcggccgcccctcccccacagcaggggcggggtcccgcgccc
accggaaggagcgggctcggggcgggcggcgctgattggccggggcgggcctgacgccgacgcggctATAAGAGACCAC
AAGCGACCCGCAGGGCCAGACGTTCTTCGCCGAGAGTCGTCGGGGTTTCCTGCTTCAACAGTGCTTGGACGGAACCCGG
CGCTCGTTCCCCACCCCGGCCGGCCGCCCATAGCCAGCCCTCCGTCACCTCTTCACCGCACCCTCGGACTGCCCCAAGG
CCCCCGCCGCCGCTCCAGCGCCGCGCAGCCACCGCCGCCGCCGCCGCCTCTCCTTAGTCGCCGCCATGACGACCGCGTC
CACCTCGCAGGTGCGCCAGAACTACCACCAGGACTCAGAGGCCGCCATCAACCGCCAGATCAACCTGGAGCTCTACGCC
TCCTACGTTTACCTGTCCATG 
 
Ferritin Light Polypeptide (FTL); ENSG00000087086. 
cagggtctctgtacccctctgtctccgggtctgttttcccctctctctgggtctctgtccccctctctctcagggtctc
tgtctgagtctctttttctctgggcctctgtctccccaccccacgttctctatggtcttcagatcctgtctctctcagc
ccctcctctccctccacctatgggccccaaggcccctctcggccgactaaaggtctctgggctgaggtatgacatttgg
taaatgagtaactcgggccccacagtcaacggggtgctttggacggctgcccctcctccatggactcttcccagagacc
ccaagtcaggggagagagaggggcagaggatcaatgagtgtacactgagccaccacccagagtgaggggacaatatggc
cacaggcaggatcccagaaaaaaaaaaattatgggaaccaaaaagacacggagacaaagcacacagccggcttccaaca
aggggggaccttggggtagggggcccgatttgggtctgagccaggtctagttctgagggtcccaccaaaaaagtcgggg
agtgccaaggggatgaggtcagcgagtggccccacccccatccgtccccgcgggggccccttcccgcgctgagctcagc
atgactcagcagtcgctgcctgcaacaaggaccccagataccggcctggcggggcatctgcagatcccctcggtcaggg
gctgccccgcctgggctgttcggagcagctcctctgtagggcagggcctgacctcaccccacaccccagtggcttcagc
tccctgcccagcgcacgggctgcctccatcagggcacttaagtagagtcaaggtttgcgccgactccgtctcccagaaa
tcaacgtggaccaggcccacttaaaaaatatgcattagtcgaagacagacgtctcgtccataggtccccagactgtttg
tccacaacgcagggcttctctttgtgggcctgaaggagcacacgtcaggcaagacacgagggcaacttcagagacactg
ttcagggccacggagaattctcgaagtctgtgagttgtctccaaaacagcctccaggaaatgcaatcccagagacaccg
caaagctcaaaacagacttttcattcctccccatttccactcccagaaaaagcctgggcccctgaaagagctccaaggt
atccccaaagtcccagcccatctttggagggttccagagggctgtccagggttccagaagtcaccctacctcatacaat
gctcctcctgggcttcccgcactgggtgaaacccacggctccagaataactgccctttccaacttgcagagcacctcaa
gaacctaaagatttccccggggagggctccaaaatatagagagtttgcatcgtgaacccccacccctgtaaatcccagg
actccagtccccgcaacactccatcttccagagatctccaggggtccagaaataacacctcacagccttccaagcttcc
caaggatccggagactccttatctcgcagcgcaaacctcaggcaactacaggtcctccctgcacctttgaggtgcccct
ccccccactcaaggttccagaaaaatccatgccctcggaaaccccagaatcttactttcccgaggcaccccaggacccc
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agggtcatcagttcacagggctgttagtgctcccataaaactctagcctcccagagggaccccagcccccaccctcccg
cccacgaacccctgcatttccagaatcagccccagggccccaacccccccaagcccccatttcacaacacgctggcgct
acaggcgcgtgacttccccttgctttggggcggggggctgagactcctatgtgctccggattggtcaggcacggccttc
ggccccgcctcctgccaccgcagattggccgctagccctccccgagcgccctgcctccgagggccggcgcaccataaaa
gaagccgccctagccacgtcccctcGCAGTTCGGCGGTCCCGCGGGTCTGTCTCTTGCTTCAACAGTGTTTGGACGGAA
CAGATCCGGGGACTCTCTTCCAGCCTCCGACCGCCCTCCGATTTCCTCTCCGCTTGCAACCTCCGGGACCATCTTCTCG
GCCATCTCCTGCTTCTGGGACCTGCCAGCACCGTTTTTGTGGTTAGCTCCTTCTTGCCAACCAACCATG 
Hepcidin antimicrobial peptide (HAMP); ENSG00000105697. 
gatgcagcgatgcctggtagggctgggggctgctcctgtgtctccccaggtgagcacacccctattcactgggccctgc
ttcagcctgcagcacccttcaactcccaggagctgggcttgccactctgctcaccttgtggagctccatctgcctttcc
tccccaattcccccactccctgcactcgtctcttcccacaagagccctgtctccttttcctagctattcccatctgagg
ccatctttattcatttagtttttagagacagggtttcactctcacccaggctggggtgcagtggcacacaatcacggct
cactgcagccttgaccaactacaggtgcgtagcaccacagccaagtttttgtatagatggggtctcgctttgttaccca
ggctgtgacaagaggagcctcccacgtggtgtggatgaggaggcagatggcagggcctgtgcatttctgtgcttgagtg
ggccttgaaagtggttcagcaaccaggaagaagtgttcattcctcgacaacaacatccccgggctctggtgacttggct
gacactggatggccctggaatgaaaaaggcaaagaggcaaaatgtgcaagggcccatctggaaccaaggtttgttgatc
ccctgggccgtgtgcaccctgagctgggcctggtagtggaaaggaatgaaggcactgcagtcaggcagcctgggttcat
cccccagctagtggtgtcctaaggaaccggctccccaaaaacatccctggcttgtagtgcttgccaatttctgggtgtc
aagactcccactgctgctgatttcaggataccagcatgatgccactgaatgcagagtttcgagatgtgcatggtctgct
atgttgagccaggtctagcataccgctgtgccctgctgtgttttaggggagatggggaaacctggtgggtaagagcaaa
agccctggagtcaggctgtccaggctagaatctcagctctgcctctggctgagcaagcttgggccatgccctgatctct
gccttcagtgccttttctgtaaagtgaaggaaatgagtgtccgacggggaggaggttcctaaaagggagcagggtctgg
ggagcccaggcctctggggttgggtgactgagaaggcagcccctgaatacagagcagagctgaaggtggggcagtaagt
gctgctgggagaacaggcagcacaggctgagttggtgcagaagtgagtcaacatatgtgccatcgtataaaatgtactc
atcggactgtagatgttagctattactattactgctattttatgttttatagacagggtctcactctgtcacccaggct
ggagtgcagtcacacaatcatagctcactgcaacctcagcctcctgggcttaagcgatctgcctcagcctcccaagtag
ctgggactacagatgtgtgccaccacgcctggctaaatttgtttaaaattttttttgtagagatggggtctccctatgt
tgcccaggctagtcttgaacttctgggctcaagcgaccctcctgccttggcctcccaaattgctgggattacaggcata
agccactgtgctgggccatattactgctgtcatttatggccaaaagtttgctcaaacattttccagttaccagagccac
atctcaagggtctgacactgggaaaacaccacgtgcggatcgggcacacgctgatgcttgccctgctcagggctatcta
gtgttccctgccagaacctatgcacgtgtggtgagagcttaaagcaatggatgcttcccccaacatgccagacactcct
gaggagcctggcggctgctggccatgccccgtgtgcatgtaggcgatggggaagtgagtggaggagagcggaaccttga
ttctgctcatcaaactgcttaaccgctgaagcaaaagggggaacttttttcccgatcagcagaatgacatcgtgatggg
gaaagggctccccagatggctggtgagcagtgtgtgtctgtgaccccgtctgccccaccccctgaacacacctctgccg
gctgagggtgacacaaccctgttccctgtcgctctgttcccgcttatctctcccgccttttcggcgccaccaccttctt
ggaaatgagacagagcaaaggggagggggctcagaccaccgcctcccctggcaggccccataaaagcGACTGTCACTCG
GTCCCAGACACCAGAGCAAGCTCAAGACCCAGCAGTGGGACAGCCAGACAGACGGCACGATGGCACTGAGCTCCCAGAT
CTGGGCCGCTTGCCTCCTGCTCCTCCTCCTCCTCGCCAGCCTGACCAGTGGCTCTGTTTTCCCACAACAG 
Hephaestin (HEPH); ENSG00000089472. 
tacccagagcaagcctagggctgtcacacatcacagcaatgcagagcaacctttccaaagcataacagagtctgctggt
cagaagtggtggtggggagtggcttcagagatgtggtttctgggggacaaccccctcttccctgcacccctccaccttt
ccccagaggtcttctttttaagaaactgctaagggcaagctcatcagaggatcctgaggtaaaggggttagactgtctg
tgccaaggcactgcccatggcttttaattttctcctggtacctgatactgtcacaaaatttaactgtggaaaatatagg
aaggaaaacaacatttactgggggtctgaacatgctgagcactgtgctaagggttcacacaaatgccagctgatttaat
cctcacaatatttcagtcatggaagtgttattattcctgttctgcagatgagggaccagaggctcgaaaaagttaagtg
atttgcccgaggtcacatagctcagaaaaaggcagccaagatacaatccttagtctttctgactccaaatgccatgctt
ctcaccctagaccatgttgactctaatgtgaaggtccctggggtcctctcctctttgtagccaccccagggccatgtgt
tattgatggcccatagatgagtaacctggaaatattggttgaatgaataaacgaaaagatgttctagtgacagagttta
acacatgaaggacccttaaggatattctggtcttacggttttccaatctgtttttagtgtcctagacatttcttactgg
tgctccagacacaatcacattgtctaggaaaccagtcatacccagtggacaggttcctctgtctcttcacccttgccca
tttctatctccttccctgccttacctagaacaaatcactttcatcttccataagtagtgggtgtttactaagattctgt
ttggggaaagggttctgctgccaaaattaattttgagaaacccaaatctagaccacctttttcatgttataggtgaaga
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aactgagtgatagaaaggcaaaaagacttgtccagggtcactgtgtgctctttagtagcataactagaatgtgaagcca
ggattcttgaaacattcttcttttttgacacaagttaatacagtttgtgtcctaacgaggaaataattatttagatttc
aacaattatttagaattgaaaaattaaaaattataactctaatttttgcctttactatgttccagttattgtgctaaat
agttaatacgtatagccttatttaagttcttataacagtcttataaaataggtaatattattatctccatttgaaaact
gaggtttagggggattaaattactttaatcatagaatcaggaaatggcagagttgggatttcagttcagaatatctgat
ttcagttttcatgctcttaacagtgatgccatattgcaaatgtctatattgaaaaaaaagtctatttagcctgctgctt
gttttgtaaattaatttttattggcacaatgatataccttgagagctacaaagacaaatttgtgtagttatggcaaaca
gaaactgtatgctctggaaataaatgatttagtagctagccctttatagaaaaaatctgccaacctctggtctgtagac
accaactttaaaatgtttttcaagtgacctccaggagaaggaaccagaaatgtaccccggatttgcagaaaaggtgggt
gctgtttgtactctcagtgaaattggtgaatgaataatacaaacctggaaacctggcctacctggcctcctgcagtctt
cactgtgttgattcaagtctattatgacctgttcttgttgtctttcatgagtcagagcagaggccttatcccttcccct
ccctgtcataaatgccttagagcttggacttggatctcagcttaatcagttttgtctccacttcccctttcttgcttca
aggttcacatgtgtgcgaggcagatAATTCTAGGGGCTGCCATGGCTTGGCTAAGCTTCCCTTGACCACTGAGCATTTC
TAAGGGAGTTGAGGCTGGTGGCTCCTCCTTCCTTCCTACTGGTGCTTCCACCTGCCTTGGTCTGAGTTGCAGTCCATGG
GGCAGCGCCTAAGTGTCTGAGCACACTTAAGAATCTCTAGTGGTTTATGACCCAGACTTTGCCCTACCACCTCAGTCTT
CTGAATGTTCTCTTCCCTGGACCCTGCTCCAGACACTTTAAATTCAGAAGAGGAAAATGTGCCCAGCCTGCCTGGAGAA
AAGTGTCTGCTCCTAGCCAAGATCTCCTCATCACAAA 
Hereditary Haemochromatosis (HFE); ENSG00000010704. 
tactaaatgttccaaatagaaagaaagtagattaaagattgtctagggctgggaggggaggaggaggagaatggaggaa
tctgggaggcgatgaattaagggtactgaattaggggaacatggtttctttttggggagatagaaatgtaaaattttgg
taatggttgcacatctctgtaaatatactaaaatccattaatttttgcattttattttatttattttatttttgagacg
gagtttcgctcttgttgcccaggctggagtgcaatggcatgatctcggctcaccacaacctccgcctcccaggttcaag
cgattctcctgtctcagcttcccgagtagctggaattacaggtgcatgccaccacacccagctaattttttttttttga
gatgaagtcttgctcttgtctcccatgctggagtgtgatggcacgatcttagctcactgcaacctacgcctcccgggtt
caagcgattctcctgcctcagcctctaatgtagctgggattacagttgcctgctatcacgcccggctaatttttgtatt
tttagtaaagacggggtttcaccatgttggccaggctggtctcgaacccctgatctcaggtgatctgccttcctcggcc
gcccaaagtgctgggattacaagcgtgagccactgagccgggccaatttttgcattttacatagatgaattatatggta
tgctaattatatcttaccaaaaattgaaaaaaaggaatagtactatcagccccaatgtgcccatcatcaatattctaca
tgtttccaatgttattgtatctgtttgcctacagtcgaggccctgatatcctgtttgattttcttgaattgccaaaatt
tgcatacatgcttacaaaaataatgcctgttgaatttgctagatatgtaaaggtttggagcaaatcaggtgtattaaat
ttattaatattgtttgaaatgtctaaggcaataattcccaaacttcgttgagggagaaggaaagcttttaaaatcccat
tgcccaggtggcatcccatactgttactgggaattatgcattgggatggatcctttaaccgaggagattattatagccg
gagctctgaaccagcaatctcagttcttgtgatagtgagcaaagaactacaaactaacaccaaaatgcaagcttaaagc
aaagtttattgaagcacaataatacactctgagggacagcgggcttatttctgcgaagtgaactcagcacttctttaca
gagctcaaggtgcttttatggggtttgtggggaggagttgaggtttgggctgtatctgagtgacaggatgatgttattt
gattgaagtgtatagctatacaatctaaaattaaactgtgcatggtcttacctataatttgttaagaaaagcctcccag
ggatgggggggcaaaactgtatgtaaattctattataatgatggcatgatgaacttggggtgaacttgaagacaggctt
ttgtgttgttgggcatgtgccaccttagggaatttccacctgtaccctcctttctctttctccaggatattttggccac
agactttatcataaactccatcccttagggtggcattagggtagtcttgggcctgaatttaggtgggccagtggctgtc
ttagtgacagcctttccgctctcttctgtcatcccctcccaactgctaatgtctaactacctaacaattacccattaaa
tcagtgtgtctggggttaggagcaggcctcaatatgtttaatcattctccagataatcccaatactgtaaagtttgtga
aacacttgtcagataattcaattatgaaggctgtggaaggtgtttcagtaggatctaattggttaatgttatgacttaa
ttaatttgaatcaaaaaacaaaatgaaaaagctttatatttctaagtcaaataagacataagttggtctaaggttgaga
taaaatttttaaatgtatgattgaattttgaaaatcataaatatttaaatatctaaagttcagatcagaacattgcgaa
gctactttccccaatcaacaacaccccttcaggatttaaaaaccaagggggacactggatcacctagtgtttcacaagc
aggtaccttctgctgtaggagagagagaactaaagttctgaaagacctgttgcttttcaccaggaagTTTTACTGGGCA
TCTCCTGAGCCTAGGCAATAGCTGTAGGGTGACTTCTGGAGCCATCCCCGTTTCCCCGCCCCCCAAAAGAAGCGGAGAT
TTAACGGGGACGTGCGGCCAGAGCTGGGGAAATG 
 
Hemojuvelin (HFE2); ENSG00000168509. 
ttttctggcattatagtatatcccacttaggctgtcatagtcaaattattatgttttaaagtcacttgaatagtttggt
tagaagcattttacatttctataatgaaactgcttgtgatatggcctctaatggttgagaaatatttgtcatatatata
tacctgagaagagtgctatgagggcctctagactctgtattaaaatagagccaactggtaaagatggcttagtgattgt
gttggttattactgagtgtcaatttgattggattgaaggatacaaagtattgatcctgggtgtgtctgtgagggtgttg
ccaaaagaaattaacatttgagtcagtgggctgggaaaggcagatccacccttaatctgggtgagcacaatctaattca
ctgccagcacagctagaataaaaagcaggcagaaaaatatgaaaggagagactggcctagcctcccagcctacatattt
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ctcccatgctggatgcttcctgcccttgaacatcagactccaagttcttcaattttgagactgagactggctctccttg
cccctcaagcttgcagacagcctactgtgggaccctgtgatcgtgtaagttaatacttaataaattcccctttatttat
atatctacctatatagatatccatatctatatagatattaataaatctagagagacagaaagcagactggtgatggcca
gtctagatggctagatagatagacatggatatagatatagatctctatatagatagaggtagatacagatatagatata
tgccctattagttctgttcctctagagaaccctaatacagtgaccgtatttggaatcggtccttctgttaatttcactt
ggcaagtactaaaagatgatgatctcagatatacctatggctgcaaaaacatgacatggctaaatcccttggttgcagt
atctcttttcttttttaaggggggtgggggggcgggtctcactgttgcccaggctggagtgcaatggcgttatcatagc
tcactgcagcctcaaactcctgcgctcaagtgaccctcctgcctcagctcccaaagtgctgagattttgcaatatttat
ggtcacaagattatgttattccataaaagtatctttctgaggctaggcatgttggttcacacttgtaatcccagcactc
tgagaggctgagatggaaggattcattgaggcaaggagttcaagaccagcctggtcaacatagtgagacctcatctcgg
aaggaaggaaggaaggagggagggaggaagggagggagtgaaggaaggaaggaaggaaggaaggaaggaaggaaggaag
gaaggaaggaaggaaaagtatatttttgaatctttttctatttctccaactctttctttagaagaattctatttccatt
ctttcttcacctctttgcctttgttagccttctctccaagcaaatcgggagcctttattttttgtgtattcatgaggga
gaggaagatgaattgctgtacaaactaaagtaatgaaaatggagtaggtaggaggatagacagctgcaaggatctgagc
tggatagactgaacaaaccctcatcctaagcaactcacagctcagatttcttctctggacagctggcttttttcgtcct
tctgaaatactctgcaaagataggagaggggctatgaactacctctgctatggatcttattcaaagtcagctacctcct
agatactatctgtagaacctaaatgtaatattcagcatagcagggatgaacatggtaaatgaaaggtatccaattgccc
actgtaatttttaaaggccaggagctcaacattattgaaaatgctggagggctgcctggagtaggcagtgaccacagag
tcacacaagctggaattggatatccaacttgtctgtcatatttctctcctccctccctgacttggcactcaatactcca
tattctttctaatcctctaaccctccccactcccccaactcccacaccctacccccaccaacgttcctggaattttgga
cttagctatttttaaaaccgtcaactcagtagccacctccctccctgctcagctgtccagtactctggccagccatata
ctcccccttccccccataccaaacCTTCTCTGGTTCCCTGACCTCAGTGAGACAGCAGCCGGCCTGGGGACCTGGGGGA
GACACGGAGGACCCCCTGGCTGGAGCTGACCCACAGAGTAGGGAATCATGGCTGGAGAATTGGATAGCAGAGTAATGTT
TGACCTCTGGAAACAgtaagtcaaaatgaaattgcaattcctttaataagcttttatattgaagttagacttttataaa
attacaaacacctacttggatgtctctcgtccaaatgctgggatctctccctaccaaggtgccccaatctccatttctc
tttctgtcttatttctttctggcctctggcctctagctttttgaagtttaattctctgtctctcctctggcagtcttag
ccctctctttaccttattacctcaagactcctgatgaagttttagaaggagttccctacgtcctctattctgtagtttt
cttaccaaggccaaatatgacctcagatgatgagtcactgatacccttctatcctgcccccacttagcaatgcccttca
cattgagattccaagcatgggggctgctccctgtaaatgatttctccccacaactctagtccctccattctattctccc
tcttgcaggactcttcccccaatcatatccttacccataagataggggagttaggcaggagggatttagcccctctcca
actcctgtcatcataaaagactgagaacttcagaatttgaaaagaagagattaatggaaggagtgatatttgggaaaat
acaagaactgttgacttagaaaaaacaaatattgatttgcatgtttggtttgcatcccattattccatgagagagggag
attaaaattgcagctctctagagctgatgaaaagagattggtttccttttcatttgaatactgatattctagacgggat
gggtatgccacccttaatccttcttgtgttctgacacaaaggaggaaaagaaatgtatgactcctagagggcatctcct
cctaatggagagggacaaataagaagtatgtttctgaaatattttcaggtcctaattttactagggtacccactaggat
tactggtatctgatctagccccatgattcctccatctttgacatacctgctgtttggtagctcagaatggagcaataca
gtggactctgcccccttgagttcactcaaccttccctccacccccacctaggggtattgcacaagggccctaaaagtgg
ccacaggaacagggcaaagaggcttaactgccacacttatagtttgaggaactccaatctccccaaattccagtctgtt
catccttttcttgatctccccagattcactccacattatccttaccaatcttcaattcttctctctctccatgtccagc
caaatttcttttttcagTCACTTACAGGGCTTCCGGTCAAAATTCACTAGGTAGGAGGGTCATCAGCTGGGAAGAACCG
GCGCCTGGGAAACCTGGCTGGATAGGTATG 
Heme Oxygenase 1 (HMOX1); ENSG00000100292. 
cccagaaagagaccttgaagcatctattcattcaggcatgcattcagtattaactgtgacctaccaggcactattccag
gaactgggaatttacaaagcaaagtagtaggcaaggtctccacctttgtgctttacatgccactgttggggctcagaaa
gtgataccaggacaactggtgctttgacatgatgagaggccttaggagctgcctcagagtcaaggtccctgtaagcttg
tcttgttcccccgacaagcacagggagagacgctctctggaatttccttatctgaccaagaacacttctttacaaaaga
aatgcaattgtgttaagtctttttttcctttgagacagagtctcgctcttgtcacccaggctggagtgcagtggcacta
tcttggctcactgcaacctcctcctcctcccgggttcaagcgattctcctgcctcagcctcccaaagtgctgggattac
aggtgtgagccaccgcgcccggccagtgttaagccctttttctagtaatctcatcaaatatccaggaaagatcaaccac
tggagagagaaagagactgggagtcatcaccagacccagacagatttacctgttcttctgaggacagtgccaagagatt
acctgggggactttatctgcctaggacaacctttgtccctgtgcggctccacctccaccttcccttaaagtcggccttt
cacctccagggccattccttcttgctaatgatttactgtctttcaaaagaattgtctgcattccctatctcccttctcc
cctataaaaaaggctgggtagcctctgtactccactgggttacagggtcaccattcttccgtgattaccccattacaat
acatttttgtatgtcttttctcctcttaacctgacttttgtcggttggttttcggggaaccttcagaggaagaagggga
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atttttttcaaggccccttagctcacccttgggaggatgatcctttccaatacaatctcagaagtgcctctgggctgta
gtggccctaggctgaattccaggaagttttttttttttttttttgtttttttttttttttgagggacagcgtcttgttc
tgttgcccaggttagaatacagtagcgtggtcacagctcactccagcctctacatcccaggctcaagtgaacctccagc
ctcagcctcccaagtagctgggaccacaggcatgtgccaccatgcccagctaatttattttatattttgtagagacagg
gtctccctatgttgcccaggccagtctcgaactcaaagcaatcttcccacctcgactgggctcaaagcgctcttcccac
ctcaacctcccaaagtactgggactacaggtgtgagctaccatgccaggcctgaaagccatcttaaaaaaaaaatctta
gaatgagaatcacagtattgggaaaggactgtatgaatcatctggtccattcgttttgtcctctgggttcacccagtga
ccctatttcccccgagttctaaggagtccacctcatgcagaattgattcaataggcgatcagcaagggccagctctgct
ctgggccctgagcaggcactgagtataagtcagacctgaatgtgcctggaagagtgtcccacgcattccagcagggaag
cagtttgtatgacaggtgtcccagtccaggcggataccaggtgctgccagagtgtggaggaggcaggcggggacttagt
ctcctccctgggtttggacactggcatcctgctttatgtgtgacaccactgcacccctctgagcctcggtttccccatc
tgtaaaatagaagcgatctaccctcacaggtcagttgtagggatgaaccatgaaaatactagagtctctgttttttgac
aggaactcaaaaaacagatcctaaatgtacatttaaagagggtgtgaggaggcaagcagtcagcagaggattccagcag
gtgacattttagggagctggagacagcagagcctggggttgctaagttcctgatgttgcccaccaggctattgctctga
gcagcgctgcctcccagctttctggaaccttctgggacgcctggggtgcatcaagtcccaaggggacagggagcagaag
ggggggctctggaaggagcaaaatcacacccagagcctgcagcttctcagatttccttaaaggttttGTGTGTGTGTGT
GTGTGTGTGTGTGTGTGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGTTTTCTCTAAAAGTCCTATGGCCAGACTTTGT
TTCCCAAGGGTCATATGACTGCTCCTCTCCACCCCACACTGGCCCGGGGCGGGCTGGGCGCGGGCCCCTGCGGGTGTTG
CAACGCCCGGCCAGAAAGTGGGCATCAGCTGTTCCGCCTGGCCCACGTGACCCGCCGAGCATAAATGTGACCGGCCGCG
GCTCCGGCAGTCAACGCCTGCCTCCTCTCGAGCGTCCTCAGCGCAGCCGCCGCCCGCGGAGCCAGCACGAACGAGCCCA
GCACCGGCCGGATG 
Iron-responsive Element-binding Protein 2 (IREB2); ENSG00000136381. 
aagtgctgggattacaggcgtgagccaccgccccggccttatctttttttgagacagggtttcattctgtctcccaggt
tggagtgcagtggcacaatcatagctcactgtaatcttgaatttctgggctcaagtgatcctcctgcctctgtctcacg
gtagctggtactacaggcatgcaccactatgtctggctaactctttaagtttttgtagagacagggtctcaccatgttg
cccaggctagtctcaaactcctagcatcaagcgatcctgcagctttggcttcccaaagtgctgggattacaagcttgag
ctaccaactgtgcctggcccagtcgaatattatatgtcctgtaaaaccaaactcattcgttataaatagatacaagcat
ctgactactcaattttgtcatctaatatagacatgcctgtgcagctacgtattataatacatattattttctaataaat
tactttcctatttttctcctttatattacagttaggtcattaagtagattatttatcgtgtatgtagattatattacct
atgaatttcatgctgggattgtaaaggagatgttacaaaatatagcaaggtgaataaaggaaatatattggagtttggg
ttgacagggcttggatcaatgattaaagggagtggatgaaggagtcaggtataatgtgttgatttctggcttgggcaac
caggtggatggtggcgccattcgctaatacaggcaatacaaaaggaatagtaggtttaaggagggaaatgacgagttca
gttttggagatttttagtttgaggtgccttgggatgtggaggcatcccatgggtactaggatatacacctccgggttta
ggagataggctcaggtcacaggcagactgggaagcatcaacatattaactaataactgaagtcaaaggaagtgtgagat
gggccagggaaaatggacagagggaggaggtacaaggccagagccctgggacacatttaatgtccaatatatttttttt
tgagacagggtcttgctgtgttgctcaggctggagtgcagtggtgcaatcatggctcaccacagcctcaatctcctggg
cccaagtgatcctcccacctcagcctcctgagtagctgagactacaggtgcatgccaccacactcagctaatttttaaa
ttttttttgtagagatagggtctcactacgttgctgtgtttggtcttgaacttttcagctcaagccatcctcccacttt
ggcctcctaaagtgctggaattacaggcatgagctactgtgcccatcaagtgcccagtacatttaaaagctgggcggag
gaagaggtctgcagaggagcctgagatcaagcacccttaggagaagaaacaaaagtagagtctgaagtcacagaagctg
atggaagagtatttttcaacaatgggagagaaccagtcaagattgagatatgtgagattagaaagtggagttatagctg
gccttggctaaaggcatttctgggagtggaagccagactggaagaggataagaagtgggtgggggagagccgagtatga
gcgactctttctggtaagttgctgcgacaggagataatgctgggtaggtggagaacacagggaccggaggagctgaggc
ggaaggatggagaggcttaagcatgtgttaactgccactgggaagaagtcggcaatcacggaagctaccggagggtaag
aaaaaattcattcattcaacagttgagcgcctcccacgcgcccgatcagtatggccgcccccacttgaaaacacgcgtg
tgggccgcccacgtctgacaagttaatgcaaggctttatagttaggggaaagcggttctccttgagctctttctcctag
cagttccgattccgaccctgactccaacagacaccttgcgggaacgcaaacaccgctcgaattcatgaccccaatagaa
aacttaaggccgcaactaagtaacggatcgctgcgaaggccaaactagccacgccaacgcccccactggagcctcccca
gcgctccgcccccgctcgcgagaacagcggcgacggcgcgagaaatcgctttctggttagctccgccccttccctttct
ttgttttcctgtccgacgatctcgcgggagttaggcgacaaatcccgcgagcgcagacccggggctgGCTCTGCTGCTC
TCGCGATATTTGCGCGAGCCTGCTTCCTTCTTTCCTCCCTTGCCAGTCCGCCTGTCTTCCTCCCCGTCTTCCCTGCCCG
GCCTCCCCCTTCTTCCCCCGCTGGCCCCCTCCCCGGAGGGATAATATGGTCTCCGGCGATG 
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Lactotransferrin (LTF); ENSG00000012223. 
agggagcctctgtgatagaagtgcattcctgtgactgtccctcccccatagtgctgtgagctcctgagggcaaggacag
acccctcttctctgtctctcatggcatctaccagttctggcatgaatgaatgaatgaatgaatgaatgaatgctgttaa
tagatcagtgaaacttcattgttttttggggcagactcatcccctacatcagcctcctctgcaaatggccttgaggggc
tgctctgcctgtgtccagatgctcacatccctgccctggggctgggctgttccaacaggcacagcaggaaaacagtctg
ccctgttgcctacccatgctgccttcagggcactccttaagctgagcctcttggtagtggccccaggttctctgtgttc
ttgccaacactgtaacatacttaagagggcccagggccctctgacctcccagtcatccttttttaaaatttggactcag
aaaaagagacacgggttatgatgtttcttaattcttttataatgatgaaaaggcaaagtcttgttgccaatttaggtac
aaagatgcttcagcactcctgggaattagtcaattttgtatttcttcagtatttttgaaagaacttattgcaattattg
atgatggcaactttaaatggtgcaatatcatgtttccaaacaatgagagaccttggatctgtcaccccaaaacccagct
ggtgattctagcaccaaatctcagaccccagtctcatggcaggcaagcatgatccctgattagcctccaccctgtgcct
tggcaggatcatgcccagaaatggaggggctccccagcctccttaatggcctctccaccttgggctgagcctgcttctc
catggctaggtgcccactgcatgctcactcttggcagagctggctccctggggcattgcctatctgctccaggaaatgc
tttttagtaccaagtagtctaagcagagtcaagaccagcttttcagaataagcagatttcagagtcacatattggtcag
actcacctgccaagaaaggtgttcaggtgacctattatttccctcactgttagtaccttttttcttcacttagttaccc
tttttttttttggtgggggttacagagtcttactctattgcccaggctgcagtgcagtgacatgatcatggctcactgc
caccttcatctcccaggctcaaatggtcctcccactttagcctcccaagtagctgggaccataggcatacaccaccatg
ctgggctaatttttgtattttttgtagagatgggggtttccctatgttgcccaggctagtcttgaactcctgggctcaa
gcgatcctcccatcttggcctcccaaagtgctgggattacaggcatgagccactgtgccctgcctagttactcttgggc
taagttcacatccatacacacaggatattctttctgaggcccccaatgtgtcccacaggcaccatgctgtatgtgacac
tcccctagagatggatgtttagtttgcttccaactgattaatggcatgcagtggtgcctggaaacatttgtacctgggg
tgctgtgtgtcatgggaatgtatttacgagatgtattcttagaagcagtattctagcttttgaattttaaaatctgaca
tttatggcgattgttaaaatgaggttaccatttcctactgaatactatcaacaccaaaaaagaagaaggaggagatgga
gaaaaaaaagacaaaaaaaaaaaaaagtggtagggcatcttagccatagggcatctttctcattggcaaataagaacat
ggaaccagccttgggtggtggccattcccctctgaggtccctgtctgttttctgggagctgtattgtgggtctcagcag
ggcagggagataccccatgggcagcttgcctgagactctgggcagcctctcttttctctgtcagctgtccctaggctgc
tgctgggggtggtcgggtcatcttttcaactctcagctcactgctgagccaaggtgaaagcaaatccacctgccctaac
tggctcctaggcaccttcaaggtcatctgctgaagaagatagcagtctcacaggtcaaggcgatcttcaagtaaagacc
ctctgctctgtgtcctgccctctagaaggcactgagaccagagctgggacagggctcagggggctgcGACTCCTAGGGG
CTTGCAGACTAGTGGGAGAGAAAGAACATCGCAGCAGCCAGGCAGAACCAGGACAGGTGAGGTGCAGGCTGGCTTTCCT
CTCGCAGCGCGGTGTGGAGTCCTGTCCTGCCTCAGGGCTTTTCGGAGCCTGGATCCTCAAGGAACAAGTAGACCTGGCC
GCGGGGAGTGGGGAGGGAAGGGGTGTCTATTGGGCAACAGGGCGGGGCAAAGCCCTGAATAAAGGGGCGCAGGGCAGGC
GCAAGTGGCAGAGCCTTCGTTTGCCAAGTCGCCTCCAGACCGCAGACATGAAACTTGTCTTCCTCGTCCTGCTGTTCCT
CGGGGCCCTCG 
 
Solute Carrier Family 11 (proton-coupled divalent metal ion transporters) (SLC11A2); 
ENSG00000110911. 
 
ggagttttctgttcttctgtgactaccctatgttattcttgtctcaattttttaatggaagggaattgtttaaggtgta
caagatggaggtcccaatatggtgtggtggttgagtcttggctcgtgggtctaacagatttgtgttcaaagcctggctt
tgccactaactagctgtgtccttaggcaaattatactccaagtctcagattcctaatttgcaaaatgagaataataata
aataatacttcctgccccattagtttattatgaggattgtttttttggtagagtcatggtctcgctatgttgcccaggc
tgttttcaaactcctggcctcaagtgatctgcctgcctcggcctcccaaagtgctgggattgcaggcgtgaatttttgt
gccagcctactacaaggattaatgcttgtgaagtgttaaatatagcgtttggtacacaataaaaattcaattaaggttg
tcagttactcttaagtataaattggggaccaagaaggcaaaaatggagtgtgttttttgcagatggacggaggggagcc
aggacacagctcagcttgctcatgctcagagagttaagctgctgaccctgaaggcagggggcacacaactgtatgtggg
agccagactaagcagtcgagacagggcagacagtgtgagaaagctgttgatgagagctgctgctgaataaaatcatctt
tcacctgtctacagctccccaagtgttctttctgctcatccacccactacctccggacctcaacatgacctttggcgta
gtctaaacctgacactcataacagttacagatttctttgtcccttctacactcccacttttttgagacagggtcttgct
ctgtcgcagaggctggagtgctctggtgtgatcacgacgcactgcagccttgacctcctagcctcaaatgatcctccca
cctcagcctcccaagaagctgggatgttccacaggcacgttccactacactcaggtaattttaaaattttttgtagaga
gggggtctccttatgttgcccagggtaagaattcctaaactcaaataggctttttcctgccaagactttagttcgtggg
tgattttacaggtgcttctattttcccttcaagtggaacaaattggcccccagtccaatctgcagagacagctttgcct
tggggaagttacctgatgtagaacaaggacaggagacaggtcaagttgtagttatttgactttcgtgattaagagagcc
ctgaagcaaagagacctttcatctggatccctgggcaggagatccataattctttctcctgactcaatggttgttctag
gtaggaaccagaaccacttgctggaagcctgcattgacttatttgaatcgattactgcttttctttcttttccattcta
agctattatgtttttatggtactaagcagattttcttgaaaacttctagaaaactgcctgctacctgcaagaaactgtt
ttcttctctcctgtattttacgccaccccaatgcttctcctatgcagctttgtcgtctaagttatttccctgaggcaaa
atttccccattctttcagctcccctcctcccagattgagaaattctaggcttgccctggacttctgtcttgtagtctct
gggtttttttcctttctttttcttttccatcaggcaccaagtccggagtttgcgtggctctgatgtctgctcgtggatc
actgattgaccaggctgaagccagagggtcctttagatcccgagggataatagagcaggcagcatttccacccacgttc
tgagactcctcataattgcctcagtgctgcacgtacctatatggaaaatacaagtgcactgtcaggcttggggttaatg
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gtttcacctcacgtctcagaggagcagagtcctagtgcacctgtggagcctgaaccagctgcactccaagaggagcaga
gaagggaagcaatttcttactccacCCCTTTCAACCACTGGCACTCACAGGCTTGCCACCTACTCTTGCTCCTGCCAAA
TGgtacagagatgaaatcttagaataaaatttttgaactcaataaattgttaattaatatctaggagtggcagatatat
aatgcttctcttttcacgacagGTCAAAGATGAAATCTGATTAGGCTTTGGAGGGCGTGGTTTGCCTCTTGAAATTCCT
TGCTCGTCTTTAGAAAGCTGTGTTGCTTAGAGCACCCAAAAGTGCCCTTTATCTAACTGAGGGAGGCGCACTTGTCTTC
ATATATAGAGGCAGGAGCTGGCATTGGGAAAGTCAAACTAGTTCTGCACCATGAGGAAGAAGCAGCTGAAGACGGAGGC
AGCTCCACACTGTGAACTAA 
 
Solute Carrier Family 40 A Member 1 (SLC40A1); ENSG00000138449. 
ttattctattttcattttcaatttctttccatttcataagccccaactaacatatctcaactattctcattaattaggat
ttaagattccccttccacagctcactcactggttttaatgtcatgaaccttgcttgttttctttccaaagtatctttcct
acttgcttcactgcagtatcccatttgttctttataacattctctcggttttggcttctggggactccttggtgacaatg
gagaacagagactccatatcacattttgaggtatatgctgacttagccactctttccacaaatacttcttaaacagtgtc
tacgggaagtaattttttttttaaccaaccgaacttttaaaaagccacctggaagttggggacagcatgacaccccttct
tataatatgtaataattaatgtaaagcacttggaggtccttgttgctgagacacactctgacaaatgtgcaaactatcac
tatcctttgtgccttgttgaggacctgtcaaaaaattcatctctaataagggatcgccataaagtggaggggtttattta
ccagttcactccttcactttagttcactcatctgagtatactttggtttattctcaaggatgcatgtataaatgacccta
ttctccacggttagcaaaccaaaacctctctaaattgggagaaagaacttgaatgtcgtgtgaaagaaaggaaaaaagag
ggcttgaaaaggcaaaaagcagtgaaaagcagtagttaaactgtaacccctatctctactcaccagaccacatcccaacc
gaatccagctgcacccaccccgtagacctttggggctcctgattgagagtgcagatacagggcacatactcatgcgtggc
tcccttcactactgggtgtcagtctggcctgtgctcaaggtgtggcatctggttggagtttcaatatgtaggatccacta
ccagggttttcgtgagattaagaagggtaaggtaacctactggcaaaaggggctggtatgccccaggggttggtttggca
cagcaggattaaaacgaagtcaaccaaggctagagtctggtgttctttagtcattcacctcaccctccaggaggccaccg
aatggctttatctggacagggacagatccagggacacaactgggataaccggtattcctggtaagcctgtcactggggca
tttggaggttaggtggggaagggacgcgcgcgtgggggcggggtgagagggtacagagggagaaggaatgatggtgaagg
gtttgctggggctgcagcatcctcattctgtctccaggacggatttggaggccccagtttggggatacgggtaggtctgt
aactcgctgcgggacttcacctttgcaagcctccgtttgctcctctcaagagggatggactctgatctttgcgccccctt
cctgccctttgattctggttctttgagggaagccctgctatgcagtccggggaaggaaaggcattctctgctgcaggcgg
gccggaatgggacggccaggaaagcggcctctgtggcatgaattatatttatttagatacctgtattaaaaattattttc
gttaaaaaaggaatccccacccaccaagctcgcgctggagctttgcactgcgaccgtccggcggccgccctttccctgaa
ctgcggggtagccggtgcgcagcgctttcttccagcacctgacgcttagtttcgcgcagaatctccctacgccgccccgc
cggctccacgcgccttcctccttttcccagccccacggccgccccccgaggttgccctcgcggcttcccggagagcagga
aaacccggggagtggaacgcgtcgaggcgaaggtccccgcaagccgcgcagggtgtctgcggccggttggacgcttgcgc
ccggggtgggcgactcctccgggcaagggcgcggggacggcccggcgcgcaaggttgacgggagctcgtctcgcgccgcg
GGGACGCCCGGGCGGCCCTGAAGGGGACGGGGCGGCCCCAGTCGGAGGTCGCAGGGAGCTCCGCCCCCGACTCGGTATAA
GAGCTGGGCCCGGCCCACGGCGGCGGCGGCGGCGGCGGAGAGAGCTGGCTCAGGGCGTCCGCTAGGCTCGGACGACCTGC
TGAGCCTCCCAAACCGCTTCCATAAGGCTTTGCCTTTCCAACTTCAGCTACAGTGTTAGCTAAGTTTGGAAAGAAGGAAA
AAAGAAAATCCCTGGGCCCCTTTTCTTTTGTTCTTTGCCAAAGTCGTCGTTGTAGTCTTTTTGCCCAAGGCTGTTGTGTT
TTTAGAGGTGCTATCTCCAGTTCCTTGCACTCCTGTTAACAAGCACCTCAGCGAGAGCAGCAGCAGCGATAGCAGCCGCA
GAAGAGCCAGCGGGGTCGCCTAGTGTCATG 
STEAP Family Member 3 (STEAP3); ENSG00000076351. 
 
gaacaagcaccaaaggtcaacggcgtgggcggtggcctctctgccaaagtgtgtgggcccaagtagggtattcacctcc
ctccctgtctgtgagaaatttcagacccctctactttttccagcaggagttcatgttccttttaagataatcctctata
gacctctggcagcccagccttcaaaatgtctccccctgtctctcttactcatggagagccccgcttccccgcctcaaaa
aaaagtcttcctctctcttactcatgcatggagagccccacaaaaagacactggttcccagggattcttccaaagatgc
tggaagacctctcagtgtttgcatttcccaagctcggtttccttgtgctgtccttgggcattaaaggaaggctattcag
ccatccccatcagcaggagcaggcatcaaaagaacagctactgcagggggagcatattaggggcaccagagggggctag
gaactgggtcttgtcttctcaaagtttacaacccactgcaggggccactcaccagccctggcaccctaagggcaggaac
ctccattgggcacgtgtgtctccagcactgggagcactgtctggcacctggggcactgtgagtgttgaatggataaagg
acctgtaagaattgccataagaggtgttgccctggggcaaggtgggacaggaaagttcttgcaagagaagagaggctct
ggccttgggccctggctgagcagagagctgggaggtgggtattcgggtaggaggaaagctgtggagggggaaagcaaac
tgcctgcgggggtgggggggttctcggcgggagttgggggtggagggaaaggcgctttacagcagcactccctccacag
ggagaccagagctctgcctcttcctccccaccgtgccctttggggtccagttgtggggccttccttgaggcccagctcc
tgcctctggcctccggaggcttatctccccaacagaggctggctccccagaaaacaggattcttagacttcctaaaaat
aacctgaagctccttatcagaggctaatagtgtatgtctcccaggaatactctagaaagagtaccaggggtcaggaacc
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cccactcagcctccacgaatctgagcggaaaagcccgggtctcctcacctgtaaagaaaataactgcagccggcaaatg
tgaccacaggtgagaaggggcttcggaccagggcgcacacctctagagaggtgcccacagacagcctccccttacttac
gccctgcttcgctgcagtgctgtgaagccatcggcattggaagtgcggagggcagcgggcagtgccccagggggaaggg
gggacgggtagggtttcagagcccagaaggcctagacagggaggcagctccgggagaaaggtacccgccatcccaccgg
tcttggaacctgaggactgctgggaagggtcaaaagtctgccctaagggtggacaagggacagagattggggggggacc
acaaaggcctgggcgcaaccttgttgagagggaagggatccggacccaatctggagccctggtctcttcccacctgcaa
ccgtggctgccacttggcctcggttataaaatggacaaggattcgaggtgctcctcaggttaagagaggggggcctaga
ggtcaccctggcctcggtgccctccgtggccgggttaagaggaggtcccggagttctgctcacttcagccgtgtgccgg
gcactgcaaatcaggaagtgttggcgccggctggcgacctcccgcctggggccaggggaggagggtggttggacgctgc
caccgctgccggggctgtgcagggctgggcggggagcgaggacccggcggctcctgattgcggccccgggggaggtggc
cgagccggataagctgcggcgggctggagggcggccacctcccctgcaggtccggccctcccgggcgggtggggcgcgg
gggaggaggagcctcgggccgagccACCGCCTTCGCCGCGGACCTTCAGCTGCCGCGGTCGCTCCGAGCGGCGGGCCGC
AGAGgtgagtgtaccctcccccggtctccgctcacgtgtgtgtgcgcgcgttagATGACATTTATTCATTTTATGCATC
CTGGGTTCTACTGGTCGTCCCACCTCAGTTCCTGTAGCAAAGAGACTTGAGTCTGAGCCACTAATTATCACCCGTGAGG
TTTCCTCCCCGAGCAGGAAGCAGCAGGCCAGAGCTGCGCTCTCTCAGTGCACTCTCCAACCAAGCATCAGTCACCACTC
CCGGTCCAGCCCCTGTGGCCAAGAGCTGGCGTGCAGGCTGCGGGAGGCAGCTGGCTGTGCAAGACCCTGGCAGGGCCCT
CGCCTCCTGAGAAACCGAGAGTCAGAACCAAAGCCAGGCTGTCCTGGTTGGAGACTGAGCCAGAAAGGGTGGCTCACCT
CACGGTGAGGCTGTCGAGTGACCTGAGAGCCTCAGACCCTCACGTCAGCCGGATGTCGCACCAGCCTGCTGTTG 
 
Transferrin (TF); ENSG00000091513. 
tgtcctcttgagcaaaagccaaggccctggcctctccatctaggtgtgtgtagatgacgtgggagcaccagttctctat
gtcttgtctgagcttccttcatatcccatgaggctgtatatttccttcccagcacctgtcttgggcttggactcaaagg
acccttctgaggacagggcatagagctggctgctctggagaggactcagcctggccagtaggtagttgctccctgctga
ggggctctggctaggctatgggcctgtggctggaggactggcctcagcggggcttagtctacgaatgtagatgggctcc
agaaaaggagaatcactgaccatcttctttccatgccctgcgttgagcttccctgagtttgtggcatgggctcaacctt
tcgtaactgcacttcctgctctctggcagaccctgcaagcttactacagggcctgtccatgcatcagctgtatgtgtgc
atgctgctctgctgggtgccttccagttagccttgcccctgacttttcctgctcatctcacatccttacctcaaggtct
ccaaatgaatccagaccactgcctagagcctgctgcaggggcagtaggaatatggccctcatgctaacagtcttctttc
cctatggctcaagcacaaggggcccgtggacgggcaaggggggagtaagacagggcagcagtggtcactctccctcgct
ggtgaggctgatgtgttgggaaagccagacttgacttctgtcctcactgtaaacagaaagcttctgtagtggactctaa
agtgggaggtatgtaacccctttgcatatgagataatcttttggagtgtgggagaacataatctaacttccagttatat
ttattgttattgcaaaagattaacaaattatcattcattcatattgaatgtgtgaattggccctatctcccacctgagt
ctgcagtcatgacagatggagcctttcaggtgtcctaagggaagatggggttcacctcacaatgctaaaggtgaaaagg
ggagtgccgaccctgccctttgttttggcatttttatttccatactttgtggtttgtatgtgcccagttaaacggatgt
acagattagataatctggctttaactccaaccttcacgagatgcacacatgccttaaaaagattcttacaaagaaacta
gaattaggagacaattctgacaacacaaaaacaagtgaacaaaaatcaaatgactgacctgacgtgtccactaggcttg
atatgagcttggtcaactaaaacatgagacagaatgaatgaccatctggtcaggttggataagaagtaacttttggcaa
aatctctgaagtctggatttacacttcgtggaaggaatcttgacctttccccaagtatattatgccttgagataataat
cctgtataaggccgcataagcaaaacgacatttgaaaatgagtttcatctttagctcatccttttacaaatttctattc
cttgtgcatgattgaagtgtacacattttttagttaaaatataagcatatagaaggcacaagttcaatatttttcatga
taaggatgtgtaattaaactggttaggagactcatcgactagagggggacatggtggccccaggctgtaagaacaggcc
acaccgtccactgggccgcttgctttgtgctaagatgacactttgttctgagcctcacagtgtcttgaccatgttcctg
gaaccttcttgttggagggagttcatcttcccctatgactctgtccctagtctaaggtgtcccacaggaagcttgaggg
cgggaagttttccagcccaggagcctgagctcagcggggcaggaagagggagcagctcctccgtgggggacctttgaga
gcccaggagcaggatttcgagggacacctggtggggagcaaaaggtgctgagtctgtctttgaccttgagcccagcttg
tttctcctgcatcctcccccaaaagGGGCTTTGCCTGTCATTCTGCAGTTCTAGTGTGGGGTCTGGGCGCAGTTCTTTT
CCCTCTCCAGCCTCGGAGTCTTCCTCTGTGGACTGCGCAGATAGGACTGGTGGCACGGACCAGCTCTGCAGCCCTGGAG
TCAGGAGCAGAGCCCCCCGGCTCCCAGCCCGCCGTAGCCGCTCCTGGCACCGAGCGAGCCGCGATGACAATGGCTGCAT
TGTGCTTCATGTCCCTTCCCATCAACATTTCTGTGCTGGACTCCTTCCACTCGCGGGTCGTCTCCAGAGCTCAGAAAAT
GAGGTGATCAGTGGGACGAGTAAGGAAGGGGGGTTGGGAGAGGGGCGATTGGGCAACCCGGCTGCACAAACACGGGAGG
TCAAAGATTGCGCCCAGCCCGCCCAGGCCGGGAATGGAATAAAGGGACGCGGGGCGCCGGAGGCTGCACAGAAGCGAGT
CCGACTGTGCTCGCTGCTCAGCGCCGCACCCGGAAGATG 
 
Transferrin Receptor 1 (TFRC); ENSG00000072274. 
 
gacagagtcttgctctgctgcccaggctgaagggcagtggtgtgatctcagctcactgcagccacccccctcccgggtt
caaacgattctcctgcctcagcctctggagtagctgggactacaggtgtgcgccaccacgccagactaaattttgtatt
tttagttgtgatggggttttatcatgctggccaggctggtcttgaactcctgacctcagaagatccacctgcctcagtc
tcccaaagtgttgggattacagggattagccatcgcatctggccacctaaacctatgtcctccatgaggctataagatt
ttcacctgcaaataccagcattgtttgtttctttttaaaagatacttcagtcaaggaaaggcagaaagccaggcatgtt
agctcatgcctataatcccagcactttgggagaccggaggcaggaggattgtttgagcccaggagttcaagactagtct
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gggctacatagcaaaccctgcgtcaaattaaaaataaaaaataaataggctgggcatggtggctcatgcctgttatccc
aacattttaggaggccaaggtgggcagatcacctgaggtcaggaattcgagacaagcctggccaacatgataaaatccc
gtcactcctcaaaatacaaaaattagcctggcatggtggcacacacctgtagtcccagctacttgggaggctgaggcag
gagaatcgcttgaatccggaggcagaggttgcagtgagcccgagatcatgccactgtactccagccagggtgacagagc
aagacactgtcttaaaagtaaaaataataaaaataaataaaattaataattaaagaaataaagaaggaacaccacaggg
gagcaggcctggtgtctgaatgttaaggtaggccctctgtggatgtgcatccttaaccttttcctgattagatcattaa
aggtgcagcaatgctcctgctcatatgacttttttttttttttgagatggaatcttgctctgtcgcccaggttggagtg
caatggcgcgatcttggctcactgcaacctccgcctcttgggttcaagcgattcttctgcctcagcctcctgagtagct
gggattacaggcgcgtgccactatgcctggctaattttttttgaaatttttttagtagagatggggtttcaccatattg
gtcaggctggtctcgaactccagacctcgtgatccgctcacctcggcctcccaaagtgttaggattgcaggcgtgagcc
accgcgcctggcaactcatatgacttttaaacacttctctttggggagagagattttagagaatgggagtaaagagaaa
ggcggtgagaatcccaagtactttctctatcttagagcagaagaaataaagggaagagtaaaagcccaaggcccagaaa
cggatttgcttcttaaagggctgttctgtgtccctacgggcctgaaggtcagtttatgtgcaatgctttttaaggtatg
ggttgctttcttgcattgtagctactacctccctggcctgctggttactgaccagagggagggagagggtgtgattgtt
tggaaagagtttaaacagtgacaagaattgaattttatttatttgttattcattgcacaatccaataacagcgatggca
atgaaaacgaaagttaatctacaatcctatcaccctattaagtcacttgtttctattttcccttttattccctcatgca
ttaaacattacgcaaagcactccgctagtcttggttaaagtgcagcttgtatacattctgaataaaaatttgcattttg
cttttcttttcctttttgtatttctgaggctgcaaaatacatcttcacaagagtggctttaatagttacctaacattcc
atcctgcacgtacatttcaaggcactgccgcagtgcaatatccaacatttaagcgtcaacgccaacagattggacctag
cactgcagggactggaggttggtcaaggtcaggcggaggctgccaggctaccagggtggaggaaggcgccgaggcagag
gccagtgcgcccatcgcgcggctcctcggggcacctgctgccttggcgccttttcccttggccttcgcctcgcccgcag
cgccctccgcatagggccccgcccgctgcgcgcgcatccccgccccccgggcgatctgtcagagcacCTCGCGAGCGTA
CGTGCCTCAGGAAGTGACGCACAGCCCCCCTGGGGGCCGGGGGCGGGGCCAGGCTATAAACCGCCGGTTAGGGGCCGCC
ATCCCCTCAGAGCGTCGGGATATCGGGTGGCGGCTCGGGACGGAGGACGCGCTAGTgtgagtgcgggcttctagaacta
caccgaccctcgtgtcctcccttcatcctgcggggctggctggagcggccgctccggtgctgtccagcagccataggga
gccgcacggggagcgggaaagcggtcgcggccccaggcggggcggccgggatggagcggggccgcgagcctgtggggaa
ggggctgtggcggcgcctcgagcggctgcaggtacacggggtcggcggctgtgcgcagaggcgtccctgcgcctctcgt
cccttcgcctctcgtcccttcccttctctctgccttcttgcccgcctcctcggtcacagagcgacgaatgacgagacca
ggtgtacccccactgtcgctctcagccccggggacttcgggtcctcgcccttgaaggccgcaggccctagtgcgccggc
tccgggctgcgggtccgggagcgcgggcgcagccaaggtgcagctgcgcggcgtgcggcgccgggggaacacgtggctg
ctccaggaagtcgccccagggaacggctgggattcgtgggtgaccttgggctcctaaaccttcggttccccgggctccg
ggcgggccccgttctcactgcggaaagggacaaagctgtccccgattcggttactagcgtgttacaggcattaattaga
tacgggtttctgtaaacttacccttcggctctggtacaacctgatcttgccatgctctgcctgttcgccttgtgtgtgg
attctgttttctcaaggcagaatccgactgaacgccgcaggtgttcacattaagaatattgctagcagttctcactaca
agacgggagccataggagtgacttatttgtgaaagatacttggagattagcggtgtggtcagagggctgtgctggattg
atgggcgccggagaggccgattgtgtcacattctgctggacagttcttttaaggttgggagggtgggtaagaaaataca
ttctgattcggctcttttcggataacgctttccctctgcttactgcttgtagagacctcacttacccgggggactggat
tctgcagctttttccattttcttccccgttgataagaggattaaagtaggaaattgtatttggctaccccatgcttata
tgctaagcttactgtgaaaattaaggttaggctgtctagagtacttgtggaccctgctggttccccccgccccccggcc
ctgaattttgggttacaatatgcttctcaagaaaactcagagttaagataatttttgtcatcgattttgcaaggttata
tatagcatagcatccttcaatttcctttggatgttcttatcaagtaatggtggctgtaaacctagcctgtgttgaagat
tgttagatagacagcagtttggctaactccgccctaaggcgaggcagttacttgcctctgataatgtatttaaatgtca
tggagcaagattcccagctaaacctgaatcgatcacaatgctagttaaaaatgaccctcggctgggcgcattggctccc
gcctgtaatcccagcactttgggaggccaaggcaggcggatcacctaaggtcaggagttcgagtccagtctgactaaca
tggtgaaatcctgtctctactaaaaacacaaaaattagccgggcatggtggctcacgtctgtaattccagcactttggg
aggccgaggcaggtggatcacttgtggtgaggagttcgagactagcctggccaacatggtgaaaccccgtctctacgaa
aaatacaaaaattagctgggcatggtggtgcacacctgtaatcccagccactcaggaggctgaggctcgagagtcgctt
taacctgggaggcagaggttgtagtgagctgagatcgtgctactgcactccagcctgcgcgacagcgagatgccatctc
aaaaacaacaacaaaaaaactccctactaaaccagaagagtgatggggacgggaaaagattcctggtccaatgttttca
ttatatttttcatatcatttggaatctcatgcatcaggcatgccccagtactgttaaagacaatatttttactcattat
caggtagttcaataccagttattacaggatagggaagtcagtcagagaaggcttcatagagatgaagccttgagctgag
cctggaagaaatgaggaggacctcaaggaacagagaagaatgttggtgggtaaaaacaggggctggattctgtctgatt
ttggagaaaatagagggtagtgaagttgttaggcagtgaatgtgttccatttcatggttcaaaacgtggggctacgttt
tgcctacctgagcttcattattaatgtgagaaattgaattgttgttttcagtcaccattgagaacaccaaagataacac
aagtagcttagattattatttatttatttatttttgacagagtttcacgcttgttgcccaggctgtagtgcaatggtgt
gatctcggctccctgcaacctccacctcccccaggttcaagtgattctcctgcctcagcctccccagtagctgggatta
Stellenbosch University http://scholar.sun.ac.za
APPENDIX TWO: Gene promoter sequences 
 
175 
 
caggcatgcgccaccatgcccggctaattttgtatttttttggtagagatgggatttctccatgtttggtcaggctagt
ctcaaactctcaacctcaggtgatctgctcgcctcggcctcccaaagtgttgctgggattacaggcgtgagccaccatg
cccggccatcgctttgtgttcttaaaattaatttaaaacaagaaaacttgaggaatgatggttcagatgagtgttaaaa
cttgcaagatgttttttcctagaaaaggatgattaaaattggttcagggtggggccttccagttctggctctaatgatt
gggtccttactgttctggtggagtggtagtgataagctttttgtaacagaaggggcaaaagattgtgcttctggctggg
cgcagtggctcacgccttcgatttccttgggatgttcttatcaagtaactaatcttagcactttgggaggccaggtggg
tggatcaccctaggtcagaagttccagaccagcctggccaacgtggtaaaatcccgtctctactaaaaatacaaaaatt
agctgggcatggtggtgggcacctgtaatcccagctactcggagtctgaggtgggaaaatggcttgaacccgggagggg
gaggttgcagtgagccgagatcctgccattgcactccagcctaggcaacaagaccgaaactctgtctcaagaaaaaaaa
aaagattatgcttctaagaatatggtctattgcatatggacactggtttttaaagcttgaatttaaaaagaattttttg
taataggttttagagctttttctttttcttttttattatttttttgagatggagtttcactccgtcacccaggctggag
tgcagtggtgccatctcggctcactgcaacctccacctcccgggttcaagcgattctcctgcctcagcctccccagtag
ctgggattacaggtgcccaccaccacgcccatctaatttttgtatttttagtagagatggggtttcaccaccttggcca
ggctggtctcaaactcctgacctcgtgatccacctgcctcggcctcccaaagtgttgggattacaggcatgagccaccg
tgcctggccagaaagctttttcttaatgccagttataataccctttgctttacaatttgcgtatacctcacagcttgct
ttgtgccgtgtgtgtttaatatgccctaagtgtactcgtatataggaaaagctttaaaatggtatccaataaatgtcca
ttttgcaaatctcaggataatgtcattttcaagtatctagatgccctcaaaccaaattaactggaaaattcagatttca
gttaaggcctttaacttaacttaggactttgattacagagatgtattttgctttgacaaaagttaaggttaatgtctta
aatttccagagatgataacacaatttctataacccagtaacccatttaacttcgcttagattatcaattttcagccttg
aacaggccacttagtttctctaataactggcctcttcatctgtaaaacagcgtaatctgtgtttcatgtttcttcttgt
gtcaaagatcgaatcacttgtaggaactattcattcagtcaggatcagtatttcttccccttcccattggagatggttt
gtggtatttgtagcataactggtcttgtctgccttagtcttaattttgtctttttgtatgtgtcactttcttttttttt
tgagacagagttttgctcttgttttccaggctggagtgcagtggcgcgatcttggctcactgcaagctccacctcctgg
gttcacgccattctcctgcctcaggctcccgagtggctgggattacaggcgcccaccaccacgtccggctaatttttgt
atttttagtagagacagggtttctccatgttggccaggctggtcttgaactcctgacctcaggtgatccacccatctca
gcctcccaaagtgctaggattacaggtgtgagccaccccgcccagcagtatgtgtcacttttgtctactcagaacatag
tggttcgtacttataattgcagcactttgggaggccaaggtgggaggattgtttgaggccaggagttcaagaccagcct
gggcaacatagggtgaccttgtctctacaaaaagaaaaaaaaagaattatgtatataacaaactttaaaaaggatccca
cttaatttagttgtcatgtaaactatggttaaataccttttctagaaaagtgataatgtattttaaaaatttaatgtat
catttagcctggtaatagaaagctcactaatctgatacagtagtatctttctcaataattctctattctgatacctagG
TTCTTCTGTGTGGCAGTTCAGAATG 
Transferrin Receptor 2 (TFR2); ENSG00000106327. 
taatcccagcactttgagaggccaaggcgggaggatcatttgagcccaaaatttctagaccagcctgggcaacaaagcg
agacctcatctctacaaaaaatttaaaaagcaactggcaatgtggcgcatacctgtagtcccacctacttgggaggcca
aggttggaggatcactggaacctggaaggttgaggctgcagtgagctgtgccactgcattccaacctgggtgacagagc
aagatcctgtctcaaaaaaaacccaaaaaaattgggtgtgtattttccacttagagcacgtctcaatttggaccagggc
tggtgagctacaggaagctagtggccactgcattggacagcacatgtgtgtaggctgagaaagatcaaagaagcccagc
cgtggtagctcacgcctgtaatcccaacattatgggaggctgaggtggaacgattacttgagcccaggagtttgagacc
aggctgggcaacatagtgagacaccatctctacaaaaaataaaaattaggctgggcgcggtggctcacgcttgtaatcc
cagcactttgggaggccgaggcgggcggatcatctgaggtcaggagtttgagaccagcttggccaacatggcgaaaccc
tgtctctactaaaaatacaaaaattagccgggcgtgttggcacgcgcctgtaatcccagctacccagcaggctgaagca
ggagaatcgctggaacctgggaggcggaggctgcagtgagccaagatcgcaccactgcattccagcctgggcgacagag
caagactccatctcaaaaaaataaaataaaaataaaaataattaaaattaaaattttaaaaaaatagagagaagggaca
ctctgagatgctcattgcaggaaccctcaaggggcaagttgtaatgccgaaggctgcagatggggtgccacagtgttgg
aatggtgaggtggagggaatatcttccttgggaaagagggagactggcggtgttccaaagccctgatggagtgagaaga
ggacacctggtggggaaggactgtgtgtgtgtagggggtgttgagtgccaggtgcaggttgcctggcctggggctgtgc
gtgccatccccccagctcaggaacagggcctagctcagggcagagactgctgttcaataatacttgttgaatgaatgaa
ttattgattgaatgatatgaagaggatactctccctctgaatatgaaaggggacagaccgaggaggggaggatgaggtg
gggaggggcttcagagggatgtgaacccaaggggtggttggggcctgttggaggattcccaggggctgcacctgcctgt
ccacacctccctccaaggccaccctgaccctgatattaccccctccacccagggcactttccagcagatgtggatctcc
aagcaggaatatgaggagggcgggaagcagtgcgtggagcgaaagtgcccctgatggcactcctccccacacacctgct
cccaagctcagatggaagtcccttaacccccatgccacattgcccccctcctcctttccctcttgtcctcattaatggt
gatgtttctgggttgaaagaagtaaaaatgttttaagaaaaaaaagtttggcctccgtggggtggggagtgggcacagg
ggtctggagggaggtgaggggagggagtctcacttctacacccatgccgatcccacagtgggtgctgggacacagcccc
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aggggccatggattcctcaggtttcctaggggttgtgacccagggagggccacatgacgaggaccgggggttgggggag
ttgctgggggctaacagttgtggtgggaggtgggaggggctgcagggtgcagtggaggggcacggcctggggtgagtgt
ggcaggaggtgggtggagcaggaggtgaagcctggatgggcggaacaggaggtggggcctggtgggcggggcctcagcg
taggccttaggtctcaggggagcagACGCCTGAGCACCCCAGGACCTGCGCTCAGgtgagatgcgctatgccttccttc
ctggggctcttggtggtgacagacatggggcggggactagggcgctggtgcatcccagcagctcggaacttctctggac
ctgagtaggagctgatgtttcccaggggaaacccgaaagggaaacttggtgggaccctgagccctcctcttcagagcta
cttgtcttggggccctcggaagggtttggggacctgcgccccctgcctgtttagcagtttatgcctgtgacatgtttct
ggggtgaggctaactggcctttcatcagcctcagaacccaaagaggtagaaacccatgtgatccaagtccttcggtgac
caaacgggccggtgcccagggaggaccatgacttgtccagggtcacccagctctgcccacaccttggcggggactctga
tcactcctccccactgacccacatatccctgaccccaggacccctatctgggagctctcgctggtctcatctgaccatg
tgctcccacctgtgcccctccttctccagcagccagcaggagtctgagaacgacctttcaaaagagacacacatgcaca
ccaccagaccagacccccaagtcacaccactgtggtgcctccagcttagaatgccactggggcaagtgtcaggacaggg
aggacagctgatatgtcacaggaccggggcactgggggactctgaaggccagatgaggaaggggcagatgtcttagggg
tgaatcttccacctgggcatggcggggcttaggaaggggtccccaggatccagggaggggtaaaagcaggagaggggag
ggggcacccatgtctctgccctcccccactatcggcccccttcccccacccctgatgggaactaggaggccaaagtccg
ccccaaggtcaaaaaattgattgttttgcagGGAGGAGGCAGGCGTGGGGCTGTGGAGAGATTGGCAGGGGAGAGCACA
GCCCCTTGTGCTCTGGCCTGGACCCGGGGGCCACGTCTGGAAGGCTGGACTGAGGCCAGGACTGTGCCCCCACCCTTGG
GGGTGGTGAGGAGCAGCCTTGGTTCAGGCTGCCTGCCAGGACTGATAAGGGGCCCTCCTAGGGCTCCCACAAACGGTTT
ATCGGTTTATCGCTGGGGGACAGCCTGCAGGCTTCAGGAGGGGACACAAGCATG 
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Appendix 3: pGL4 Vector Maps 
 
Figure A3.1 pGL4.10[luc2] vector map. 
Source: http://www.promega.com/products/vectors 
 
 
Figure A3.2 pGL4.23[luc2/minP] vector map. 
Source: http://www.promega.com/products/vectors 
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Figure A3.3 pGL4.73[hRluc/SV40] vector map. 
Source: http://www.promega.com/products/vectors 
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Appendix 4: In Silico Promoter Analyses Supplementary Data. 
 
 
Figure S1 mVISTA sequence alignments of the CR in each of the nine iron metabolism genes.    
Pink coloured areas indicate regions of sequence similarity. Each gene in turn was utilized as the base genome 
for visualization of the alignments: A.) FTH1 and B.) HAMP.                   
Abbreviations: CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin heavy polypeptide 1 gene; HAMP, 
Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; HMOX1, Haem 
oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2 gene; LTF, Lactotransferrin gene; TFRC, 
Transferrin receptor protein 1 gene. 
B.) HAMP 
A.) FTH1 
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Figure S1 Cont. mVISTA sequence alignments of the CR in each of the nine iron metabolism genes.   
Pink coloured areas indicate regions of sequence similarity. Each gene in turn was utilized as the base genome 
for visualization of the alignments: C.) HFE and D.) HFE2.                                    
Abbreviations: CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin heavy polypeptide 1 gene; HAMP, 
Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; HMOX1, Haem 
oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2 gene; LTF, Lactotransferrin gene; TFRC, 
Transferrin receptor protein 1 gene. 
C.) HFE 
D.) HFE2 
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Figure S1 Cont. mVISTA sequence alignments of the CR in each of the nine iron metabolism genes.   
Pink coloured areas indicate regions of sequence similarity. Each gene in turn was utilized as the base genome 
for visualization of the alignments: E.) HMOX1 and F.) IREB2.                                    
Abbreviations: CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin heavy polypeptide 1 gene; HAMP, 
Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; HMOX1, Haem 
oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2 gene; LTF, Lactotransferrin gene; TFRC, 
Transferrin receptor protein 1 gene. 
E.) HMOX1 
F.) IREB2 
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Figure S1 Cont. mVISTA sequence alignments of the CR in each of the nine iron metabolism genes.   
Pink coloured areas indicate regions of sequence similarity. Each gene in turn was utilized as the base genome 
for visualization of the alignments: G.) LTF and H.) TFRC.                                    
Abbreviations: CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin heavy polypeptide 1 gene; HAMP, 
Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; HMOX1, Haem 
oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2 gene; LTF, Lactotransferrin gene; TFRC, 
Transferrin receptor protein 1 gene. 
G.) LTF 
H.) TFRC 
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Figure S2 CRM discovery using MEME.                                                                              
The sequences of the detected motifs in the CR of each gene are shown to demonstrate the level of nucleotide 
conservation at each site. A.) Motif 1; B.) Motif 2; C.) Motif 3; D.) Motif 4. Individual p-value scores for the four 
motifs are listed.                              
Abbreviations: CR, conserved region; CRM, cis-regulatory module; CYBRD1, Cytochrome b reductase 1 gene; 
FTH1, Ferritin heavy polypeptide 1 gene; HAMP, Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis 
gene, HFE2, Hemojuvelin gene; HMOX1, Haem oxygenase 1 gene; IREB2, Iron-responsive element-binding 
protein 2 gene; LTF, Lactotransferrin gene; TFRC, Transferrin receptor 1 gene. 
A. 
B. 
C. 
D. 
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Figure S3 rVISTA TfBS prediction of the CR.                                                              
Green bars denote the alignment and conservation of the TfBSs sites indicated on the left of the figure. The 
pink shaded area at the bottom of the figure indicates the consensus CR sequence submitted to rVISTA. 
Abbreviations: CR, conserved region; CEBP, CCAAT enhancer binding protein; FOXD3, Forkhead box protein 
D3; FOXM1, Forkhead box protein M1; FOXO3a, Forkhead box O3a; FOXO4, Forkhead box O4; GATA-1, GATA-
binding protein 1; GATA-2, GATA-binding protein 2; GATA-3, GATA-binding protein 3; HNF-1, Hepatocyte 
nuclear factor 1; HNF-3, Hepatocyte nuclear factor 3 HNF-4, Hepatocyte nuclear factor 4; HNF-4A, Hepatocyte 
nuclear factor 4A; MEF2A, Myocyte-specific enhancer factor 2A; NF-1, Nuclear transcription factor 1, NKX2-5, 
NK 2 homeobox 5; NKX3-1, NK 3 homeobox 1; PAX4, Paired box 4; PAX5, Paired box 5; PAX6, Paired box 6; 
PPAR, Peroxisome proliferator-activated receptor; RXR, Retinoid X receptor; SMAD-1, mothers against 
decapentaplegic homolog 1; SMAD-3, mothers against decapentaplegic homolog 3; SMAD-4, mothers against 
decapentaplegic homolog 4; SP1, Specificity protein 1; USF, Upstream transcription factor; YY1, Ying Yang 1. 
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Appendix 5: Functional Promoter Analyses Supplementary Data. 
 
 
 
Figure S4 Agarose gel electrophoresis of PCR products.        
PCR products highlighted in red were excised from the agarose gel and used in a Wizard® SV Gel and PCR 
Clean-up. A.) 2 kb fragment PCR amplification and B.) 140 bp CR element PCR amplification.                       
Abbreviations: bp, base pair; CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin heavy polypeptide 1 
gene; HAMP, Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; 
HMOX1, Haem oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2  gene; kb, kilobase pair; L., 
Ladder; LTF, Lactotransferrin gene; PCR, polymerase chain reaction; TFRC, Transferrin receptor protein 1 gene. 
 
 
 
 
 
100 bp 
1 kb 
2 kb 
 
A. 
B. 
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Figure S5 Clone selection.                   
Colonies were subjected to plasmid minipreps followed by double digestion of the extracted plasmids. 
Digestion products were electrophoresed on a 1% agarose gel and inserts of the correct size are highlighted in 
red. Larger bands above the insert of interest represent digested pGL4 plasmids (~4 kb) or undigested 
constructs (~6 kb). A.) 2 kb promoter constructs and B.) 1.86 kb CR-removed promoter constructs. C.) Colonies 
were subjected to colony PCR amplification to identify positive clones. For each gene, four separate colonies 
were chosen and were electrophoresed adjacent to each other on the 1% agarose gel.                        
Abbreviations: bp, base pair; CYBRD1, Cytochrome b reductase 1 gene; FTH1, Ferritin heavy polypeptide 1 
gene; HAMP, Hepcidin antimicrobial peptide gene; HFE, Haemochromatosis gene, HFE2, Hemojuvelin gene; 
HMOX1, Haem oxygenase 1 gene; IREB2, Iron-responsive element-binding protein 2 gene; kb, kilobase pair; L., 
Ladder; LTF, Lactotransferrin gene; PCR, polymerase chain reaction; TFRC, Transferrin receptor protein 1 gene. 
C. 
1 kb 
2 kb 
4 kb 
100 bp 
100 bp 
4 kb 
2 kb 
1 kb 
A. 
B. 
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Figure S6 CLC Sequence Viewer 6.7.1 alignments of the 1.86 kb CR-removed promoter.                  
Sequencing results from the 1.86 kb CR-removed promoter constructs were aligned to the 2 kb reference sequence from each gene in order to confirm accurate deletion of 
the 140 bp CR element. A.) CYBRD1, B.) FTH1, C.) HAMP and D.) HFE.                         
Abbreviations: BP, Cytochrome b reductase 1 gene; F, Forward primer; FP, Ferritin heavy polypeptide 1 gene; HP, Haemochromatosis gene, PP, Hepcidin antimicrobial 
peptide gene; R, Reverse primer; RV3, Plasmid-specific forward primer. 
A. B. 
C. D. 
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Figure S6 Cont. CLC Sequence Viewer 6.7.1 alignments of the 1.86 kb CR-removed promoter.                   
Sequencing results from the 1.86 kb CR-removed promoter constructs were aligned to the 2 kb reference sequence from each gene in order to confirm accurate deletion of 
the 140 bp CR element. E.) HFE2, F.) HMOX1, G.) IREB2 and H.) LTF.                         
Abbreviations: F, Forward primer; IP, Iron-responsive element-binding protein 2 gene; JP, Hemojuvelin gene; LP, Lactotransferrin gene; R, Reverse primer; RV3, Plasmid-
specific forward primer; XP, Haem oxygenase 1 gene. 
E. F. 
G. H. 
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Figure S6 Cont. CLC Sequence Viewer 6.7.1 alignments of the 1.86 kb CR-removed promoter.                   
Sequencing results from the 1.86 kb CR-removed promoter constructs were aligned to the 2 kb reference sequence from each gene in order to confirm accurate deletion of 
the 140 bp CR element. I.) TFRC.                           
Abbreviations: F, Forward primer; R, Reverse primer; RV3, Plasmid-specific forward primer; TP, Transferrin receptor protein 1 gene. 
I. 
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Normalized Luciferase Data 
Normalized values were calculated by dividing firefly luciferase values by the internal control 
Renilla luciferase vaules for each construct. Boxes shaded in grey indicate the construct and 
condition used as reference for calculating the fold change in expression levels. Values 
followed by an asterisk were excluded from further analysis as they did not lie within 20% of 
each other. 
 
Table S1.1 Normalized luciferase data for CYBRD1 constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
140 bp (dH2O) 1 10.18 
1.18 140 bp (dH2O) 2 9.83 
140 bp (dH2O) 3 10.33 
140 bp (FAC) 1 10.38 
1.22 140 bp (FAC) 2 10.72 
140 bp (FAC) 3 10.46 
pGL4.23 (dH2O) 1 8.55 
1.00 pGL4.23 (dH2O) 2 8.63 
pGL4.23 (dH2O) 3 1118.48 * 
pGL4.23 (FAC) 1 7.48 
0.95 pGL4.23 (FAC) 2 8.63 
pGL4.23 (FAC) 3 8.34 
2 
140 bp (dH2O) 1 2.75 
1.07 140 bp (dH2O) 2 2.84 
140 bp (dH2O) 3 2.74 
140 bp (FAC) 1 3.08 
1.18 140 bp (FAC) 2 2.85 
140 bp (FAC) 3 3.24 
pGL4.23 (dH2O) 1 2.49 
1.00 pGL4.23 (dH2O) 2 2.84 
pGL4.23 (dH2O) 3 2.48 
pGL4.23 (FAC) 1 3.02 
1.15 pGL4.23 (FAC) 2 3.04 
pGL4.23 (FAC) 3 2.91 
3 
140 bp (dH2O) 1 0.66 
0.93 140 bp (dH2O) 2 0.73 
140 bp (dH2O) 3 0.82 
140 bp (FAC) 1 0.78 
1.11 140 bp (FAC) 2 0.96 
140 bp (FAC) 3 0.87 
pGL4.23 (dH2O) 1 0.74 
1.00 pGL4.23 (dH2O) 2 0.83 
pGL4.23 (dH2O) 3 0.79 
pGL4.23 (FAC) 1 0.93 
1.17 pGL4.23 (FAC) 2 0.44 * 
pGL4.23 (FAC) 3 0.91 
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Table S1.2 Normalized luciferase data for CYBRD1 constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
2 kb (dH2O) 1 1.88 * 
1.00 2 kb (dH2O) 2 2.43 
2 kb (dH2O) 3 3.05 
2 kb (FAC) 1 3.39 
1.27 2 kb (FAC) 2 3.46 
2 kb (FAC) 3 3.58 
1.8 kb (dH2O) 1 20.02 
7.59 1.8 kb (dH2O) 2 20.27 
1.8 kb (dH2O) 3 22.08 
1.8 kb (FAC) 1 15.71 
5.59 1.8 kb (FAC) 2 14.95 
1.8 kb (FAC) 3 1.50 * 
pGL4.10 (dH2O) 1 0.01 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.01 
0.00 pGL4.10 (FAC) 2 0.01 
pGL4.10 (FAC) 3 0.01 
2 
2 kb (dH2O) 1 1.87 
1.00 2 kb (dH2O) 2 2.08 
2 kb (dH2O) 3 2.28 
2 kb (FAC) 1 1.90 * 
1.19 2 kb (FAC) 2 2.46 
2 kb (FAC) 3 2.49 
1.8 kb (dH2O) 1 29.81 
13.05 1.8 kb (dH2O) 2 24.32 
1.8 kb (dH2O) 3 27.11 
1.8 kb (FAC) 1 22.88 
10.92 1.8 kb (FAC) 2 21.73 
1.8 kb (FAC) 3 23.42 
pGL4.10 (dH2O) 1 0.01 * 
0.00 pGL4.10 (dH2O) 2 0.01 
pGL4.10 (dH2O) 3 0.01 
pGL4.10 (FAC) 1 0.01 
0.00 pGL4.10 (FAC) 2 0.01 * 
pGL4.10 (FAC) 3 0.01 
3 
2 kb (dH2O) 1 2.86 
1.00 2 kb (dH2O) 2 2.46 
2 kb (dH2O) 3 2.42 
2 kb (FAC) 1 3.38 * 
1.90 2 kb (FAC) 2 4.86 
2 kb (FAC) 3 4.92 
1.8 kb (dH2O) 1 38.07 
15.06 1.8 kb (dH2O) 2 51.30 * 
1.8 kb (dH2O) 3 39.61 
1.8 kb (FAC) 1 25.79 
10.44 1.8 kb (FAC) 2 19.23 * 
1.8 kb (FAC) 3 28.05 
pGL4.10 (dH2O) 1 0.01 * 
0.00 pGL4.10 (dH2O) 2 0.01 
pGL4.10 (dH2O) 3 0.01 
pGL4.10 (FAC) 1 0.01 
0.00 pGL4.10 (FAC) 2 0.01 
pGL4.10 (FAC) 3 0.01 
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Table S1.3 Normalized luciferase data for CYBRD1 constructs transfected into COS-1 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
140 bp (dH2O) 1 0.45 
0.96 140 bp (dH2O) 2 0.43 
140 bp (dH2O) 3 0.46 
140 bp (FAC) 1 0.58 * 
0.90 140 bp (FAC) 2 0.44 
140 bp (FAC) 3 0.40 
pGL4.23 (dH2O) 1 0.49 
1.00 pGL4.23 (dH2O) 2 0.49 
pGL4.23 (dH2O) 3 0.42 
pGL4.23 (FAC) 1 0.57 
1.23 pGL4.23 (FAC) 2 0.62 
pGL4.23 (FAC) 3 0.52 
2 
140 bp (dH2O) 1 1.50 * 
0.77 140 bp (dH2O) 2 0.55 
140 bp (dH2O) 3 0.58 
140 bp (FAC) 1 0.59 
0.76 140 bp (FAC) 2 0.52 
140 bp (FAC) 3 2.58 * 
pGL4.23 (dH2O) 1 0.71 
1.00 pGL4.23 (dH2O) 2 0.76 
pGL4.23 (dH2O) 3 0.72 
pGL4.23 (FAC) 1 0.72 
0.94 pGL4.23 (FAC) 2 0.67 
pGL4.23 (FAC) 3 0.68 
3 
140 bp (dH2O) 1 0.33 
0.83 140 bp (dH2O) 2 0.45 * 
140 bp (dH2O) 3 0.38 
140 bp (FAC) 1 0.31 
0.81 140 bp (FAC) 2 0.37 
140 bp (FAC) 3 0.36 
pGL4.23 (dH2O) 1 0.39 
1.00 pGL4.23 (dH2O) 2 0.46 
pGL4.23 (dH2O) 3 0.43 
pGL4.23 (FAC) 1 0.54 
1.26 pGL4.23 (FAC) 2 0.60 
pGL4.23 (FAC) 3 0.47 
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Table S1.4 Normalized luciferase data for CYBRD1 constructs transfected into COS-1 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
2 kb (dH2O) 1 0.75 
1.00 2 kb (dH2O) 2 1.35 * 
2 kb (dH2O) 3 0.78 
2 kb (FAC) 1 0.71 
0.92 2 kb (FAC) 2 0.69 
2 kb (FAC) 3 1133.33 * 
1.8 kb (dH2O) 1 2.33 
3.02 1.8 kb (dH2O) 2 2.31 
1.8 kb (dH2O) 3 2.29 
1.8 kb (FAC) 1 2.14 
2.97 1.8 kb (FAC) 2 2.35 
1.8 kb (FAC) 3 2.34 
pGL4.10 (dH2O) 1 0.00 * 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
2 
2 kb (dH2O) 1 0.92 
1.00 2 kb (dH2O) 2 0.89 
2 kb (dH2O) 3 0.69 * 
2 kb (FAC) 1 0.99 
1.11 2 kb (FAC) 2 0.80 * 
2 kb (FAC) 3 1.02 
1.8 kb (dH2O) 1 2.52 
2.79 1.8 kb (dH2O) 2 2.51 
1.8 kb (dH2O) 3 2.51 
1.8 kb (FAC) 1 1.86 * 
2.71 1.8 kb (FAC) 2 2.44 
1.8 kb (FAC) 3 2.44 
pGL4.10 (dH2O) 1 0.00 * 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 * 
pGL4.10 (FAC) 3 0.00 
3 
2 kb (dH2O) 1 0.82 
1.00 2 kb (dH2O) 2 1.18 * 
2 kb (dH2O) 3 0.75 
2 kb (FAC) 1 1.18 
1.35 2 kb (FAC) 2 0.96 
2 kb (FAC) 3 1.03 
1.8 kb (dH2O) 1 3.35 
4.18 1.8 kb (dH2O) 2 3.15 
1.8 kb (dH2O) 3 3.34 
1.8 kb (FAC) 1 2.40 
3.33 1.8 kb (FAC) 2 2.83 
1.8 kb (FAC) 3 1.97 * 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 * 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
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Table S2.1 Normalized luciferase data for FTH1 constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
140 bp (dH2O) 1 78.00 
8.73 140 bp (dH2O) 2 73.24 
140 bp (dH2O) 3 73.78 
140 bp (FAC) 1 93.87 
10.96 140 bp (FAC) 2 94.25 
140 bp (FAC) 3 94.23 
pGL4.23 (dH2O) 1 8.55 
1.00 pGL4.23 (dH2O) 2 8.63 
pGL4.23 (dH2O) 3 1118.48 * 
pGL4.23 (FAC) 1 7.48 
0.95 pGL4.23 (FAC) 2 8.63 
pGL4.23 (FAC) 3 8.34 
2 
140 bp (dH2O) 1 21.79 
8.78 140 bp (dH2O) 2 24.12 
140 bp (dH2O) 3 22.66 
140 bp (FAC) 1 28.59 
11.10 140 bp (FAC) 2 30.16 
140 bp (FAC) 3 27.94 
pGL4.23 (dH2O) 1 2.49 
1.00 pGL4.23 (dH2O) 2 2.84 
pGL4.23 (dH2O) 3 2.48 
pGL4.23 (FAC) 1 3.02 
1.15 pGL4.23 (FAC) 2 3.04 
pGL4.23 (FAC) 3 2.91 
3 
140 bp (dH2O) 1 6.59 
9.51 140 bp (dH2O) 2 6.90 
140 bp (dH2O) 3 7.40 
140 bp (FAC) 1 9.49 
12.61 140 bp (FAC) 2 8.97 
140 bp (FAC) 3 5.79 * 
pGL4.23 (dH2O) 1 0.71 
1.00 pGL4.23 (dH2O) 2 0.75 
pGL4.23 (dH2O) 3 1.07 * 
pGL4.23 (FAC) 1 0.61 
0.82 pGL4.23 (FAC) 2 0.63 
pGL4.23 (FAC) 3 0.57 
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Table S2.2 Normalized luciferase data for FTH1 constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
2 kb (dH2O) 1 2.48 
1.00 2 kb (dH2O) 2 2.19 
2 kb (dH2O) 3 1.79 * 
2 kb (FAC) 1 3.37 
1.54 2 kb (FAC) 2 3.83 
2 kb (FAC) 3 2.34 * 
1.8 kb (dH2O) 1 0.87 
0.37 1.8 kb (dH2O) 2 0.90 
1.8 kb (dH2O) 3 0.85 
1.8 kb (FAC) 1 1.75 
0.75 1.8 kb (FAC) 2 1.77 
1.8 kb (FAC) 3 1.76 
pGL4.10 (dH2O) 1 0.01 * 
0.00 pGL4.10 (dH2O) 2 0.01 
pGL4.10 (dH2O) 3 0.01 
pGL4.10 (FAC) 1 0.01 
0.00 pGL4.10 (FAC) 2 0.01 
pGL4.10 (FAC) 3 0.01 
2 
2 kb (dH2O) 1 2.54 
1.00 2 kb (dH2O) 2 2.90 
2 kb (dH2O) 3 2.52 
2 kb (FAC) 1 3.86 
1.44 2 kb (FAC) 2 3.99 
2 kb (FAC) 3 3.60 
1.8 kb (dH2O) 1 0.57 
0.22 1.8 kb (dH2O) 2 0.57 
1.8 kb (dH2O) 3 1.18 * 
1.8 kb (FAC) 1 1.19 
0.42 1.8 kb (FAC) 2 1.15 
1.8 kb (FAC) 3 1.04 
pGL4.10 (dH2O) 1 0.01 * 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.01 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.01 
pGL4.10 (FAC) 3 0.00 
3 
2 kb (dH2O) 1 2.12 
1.00 2 kb (dH2O) 2 1.97 
2 kb (dH2O) 3 2.03 
2 kb (FAC) 1 4.64 * 
1.50 2 kb (FAC) 2 3.18 
2 kb (FAC) 3 2.93 
1.8 kb (dH2O) 1 0.91 
0.44 1.8 kb (dH2O) 2 0.89 
1.8 kb (dH2O) 3 1.33 * 
1.8 kb (FAC) 1 1.38 
0.67 1.8 kb (FAC) 2 1.41 
1.8 kb (FAC) 3 1.34 
pGL4.10 (dH2O) 1 0.01 * 
0.00 pGL4.10 (dH2O) 2 0.01 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.01 
0.00 pGL4.10 (FAC) 2 0.01 * 
pGL4.10 (FAC) 3 0.01 
 
Stellenbosch University http://scholar.sun.ac.za
APPENDIX FIVE: Chapter 4 supplementary data 
 
196 
 
Table S2.3 Normalized luciferase data for FTH1 constructs transfected into COS-1 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
140 bp (dH2O) 1 2.05 
4.88 140 bp (dH2O) 2 1.67 
140 bp (dH2O) 3 2.32 
140 bp (FAC) 1 2.24 
5.15 140 bp (FAC) 2 2.15 
140 bp (FAC) 3 1.98 
pGL4.23 (dH2O) 1 0.40 
1.00 pGL4.23 (dH2O) 2 0.42 
pGL4.23 (dH2O) 3 0.51 * 
pGL4.23 (FAC) 1 0.58 
1.34 pGL4.23 (FAC) 2 0.43 * 
pGL4.23 (FAC) 3 0.52 
2 
140 bp (dH2O) 1 1.72 
4.05 140 bp (dH2O) 2 1.87 
140 bp (dH2O) 3 2.07 
140 bp (FAC) 1 2.60 
5.82 140 bp (FAC) 2 2.65 
140 bp (FAC) 3 2.89 
pGL4.23 (dH2O) 1 0.49 
1.00 pGL4.23 (dH2O) 2 0.49 
pGL4.23 (dH2O) 3 0.42 
pGL4.23 (FAC) 1 0.57 
1.23 pGL4.23 (FAC) 2 0.62 
pGL4.23 (FAC) 3 0.52 
3 
140 bp (dH2O) 1 1.76 
4.38 140 bp (dH2O) 2 1.94 
140 bp (dH2O) 3 1.88 
140 bp (FAC) 1 2.29 
5.38 140 bp (FAC) 2 2.29 
140 bp (FAC) 3 2.28 
pGL4.23 (dH2O) 1 0.39 
1.00 pGL4.23 (dH2O) 2 0.46 
pGL4.23 (dH2O) 3 0.43 
pGL4.23 (FAC) 1 0.54 
1.26 pGL4.23 (FAC) 2 0.60 
pGL4.23 (FAC) 3 0.47 
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Table S2.4 Normalized luciferase data for FTH1 constructs transfected into COS-1 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
2 kb (dH2O) 1 2.69 
1.00 2 kb (dH2O) 2 2.68 
2 kb (dH2O) 3 2.91 
2 kb (FAC) 1 4.66 
1.68 2 kb (FAC) 2 4.64 
2 kb (FAC) 3 3.42 * 
1.8 kb (dH2O) 1 0.83 
0.30 1.8 kb (dH2O) 2 0.84 
1.8 kb (dH2O) 3 1.30 * 
1.8 kb (FAC) 1 1.40 
0.50 1.8 kb (FAC) 2 1.39 
1.8 kb (FAC) 3 1.35 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
2 
2 kb (dH2O) 1 2.64 
1.00 2 kb (dH2O) 2 2.50 
2 kb (dH2O) 3 2.67 
2 kb (FAC) 1 3.38 
1.26 2 kb (FAC) 2 3.03 
2 kb (FAC) 3 3.45 
1.8 kb (dH2O) 1 1.03 
0.39 1.8 kb (dH2O) 2 1.02 
1.8 kb (dH2O) 3 1.02 
1.8 kb (FAC) 1 1.35 
0.52 1.8 kb (FAC) 2 1.37 
1.8 kb (FAC) 3 1.33 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
3 
2 kb (dH2O) 1 2.38 
1.00 2 kb (dH2O) 2 2.35 
2 kb (dH2O) 3 2.32 
2 kb (FAC) 1 3.07 
1.31 2 kb (FAC) 2 3.10 
2 kb (FAC) 3 2.40 * 
1.8 kb (dH2O) 1 0.75 
0.33 1.8 kb (dH2O) 2 0.71 
1.8 kb (dH2O) 3 0.84 
1.8 kb (FAC) 1 1.07 
0.44 1.8 kb (FAC) 2 1.07 
1.8 kb (FAC) 3 1.00 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
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Table S3.1 Normalized luciferase data for HAMP constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold change 
1 
140 bp (dH2O) 1 1.28 
0.47 140 bp (dH2O) 2 1.25 
140 bp (dH2O) 3 1.24 
140 bp (FAC) 1 1.37 
0.49 140 bp (FAC) 2 1.31 
140 bp (FAC) 3 1.30 
pGL4.23 (dH2O) 1 2.76 
1.00 pGL4.23 (dH2O) 2 2.78 
pGL4.23 (dH2O) 3 2.53 
pGL4.23 (FAC) 1 3.67 
1.24 pGL4.23 (FAC) 2 3.03 
pGL4.23 (FAC) 3 1.85 * 
2 
140 bp (dH2O) 1 4.46 
0.51 140 bp (dH2O) 2 4.44 
140 bp (dH2O) 3 4.12 
140 bp (FAC) 1 4.67 
0.58 140 bp (FAC) 2 4.98 
140 bp (FAC) 3 5.21 
pGL4.23 (dH2O) 1 8.55 
1.00 pGL4.23 (dH2O) 2 8.63 
pGL4.23 (dH2O) 3 1118.48 * 
pGL4.23 (FAC) 1 7.48 
0.95 pGL4.23 (FAC) 2 8.63 
pGL4.23 (FAC) 3 8.34 
3 
140 bp (dH2O) 1 1.38 
0.54 140 bp (dH2O) 2 1.45 
140 bp (dH2O) 3 1.37 
140 bp (FAC) 1 1.53 
0.63 140 bp (FAC) 2 1.67 
140 bp (FAC) 3 1.69 
pGL4.23 (dH2O) 1 2.49 
1.00 pGL4.23 (dH2O) 2 2.84 
pGL4.23 (dH2O) 3 2.48 
pGL4.23 (FAC) 1 3.02 
1.15 pGL4.23 (FAC) 2 3.04 
pGL4.23 (FAC) 3 2.91 
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Table S3.2 Normalized luciferase data for HAMP constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
2 kb (dH2O) 1 5.12 * 
1.00 2 kb (dH2O) 2 1.98 
2 kb (dH2O) 3 2.16 
2 kb (FAC) 1 2.39 
1.07 2 kb (FAC) 2 1.95 
2 kb (FAC) 3 2.33 
1.8 kb (dH2O) 1 1.95 
0.92 1.8 kb (dH2O) 2 1.92 
1.8 kb (dH2O) 3 1.80 
1.8 kb (FAC) 1 2.15 
1.02 1.8 kb (FAC) 2 1.68 * 
1.8 kb (FAC) 3 2.06 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 * 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 * 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
2 
2 kb (dH2O) 1 1.72 
1.00 2 kb (dH2O) 2 2.66 * 
2 kb (dH2O) 3 1.99 
2 kb (FAC) 1 2.46 
1.16 2 kb (FAC) 2 2.05 
2 kb (FAC) 3 1.97 
1.8 kb (dH2O) 1 1.87 
1.04 1.8 kb (dH2O) 2 1.94 
1.8 kb (dH2O) 3 1.98 
1.8 kb (FAC) 1 2.27 
1.14 1.8 kb (FAC) 2 2.77 * 
1.8 kb (FAC) 3 1.97 
pGL4.10 (dH2O) 1 0.01 * 
0.00 pGL4.10 (dH2O) 2 0.01 
pGL4.10 (dH2O) 3 0.01 
pGL4.10 (FAC) 1 0.01 
0.00 pGL4.10 (FAC) 2 0.01 
pGL4.10 (FAC) 3 0.01 
3 
2 kb (dH2O) 1 1.68 
1.00 2 kb (dH2O) 2 1.66 
2 kb (dH2O) 3 1.70 
2 kb (FAC) 1 2.72 
1.69 2 kb (FAC) 2 2.81 
2 kb (FAC) 3 2.96 
1.8 kb (dH2O) 1 1.95 
1.16 1.8 kb (dH2O) 2 1.17 * 
1.8 kb (dH2O) 3 1.94 
1.8 kb (FAC) 1 1.98 
1.18 1.8 kb (FAC) 2 1.80 * 
1.8 kb (FAC) 3 1.98 
pGL4.10 (dH2O) 1 0.01 * 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.01 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.01 
pGL4.10 (FAC) 3 0.00 
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Table S3.3 Normalized luciferase data for HAMP constructs transfected into COS-1 cell line. 
Experiment Construct Repeat Normalized Value Fold change 
1 
140 bp (dH2O) 1 0.48 
0.97 140 bp (dH2O) 2 0.43 
140 bp (dH2O) 3 0.76 * 
140 bp (FAC) 1 0.52 
1.05 140 bp (FAC) 2 0.45 
140 bp (FAC) 3 0.48 
pGL4.23 (dH2O) 1 0.49 
1.00 pGL4.23 (dH2O) 2 0.49 
pGL4.23 (dH2O) 3 0.42 
pGL4.23 (FAC) 1 0.57 
1.23 pGL4.23 (FAC) 2 0.62 
pGL4.23 (FAC) 3 0.52 
2 
140 bp (dH2O) 1 0.57 
0.77 140 bp (dH2O) 2 0.51 
140 bp (dH2O) 3 0.61 
140 bp (FAC) 1 0.64 
0.86 140 bp (FAC) 2 0.80 * 
140 bp (FAC) 3 0.62 
pGL4.23 (dH2O) 1 0.71 
1.00 pGL4.23 (dH2O) 2 0.76 
pGL4.23 (dH2O) 3 0.72 
pGL4.23 (FAC) 1 0.72 
0.94 pGL4.23 (FAC) 2 0.67 
pGL4.23 (FAC) 3 0.68 
3 
140 bp (dH2O) 1 0.36 * 
0.65 140 bp (dH2O) 2 0.29 
140 bp (dH2O) 3 0.26 
140 bp (FAC) 1 0.28 
0.66 140 bp (FAC) 2 0.35 * 
140 bp (FAC) 3 0.29 
pGL4.23 (dH2O) 1 0.39 
1.00 pGL4.23 (dH2O) 2 0.46 
pGL4.23 (dH2O) 3 0.43 
pGL4.23 (FAC) 1 0.54 
1.19 pGL4.23 (FAC) 2 0.50 
pGL4.23 (FAC) 3 0.47 
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Table S3.4 Normalized luciferase data for HAMP constructs transfected into COS-1 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
2 kb (dH2O) 1 1.43 
1.00 2 kb (dH2O) 2 1.56 
2 kb (dH2O) 3 1.24 
2 kb (FAC) 1 1.35 * 
1.13 2 kb (FAC) 2 1.55 
2 kb (FAC) 3 1.62 
1.8 kb (dH2O) 1 0.85 
0.61 1.8 kb (dH2O) 2 1.06 * 
1.8 kb (dH2O) 3 0.86 
1.8 kb (FAC) 1 1.10 
0.78 1.8 kb (FAC) 2 1.10 
1.8 kb (FAC) 3 1.08 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 * 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 * 
2 
2 kb (dH2O) 1 1.62 
1.00 2 kb (dH2O) 2 1.06 * 
2 kb (dH2O) 3 1.37 
2 kb (FAC) 1 1.51 
1.00 2 kb (FAC) 2 1.50 
2 kb (FAC) 3 1.49 
1.8 kb (dH2O) 1 0.86 
0.57 1.8 kb (dH2O) 2 0.83 
1.8 kb (dH2O) 3 0.85 
1.8 kb (FAC) 1 1.22 * 
0.68 1.8 kb (FAC) 2 1.07 
1.8 kb (FAC) 3 0.95 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 * 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 * 
3 
2 kb (dH2O) 1 1.37 
1.00 2 kb (dH2O) 2 1.40 
2 kb (dH2O) 3 1.36 
2 kb (FAC) 1 1.38 
1.01 2 kb (FAC) 2 1.40 
2 kb (FAC) 3 1.39 
1.8 kb (dH2O) 1 0.78 
0.61 1.8 kb (dH2O) 2 0.85 
1.8 kb (dH2O) 3 0.89 
1.8 kb (FAC) 1 1.04 
0.76 1.8 kb (FAC) 2 1.04 
1.8 kb (FAC) 3 1.08 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
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Table S4.1 Normalized luciferase data for HFE constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
140 bp (dH2O) 1 0.01 * 
0.00 140 bp (dH2O) 2 0.01 
140 bp (dH2O) 3 0.01 
140 bp (FAC) 1 0.01 * 
0.01 140 bp (FAC) 2 0.01 
140 bp (FAC) 3 0.01 
pGL4.23 (dH2O) 1 2.76 
1.00 pGL4.23 (dH2O) 2 2.78 
pGL4.23 (dH2O) 3 2.53 
pGL4.23 (FAC) 1 3.67 
1.24 pGL4.23 (FAC) 2 3.03 
pGL4.23 (FAC) 3 1.85 * 
2 
140 bp (dH2O) 1 0.01 
0.00 140 bp (dH2O) 2 0.01 
140 bp (dH2O) 3 22.35 * 
140 bp (FAC) 1 0.02 
0.01 140 bp (FAC) 2 0.02 
140 bp (FAC) 3 0.02 
pGL4.23 (dH2O) 1 2.49 
1.00 pGL4.23 (dH2O) 2 2.84 
pGL4.23 (dH2O) 3 2.48 
pGL4.23 (FAC) 1 3.02 
1.15 pGL4.23 (FAC) 2 3.04 
pGL4.23 (FAC) 3 2.91 
3 
140 bp (dH2O) 1 0.05 * 
0.01 140 bp (dH2O) 2 0.01 
140 bp (dH2O) 3 0.01 
140 bp (FAC) 1 0.01 * 
0.01 140 bp (FAC) 2 0.02 
140 bp (FAC) 3 0.02 
pGL4.23 (dH2O) 1 1.74 
1.00 pGL4.23 (dH2O) 2 1.83 
pGL4.23 (dH2O) 3 1.79 
pGL4.23 (FAC) 1 1.93 
1.08 pGL4.23 (FAC) 2 1.44 * 
pGL4.23 (FAC) 3 1.91 
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Table S4.2 Normalized luciferase data for HFE constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
2 kb (dH2O) 1 1.25 
1.00 2 kb (dH2O) 2 1.20 
2 kb (dH2O) 3 0.99 
2 kb (FAC) 1 3.71 * 
1.25 2 kb (FAC) 2 1.45 
2 kb (FAC) 3 1.42 
1.8 kb (dH2O) 1 3.20 * 
2.17 1.8 kb (dH2O) 2 2.52 
1.8 kb (dH2O) 3 2.45 
1.8 kb (FAC) 1 2.22 
2.10 1.8 kb (FAC) 2 2.43 
1.8 kb (FAC) 3 2.59 
pGL4.10 (dH2O) 1 0.01 * 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.01 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.01 
pGL4.10 (FAC) 3 0.00 
2 
2 kb (dH2O) 1 1.02 
1.00 2 kb (dH2O) 2 0.86 * 
2 kb (dH2O) 3 1.18 
2 kb (FAC) 1 1.72 
1.55 2 kb (FAC) 2 2.02 * 
2 kb (FAC) 3 1.70 
1.8 kb (dH2O) 1 2.11 
1.98 1.8 kb (dH2O) 2 2.25 
1.8 kb (dH2O) 3 2.18 
1.8 kb (FAC) 1 1.74 
1.61 1.8 kb (FAC) 2 1.75 
1.8 kb (FAC) 3 1.81 
pGL4.10 (dH2O) 1 0.01 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.01 
0.01 pGL4.10 (FAC) 2 0.01 
pGL4.10 (FAC) 3 0.01 
3 
2 kb (dH2O) 1 2.30 
1.00 2 kb (dH2O) 2 1.70 * 
2 kb (dH2O) 3 2.63 
2 kb (FAC) 1 2.60 
1.10 2 kb (FAC) 2 2.77 
2 kb (FAC) 3 2.80 
1.8 kb (dH2O) 1 3.38 
1.38 1.8 kb (dH2O) 2 3.43 
1.8 kb (dH2O) 3 4.30 * 
1.8 kb (FAC) 1 3.51 
1.49 1.8 kb (FAC) 2 3.60 
1.8 kb (FAC) 3 3.92 
pGL4.10 (dH2O) 1 0.01 * 
0.00 pGL4.10 (dH2O) 2 0.01 
pGL4.10 (dH2O) 3 0.01 
pGL4.10 (FAC) 1 0.01 
0.00 pGL4.10 (FAC) 2 0.01 * 
pGL4.10 (FAC) 3 0.01 
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Table S4.3 Normalized luciferase data for HFE constructs transfected into COS-1 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
140 bp (dH2O) 1 0.01 
0.01 140 bp (dH2O) 2 0.00 * 
140 bp (dH2O) 3 0.01 
140 bp (FAC) 1 0.01 
0.02 140 bp (FAC) 2 0.01 
140 bp (FAC) 3 0.01 * 
pGL4.23 (dH2O) 1 0.40 
1.00 pGL4.23 (dH2O) 2 0.42 
pGL4.23 (dH2O) 3 0.51 * 
pGL4.23 (FAC) 1 0.58 
1.34 pGL4.23 (FAC) 2 0.43 * 
pGL4.23 (FAC) 3 0.52 
2 
140 bp (dH2O) 1 0.01 
0.01 140 bp (dH2O) 2 0.01 
140 bp (dH2O) 3 0.01 
140 bp (FAC) 1 0.01 
0.02 140 bp (FAC) 2 0.01 
140 bp (FAC) 3 0.01 * 
pGL4.23 (dH2O) 1 0.49 
1.00 pGL4.23 (dH2O) 2 0.49 
pGL4.23 (dH2O) 3 0.42 
pGL4.23 (FAC) 1 0.57 
1.23 pGL4.23 (FAC) 2 0.62 
pGL4.23 (FAC) 3 0.52 
3 
140 bp (dH2O) 1 0.01 * 
0.01 140 bp (dH2O) 2 0.01 
140 bp (dH2O) 3 0.01 
140 bp (FAC) 1 0.01 
0.02 140 bp (FAC) 2 0.01 
140 bp (FAC) 3 0.01 
pGL4.23 (dH2O) 1 0.71 
1.00 pGL4.23 (dH2O) 2 0.76 
pGL4.23 (dH2O) 3 0.72 
pGL4.23 (FAC) 1 0.72 
0.94 pGL4.23 (FAC) 2 0.67 
pGL4.23 (FAC) 3 0.68 
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Table S4.4 Normalized luciferase data for HFE constructs transfected into COS-1 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
2 kb (dH2O) 1 0.90 * 
1.00 2 kb (dH2O) 2 0.75 
2 kb (dH2O) 3 0.71 
2 kb (FAC) 1 0.75 * 
1.43 2 kb (FAC) 2 1.14 
2 kb (FAC) 3 0.94 
1.8 kb (dH2O) 1 0.83 
1.11 1.8 kb (dH2O) 2 0.85 
1.8 kb (dH2O) 3 0.75 
1.8 kb (FAC) 1 0.79 
1.08 1.8 kb (FAC) 2 0.82 
1.8 kb (FAC) 3 0.75 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 * 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 * 
2 
2 kb (dH2O) 1 0.54 
1.00 2 kb (dH2O) 2 0.59 
2 kb (dH2O) 3 0.56 
2 kb (FAC) 1 0.62 * 
1.41 2 kb (FAC) 2 0.83 
2 kb (FAC) 3 0.76 
1.8 kb (dH2O) 1 0.54 
1.02 1.8 kb (dH2O) 2 0.59 
1.8 kb (dH2O) 3 0.59 
1.8 kb (FAC) 1 0.55 
1.01 1.8 kb (FAC) 2 0.58 
1.8 kb (FAC) 3 0.59 
pGL4.10 (dH2O) 1 0.00 * 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 * 
pGL4.10 (FAC) 3 0.00 
3 
2 kb (dH2O) 1 0.51 
1.00 2 kb (dH2O) 2 0.71 * 
2 kb (dH2O) 3 0.54 
2 kb (FAC) 1 0.60 
1.19 2 kb (FAC) 2 0.65 
2 kb (FAC) 3 0.63 
1.8 kb (dH2O) 1 0.62 
1.30 1.8 kb (dH2O) 2 0.72 
1.8 kb (dH2O) 3 0.71 
1.8 kb (FAC) 1 0.68 
1.27 1.8 kb (FAC) 2 0.67 
1.8 kb (FAC) 3 0.66 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 * 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
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Table S5.1 Normalized luciferase data for HFE2 constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
140 bp (dH2O) 1 10.96 
4.52 140 bp (dH2O) 2 12.47 
140 bp (dH2O) 3 13.05 
140 bp (FAC) 1 15.04 
6.00 140 bp (FAC) 2 15.69 
140 bp (FAC) 3 17.70 
pGL4.23 (dH2O) 1 2.76 
1.00 pGL4.23 (dH2O) 2 2.78 
pGL4.23 (dH2O) 3 2.53 
pGL4.23 (FAC) 1 3.67 
1.06 pGL4.23 (FAC) 2 3.03 
pGL4.23 (FAC) 3 1.85 * 
2 
140 bp (dH2O) 1 10.20 
4.27 140 bp (dH2O) 2 12.16 
140 bp (dH2O) 3 10.79 
140 bp (FAC) 1 18.62 
7.68 140 bp (FAC) 2 20.29 
140 bp (FAC) 3 20.71 
pGL4.23 (dH2O) 1 2.55 
1.00 pGL4.23 (dH2O) 2 2.63 
pGL4.23 (dH2O) 3 18.48 * 
pGL4.23 (FAC) 1 2.48 
0.96 pGL4.23 (FAC) 2 2.63 
pGL4.23 (FAC) 3 2.34 
3 
140 bp (dH2O) 1 10.21 
4.08 140 bp (dH2O) 2 11.63 
140 bp (dH2O) 3 10.02 
140 bp (FAC) 1 12.46 
5.34 140 bp (FAC) 2 14.67 
140 bp (FAC) 3 14.61 
pGL4.23 (dH2O) 1 2.49 
1.00 pGL4.23 (dH2O) 2 2.84 
pGL4.23 (dH2O) 3 2.48 
pGL4.23 (FAC) 1 3.02 
1.15 pGL4.23 (FAC) 2 3.04 
pGL4.23 (FAC) 3 2.91 
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Table S5.2 Normalized luciferase data for HFE2 constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
2 kb (dH2O) 1 0.99 * 
1.00 2 kb (dH2O) 2 0.84 
2 kb (dH2O) 3 0.80 
2 kb (FAC) 1 0.89 
1.12 2 kb (FAC) 2 0.87 
2 kb (FAC) 3 0.99 
1.8 kb (dH2O) 1 0.78 
0.93 1.8 kb (dH2O) 2 0.73 
1.8 kb (dH2O) 3 0.79 
1.8 kb (FAC) 1 1.49 * 
1.38 1.8 kb (FAC) 2 1.12 
1.8 kb (FAC) 3 1.15 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
2 
2 kb (dH2O) 1 0.59 * 
1.00 2 kb (dH2O) 2 0.79 
2 kb (dH2O) 3 0.81 
2 kb (FAC) 1 1.08 
1.39 2 kb (FAC) 2 1.63 * 
2 kb (FAC) 3 1.14 
1.8 kb (dH2O) 1 0.69 
0.86 1.8 kb (dH2O) 2 0.87 * 
1.8 kb (dH2O) 3 0.67 
1.8 kb (FAC) 1 0.96 
0.80 1.8 kb (FAC) 2 0.99 
1.8 kb (FAC) 3 1.13 * 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.02 * 
3 
2 kb (dH2O) 1 1.02 
1.00 2 kb (dH2O) 2 1.12 
2 kb (dH2O) 3 1.05 
2 kb (FAC) 1 1.31 
1.23 2 kb (FAC) 2 1.31 
2 kb (FAC) 3 1.53 * 
1.8 kb (dH2O) 1 1.05 
1.01 1.8 kb (dH2O) 2 1.09 
1.8 kb (dH2O) 3 1.08 
1.8 kb (FAC) 1 1.28 
1.20 1.8 kb (FAC) 2 2.01 * 
1.8 kb (FAC) 3 1.27 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
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Table S5.3 Normalized luciferase data for HFE2 constructs transfected into COS-1 cell line. 
Experiment Construct Repeat Normalized Value Fold change 
1 
140 bp (dH2O) 1 1.02 
2.79 140 bp (dH2O) 2 1.28 
140 bp (dH2O) 3 1.43 * 
140 bp (FAC) 1 1.06 
2.44 140 bp (FAC) 2 0.96 
140 bp (FAC) 3 0.99 
pGL4.23 (dH2O) 1 0.40 
1.00 pGL4.23 (dH2O) 2 0.42 
pGL4.23 (dH2O) 3 0.51 * 
pGL4.23 (FAC) 1 0.58 
1.34 pGL4.23 (FAC) 2 0.43 * 
pGL4.23 (FAC) 3 0.52 
2 
140 bp (dH2O) 1 1.26 
2.56 140 bp (dH2O) 2 1.18 
140 bp (dH2O) 3 1.14 
140 bp (FAC) 1 0.99 
2.20 140 bp (FAC) 2 1.08 
140 bp (FAC) 3 1.00 
pGL4.23 (dH2O) 1 0.49 
1.00 pGL4.23 (dH2O) 2 0.49 
pGL4.23 (dH2O) 3 0.42 
pGL4.23 (FAC) 1 0.57 
1.23 pGL4.23 (FAC) 2 0.62 
pGL4.23 (FAC) 3 0.52 
3 
140 bp (dH2O) 1 1.55 
2.02 140 bp (dH2O) 2 2.41 * 
140 bp (dH2O) 3 1.39 
140 bp (FAC) 1 1.29 
1.64 140 bp (FAC) 2 1.14 
140 bp (FAC) 3 1.17 
pGL4.23 (dH2O) 1 0.71 
1.00 pGL4.23 (dH2O) 2 0.76 
pGL4.23 (dH2O) 3 0.72 
pGL4.23 (FAC) 1 0.72 
0.94 pGL4.23 (FAC) 2 0.67 
pGL4.23 (FAC) 3 0.68 
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Table S5.4 Normalized luciferase data for HFE2 constructs transfected into COS-1 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
2 kb (dH2O) 1 2.27 
1.00 2 kb (dH2O) 2 2.18 
2 kb (dH2O) 3 2.10 
2 kb (FAC) 1 3.96 
1.78 2 kb (FAC) 2 3.80 
2 kb (FAC) 3 3.88 
1.8 kb (dH2O) 1 2.40 
1.11 1.8 kb (dH2O) 2 2.38 
1.8 kb (dH2O) 3 2.49 
1.8 kb (FAC) 1 2.64 
1.27 1.8 kb (FAC) 2 2.65 
1.8 kb (FAC) 3 3.02 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
2 
2 kb (dH2O) 1 3.05 
1.00 2 kb (dH2O) 2 2.71 
2 kb (dH2O) 3 2.83 
2 kb (FAC) 1 3.63 
1.18 2 kb (FAC) 2 3.31 
2 kb (FAC) 3 3.22 
1.8 kb (dH2O) 1 3.19 
1.03 1.8 kb (dH2O) 2 2.82 
1.8 kb (dH2O) 3 2.83 
1.8 kb (FAC) 1 3.03 
1.07 1.8 kb (FAC) 2 3.27 
1.8 kb (FAC) 3 2.91 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 * 
pGL4.10 (FAC) 3 0.00 
3 
2 kb (dH2O) 1 2.36 
1.00 2 kb (dH2O) 2 2.56 
2 kb (dH2O) 3 2.45 
2 kb (FAC) 1 2.09 * 
1.08 2 kb (FAC) 2 2.63 
2 kb (FAC) 3 2.66 
1.8 kb (dH2O) 1 2.13 
0.92 1.8 kb (dH2O) 2 2.54 
1.8 kb (dH2O) 3 2.09 
1.8 kb (FAC) 1 2.60 
1.02 1.8 kb (FAC) 2 2.23 
1.8 kb (FAC) 3 2.71 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 * 
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Table S6.1 Normalized luciferase data for HMOX1 constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold change 
1 
140 bp (dH2O) 1 1.10 
0.40 140 bp (dH2O) 2 1.03 
140 bp (dH2O) 3 1.08 
140 bp (FAC) 1 1.29 
0.49 140 bp (FAC) 2 1.26 
140 bp (FAC) 3 1.42 
pGL4.23 (dH2O) 1 2.76 
1.00 pGL4.23 (dH2O) 2 2.78 
pGL4.23 (dH2O) 3 2.53 
pGL4.23 (FAC) 1 3.67 
1.24 pGL4.23 (FAC) 2 3.03 
pGL4.23 (FAC) 3 1.85 * 
2 
140 bp (dH2O) 1 3.71 
0.43 140 bp (dH2O) 2 3.74 
140 bp (dH2O) 3 7.06 * 
140 bp (FAC) 1 4.41 
0.52 140 bp (FAC) 2 4.25 
140 bp (FAC) 3 4.84 
pGL4.23 (dH2O) 1 8.55 
1.00 pGL4.23 (dH2O) 2 8.63 
pGL4.23 (dH2O) 3 1118.48 * 
pGL4.23 (FAC) 1 7.48 
0.95 pGL4.23 (FAC) 2 8.63 
pGL4.23 (FAC) 3 8.34 
3 
140 bp (dH2O) 1 1.42 
0.55 140 bp (dH2O) 2 1.39 
140 bp (dH2O) 3 1.51 
140 bp (FAC) 1 1.56 
0.62 140 bp (FAC) 2 1.78 
140 bp (FAC) 3 1.52 
pGL4.23 (dH2O) 1 2.49 
1.00 pGL4.23 (dH2O) 2 2.84 
pGL4.23 (dH2O) 3 2.48 
pGL4.23 (FAC) 1 3.02 
1.15 pGL4.23 (FAC) 2 3.04 
pGL4.23 (FAC) 3 2.91 
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Table S6.2 Normalized luciferase data for HMOX1 constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
2 kb (dH2O) 1 38.10 
1.00 2 kb (dH2O) 2 23.97 * 
2 kb (dH2O) 3 32.86 
2 kb (FAC) 1 52.59 
1.64 2 kb (FAC) 2 62.75 
2 kb (FAC) 3 59.61 
1.8 kb (dH2O) 1 249.62 
6.98 1.8 kb (dH2O) 2 209.62 
1.8 kb (dH2O) 3 283.78 
1.8 kb (FAC) 1 314.96 
9.57 1.8 kb (FAC) 2 364.40 
1.8 kb (FAC) 3 123.36 * 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 * 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 * 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
2 
2 kb (dH2O) 1 25.26 
1.00 2 kb (dH2O) 2 28.43 
2 kb (dH2O) 3 28.60 
2 kb (FAC) 1 34.46 
1.31 2 kb (FAC) 2 53.55 * 
2 kb (FAC) 3 37.66 
1.8 kb (dH2O) 1 199.34 * 
6.00 1.8 kb (dH2O) 2 157.54 
1.8 kb (dH2O) 3 171.69 
1.8 kb (FAC) 1 216.37 
7.51 1.8 kb (FAC) 2 191.27 
1.8 kb (FAC) 3 210.36 
pGL4.10 (dH2O) 1 0.01 * 
0.00 pGL4.10 (dH2O) 2 0.01 
pGL4.10 (dH2O) 3 0.01 
pGL4.10 (FAC) 1 0.01 
0.00 pGL4.10 (FAC) 2 0.01 
pGL4.10 (FAC) 3 0.01 
3 
2 kb (dH2O) 1 32.95 
1.00 2 kb (dH2O) 2 36.58 
2 kb (dH2O) 3 42.02 * 
2 kb (FAC) 1 55.63 
1.62 2 kb (FAC) 2 57.60 
2 kb (FAC) 3 55.61 
1.8 kb (dH2O) 1 176.62 
5.12 1.8 kb (dH2O) 2 203.82 
1.8 kb (dH2O) 3 153.76 
1.8 kb (FAC) 1 263.40 
7.14 1.8 kb (FAC) 2 373.85 * 
1.8 kb (FAC) 3 233.39 
pGL4.10 (dH2O) 1 0.01 * 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.01 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.01 
pGL4.10 (FAC) 3 0.00 
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Table S6.3 Normalized luciferase data for HMOX1 constructs transfected into COS-1 cell line. 
Experiment Construct Repeat Normalized Value Fold change 
1 
140 bp (dH2O) 1 0.48 
1.05 140 bp (dH2O) 2 0.51 
140 bp (dH2O) 3 0.48 
140 bp (FAC) 1 0.54 
1.20 140 bp (FAC) 2 0.54 
140 bp (FAC) 3 0.59 
pGL4.23 (dH2O) 1 0.49 
1.00 pGL4.23 (dH2O) 2 0.49 
pGL4.23 (dH2O) 3 0.42 
pGL4.23 (FAC) 1 0.57 
1.23 pGL4.23 (FAC) 2 0.62 
pGL4.23 (FAC) 3 0.52 
2 
140 bp (dH2O) 1 0.41 
0.76 140 bp (dH2O) 2 0.47 
140 bp (dH2O) 3 0.46 
140 bp (FAC) 1 0.53 
0.81 140 bp (FAC) 2 0.44 
140 bp (FAC) 3 0.46 
pGL4.23 (dH2O) 1 0.66 * 
1.00 pGL4.23 (dH2O) 2 0.52 
pGL4.23 (dH2O) 3 0.57 
pGL4.23 (FAC) 1 0.72 
1.21 pGL4.23 (FAC) 2 0.71 
pGL4.23 (FAC) 3 0.70 
3 
140 bp (dH2O) 1 0.41 
1.01 140 bp (dH2O) 2 0.44 
140 bp (dH2O) 3 0.44 
140 bp (FAC) 1 0.50 
1.12 140 bp (FAC) 2 0.46 
140 bp (FAC) 3 0.47 
pGL4.23 (dH2O) 1 0.39 
1.00 pGL4.23 (dH2O) 2 0.46 
pGL4.23 (dH2O) 3 0.43 
pGL4.23 (FAC) 1 0.54 
1.26 pGL4.23 (FAC) 2 0.60 
pGL4.23 (FAC) 3 0.47 
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Table S6.4 Normalized luciferase data for HMOX1 constructs transfected into COS-1 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
2 kb (dH2O) 1 16.26 
1.00 2 kb (dH2O) 2 16.76 
2 kb (dH2O) 3 17.13 
2 kb (FAC) 1 20.54 
1.20 2 kb (FAC) 2 15.47 * 
2 kb (FAC) 3 19.66 
1.8 kb (dH2O) 1 30.47 
1.88 1.8 kb (dH2O) 2 30.26 
1.8 kb (dH2O) 3 33.62 
1.8 kb (FAC) 1 36.08 
2.24 1.8 kb (FAC) 2 37.88 
1.8 kb (FAC) 3 38.44 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 * 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 * 
2 
2 kb (dH2O) 1 15.24 
1.00 2 kb (dH2O) 2 18.37 
2 kb (dH2O) 3 18.24 
2 kb (FAC) 1 24.95 
1.48 2 kb (FAC) 2 24.55 
2 kb (FAC) 3 27.13 
1.8 kb (dH2O) 1 42.59 
2.42 1.8 kb (dH2O) 2 43.51 
1.8 kb (dH2O) 3 39.38 
1.8 kb (FAC) 1 45.94 
2.58 1.8 kb (FAC) 2 46.32 
1.8 kb (FAC) 3 41.74 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 * 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 * 
3 
2 kb (dH2O) 1 10.42 
1.00 2 kb (dH2O) 2 9.97 
2 kb (dH2O) 3 11.38 
2 kb (FAC) 1 21.16 
1.97 2 kb (FAC) 2 20.64 
2 kb (FAC) 3 20.64 
1.8 kb (dH2O) 1 27.93 
2.68 1.8 kb (dH2O) 2 28.78 
1.8 kb (dH2O) 3 19.35 * 
1.8 kb (FAC) 1 29.42 
2.74 1.8 kb (FAC) 2 29.34 
1.8 kb (FAC) 3 28.37 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
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Table S7.1 Normalized luciferase data for IREB2 constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
140 bp (dH2O) 1 0.25 
0.25 140 bp (dH2O) 2 0.27 
140 bp (dH2O) 3 0.24 
140 bp (FAC) 1 0.28 
0.29 140 bp (FAC) 2 0.29 
140 bp (FAC) 3 0.29 
pGL4.23 (dH2O) 1 0.65 
0.64 pGL4.23 (dH2O) 2 0.63 
pGL4.23 (dH2O) 3 1.85 * 
pGL4.23 (FAC) 1 0.79 
0.83 pGL4.23 (FAC) 2 0.86 
pGL4.23 (FAC) 3 0.83 
2 
140 bp (dH2O) 1 0.25 
0.25 140 bp (dH2O) 2 0.26 
140 bp (dH2O) 3 0.25 
140 bp (FAC) 1 0.29 
0.29 140 bp (FAC) 2 0.44 * 
140 bp (FAC) 3 0.30 
pGL4.23 (dH2O) 1 0.74 
0.79 pGL4.23 (dH2O) 2 0.83 
pGL4.23 (dH2O) 3 0.79 
pGL4.23 (FAC) 1 0.93 
0.92 pGL4.23 (FAC) 2 0.44 * 
pGL4.23 (FAC) 3 0.91 
3 
140 bp (dH2O) 1 0.31 * 
0.22 140 bp (dH2O) 2 0.22 
140 bp (dH2O) 3 0.22 
140 bp (FAC) 1 0.31 
0.27 140 bp (FAC) 2 0.26 
140 bp (FAC) 3 0.23 
pGL4.23 (dH2O) 1 0.61 
0.81 pGL4.23 (dH2O) 2 0.75 
pGL4.23 (dH2O) 3 1.07 
pGL4.23 (FAC) 1 0.61 
0.60 pGL4.23 (FAC) 2 0.63 
pGL4.23 (FAC) 3 0.57 
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Table S7.2 Normalized luciferase data for IREB2 constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
2 kb (dH2O) 1 1022.94 
1.00 2 kb (dH2O) 2 1048.32 
2 kb (dH2O) 3 934.16 
2 kb (FAC) 1 954.04 
1.03 2 kb (FAC) 2 1089.60 
2 kb (FAC) 3 1051.40 
1.8 kb (dH2O) 1 1133.88 
0.99 1.8 kb (dH2O) 2 952.08 
1.8 kb (dH2O) 3 878.94 
1.8 kb (FAC) 1 1055.33 
1.04 1.8 kb (FAC) 2 1048.34 
1.8 kb (FAC) 3 1025.92 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.02 * 
2 
2 kb (dH2O) 1 1446.29 
1.00 2 kb (dH2O) 2 1463.71 
2 kb (dH2O) 3 1396.98 
2 kb (FAC) 1 1369.75 
1.09 2 kb (FAC) 2 1664.37 
2 kb (FAC) 3 1652.96 
1.8 kb (dH2O) 1 1514.93 
0.98 1.8 kb (dH2O) 2 1414.18 
1.8 kb (dH2O) 3 1308.59 
1.8 kb (FAC) 1 1715.78 
1.17 1.8 kb (FAC) 2 1726.83 
1.8 kb (FAC) 3 1602.60 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
3 
2 kb (dH2O) 1 1092.35 
1.00 2 kb (dH2O) 2 1007.84 
2 kb (dH2O) 3 985.80 
2 kb (FAC) 1 1029.80 
1.12 2 kb (FAC) 2 1202.11 
2 kb (FAC) 3 1212.50 
1.8 kb (dH2O) 1 1231.66 
1.14 1.8 kb (dH2O) 2 1096.89 
1.8 kb (dH2O) 3 1194.75 
1.8 kb (FAC) 1 1267.58 
1.27 1.8 kb (FAC) 2 1337.91 
1.8 kb (FAC) 3 1025.94 * 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
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Table S7.3 Normalized luciferase data for IREB2 constructs transfected into COS-1 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
140 bp (dH2O) 1 0.27 
0.61 140 bp (dH2O) 2 0.23 
140 bp (dH2O) 3 1.31 * 
140 bp (FAC) 1 0.29 
0.66 140 bp (FAC) 2 0.54 * 
140 bp (FAC) 3 0.26 
pGL4.23 (dH2O) 1 0.40 
1.00 pGL4.23 (dH2O) 2 0.42 
pGL4.23 (dH2O) 3 0.51 * 
pGL4.23 (FAC) 1 0.58 
1.34 pGL4.23 (FAC) 2 0.43 * 
pGL4.23 (FAC) 3 0.52 
2 
140 bp (dH2O) 1 0.26 
0.57 140 bp (dH2O) 2 0.25 
140 bp (dH2O) 3 0.29 
140 bp (FAC) 1 0.40 
0.79 140 bp (FAC) 2 0.34 
140 bp (FAC) 3 0.36 
pGL4.23 (dH2O) 1 0.49 
1.00 pGL4.23 (dH2O) 2 0.49 
pGL4.23 (dH2O) 3 0.42 
pGL4.23 (FAC) 1 0.57 
1.23 pGL4.23 (FAC) 2 0.62 
pGL4.23 (FAC) 3 0.52 
3 
140 bp (dH2O) 1 0.43 
0.58 140 bp (dH2O) 2 0.43 
140 bp (dH2O) 3 0.42 
140 bp (FAC) 1 0.51 
0.70 140 bp (FAC) 2 0.51 
140 bp (FAC) 3 0.95 * 
pGL4.23 (dH2O) 1 0.71 
1.00 pGL4.23 (dH2O) 2 0.76 
pGL4.23 (dH2O) 3 0.72 
pGL4.23 (FAC) 1 0.72 
0.94 pGL4.23 (FAC) 2 0.67 
pGL4.23 (FAC) 3 0.68 
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Table S7.4 Normalized luciferase data for IREB2 constructs transfected into COS-1 HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
2 kb (dH2O) 1 873.15 
1.00 2 kb (dH2O) 2 920.37 
2 kb (dH2O) 3 908.69 
2 kb (FAC) 1 855.62 
0.92 2 kb (FAC) 2 585.75 * 
2 kb (FAC) 3 802.89 
1.8 kb (dH2O) 1 822.70 
0.87 1.8 kb (dH2O) 2 787.78 
1.8 kb (dH2O) 3 738.47 
1.8 kb (FAC) 1 680.80 
0.80 1.8 kb (FAC) 2 698.90 
1.8 kb (FAC) 3 770.22 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 * 
pGL4.10 (FAC) 3 0.00 
2 
2 kb (dH2O) 1 1025.68 
1.00 2 kb (dH2O) 2 983.37 
2 kb (dH2O) 3 956.62 
2 kb (FAC) 1 939.79 
0.96 2 kb (FAC) 2 976.14 
2 kb (FAC) 3 943.19 
1.8 kb (dH2O) 1 862.67 
0.85 1.8 kb (dH2O) 2 827.19 
1.8 kb (dH2O) 3 2.00 * 
1.8 kb (FAC) 1 847.27 
0.83 1.8 kb (FAC) 2 829.95 
1.8 kb (FAC) 3 796.62 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 * 
3 
2 kb (dH2O) 1 1241.81 
1.00 2 kb (dH2O) 2 1059.02 
2 kb (dH2O) 3 1182.93 
2 kb (FAC) 1 1126.22 
0.98 2 kb (FAC) 2 1111.77 
2 kb (FAC) 3 1168.62 
1.8 kb (dH2O) 1 992.71 
0.88 1.8 kb (dH2O) 2 1019.39 
1.8 kb (dH2O) 3 1045.29 
1.8 kb (FAC) 1 951.64 
0.82 1.8 kb (FAC) 2 973.72 
1.8 kb (FAC) 3 926.35 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 * 
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Table S8.1 Normalized luciferase data for LTF constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
140 bp (dH2O) 1 0.68 
0.27 140 bp (dH2O) 2 0.77 
140 bp (dH2O) 3 0.72 
140 bp (FAC) 1 0.93 
0.36 140 bp (FAC) 2 1.03 
140 bp (FAC) 3 0.98 
pGL4.23 (dH2O) 1 2.76 
1.00 pGL4.23 (dH2O) 2 2.78 
pGL4.23 (dH2O) 3 2.53 
pGL4.23 (FAC) 1 3.67 
1.24 pGL4.23 (FAC) 2 3.03 
pGL4.23 (FAC) 3 1.85 * 
2 
140 bp (dH2O) 1 1.92 
0.24 140 bp (dH2O) 2 2.34 
140 bp (dH2O) 3 1.98 
140 bp (FAC) 1 2.35 
0.30 140 bp (FAC) 2 2.73 
140 bp (FAC) 3 2.58 
pGL4.23 (dH2O) 1 8.55 
1.00 pGL4.23 (dH2O) 2 8.63 
pGL4.23 (dH2O) 3 1118.48 * 
pGL4.23 (FAC) 1 7.48 
0.95 pGL4.23 (FAC) 2 8.63 
pGL4.23 (FAC) 3 8.34 
3 
140 bp (dH2O) 1 0.90 
0.33 140 bp (dH2O) 2 0.79 
140 bp (dH2O) 3 0.90 
140 bp (FAC) 1 1.05 
0.39 140 bp (FAC) 2 1.04 
140 bp (FAC) 3 0.94 
pGL4.23 (dH2O) 1 2.49 
1.00 pGL4.23 (dH2O) 2 2.84 
pGL4.23 (dH2O) 3 2.48 
pGL4.23 (FAC) 1 3.02 
1.15 pGL4.23 (FAC) 2 3.04 
pGL4.23 (FAC) 3 2.91 
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Table S8.2 Normalized luciferase data for LTF constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
2 kb (dH2O) 1 4.31 * 
1.00 2 kb (dH2O) 2 0.87 
2 kb (dH2O) 3 0.90 
2 kb (FAC) 1 0.37 
0.48 2 kb (FAC) 2 0.48 
2 kb (FAC) 3 0.72 * 
1.8 kb (dH2O) 1 0.55 
0.63 1.8 kb (dH2O) 2 1.29 * 
1.8 kb (dH2O) 3 0.56 
1.8 kb (FAC) 1 0.16 * 
0.49 1.8 kb (FAC) 2 0.46 
1.8 kb (FAC) 3 0.41 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 * 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.01 
0.01 pGL4.10 (FAC) 2 0.00 * 
pGL4.10 (FAC) 3 0.01 
2 
2 kb (dH2O) 1 0.64 
1.00 2 kb (dH2O) 2 0.58 
2 kb (dH2O) 3 0.73 
2 kb (FAC) 1 0.36 
0.62 2 kb (FAC) 2 0.42 
2 kb (FAC) 3 0.42 
1.8 kb (dH2O) 1 0.41 
0.70 1.8 kb (dH2O) 2 0.48 
1.8 kb (dH2O) 3 0.49 
1.8 kb (FAC) 1 0.53 * 
0.61 1.8 kb (FAC) 2 0.42 
1.8 kb (FAC) 3 0.37 
pGL4.10 (dH2O) 1 0.01 * 
0.01 pGL4.10 (dH2O) 2 0.01 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.01 
0.01 pGL4.10 (FAC) 2 0.01 * 
pGL4.10 (FAC) 3 0.01 
3 
2 kb (dH2O) 1 0.95 
1.00 2 kb (dH2O) 2 0.68 * 
2 kb (dH2O) 3 0.83 
2 kb (FAC) 1 0.28 * 
0.47 2 kb (FAC) 2 0.39 
2 kb (FAC) 3 0.45 
1.8 kb (dH2O) 1 0.45 
0.52 1.8 kb (dH2O) 2 1.07 * 
1.8 kb (dH2O) 3 0.47 
1.8 kb (FAC) 1 0.39 
0.44 1.8 kb (FAC) 2 0.38 
1.8 kb (FAC) 3 0.57 * 
pGL4.10 (dH2O) 1 0.01 * 
0.01 pGL4.10 (dH2O) 2 0.01 
pGL4.10 (dH2O) 3 0.01 
pGL4.10 (FAC) 1 0.01 
0.01 pGL4.10 (FAC) 2 0.01 
pGL4.10 (FAC) 3 0.01 
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Table S8.3 Normalized luciferase data for LTF constructs transfected into COS-1 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
140 bp (dH2O) 1 0.22 
0.54 140 bp (dH2O) 2 0.22 
140 bp (dH2O) 3 0.22 
140 bp (FAC) 1 0.64 * 
0.83 140 bp (FAC) 2 0.36 
140 bp (FAC) 3 0.33 
pGL4.23 (dH2O) 1 0.40 
1.00 pGL4.23 (dH2O) 2 0.42 
pGL4.23 (dH2O) 3 0.51 * 
pGL4.23 (FAC) 1 0.58 
1.34 pGL4.23 (FAC) 2 0.43 * 
pGL4.23 (FAC) 3 0.52 
2 
140 bp (dH2O) 1 0.28 
0.62 140 bp (dH2O) 2 0.32 
140 bp (dH2O) 3 0.27 
140 bp (FAC) 1 0.36 
0.74 140 bp (FAC) 2 0.33 
140 bp (FAC) 3 0.36 
pGL4.23 (dH2O) 1 0.49 
1.00 pGL4.23 (dH2O) 2 0.49 
pGL4.23 (dH2O) 3 0.42 
pGL4.23 (FAC) 1 0.57 
1.23 pGL4.23 (FAC) 2 0.62 
pGL4.23 (FAC) 3 0.52 
3 
140 bp (dH2O) 1 0.28 
0.64 140 bp (dH2O) 2 0.30 
140 bp (dH2O) 3 0.24 
140 bp (FAC) 1 0.34 
0.75 140 bp (FAC) 2 0.19 
140 bp (FAC) 3 0.30 
pGL4.23 (dH2O) 1 0.39 
1.00 pGL4.23 (dH2O) 2 0.46 
pGL4.23 (dH2O) 3 0.43 
pGL4.23 (FAC) 1 0.54 
1.26 pGL4.23 (FAC) 2 0.60 
pGL4.23 (FAC) 3 0.47 
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Table S8.4 Normalized luciferase data for LTF constructs transfected into COS-1 cell line. 
1 
2 kb (dH2O) 1 1.12 
1.00 2 kb (dH2O) 2 0.96 
2 kb (dH2O) 3 0.77 * 
2 kb (FAC) 1 1.16 
1.01 2 kb (FAC) 2 0.93 
2 kb (FAC) 3 1.81 * 
1.8 kb (dH2O) 1 1.10 
0.92 1.8 kb (dH2O) 2 0.75 * 
1.8 kb (dH2O) 3 1.00 
1.8 kb (FAC) 1 0.86 
0.83 1.8 kb (FAC) 2 0.86 
1.8 kb (FAC) 3 0.67 * 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
2 
2 kb (dH2O) 1 0.77 
1.00 2 kb (dH2O) 2 0.80 
2 kb (dH2O) 3 0.68 
2 kb (FAC) 1 0.83 
1.14 2 kb (FAC) 2 0.80 
2 kb (FAC) 3 0.93 
1.8 kb (dH2O) 1 0.44 
0.53 1.8 kb (dH2O) 2 0.32 * 
1.8 kb (dH2O) 3 0.40 
1.8 kb (FAC) 1 0.42 
0.51 1.8 kb (FAC) 2 0.36 
1.8 kb (FAC) 3 0.37 
pGL4.10 (dH2O) 1 0.00 * 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 * 
3 
2 kb (dH2O) 1 0.90 * 
1.00 2 kb (dH2O) 2 0.79 
2 kb (dH2O) 3 0.77 
2 kb (FAC) 1 0.75 * 
1.15 2 kb (FAC) 2 0.93 
2 kb (FAC) 3 0.87 
1.8 kb (dH2O) 1 0.51 * 
0.52 1.8 kb (dH2O) 2 0.41 
1.8 kb (dH2O) 3 0.40 
1.8 kb (FAC) 1 0.46 
0.60 1.8 kb (FAC) 2 0.43 
1.8 kb (FAC) 3 0.51 
pGL4.10 (dH2O) 1 0.00 * 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 * 
pGL4.10 (FAC) 3 0.00 
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Table S9.1 Normalized luciferase data for TFRC constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
140 bp (dH2O) 1 1.15 
0.50 140 bp (dH2O) 2 1.46 
140 bp (dH2O) 3 1.45 
140 bp (FAC) 1 1.85 
0.71 140 bp (FAC) 2 1.77 
140 bp (FAC) 3 2.12 
pGL4.23 (dH2O) 1 2.76 
1.00 pGL4.23 (dH2O) 2 2.78 
pGL4.23 (dH2O) 3 2.53 
pGL4.23 (FAC) 1 3.67 
1.24 pGL4.23 (FAC) 2 3.03 
pGL4.23 (FAC) 3 1.85 * 
2 
140 bp (dH2O) 1 2.93 
0.36 140 bp (dH2O) 2 3.05 
140 bp (dH2O) 3 3.28 
140 bp (FAC) 1 3.67 
0.47 140 bp (FAC) 2 4.16 
140 bp (FAC) 3 4.35 
pGL4.23 (dH2O) 1 8.55 
1.00 pGL4.23 (dH2O) 2 8.63 
pGL4.23 (dH2O) 3 1118.48 * 
pGL4.23 (FAC) 1 7.48 
0.95 pGL4.23 (FAC) 2 8.63 
pGL4.23 (FAC) 3 8.34 
3 
140 bp (dH2O) 1 0.33 
0.44 140 bp (dH2O) 2 0.37 
140 bp (dH2O) 3 0.39 
140 bp (FAC) 1 0.40 * 
0.59 140 bp (FAC) 2 0.46 
140 bp (FAC) 3 0.46 
pGL4.23 (dH2O) 1 0.74 
1.00 pGL4.23 (dH2O) 2 0.83 
pGL4.23 (dH2O) 3 0.79 
pGL4.23 (FAC) 1 0.93 
1.17 pGL4.23 (FAC) 2 0.44 * 
pGL4.23 (FAC) 3 0.91 
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Table S9.2 Normalized luciferase data for TFRC constructs transfected into HepG2 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
2 kb (dH2O) 1 1561.48 * 
1.00 2 kb (dH2O) 2 1959.32 
2 kb (dH2O) 3 2220.00 
2 kb (FAC) 1 2402.91 
1.14 2 kb (FAC) 2 2358.86 
2 kb (FAC) 3 2396.49 
1.8 kb (dH2O) 1 3394.73 
1.74 1.8 kb (dH2O) 2 3869.85 
1.8 kb (dH2O) 3 4578.00 * 
1.8 kb (FAC) 1 3950.74 
1.90 1.8 kb (FAC) 2 4080.39 
1.8 kb (FAC) 3 3869.76 
pGL4.10 (dH2O) 1 0.01 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.01 
0.00 pGL4.10 (FAC) 2 0.01 
pGL4.10 (FAC) 3 0.01 
2 
2 kb (dH2O) 1 2383.80 
1.00 2 kb (dH2O) 2 2605.69 
2 kb (dH2O) 3 2345.92 
2 kb (FAC) 1 2752.55 
1.17 2 kb (FAC) 2 2836.53 
2 kb (FAC) 3 3026.49 
1.8 kb (dH2O) 1 3369.28 
1.43 1.8 kb (dH2O) 2 2711.79 * 
1.8 kb (dH2O) 3 3631.84 
1.8 kb (FAC) 1 3957.70 
1.47 1.8 kb (FAC) 2 3234.97 
1.8 kb (FAC) 3 3610.48 
pGL4.10 (dH2O) 1 0.01 * 
0.00 pGL4.10 (dH2O) 2 0.01 
pGL4.10 (dH2O) 3 0.01 
pGL4.10 (FAC) 1 0.01 
0.00 pGL4.10 (FAC) 2 0.01 * 
pGL4.10 (FAC) 3 0.01 
3 
2 kb (dH2O) 1 3052.37 
1.00 2 kb (dH2O) 2 3780.56 * 
2 kb (dH2O) 3 3003.57 
2 kb (FAC) 1 3591.05 
1.15 2 kb (FAC) 2 3127.73 
2 kb (FAC) 3 3683.32 
1.8 kb (dH2O) 1 3712.74 
1.18 1.8 kb (dH2O) 2 3420.48 
1.8 kb (dH2O) 3 3593.06 
1.8 kb (FAC) 1 3643.50 
1.18 1.8 kb (FAC) 2 3720.85 
1.8 kb (FAC) 3 3366.18 
pGL4.10 (dH2O) 1 0.01 * 
0.00 pGL4.10 (dH2O) 2 0.01 
pGL4.10 (dH2O) 3 0.01 
pGL4.10 (FAC) 1 0.01 
0.00 pGL4.10 (FAC) 2 0.01 
pGL4.10 (FAC) 3 0.01 
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Table S9.3 Normalized luciferase data for TFRC constructs transfected into COS-1 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
140 bp (dH2O) 1 0.60 * 
0.98 140 bp (dH2O) 2 0.39 
140 bp (dH2O) 3 0.42 
140 bp (FAC) 1 0.50 
1.24 140 bp (FAC) 2 0.48 
140 bp (FAC) 3 0.56 
pGL4.23 (dH2O) 1 0.40 
1.00 pGL4.23 (dH2O) 2 0.42 
pGL4.23 (dH2O) 3 0.51 * 
pGL4.23 (FAC) 1 0.48 
1.08 pGL4.23 (FAC) 2 0.43 
pGL4.23 (FAC) 3 0.42 
2 
140 bp (dH2O) 1 0.41 
0.94 140 bp (dH2O) 2 0.49 
140 bp (dH2O) 3 0.42 
140 bp (FAC) 1 0.54 
1.18 140 bp (FAC) 2 0.56 
140 bp (FAC) 3 1.05 * 
pGL4.23 (dH2O) 1 0.49 
1.00 pGL4.23 (dH2O) 2 0.49 
pGL4.23 (dH2O) 3 0.42 
pGL4.23 (FAC) 1 0.47 
1.08 pGL4.23 (FAC) 2 0.52 
pGL4.23 (FAC) 3 0.52 
3 
140 bp (dH2O) 1 0.37 
0.86 140 bp (dH2O) 2 0.36 
140 bp (dH2O) 3 0.28 * 
140 bp (FAC) 1 0.49 
1.10 140 bp (FAC) 2 0.49 
140 bp (FAC) 3 0.42 
pGL4.23 (dH2O) 1 0.39 
1.00 pGL4.23 (dH2O) 2 0.46 
pGL4.23 (dH2O) 3 0.43 
pGL4.23 (FAC) 1 0.44 
1.03 pGL4.23 (FAC) 2 0.40 
pGL4.23 (FAC) 3 0.47 
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Table S9.4 Normalized luciferase data for TFRC constructs transfected into COS-1 cell line. 
Experiment Construct Repeat Normalized Value Fold Change 
1 
2 kb (dH2O) 1 418.77 
1.00 2 kb (dH2O) 2 435.12 
2 kb (dH2O) 3 495.22 
2 kb (FAC) 1 575.02 
1.34 2 kb (FAC) 2 608.51 
2 kb (FAC) 3 627.90 
1.8 kb (dH2O) 1 726.82 
1.65 1.8 kb (dH2O) 2 756.36 
1.8 kb (dH2O) 3 736.42 
1.8 kb (FAC) 1 880.86 
1.85 1.8 kb (FAC) 2 808.45 
1.8 kb (FAC) 3 801.80 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
2 
2 kb (dH2O) 1 619.53 
1.00 2 kb (dH2O) 2 572.35 
2 kb (dH2O) 3 615.83 
2 kb (FAC) 1 719.25 
1.20 2 kb (FAC) 2 744.23 
2 kb (FAC) 3 708.99 
1.8 kb (dH2O) 1 787.37 
1.34 1.8 kb (dH2O) 2 806.31 
1.8 kb (dH2O) 3 835.16 
1.8 kb (FAC) 1 831.51 
1.42 1.8 kb (FAC) 2 899.91 
1.8 kb (FAC) 3 841.06 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
3 
2 kb (dH2O) 1 658.70 
1.00 2 kb (dH2O) 2 655.34 
2 kb (dH2O) 3 624.76 
2 kb (FAC) 1 699.74 
1.06 2 kb (FAC) 2 683.25 
2 kb (FAC) 3 666.69 
1.8 kb (dH2O) 1 740.93 
1.18 1.8 kb (dH2O) 2 763.77 
1.8 kb (dH2O) 3 777.99 
1.8 kb (FAC) 1 766.19 
1.19 1.8 kb (FAC) 2 755.45 
1.8 kb (FAC) 3 781.03 
pGL4.10 (dH2O) 1 0.00 
0.00 pGL4.10 (dH2O) 2 0.00 * 
pGL4.10 (dH2O) 3 0.00 
pGL4.10 (FAC) 1 0.00 
0.00 pGL4.10 (FAC) 2 0.00 
pGL4.10 (FAC) 3 0.00 
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